0001171843-23-001908.txt : 20230327 0001171843-23-001908.hdr.sgml : 20230327 20230327100036 ACCESSION NUMBER: 0001171843-23-001908 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230327 DATE AS OF CHANGE: 20230327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PSYCHEMEDICS CORP CENTRAL INDEX KEY: 0000806517 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 581701987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13738 FILM NUMBER: 23761754 BUSINESS ADDRESS: STREET 1: 125 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-206-8220 MAIL ADDRESS: STREET 1: 125 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 10-K 1 pmd20221231_10k.htm FORM 10-K pmd20221231_10k.htm
0000806517 PSYCHEMEDICS CORP false --12-31 FY 2022 87 89 21,964 19,659 0.005 0.005 873 873 0 0 0 0 0.005 0.005 50,000 50,000 6,349 6,257 5,681 5,589 668 668 10,082 10,082 11,820 9,550 1,634 1,634 1,083 209 6,066 - 3,150 - 43 61 140 43 1,030 140 1,040 821 6,206 44 156 2,347 1,084 665 3,859 - - 10 1,084 665 3,869 0.19 0.12 0.70 0.19 0.12 0.70 10,082 3,754 1,624 9 9 0.18 993 993 3,859 3,859 10 10 10,082 8,606 1,634 72 72 0.05 279 279 665 665 10,082 9,550 1,634 1 78 78 0.21 1,186 1,186 1,084 1,084 10,082 11,820 1,634 1,084 665 3,859 - 2,181 - 531 371 339 377 760 424 363 585 392 2,339 183 2,013 546 417 281 967 1,078 914 751 1,387 1,776 4,890 414 4,083 21 38 7 187 182 991 208 220 858 1,186 279 993 74 68 9 664 688 678 1,924 1,035 501 - - 10 2,758 841 4,450 0 3 5 3 7 5 7 3 5 20 62 62 62 62 62 0 0 1 1 1 11 3 552 131 2,006 23 84 2 2,008 959 704 13 428 333 326 531 371 339 44 156 2,347 0.4 47.6 0.0 0.5 1.4 0.4 0.0 10.9 2.2 46.2 50.5 0.0 895 414 783 1,249 78 61 632 837 1,493 2,147 10 2 4 2000 6.1 1 1 64 5.1 4.9 90 12 30 0 0 233 294 0 1 Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares. The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of December 31, 2021, and 2020 was $7.02 and $5.09, respectively. The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 years. The options granted on May 3, 2019, have a fair value of $2.99 per share based on the $10.60 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 41% volatility, 2.4% interest rate and a 3.9% dividend yield rate. The options granted on November 11, 2020, have a fair value of $1.13 per share based on the $4.07 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 45% volatility, 0.9% interest rate and a 4.0%dividend yield rate. No options were granted during fiscal year ended December 31, 2021. For options granted during fiscal years ended December 31, 2020, and 2019, the weighted average grant date fair values were $3.47, and $3.40,respectively. For SUAs granted during fiscal years ended December 31, 2021, 2020 and 2019, the weighted average grant date fair values were $6.55, $4.89, and $12.01, respectively. 00008065172022-01-012022-12-31 iso4217:USD 00008065172022-06-30 xbrli:shares 00008065172023-03-15 thunderdome:item 00008065172022-12-31 00008065172021-12-31 iso4217:USDxbrli:shares 00008065172021-01-012021-12-31 00008065172020-01-012020-12-31 0000806517us-gaap:CommonStockMember2019-12-31 0000806517us-gaap:AdditionalPaidInCapitalMember2019-12-31 0000806517us-gaap:TreasuryStockMember2019-12-31 0000806517us-gaap:RetainedEarningsMember2019-12-31 0000806517us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 00008065172019-12-31 0000806517us-gaap:CommonStockMember2020-01-012020-12-31 0000806517us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0000806517us-gaap:TreasuryStockMember2020-01-012020-12-31 0000806517us-gaap:RetainedEarningsMember2020-01-012020-12-31 0000806517us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-31 0000806517us-gaap:CommonStockMember2020-12-31 0000806517us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000806517us-gaap:TreasuryStockMember2020-12-31 0000806517us-gaap:RetainedEarningsMember2020-12-31 0000806517us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 00008065172020-12-31 0000806517us-gaap:CommonStockMember2021-01-012021-12-31 0000806517us-gaap:TreasuryStockMember2021-01-012021-12-31 0000806517us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-31 0000806517us-gaap:RetainedEarningsMember2021-01-012021-12-31 0000806517us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-31 0000806517us-gaap:CommonStockMember2021-12-31 0000806517us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000806517us-gaap:TreasuryStockMember2021-12-31 0000806517us-gaap:RetainedEarningsMember2021-12-31 0000806517us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0000806517us-gaap:CommonStockMember2022-01-012022-12-31 0000806517us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0000806517us-gaap:TreasuryStockMember2022-01-012022-12-31 0000806517us-gaap:RetainedEarningsMember2022-01-012022-12-31 0000806517us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-31 0000806517us-gaap:CommonStockMember2022-12-31 0000806517us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000806517us-gaap:TreasuryStockMember2022-12-31 0000806517us-gaap:RetainedEarningsMember2022-12-31 0000806517us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0000806517pmd:PaycheckProtectionProgramCaresActMember2022-01-012022-12-31 0000806517pmd:PaycheckProtectionProgramCaresActMember2021-01-012021-12-31 0000806517pmd:PaycheckProtectionProgramCaresActMember2020-01-012020-12-31 utr:Y 0000806517us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MinimumMember2022-01-012022-12-31 0000806517us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MaximumMember2022-01-012022-12-31 0000806517us-gaap:OfficeEquipmentMembersrt:MinimumMember2022-01-012022-12-31 0000806517us-gaap:OfficeEquipmentMembersrt:MaximumMember2022-01-012022-12-31 0000806517pmd:LaboratoryEquipmentMembersrt:MinimumMember2022-01-012022-12-31 0000806517pmd:LaboratoryEquipmentMembersrt:MaximumMember2022-01-012022-12-31 0000806517pmd:CapitalizedSoftwareAndEquipmentMember2022-12-31 0000806517us-gaap:SoftwareDevelopmentMembersrt:MinimumMember2022-01-012022-12-31 0000806517us-gaap:SoftwareDevelopmentMembersrt:MaximumMember2022-01-012022-12-31 0000806517us-gaap:SoftwareDevelopmentMember2022-12-31 0000806517us-gaap:SoftwareDevelopmentMember2021-12-31 0000806517us-gaap:SoftwareDevelopmentMember2022-01-012022-12-31 0000806517us-gaap:SoftwareDevelopmentMember2021-01-012021-12-31 0000806517us-gaap:SoftwareDevelopmentMember2020-01-012020-12-31 0000806517us-gaap:PatentsMember2022-01-012022-12-31 0000806517us-gaap:PatentsMember2022-12-31 0000806517us-gaap:PatentsMember2021-12-31 0000806517us-gaap:PatentsMember2020-12-31 0000806517us-gaap:PatentsMember2021-01-012021-12-31 0000806517us-gaap:PatentsMember2020-01-012020-12-31 0000806517pmd:TestingMember2022-01-012022-12-31 0000806517pmd:TestingMember2021-01-012021-12-31 0000806517pmd:TestingMember2020-01-012020-12-31 0000806517pmd:ShippingCollectionHairMember2022-01-012022-12-31 0000806517pmd:ShippingCollectionHairMember2021-01-012021-12-31 0000806517pmd:ShippingCollectionHairMember2020-01-012020-12-31 0000806517pmd:OtherRevenueMember2022-01-012022-12-31 0000806517pmd:OtherRevenueMember2021-01-012021-12-31 0000806517pmd:OtherRevenueMember2020-01-012020-12-31 xbrli:pure 0000806517us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-31 0000806517us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-31 0000806517us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-31 0000806517us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-31 0000806517us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-31 0000806517us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-31 0000806517us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberpmd:CustomerOneMember2022-01-012022-12-31 0000806517us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberpmd:CustomerOneMember2021-01-012021-12-31 0000806517us-gaap:CostOfSalesMember2022-01-012022-12-31 0000806517us-gaap:CostOfSalesMember2021-01-012021-12-31 0000806517us-gaap:CostOfSalesMember2020-01-012020-12-31 0000806517us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-31 0000806517us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-31 0000806517us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-31 0000806517us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-31 0000806517us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-31 0000806517us-gaap:SellingAndMarketingExpenseMember2020-01-012020-12-31 0000806517us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-31 0000806517us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-31 0000806517us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-31 0000806517us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2022-12-31 0000806517us-gaap:StateAndLocalJurisdictionMember2022-12-31 0000806517us-gaap:StateAndLocalJurisdictionMemberus-gaap:CaliforniaFranchiseTaxBoardMember2022-12-31 0000806517us-gaap:StateAndLocalJurisdictionMemberus-gaap:CaliforniaFranchiseTaxBoardMember2022-01-012022-12-31 0000806517pmd:IncentivePlan2006Member2006-01-012006-12-31 0000806517pmd:IncentivePlan2006Member2019-01-31 0000806517pmd:IncentivePlan2006Member2021-05-31 0000806517pmd:IncentivePlan2006Member2022-12-31 0000806517srt:MinimumMember2022-01-012022-12-31 0000806517srt:MaximumMember2022-01-012022-12-31 0000806517pmd:StockUnitAwardMember2022-04-042022-04-04 0000806517pmd:StockUnitAwardMember2022-05-202022-05-20 0000806517pmd:StockUnitAwardMember2022-08-122022-08-12 0000806517pmd:August122022Memberpmd:StockUnitAwardMember2022-01-012022-12-31 0000806517pmd:May202022Memberpmd:StockUnitAwardMember2022-01-012022-12-31 0000806517pmd:April42022Memberpmd:StockUnitAwardMember2022-01-012022-12-31 0000806517pmd:May132021Memberpmd:StockUnitAwardMember2022-01-012022-12-31 0000806517pmd:March162021Memberpmd:StockUnitAwardMember2022-01-012022-12-31 0000806517pmd:January252021Memberpmd:StockUnitAwardMember2022-01-012022-12-31 0000806517pmd:December162020Memberpmd:StockUnitAwardMember2022-01-012022-12-31 0000806517pmd:November112020Member2022-01-012022-12-31 0000806517pmd:November112020Memberpmd:StockUnitAwardMember2022-01-012022-12-31 00008065172020-11-11 0000806517us-gaap:EmployeeStockOptionMember2020-11-112020-11-11 0000806517us-gaap:EmployeeStockOptionMembersrt:MaximumMember2020-11-112020-11-11 0000806517us-gaap:EmployeeStockOptionMembersrt:MinimumMember2020-11-112020-11-11 0000806517pmd:StockUnitAwardMember2022-01-012022-12-31 0000806517pmd:StockUnitAwardMember2021-01-012021-12-31 0000806517pmd:StockUnitAwardMember2020-01-012020-12-31 0000806517pmd:StockUnitAwardMember2021-12-31 0000806517pmd:StockUnitAwardMember2022-12-31 0000806517pmd:EnmaSagastumeVPsychemedicsCorporationMember2021-12-062021-12-06 0000806517pmd:EnmaSagastumeVPsychemedicsCorporationMember2021-12-31 0000806517us-gaap:LineOfCreditMemberpmd:EquipmentLoanArrangementMemberpmd:BancOfAmericaLeasingAndCapitalMember2019-12-022019-12-02 utr:M 0000806517us-gaap:LineOfCreditMemberpmd:EquipmentLoanArrangementMemberpmd:BancOfAmericaLeasingAndCapitalMemberus-gaap:LondonInterbankOfferedRateLIBORMember2017-10-302017-10-30 0000806517us-gaap:LineOfCreditMemberpmd:EquipmentLoanArrangementMemberpmd:BancOfAmericaLeasingAndCapitalMember2019-12-02 0000806517us-gaap:LineOfCreditMemberpmd:EquipmentLoanArrangementMemberpmd:BancOfAmericaLeasingAndCapitalMember2014-03-252019-12-04 0000806517us-gaap:LineOfCreditMemberpmd:EquipmentLoanArrangementMemberpmd:BancOfAmericaLeasingAndCapitalMember2022-01-012022-12-31 0000806517us-gaap:LineOfCreditMemberpmd:EquipmentLoanArrangementMemberpmd:BancOfAmericaLeasingAndCapitalMember2021-01-012021-12-31 0000806517us-gaap:LineOfCreditMemberpmd:EquipmentLoanArrangementMemberpmd:BancOfAmericaLeasingAndCapitalMember2022-12-31 0000806517pmd:PaycheckProtectionProgramCaresActMember2020-05-012020-05-01 0000806517pmd:EquipmentLoanArrangementMember2022-12-31 0000806517country:US2022-01-012022-12-31 0000806517country:US2021-01-012021-12-31 0000806517country:US2020-01-012020-12-31 0000806517us-gaap:NonUsMember2022-01-012022-12-31 0000806517us-gaap:NonUsMember2021-01-012021-12-31 0000806517us-gaap:NonUsMember2020-01-012020-12-31 0000806517us-gaap:SubsequentEventMember2023-03-212023-03-21
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

FORM 10-K
 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Fiscal Year Ended December 31, 2022

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 1-13738

 

 

 

PSYCHEMEDICS CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

58-1701987

(State or Other Jurisdiction of
Incorporation or Organization)

(I.R.S. Employer
Identification No.)

 

289 Great Road
Acton, Massachusetts

01720

(Address of Principal Executive Offices)

(Zip Code)

 

Registrant’s Telephone Number Including Area Code: (978) 206-8220
 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Class

Trading Symbol(s)

Name of each exchange on which registered

Common stock. $0.005 par value

PMD

The Nasdaq Stock Market, LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

 

Indicate by a check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Exchange Act of 1934). Yes ☐ No ☒

 

Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934). Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.) Yes ☒ No ☐

 

 

 

 
 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See definitions of “accelerated filer”, “large accelerated filer”, “non-accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934.

 

Large Accelerated Filer ☐

 Accelerated Filer ☐

Non-Accelerated Filer ☒

Smaller Reporting Company ☒Emerging Growth Company ☐    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities and Exchange Act of 1934). Yes ☐ No ☒

 

As of June 30, 2022, there were 5,626,196 shares of Common Stock of the Registrant outstanding. The aggregate market value of the Common Stock of the Registrant held by non-affiliates (assuming for these purposes, but not conceding, that all executive officers, directors and 5% shareholders are “affiliates” of the Registrant) as of June 30, 2022, was $26.9 million, computed based upon the closing price of $6.34 per share on June 30, 2022.

 

As of March 15, 2023, there were 5,684,647 shares of Common Stock of the Registrant outstanding.

 

 

 

 

 

 
 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Some of the statements under “Business,” “Risk Factors,” “Legal Proceedings,” “Market for Registrant’s Common Stock and Related Stockholder Matters” and “Management Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Annual Report on Form 10-K (this “Form 10-K”) constitute forward-looking statements under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements made with respect to future earnings, earnings per share, revenues, operating income, cash flows, competitive and strategic initiatives, potential stock repurchases, liquidity needs, cash dividends, future business, growth opportunities, profitability, pricing, new accounts, customer base, market share, test volume, sales volume, sales and marketing strategies, U.S. and foreign drug testing laws and regulations and the enforcement of such laws and regulations, required investments in plant, equipment and people, new test development, and contingencies, including litigation results. These statements involve known and unknown risks, uncertainties and other factors that may cause results, levels of activity, growth, performance, earnings per share or achievements to be materially different from any future results, levels of activity, growth, performance, earnings per share or achievements expressed or implied by such forward-looking statements.

 

The forward-looking statements included in this Form 10-K and referred to elsewhere are related to future events or our strategies or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “believe,” “anticipate,” “future,” “potential,” “estimate,” “encourage,” “opportunity,” “growth,” “leader,” “could”, “expect,” “intend,” “plan,” “expand,” “focus,” “through,” “strategy,” “provide,” “offer,” “allow,” “commitment,” “implement,” “result,” “increase,” “establish,” “perform,” “make,” “continue,” “can,” “ongoing,” “include” or the negative of such terms or comparable terminology. All forward-looking statements included in this Form 10-K are based on information available to us as of the filing date of this report, and the Company assumes no obligation to update any such forward-looking statements. Our actual results could differ materially from the forward-looking statements.

 

Factors that may cause such differences include but are not limited to: (1) intense competition in the drug testing industry, particularly among companies that test utilizing hair samples; (2) risks associated with the development of markets for new products and services offered; (3) pricing policies; (4) risks associated with capacity expansion; (5) risks associated with U.S. government regulations, including, but not limited to, Food and Drug Administration (the “FDA”) regulations, (6) risks associated with denial, suspension, or revocation of certifications or other licenses for any of our clinical laboratories; (7) Psychemedics' ability to maintain its reputation and brand image; (8) the ability of Psychemedics to achieve its business plans, productivity improvements, cost controls, leveraging of its global operating platform, and acceleration of the rate of innovation; (9) the direct and indirect impact of the COVID-19 pandemic on our business and operations; (10) information technology system failures and data security breaches; (11) the uncertain global economy; (12) our ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors; (13) Psychemedics' ability to obtain and protect intellectual property rights; (14) litigation risks; and (15) changes in economic conditions which affect demand for our products and services.

 

Additional important factors that could cause actual results to differ materially from expectations reflected in our forward-looking statements include those described in Item 1A, “Risk Factors.”

 

 

 

 

 

i
 

 

 

PSYCHEMEDICS CORPORATION

 

FORM 10-K 
ANNUAL REPORT
For the Year Ended December 31, 2022

TABLE OF CONTENTS

 

PART I

Page

Item 1.

Business

1

Item 1A.

Risk Factors

6

Item 1B.

Unresolved Staff Comments

10

Item 2.

Properties

10

Item 3.

Legal Proceedings

10

Item 4.

Mine Safety Disclosures

10

PART II

  

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

11

Item 6.

Reserved

12

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

13

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

13

Item 8.

Financial Statements and Supplementary Data

17

Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

40

Item 9A.

Controls and Procedures

40

Item 9B.

Other Information

41

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

41

PART III

  

Item 10.

Directors, Executive Officers and Corporate Governance

41

Item 11.

Executive Compensation

45

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

52

Item 13.

Certain Relationships and Related Transactions, and Director Independence

54

Item 14.

Principal Accountant Fees and Services

54

PART IV

  

Item 15.

Exhibits and Financial Statement Schedules

54

Item 16.

Form 10-K Summary

54
 

Signatures

55
 

Power of Attorney

 

 

 

 

ii
 

 

PART I

 

 

Available Information

 

Psychemedics Corporation (together with its wholly-owned subsidiaries, the “Company” or “Psychemedics”) maintains its principal executive office at 289 Great Road, Acton, MA 01720. Our telephone number is (978) 206-8220 and internet address is www.psychemedics.com. Our stock is traded on the NASDAQ Stock Market under the symbol “PMD”. The Company makes available, free of charge, on the Investor Information section of its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K from time to time, and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with the Securities and Exchange Commission (the “SEC”). Copies are also available, without charge, from Psychemedics Corporation, Attn: Investor Relations, 289 Great Road, Acton, MA 01720. Alternatively, reports filed with the SEC may be viewed or obtained at the SEC Public Reference Room in Washington, D.C., or from the SEC on its website at www.sec.gov. We do not intend for information contained in our website to be part of this Annual Report on Form 10-K.

 

Item 1. Business

 

General

 

Psychemedics Corporation is a Delaware corporation organized on September 24, 1986. The consolidated financial statements of the Company include the accounts and results of operations of Psychemedics Corporation and its wholly-owned subsidiary, Psychemedics International, LLC and their jointly-owned subsidiary, Psychemedics Laboratórios Ltd. All significant inter-company balances and transactions have been eliminated in consolidation. All the Company’s physical assets are located within the United States. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. The Company’s testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. This is fundamental to the entire process because the patented method gets virtually 100% of the drug out of the hair, and if you cannot get the drug out of the hair, you cannot measure it. The Company then performs a proprietary custom-designed patented (US 10,539,580) enzyme immunoassay (“EIA”) on the liquid supernatant, with confirmation testing by mass spectrometry.

 

The Company’s primary application of its patented technology is as a testing service that analyzes hair samples for the presence of certain drugs of abuse. The Company’s customized proprietary EIA procedures to drug test hair samples differ from the more commonly used immunoassay procedures employed by other hair testing companies. The Company’s testing results provide quantitative information that can indicate the approximate amount of drug ingested as well as historical data, which can show a pattern of individual drug use over a longer period of time, thereby providing superior detection compared to other types of drug testing. This information is useful to employers for both applicant and employee testing, as well as treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children’s drug use. The Company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines (including ecstasy, eve and Adderall®), opiates (including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax®, Valium®, and Ativan®), nicotine, Fentanyl, and alcohol.

 

Hair drug testing services are currently performed at the Company’s Culver City, California campus located at 5832 Uplander Way and 5750 Hannum Avenue.

 

Background on Drug Testing with Hair

 

When certain chemical substances enter the bloodstream, the blood carries these substances to the hair where they become “entrapped” in the protein matrix in amounts approximately proportional to the amount ingested. The Company utilizes a patented drug extraction method followed by a unique patented EIA procedure to identify drugs in the hair. The patented drug extraction method effectively releases drugs from the hair without destroying the drugs, getting virtually 100% of the drug out of the hair. The patented method can be used with a broad range of immunoassay screen techniques and mass spectrometry methods.

 

The immunoassays used by the Company have been patented under the name “Solid Phase Multi-Analyte Assay.” The immunoassays produced by the Psychemedics R&D team were uniquely designed specifically to meet and even exceed the standards of radioimmunoassay (“RIAH”), the original testing method created and utilized by the Company prior to 2013. Because Psychemedics is the only hair testing laboratory that manufactures its own screening assays, it has full control over all aspects of its technology, and that powerful advantage facilitated the Company's creation of its EIA assays with equivalence to its own previously FDA-cleared radioimmunoassays.

 

 

The EIA screened positive results are then confirmed by mass spectrometry. Depending upon the length of hair, the Company is able to provide historical information on drug use by the person from whom the sample was obtained. Because head hair grows approximately 1.3 centimeters per month, a 3.9-centimeter head hair sample can reflect drug ingestion over the approximate three months prior to the collection of the sample. Another option is sectional analysis of the head hair sample, in which the hair is sectioned into lengths which approximately correspond to certain time periods, thereby providing information on patterns of drug use.

 

1
 

 

Validation of the Company’s Proprietary Testing Methods

 

The process of analyzing human hair for the presence of drugs has been the subject of numerous peer-reviewed, scientific field studies. Many of the studies have been funded by the National Institute of Justice or the National Institute on Drug Abuse (“NIDA”). Several hundred research articles written by independent researchers have been published supporting the general validity and usefulness of hair analysis.

 

Some of the Company’s customers have also completed their own testing to validate the Company’s hair test results compared to other companies’ urine test results. These studies consistently confirmed the Company’s superior detection rate compared to urinalysis testing. When results from the Company’s hair testing methods were compared to urine results in side-by-side evaluations, 5 to 10 times as many drug abusers were accurately identified by the Company’s proprietary methods.

 

In 1998, the National Institute of Justice, utilizing Psychemedics’ previously utilized RIAH hair testing assay, completed a Pennsylvania Prison study where hair analysis revealed an average prison drug use level of approximately 7.9% in 1996. Comparatively, urinalysis revealed virtually no positives. After measures to curtail drug use were instituted (drug-sniffing dogs, searches and scanners), the usage level fell to approximately 2% according to the results of hair analysis in 1998. Again, the urine tests showed virtually no positives. The study illustrates the usefulness of hair analysis to monitor populations and the weakness of urinalysis.

 

The Company has received 510k clearance from the FDA on nine EIA assays used to test head and body hair for drugs of abuse.

 

The Company’s decontamination wash protocol and the effects in eliminating surface contamination were analyzed in a study conducted by scientists at the Laboratory of the Federal Bureau of Investigation (the “FBI”) and published in August 2014 in the Journal of Analytical Toxicology. The FBI concluded that the use of an extended wash protocol of the type used by the Company will exclude false positive results from environmental contact with cocaine. In the study, the FBI cited Psychemedics’ studies published in 1993, 2002, 2004, and 2005, and named our Vice President of Laboratory Operations, and our laboratory, in its acknowledgments. The FBI study also supported the use of metabolites known as hydroxycocaines as evidence of ingestion. These metabolites were first identified in hair by Psychemedics.

 

Advantages of Using the Company’s Patented Method

 

The Company asserts that hair testing using its patented method confers substantive advantages over detection through urinalysis. Although urinalysis testing can provide accurate drug use information, the scope of the information is short-term and is generally limited to the type of drug ingested within a few days of the test. Studies published in many scientific publications have indicated that most drugs disappear from urine within a few days.

 

In contrast to urinalysis testing, hair testing using the Company’s patented method can provide long-term historical drug use information resulting in a significantly wider window of detection. This window may be several months or longer depending on the length of the hair sample. The Company’s standard test offering, however, uses a 3.9-centimeter length head hair sample cut close to the scalp, which measures use for approximately three months prior to collection of the sample. 

 

This wider window enhances the detection efficiency of hair analysis, making it particularly useful in pre-employment and random testing. Hair testing not only identifies more drug users, but it may also uncover patterns and severity of drug use (information most helpful in determining the scope of an individual’s involvement with drugs), while serving as a deterrent against drug use. Hair testing employing the Company’s patented method greatly reduces the incidence of “false negatives” associated with evasive measures typically encountered with urinalysis testing. For example, urinalysis test results are adversely impacted by excessive fluid intake prior to testing and by adulteration or substitution of the urine sample. Moreover, a drug user who abstains from use for a few days prior to urinalysis testing can usually escape detection. Hair testing is effectively free of these problems, as it cannot be thwarted by evasive measures typically encountered with urinalysis testing. Hair testing is also attractive to customers since sample collection is typically performed under close supervision yet is less intrusive and less embarrassing for test subjects.

 

Hair testing using the Company’s patented method, along with mass spectrometry confirmation, further reduces the prospects of error in conducting drug detection tests. Urinalysis testing is more susceptible to problems such as “evidentiary false positives” resulting from passive drug exposure or poppy seeds. To combat this problem, in federally mandated testing, the opiate cutoff levels for urine testing were raised 667% (from 300 to 2,000 ng/ml) on December 1, 1998, and testing for the presence of a heroin metabolite, 6-MAM, was required. These requirements, however, effectively reduced the detection time frame for confirmed heroin use, such that 6-MAM in urine can typically only be detected for several hours post drug use. In contrast, the metabolite 6-MAM is stable in hair and can be detected for months.

 

In the event a positive urinalysis test result is challenged, a test on a newly collected urine sample is not a viable remedy. Unless the forewarned individual continues to use drugs prior to the date of the newly collected sample, a re-test may yield a negative result when using urinalysis testing because of temporary abstinence. In contrast, when the Company’s hair testing method is offered on a repeat hair sample, the individual suspected of drug use cannot as easily affect the results because historical drug use data remains locked in the hair fiber.

 

When compared to other hair testing methods, not only are the Company’s assays cleared by the FDA for head and body hair, the assays also employ a unique patented method of digesting hair that the Company believes allows for the most efficient release of drugs from the hair without destroying the drugs. The Company’s method of releasing drugs from hair is a key advantage and results in superior detection rates.

 

2
 

 

Disadvantages of Hair Testing

 

There are some disadvantages of hair testing as compared to drug detection through urinalysis. Because hair starts growing below the skin surface, drug ingestion evidence does not appear in hair above the scalp until approximately five to seven days after use. Thus, hair testing is not suitable for determining drug presence in “for cause” testing as is done in connection with an accident investigation. It does, however, provide a drug history which can complement urinalysis information in “for cause” testing.

 

The Company’s prices for its tests are generally slightly higher than prices for tests using urinalysis, but the Company believes that its superior detection rates provide more value to the customer. This higher pricing policy could, however, adversely impact the growth of the Company’s current base business and failure to obtain new business customers.

 

Hair Alcohol Testing

 

In 2013, the Company launched a test for alcohol using hair. This test measures average alcohol consumption over a period of approximately three months, indicates the approximate level of alcohol use during that time period, and can provide a behavioral indication of excessive use. The test measures the amount of ethyl glucuronide (EtG) in the hair – a trace metabolite of ethanol and a direct alcohol biomarker.

 

Intellectual Property

 

Certain aspects of the hair analysis method currently used by the Company are covered by US and foreign patents owned by the Company. The Company has been granted a total of twelve US patents, including a patent issued to the Company in 2011 that focuses on digesting hair and releasing drugs trapped in the hair without destroying the drugs. This patent can be used with a broad range of immunoassay screen techniques, mass spectrometry methods, and chromatographic procedures. In 2012, the Company received an additional US patent that extended the range of the patent received in 2011. Two US patents related to integrity testing of hair samples issued in 2015 and 2016, and a US patent application directed to detection of multiple analytes was allowed. Additional patent applications are currently pending in the U.S. and internationally. In 2019, US Patent 10,539,580 was issued covering our Solid Phase Multi-Analyte Assay used in all our cleared EIA FDA submissions.

 

The Company also relies on trade secrets to protect certain aspects of its proprietary technology. The Company’s ability to protect the confidentiality of its trade secrets is dependent upon the Company’s internal safeguards and upon the laws protecting trade secrets and unfair competition.

 

In the event that patent protection or protection under the laws of trade secrets is not sufficient and the Company’s competitors succeed in duplicating the Company’s products, the Company’s business could be materially adversely affected.

 

Target Markets

 

Workplace

 

The Company focuses its primary marketing efforts on the domestic private sector, with particular emphasis on job applicants and employee testing.

 

Most businesses use drug testing to screen job applicants and employees. The Hazeldon Foundation survey from 2007 indicated that 85% of Human Resource (“HR”) professionals believe that drug testing is an effective way to identify substance abuse. The prevalence of drug screening programs reflects a concern that drug use contributes to employee health problems and costs. As the same study found that 62% of HR professionals believe that absenteeism is the most significant problem caused by substance abuse and addiction, followed at 49% by reduced productivity, a lack of trustworthiness at 39%, a negative impact on the company’s external image at 32%t, missed deadlines at 31%, and in certain industries, safety hazards. It has been estimated that substance abuse costs to American businesses is more than $100 billion annually.

 

The principal criticism of employee drug testing programs centers on the effectiveness of the testing program. Most private sector testing programs use urinalysis. Such programs are susceptible to evasive maneuvers and the inability to obtain confirmation through repeat samples in the event of a challenged result. An industry has developed over the Internet, and through direct mail, marketing a wide variety of adulterants, dilutants, clean urine and devices to assist drug users in falsifying urine test results.

 

Moreover, scheduled tests such as pre-employment testing and some random testing programs provide an opportunity for many drug users to simply abstain for a few days in order to escape detection by urinalysis.

 

The Company presents its patented hair analysis method to potential clients as a better technology well suited to employer needs. Field studies and actual client results support the accuracy and superior effectiveness of the Company’s patented technology and its ability to detect varying levels of drug use.

 

The Company performs a confirmation test of all screened positive results through mass spectrometry. The use of mass spectrometry is an industry accepted practice used to confirm a positive test result from the screening process. The Company offers its clients an expanded drug screen with mass spectrometry confirmation of cocaine, PCP, marijuana, amphetamines, alcohol, opiates, synthetic cannabinoids and benzodiazepines.

 

3
 

 

Schools

 

The Company currently serves hundreds of schools throughout the United States and in several foreign countries. The Company offers its school clients the same five-drug screen with mass spectrometry confirmation that is used with the Company’s workplace testing service.

 

Parents

 

The Company also offers a personal drug testing service, known as “PDT-90”®, for parents concerned about drug use by their children. It allows parents to collect a small sample of hair from their child in the privacy of the home, send it directly to the Company’s laboratory and have it tested for drugs of abuse by the Company. The PDT-90 testing service uses the same patented method that is used with the Company’s workplace testing services.

 

Research

 

The Company is involved in the following ongoing studies involving use of drugs of abuse in various populations: In 2017, the Company partnered with an NIH-funded study titled “Adolescent Brain Cognitive Development” (“ABCD”) which expects to enroll 12,000 youths age 9-10 over a 2-2.5 year recruitment period. The objective of the ABCD consortium is to establish a national, multisite, longitudinal cohort and database by studying youth prospectively in order to examine brain and cognitive development in children and adolescents through a period (10 years) when significant development of intellectual and emotional functions occurs. Psychemedics’ role in this study is to test hair to detect use of drugs over the time period. The Company is also partnering with Olin Neuropsychiatry Research Center Institute of Living Hartford Hospital in a research study entitled, “Neurochemical and Functional Correlates of Memory in Emerging Adult Marijuana Users.” The study is aiming to better characterize the impact of heavy marijuana use on memory and is funded by a grant from NIDA.

 

Geographic Scope

 

Revenues outside the United States were 3%, 5%, and 9% of consolidated revenues for years ended, 2022, 2021 and 2020, respectively.

 

Distribution

 

The Company markets its corporate drug testing services through its own sales force, distributors and webinars. The Company markets its home drug testing service, PDT-90®, through the Internet.

 

Significant Customers and Concentration of Credit Risk

 

The Company had no customers that represented 10% or more of total revenue for the years ended December 31, 2022, 2021 and 2020, respectively. The Company had one customer that represented 11% and 12% of the total accounts receivable balance as of December 31, 2022 and 2021, respectively.

 

The Company maintains its cash in a bank account at one of the largest financial institutions in the U.S. The individual balance, at times, may exceed federally insured limits. These deposits may be redeemed upon demand, and the Company believes that the financial institution that holds the Company’s cash is financially sound and, accordingly, minimal credit risk exists with respect to cash.

 

Competition

 

The Company competes directly with numerous commercial laboratories that test for drugs primarily through urinalysis testing. Most of these laboratories, such as Quest Diagnostics, have substantially greater financial resources, market identity, drug testing market share, marketing organizations, facilities, and more personnel than the Company. Psychemedics has developed a strong base of corporate customers and believes that future success with new business customers is dependent on the Company’s ability to communicate the advantages of implementing a drug program utilizing the Company’s patented hair analysis method.

 

The Company’s ability to compete is also a function of pricing. The Company’s prices for its tests are generally slightly higher than prices for tests using urinalysis. However, the Company believes that its superior detection rates, coupled with the customer’s ability to test less frequently due to hair testing’s wider window of detection (three months versus approximately three days with urinalysis), provide more value to the customer. This pricing policy could, however, lead to slower volume growth for the Company.

 

The Company also competes with other hair testing laboratories. The Company distinguishes itself from hair testing competitors by emphasizing the superior results the Company obtains through use of its unique patented extraction method in combination with the Company’s FDA cleared immunoassay screen.

 

Government Regulation

 

The Company is licensed as a clinical laboratory by the State of California as well as certain other states. All tests are performed according to the laboratory standards established by the Department of Health and Human Services, through the Clinical Laboratories Improvement Amendments, and various state licensing statutes.

 

4
 

 

A substantial number of states regulate drug testing. The scope and nature of such regulations varies greatly from state to state and is subject to change from time to time. The Company addresses state law issues on an ongoing basis.

 

The Federal Food, Drug and Cosmetic Act, as amended, requires companies engaged in the business of testing for drugs of abuse using a test (screening assay) not previously recognized by the FDA to submit their assay to the FDA for recognition prior to marketing. In addition, the laboratory performing the tests is required to be certified by a recognized agency. In 2002, the Company received 510k clearance to market all five of its assays utilizing RIAH technology.

 

In 2008, the Company received the first College of American Pathologists certification specifically including hair testing.

 

In 2011, the Company received ISO/IEC 17025 International Accreditation for a broad spectrum of laboratory testing including drugs of abuse and forensics in hair and urine specimens. ISO/IEC 17025 accreditation provides formal recognition to laboratories that demonstrate technical competency and maintains this recognition through periodic evaluations to ensure continued compliance.

 

In 2012, the Company received 510k clearance from the FDA to market five of its assays utilizing the Company’s custom developed EIA technology.

 

In 2013, the Company received 510k clearance from the FDA to market two additional assays utilizing the Company’s custom developed EIA technology.

 

In 2016, the Company received accreditation from the Standards Council of Canada as an accredited testing laboratory.

 

In 2017, the Company received 510k clearance from the FDA to market one additional assay utilizing the Company’s custom developed EIA technology.

 

In 2019, the Company received 510k clearance from the FDA to market one additional assay utilizing the Company’s custom developed EIA technology.

 

Research and Development

 

The Company is continuously engaged in research and development activities. During the years ended December 31, 2022, 2021 and 2020, $1.3 million, $1.1 million and $1.3 million, respectively, were expended for research and development. The Company continues to perform research activities to develop new products and services and to improve existing products and services utilizing the Company’s proprietary technology. The Company also continues to evaluate methodologies to enhance its drug screening capabilities. Additional research using the Company’s proprietary technology is being conducted by outside research organizations through government-funded studies.

 

Employees

 

As of December 31, 2022, the Company employed 133 employees, 3 of whom were in R&D. None of the Company’s employees are subject to a collective bargaining agreement and the Company believes that overall relations with employees are good.

 

5
 

 

Item 1A. Risk Factors

 

In addition to other information contained in this Form 10-K, the following risk factors should be carefully considered in evaluating Psychemedics Corporation and its business because such factors could have a significant impact on our business, operating results, and financial condition. Additional risks not presently known to the Company, or that it presently deems immaterial, may also negatively impact the Company. These risk factors could cause actual results to materially differ from those projected in any forward-looking statements.

 

 

Risks Related to Our Business and Operations

 

The ongoing COVID-19 pandemic may continue to adversely affect our business, results of operation and financial condition.

 

The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business. Fluctuations in the number of COVID-19 cases may have a negative effect on the Company's business and financial performance. Given the continued unpredictability pertaining to the COVID-19 pandemic, the impact on the Company's business continues to be uncertain and depends on a number of evolving factors that the Company may not be able to predict or effectively respond to. These factors include: the timing, extent, trajectory, and duration of any pandemic; increases in COVID-19 infection rates and the geographic location of such increases; the development, availability, distribution and effectiveness of vaccines and treatments; the imposition of protective public safety measures; and the impact of any pandemic on supply chain and the global economy. To the extent the COVID-19 pandemic or any future pandemic adversely affects our business, results of operations and financial condition, it may also have the effect of heightening other risks.

 

The Company incurred additional costs to implement operational changes in response to this pandemic. The COVID-19 pandemic disrupted, and along with other economic factors, a resurgence in COVID-19 could continue to disrupt, the Company’s supply chain, including its ability to secure test collection and testing supplies and equipment and personal protective equipment for its employees.

 

Companies may develop products that compete with our products and some of these companies may be larger and better capitalized than we are.

 

Many of our competitors and potential competitors are larger and have greater financial resources than we do and offer a range of products broader than our products. Some of the companies with which we now compete or may compete in the future may develop more extensive research and marketing capabilities and greater technical and personnel resources than we do and may become better positioned to compete in an evolving industry. Inability to compete successfully could harm our business and prospects.

 

Increased competition, including price competition, could have a material impact on the Company’s net revenues and profitability.

 

Our business is intensely competitive, both in terms of price and service. Pricing of drug testing services is a significant factor often considered by customers in selecting a drug testing laboratory. Larger clinical laboratory providers can increase cost efficiencies afforded by large-scale automated testing. This results in greater price competition. The Company may be unable to increase cost efficiencies sufficiently, if at all, and as a result, its net earnings and operating cash flows could be negatively impacted by such price competition. The Company may also face increased competition from companies that do not comply with existing laws or regulations or otherwise disregard compliance standards in the industry. Additional competition, including price competition, could have a material adverse impact on the Company’s net revenues and profitability.

 

Inflationary pressures on the costs of direct materials, supplies, and personnel expenses could have a material impact on the Company’s gross profit and profitability.

 

Inflationary pressures have resulted in increases in the costs of shipping charges, supplies, and other services that we purchase from vendors, suppliers, and others. Inflationary pressures, along with the competition for labor, have also resulted in an increase of our labor costs, which include the costs of compensation, benefits, and other employee-related expenses. Continuation of the current inflationary environment may adversely impact the Company.

 

Our results of operations are subject in part to variation in our customers’ hiring practices and other factors beyond our control.

 

Our results of operations have been and may continue to be subject to variation in our customers’ hiring practices and job creation, which in turn is dependent, to a large extent, on the general condition of the economy, especially within our major market segments. Results for a particular quarter may vary due to several factors, including but not limited to:

 

 

•

economic conditions in our markets in general;

 

 

•

economic conditions affecting our customers and their particular industries;

 

 

•

the introduction of new products and product enhancements by us or our competitors; and

 

 

•

pricing and other competitive conditions.

 

6
 

 

A failure to obtain and retain new customers, or a loss of existing customers, or a reduction in tests ordered, could impact the Company’s ability to successfully grow its business.

 

The Company needs to obtain and retain new customers. In addition, a reduction in tests ordered, without offsetting growth in its customer base, could impact the Company’s ability to successfully grow its business and could have a material adverse impact on the Company’s net revenues and profitability. We compete primarily based on the quality of testing, timeliness of results, reputation in the industry, the pricing of services and ability to employ qualified personnel. The Company’s failure to successfully compete on any of these factors could result in the loss of customers and a reduction in the Company’s ability to expand its customer base.

 

Our business could be harmed if we are unable to protect our technology.

 

We rely primarily on a combination of trade secrets, patents and trademark laws and confidentiality procedures to protect our technology. Despite these precautions, unauthorized third parties may infringe or copy portions of our technology. In addition, because patent applications in the United States are not publicly disclosed until either: (1) 18 months after the application filing date or (2) the publication date of an issued patent wherein applicant(s) seek only US patent protection, applications not yet disclosed may have been filed which relate to our technology. Moreover, there is a risk that foreign intellectual property laws will not protect our intellectual property rights to the same extent as United States intellectual property laws. In the absence of the foregoing protections, we may be vulnerable to competitors who attempt to copy our products, processes or technology.

 

Our business could be affected by IT system failures or Cybersecurity breaches.

 

A computer or IT system failure could affect our ability to perform tests, report test results or properly bill customers for services performed. Failures could occur as a result of the standardization of our IT systems and other system conversions, telecommunications failures, malicious human acts (such as electronic break-ins or computer viruses) or natural disasters. Sustained system failures or interruption of the Company’s systems in one or more of its operations could disrupt the Company’s ability to process and provide test results in a timely manner and/or bill the appropriate party. Failure of the Company’s information systems could adversely affect the Company’s business, profitability and financial condition.

 

Our technologies, systems and networks may be subject to cybersecurity breaches. Although we have experienced occasional, actual or attempted breaches of our cybersecurity, none of these breaches has had a material effect on our business, operations or reputation. If our systems for protecting against cybersecurity risks prove to be insufficient, we could be adversely affected by having our business systems compromised, our proprietary information altered, lost or stolen, or our business operations disrupted. As cyber-attacks continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information systems and related infrastructure security vulnerabilities.

 

In addition, certain third parties to whom we outsource our services and functions, or with whom we interface, store our confidential patient data or other confidential information as also subject to the same IT risks. A breach or attack affecting these outsourced third parties could negatively impact our business.

 

Failure to maintain confidential information could result in a significant financial impact.

 

The Company maintains confidential information regarding the results of drug tests and other information including credit card and payment information from our customers. The failure to protect this information could result in lawsuits, fines or penalties. Any loss of data or breach of confidentiality, such as through a computer security breach, could expose the Company to a financial liability.

 

Adverse results in material litigation could have an adverse financial impact and an adverse impact on our client base and reputation.

 

We are or may in the future become subject to a variety of litigation and legal proceedings relating to, among other things: corporate matters; commercial matters; financial and securities regulations; and employment matters. These proceedings may result in substantial monetary damages. Results of legal and regulatory proceedings cannot be predicted with certainty and for some matters, such as class actions, no insurance is cost-effectively available. Regardless of merit, legal and regulatory proceedings may be both time-consuming and disruptive to our operations and could divert the attention of our management and key personnel from our business operations. We estimate loss contingencies and establish accruals as required by generally accepted accounting principles, based on our assessment of contingencies where liability is deemed probable and reasonably estimable, in light of the facts and circumstances known to us at a particular point in time.

 

We are subject to, and could be further subject to, governmental investigations or actions by other third parties.

 

We are subject to various federal and state laws, including employment laws and regulations, violations of which can involve civil or criminal sanctions. Responding to governmental investigations or other actions may be both time-consuming and disruptive to our operations and could divert the attention of our management and key personnel from our business operations.

 

Our future success will depend on the continued service of our key employees.

 

Our people are a critical resource. The loss of any of our key personnel, including our Chief Executive Officer, executive team and other highly skilled employees, could harm our business and prospects. We may not be able to attract and retain personnel necessary for the development of our business. We do not have key personnel under contract other than 3 officers who have agreements providing for severance and non-compete covenants in the event of termination of employment following a change of control. Further, we do not have any key man life insurance for any of our officers or other key personnel.

 

7
 

 

There is a risk that our insurance will not be sufficient to protect us from errors and omissions liability or other claims, or that in the future errors and omissions insurance will not be available to us at a reasonable cost, if at all.

 

Our business involves the risk of claims of errors and omissions and other claims inherent to our business. We maintain errors and omissions and general liability insurance subject to deductibles and exclusions. There is a risk that our insurance will not be sufficient to protect us from all such possible claims. An under-insured or uninsured claim could harm our operating results or financial condition.

 

Our research and development capabilities may not produce viable new services or products.

 

In order to remain competitive, we need to continually improve our products, develop new technologies to replace older technologies that have either become obsolete or for which patent protection is has expired. It is uncertain whether we will continually be able to develop services that are more efficient, effective or that are suitable for our customers. Our ability to create viable products or services depends on many factors, including the implementation of appropriate technologies, the development of effective new research tools, the complexity of the chemistry and biology, the lack of predictability in the scientific process and the performance and decision-making capabilities of our scientists. There is no guarantee that our research and development teams will be successful in developing improvements to our technology.

 

Improved testing technologies, or the Company’s customers using new technologies to perform their own tests, could adversely affect the Company’s business.

 

Advances in technology may lead to the development of more cost-effective technologies that can be operated by third parties or customers themselves in their own offices, without requiring the services of a freestanding laboratory. Development of such technology and its use by the Company’s customers could reduce the demand for its testing services and negatively impact our revenues.

 

We may not be able to recruit and retain the experienced scientists and management we need to compete in our industry.

 

Our future success depends upon our ability to attract, retain and motivate highly skilled scientists and management. Our ability to achieve our business strategies depends on our ability to hire and retain high caliber scientists and other qualified experts. We compete with other testing companies, research companies and academic and research institutions to recruit personnel and face significant competition for qualified personnel. We may incur greater costs than anticipated, or may not be successful, in attracting new scientists or management or in retaining or motivating our existing personnel.

 

Our future success also depends on the personal efforts and abilities of the principal members of our senior management and scientific staff to provide strategic direction, to manage our operations and maintain a cohesive and stable environment.

 

Our facilities and practices may fail to comply with government regulations.

 

Our testing facilities and processes must be operated in conformity with current government regulations. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. If we fail to comply with these requirements, we may not be able to continue our services to certain customers, or we could be subject to fines and penalties, suspension of production, or withdrawal of our certifications. We operate a facility that we believe conforms to all applicable requirements. This facility and our testing practices are subject to periodic regulatory inspections to ensure compliance.

 

Our business could be harmed from the loss or suspension of any licenses.

 

The forensic laboratory testing industry is subject to significant regulation and many of these statutes and regulations are subject to change. The Company cannot assure that applicable statutes and regulations will not be interpreted or applied by a regulatory authority in a manner that would adversely affect its business. Potential sanctions for violation of these regulations could include the suspension or loss of various licenses, certificates and authorizations, which could have a material adverse effect on the Company’s business. In addition, potential delays in renewals of licenses could also harm the Company.

 

If our use of chemical and hazardous materials violates applicable laws or regulations or causes personal injury, we may be liable for damages.

 

Our drug testing activities, including the analysis and synthesis of chemicals, involve the controlled use of chemicals, including flammable, combustible, and toxic materials that are potentially hazardous. Our use, storage, handling and disposal of these materials is subject to federal, state and local laws and regulations, including the Resource Conservation and Recovery Act, the Occupational Safety and Health Act and local fire codes, and regulations promulgated by the Department of Transportation, the Drug Enforcement Agency, the Department of Energy, and the California Department of Public Health and Environment. We may incur significant costs to comply with these laws and regulations in the future. In addition, we cannot completely eliminate the risk of accidental contamination or injury from these materials, which could result in material unanticipated expenses, such as substantial fines or penalties, remediation costs or damages, or the loss of a permit or other authorization to operate or engage in our business. Those expenses could exceed our net worth and limit our ability to raise additional capital.

 

8
 

 

Our operations could be interrupted by damage to our laboratory facilities.

 

Our operations are dependent upon the continued use of our laboratories and equipment in Culver City, California. Catastrophic events, including earthquakes, fires or explosions, could damage our laboratories, equipment, scientific data, work in progress or inventories of chemicals and may materially interrupt our business. We employ safety precautions in our laboratory activities in order to reduce the likelihood of the occurrence of certain catastrophic events; however, we cannot eliminate the chance that such events will occur. Rebuilding our facilities could be time consuming and result in substantial delays in fulfilling our agreements with our customers. We maintain business interruption insurance to cover continuing expenses and lost revenue caused by such occurrences. However, this insurance does not compensate us for the loss of opportunity and potential harm to customer relations that our inability to meet our customers’ needs in a timely manner could create.

 

Agreements we have with our employees, consultants and customers may not afford adequate protection for our trade secrets, confidential information and other proprietary information.

 

In addition to patent protection, we also rely on copyright and trademark protection, trade secrets, know-how, continuing technological innovation and licensing opportunities. In an effort to maintain the confidentiality and ownership of our trade secrets and proprietary information, we require our employees, consultants and advisors to execute confidentiality and proprietary information agreements. However, these agreements may not provide us with adequate protection against improper use or disclosure of confidential information and there may not be adequate remedies in the event of unauthorized use or disclosure. Furthermore, we may from time to time hire scientific personnel formerly employed by other companies involved in one or more areas similar to the activities we conduct. In some situations, our confidentiality and proprietary information agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants or advisors have prior employment or consulting relationships. Although we require our employees and consultants to maintain the confidentiality of all proprietary information of their previous employers, these individuals, or we, may be subject to allegations of trade secret misappropriation or other similar claims as a result of their prior affiliations. Finally, others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets. Our failure or inability to protect our proprietary information and techniques may inhibit or limit our ability to compete effectively or exclude certain competitors from the market.

 

International trade policies may impact demand for our products and our competitive position.

 

Government policies on international trade and investment such as import quotas, capital controls or tariffs, whether adopted by individual governments or addressed by regional trade blocs, can affect the demand for our services, impact the competitive position of our products or prevent us from being able to sell products in certain countries. The implementation of more restrictive trade policies, such as more detailed inspections, higher tariffs or new barriers to entry, could negatively impact our business, results of operations and financial condition. For example, a government’s adoption of “buy national” policies or retaliation by another government against such policies could have a negative impact on our results of operations.

 

Global operations are subject to extensive trade and anti-corruption laws and regulations.

 

The U.S. Foreign Corrupt Practices Act and similar foreign anti-corruption laws generally prohibit companies and their intermediaries from making improper payments or providing anything of value to improperly influence foreign government officials for the purpose of obtaining or retaining business or obtaining an unfair advantage. Recent years have seen a substantial increase in the global enforcement of anti-corruption laws. Our operations outside the United States could increase the risk of such violations. Violations of anti-corruption laws or regulations by our employees or by intermediaries acting on our behalf may result in severe criminal or civil sanctions, could disrupt our business, and result in an adverse effect on our business and results of operations or financial condition.

 

Our approach to environmental, social, and governance (ESG) matters may not satisfy all our stakeholders.

 

We assess opportunities and risks related to environmental, social and governance (ESG) matters. As part of this process, we may make decisions related to ESG matters and may set goals and targets related to ESG matters. We have a broad range of stakeholders, including our stockholders, employees, schools, and communities we serve, some of whom increasingly focus on ESG matters. Certain stakeholders may not be satisfied with our decisions related to ESG matters, the goals we set regarding ESG matters, our progress towards these goals or the resulting outcomes. This could lead to negative perceptions of, or loss of support for our business, difficulty recruiting or attracting new employees and our stock price being negatively impacted.

 

Risks Related to Our Stock

 

Our quarterly operating results could fluctuate significantly, which could cause our stock price to decline.

 

Our quarterly operating results have fluctuated in the past and are likely to fluctuate in the future. Our results are impacted by the extent to which we are able to gain new customers, competitive pricing, and on the hiring practices of our existing customers, including seasonality. Demand for drug testing can be impacted by changes in government requirements regarding testing for drugs of abuse, delays in implementation of such requirements, as well as general economic conditions. Entering into new customer contracts can involve a long lead time. Accordingly, negotiation can be lengthy and is subject to a number of significant risks, including customers’ budgetary constraints and internal reviews. Due to these and other market factors, our operating results could fluctuate significantly from quarter to quarter. In addition, we may experience significant fluctuations in quarterly operating results due to factors such as general and industry-specific economic conditions that may affect the budgets and the hiring practices of our customers.

 

Due to the possibility of fluctuations in our revenue and expenses, we believe that quarter-to-quarter comparisons of our operating results are not necessarily a good indication of our future performance. Our operating results in some quarters may not meet the expectations of stock market analysts and investors. If we do not meet analysts’ or investors’ expectations, our stock price could decline.

 

9
 

 

Payment of a cash dividend could decline or cease.

 

With some interruptions during the COVID pandemic, the Company has historically paid cash dividends. Any cessation of our program or reduction in our cash dividend could affect our stock price. If we cease this practice or reduce the amount of the regular cash dividend, due to operating or economic conditions, our stock price could suffer. Further, if the Company ceases its future cash dividends, a return on investment in our common stock would depend entirely upon future appreciation. There is no guarantee that our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.

 

Our stock price could experience substantial volatility.

 

The market price of our common stock has historically experienced and may continue to experience extensive volatility. Our quarterly operating results, the success or failure of future development efforts, changes in general conditions in the economy or the financial markets and other developments affecting our customers, our distributors, our competitors or us could cause the market price of our common stock to fluctuate substantially. This volatility may adversely affect the price of our common stock. In the past, securities class action litigation has often been instituted following periods of volatility in the market price of a company’s securities. A securities class action suit against us could result in potential liabilities, substantial costs and the diversion of management’s attention and resources, regardless of whether we win or lose.

 

Item 1B. Unresolved Staff Comments

 

Not applicable.

 

Item 2. Properties

 

The Company maintains its corporate office at 289 Great Road, Acton, Massachusetts, 01720; the office consists of six thousand square feet and is leased through February 2024.

 

The Company leases two facilities for laboratory testing purposes in Culver City, California. The first is fourteen thousand square feet of space with an additional ten thousand square feet of storage space. This facility is leased through December 2024. The second facility of sixteen thousand square feet is leased through March 2025.

 

Item 3. Legal Proceedings

 

Information pertaining to legal proceedings can be found in Item 8. Financial Statements and Supplementary Data Note 9 - “Commitments and Contingencies” to the Consolidated Financial Statements included in this Annual Report.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

 

 

10
 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities

 

The Company’s common stock is traded on the NASDAQ Stock Market under the symbol “PMD”. As of March 15, 2023, there were 157 record holders of the Company’s common stock. The number of record owners was determined from the Company’s stockholder records maintained by the Company’s transfer agent and does not include beneficial owners of the Company’s common stock whose shares are held in the names of various security holders, dealers and clearing agencies. The Company believes that the number of beneficial owners of the Company’s common stock held by others as or in nominee names exceeds 3,100.

 

The following table sets forth for the periods indicated the range of prices for the Company’s common stock as reported by the NASDAQ Stock Market and cash dividends declared by the Company.

 

   

High

    

Low

    

Dividends

  

Fiscal 2022:

                        

First Quarter

   $ 7.77     $ 6.25     $ -  

Second Quarter

     7.21       6.01       0.07  

Third Quarter

     6.94       6.05       0.07  

Fourth Quarter

     6.70       4.85       0.07  

Fiscal 2021:

                        

First Quarter

   $ 7.90     $ 4.95     $ -  

Second Quarter

     8.36       6.20       -  

Third Quarter

     8.60       8.05       -  

Fourth Quarter

     8.90       6.76       0.05  

 

The Company most recently declared a cash dividend of $0.07 per share on March 21, 2023, which will be paid on April 10, 2023.

 

Issuer Purchases of Equity Securities

 

During 2022, the Company did not repurchase any common shares for treasury.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

There were no unregistered sales of common stock of the Company during 2022.

 

 

 

 

11
 

 

Performance Graph

 
perf_graph.jpg

 

 

Calculated by the Company using www.yahoo.com/finance historical prices.

 

     

2017

    

2018

    

2019

    

2020

    

2021

    

2022

  

PMD

PSYCHEMEDICS CORPORATION

     100.00       80.54       51.36       32.49       42.12       32.83  

Russell 2000

RUSSELL 2000 INDEX

     100.00       87.82       108.66       128.61       146.23       114.70  

NASDAQ

NASDAQ COMPOSITE INDEX

     100.00       96.12       129.97       186.69       226.63       151.61  

 

(1)

The above graph assumes a $100 investment on December 31, 2017, through the end of the 5-year period ended December 31, 2022, in the Company’s Common Stock, the Russell 2000 Index and the NASDAQ Composite Index. The prices all assume the reinvestment of cash dividends.

 

(2)

The Russell 2000 Index is composed of the smallest 2,000 companies in the Russell 3,000 Index. The Company has been unable to identify a peer group of companies that engage in testing of drugs of abuse, except for large pharmaceutical companies where such business is insignificant to such companies’ other lines of businesses. The Company therefore uses in its proxy statements a peer index based on market capitalization.

 

(3)

The NASDAQ Composite Index includes companies whose shares are traded on the NASDAQ Stock Market.

 

Item 6. Reserved

 

 

 

 

 

12
 

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read together with the more detailed business information and financial statements and related notes that appear elsewhere in this annual report on Form 10-K. This annual report may contain certain “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. This information involves risks and uncertainties. Actual results may differ materially from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in Item 1A — Risk Factors.

 

Overview

 

Psychemedics Corporation is the world’s largest provider of hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company’s customers include Fortune 500 companies, as well as small to mid-size corporations, schools, and governmental entities, located in the United States and internationally. During the year ended December 31, 2022, the Company’s revenues were $25.2 million, an increase of 1% from $24.9 million in 2021. The increase was due to higher organic growth in the Company’s largest market segment offset by a decline in Brazil revenues, including the Brazil driver license business.

 

Under the provisions of the CARES Act signed into law on March 27, 2020, and the subsequent extension of the CARES Act, the Company was eligible for a refundable employee retention credit subject to certain criteria through the fiscal year ended December 31, 2021. The Company recognized $2.6 million of employee retention credits during fiscal year 2021 of which $1.8 million was included in cost of revenues and $0.8 million in operating expenses in the statement of operations.

 

As the Company has disclosed previously, most recently in its Quarterly Report on Form 10-Q in the third quarter of 2022, the Company’s Board of Directors authorized the Company to explore shareholder enhancement opportunities, including strategic alternatives, such as the potential sale or merger of the Company, capitalization optimization and cash dividend strategies. Management and the Board of Directors are committed to continuing to evaluate all avenues for enhancing shareholder value. There can be no assurances that the shareholder enhancement review process will result in a transaction or other strategic change or outcome. The Company has not set a timetable for the conclusion of its review of strategic alternatives, and it does not intend to comment further unless and until the Board has approved a specific course of action or the Company has otherwise determined that further disclosure is appropriate or required by law. The Company’s Board of Directors has designated a subcommittee of the Board to review shareholder enhancement opportunities. The Company has retained investment banking firms and corporate transaction legal advisors in connection with its exploration of shareholder enhancement opportunities.

 

The following table sets forth, for the periods indicated, the selected statements of operations data as a percentage of total revenue:

 

   

Year Ended December 31,

  
   

2022

    

2021

    

2020

  

Revenues

     100.0 %     100.0 %     100.0 %

Cost of revenues

     63.2 %     58.8 %     77.1 %

Gross profit

     36.8 %     41.2 %     22.9 %

Operating Expenses:

                        

General & administrative

     23.2 %     24.6 %     28.5 %

Marketing & selling

     12.6 %     11.3 %     16.7 %

Research & development

     5.3 %     4.5 %     6.0 %

Total Operating Expenses

     41.1 %     40.4 %     51.2 %

Operating (loss) income

     -4.3 %     0.8 %     -28.3 %
                         

Other Income (Expense):

                        

Gain on forgiveness of PPP Loan

     0.0 %     8.8 %     0.0 %

Settlements

     0.0 %     -12.6 %     0.0 %

Other income (expense)

     0.2 %     -0.2 %     -0.7 %

Total Other Income (Expense)

     0.2 %     -4.0 %     -0.7 %
                         

Net loss before provision for (benefit from) income taxes

     -4.1 %     -3.2 %     -29.0 %

Provision for (benefit from) income taxes

     0.2 %     -0.6 %     -11.0 %

Net loss

     -4.3 %     -2.6 %     -18.0 %

 

 

13
 

 

Revenue by Geographic Region

 

   

Year Ended December 31,

  
   

2022

    

2021

    

2020

  

Consolidated Revenue:

                        

United States

   $ 24,509     $ 23,584     $ 19,486  

International

     731       1,325       1,874  

Total Revenue

   $ 25,240     $ 24,909     $ 21,360  

 

Results for the Year Ended December 31, 2022, Compared to Results for the Year Ended December 31, 2021 (in thousands)

 

   

2022

    

2021

    

Change

    

%

  

Revenues

   $ 25,240     $ 24,909     $ 331       1 %

Cost of revenues

     15,949       14,645       1,304       9 %

Gross profit

     9,291       10,264       ( 973 )     -9 %

Operating Expenses:

                                

General & administrative

     5,857       6,126       ( 269 )     -4 %

Marketing & selling

     3,191       2,799       392       14 %

Research & development

     1,326       1,130       196       17 %

Total Operating Expenses

     10,374       10,055       319       3 %

Operating (loss) income

     ( 1,083 )     209       ( 1,292 )     -618 %
                                 

Other Income (Expense):

                                

Gain on forgiveness of PPP Loan

     -       2,181       ( 2,181 )     -100 %

Settlements

     -       ( 3,150 )     3,150       -100 %

Other income (expense)

     43       ( 61 )     104       -170 %

Total Other Income (Expense)

     43       ( 1,030 )     1,073       -104 %
                                 

Net loss before provision for (benefit from) income taxes

     ( 1,040 )     ( 821 )     ( 219 )     27 %

Provision for (benefit from) income taxes

     44       ( 156 )     200       -128 %

Net loss

   $ ( 1,084 )   $ ( 665 )   $ ( 419 )     63 %

 

Revenue: The revenue increase of 1% was primarily due to a 6% increase in average revenue per sample, offset by a 5% decrease in volume. Domestic revenues increased by 4% compared to the prior year period, due to an increase in average revenue per sample with similar volumes. International revenues decreased by 45% compared to the prior year period, due to decline in volume from unfavorable market forces in Brazil. See geographic breakdown of revenue above. The Company does not expect any material change in its Brazil driver license business as this market continues to be considerably uncertain.

 

Gross profit: The 9% decrease in gross profit was due to an increase in personnel and related costs, which was primarily due to the recognition of the refundable Employee Retention Tax Credits in 2021.

 

General and administrative (“G&A”) expenses: G&A expenses decreased 4% from 2021 to 2022, primarily driven by reductions in legal expenses related to lawsuit settlements and the exploration of possible strategic alternatives in the prior year. The decrease was also attributed to lower professional fees related to the employee retention tax credit recognized in 2021. As a percentage of revenue, G&A expenses represented 23.2% in 2022 compared to 24.6% in 2021.

 

Marketing and selling expenses: Marketing and selling expenses increased 14% from 2021 to 2022, primarily driven by higher personnel costs due to the employee retention tax credit recognized in 2021. As a percentage of revenue, marketing and selling expenses represented 12.6% in 2022 compared to 11.3% in 2021.

 

Income Taxes: During the year ended December 31, 2022, the Company recorded a tax expense of $0.04 million representing a tax rate of (4%) compared to a tax rate of 19% in 2021. For information regarding additional matters related to our taxes, please see Note 5 — "Income Taxes" to the Consolidated Financial Statements included in this Annual Report.

 

 

14
 

 

Results for the Year Ended December 31, 2021, Compared to Results for the Year Ended December 31, 2020 (in thousands)

 

   

2021

    

2020

    

Change

    

%

  

Revenues

   $ 24,909     $ 21,360     $ 3,549       17 %

Cost of revenues

     14,645       16,474       ( 1,829 )     -11 %

Gross profit

     10,264       4,886       5,378       110 %

Operating Expenses:

                                

General & administrative

     6,126       6,095       31       1 %

Marketing & selling

     2,799       3,577       ( 778 )     -22 %

Research & development

     1,130       1,280       ( 150 )     -12 %

Total Operating Expenses

     10,055       10,952       ( 897 )     -8 %

Operating income (loss)

     209       ( 6,066 )     6,275       103 %
                                 

Other (Expense) Income:

                                

Gain on forgiveness of PPP Loan

     2,181       -       2,181       100 %

Settlements

     ( 3,150 )     -       ( 3,150 )     100 %

Other expense

     ( 61 )     ( 140 )     79       -56 %

Total Other (Expense) Income

     ( 1,030 )     ( 140 )     ( 890 )     636 %
                                 

Net loss before benefit from income taxes

     ( 821 )     ( 6,206 )     5,385       -87 %

Benefit from income taxes

     ( 156 )     ( 2,347 )     2,191       -93 %

Net loss

   $ ( 665 )   $ ( 3,859 )   $ 3,194       -83 %

 

Revenue: The revenue increase of 17% was primarily due to a 9% increase in volume, compounded by an 8% increase in average revenue per sample, primarily as a result of business mix and increased domestic volumes. Domestic revenues increased by 21% compared to the prior year period, due to an increase in volume and growth in the base business. International revenues decreased by 29% from 2020 to 2021, due to decline in volume from unfavorable market forces in Brazil and the COVID-19 pandemic. See geographic breakdown of revenue above. The Company does not expect any material change in its Brazil driver license business as this market continues to be considerably uncertain.

 

Gross profit: The 110% increase in gross profit was due to higher sales volume and lower personnel costs. Higher volume and lower personnel costs was the primary factor in the gross profit percentage increase from 23% in 2020 to 41% in 2021. The decrease in lower labor and related costs was primarily due to the recognition of the refundable employee retention tax credits in 2021 and the retention of certain laboratory employees during 2020, to qualify for PPP Loan forgiveness with no offsetting proportional revenue.

 

General and administrative (“G&A”) expenses: G&A expenses increased 1% from 2020 to 2021, primarily driven by higher legal expenses related to the exploration of possible strategic alternatives in an effort to enhance shareholder value. As a percentage of revenue, G&A expenses represented 24.6% in 2021 compared to 28.5% in 2020.

 

Marketing and selling expenses: Marketing and selling expenses decreased 22% from 2020 to 2021, primarily driven by cost reduction initiatives; specifically, lower personnel related costs (including less travel and meals) and in addition refundable employee retention tax credits. As a percentage of revenue, marketing and selling expenses represented 11.3% in 2021 compared to 16.7% in 2020.

 

Income Taxes: During the year ended December 31, 2021, the Company recorded a tax benefit of $0.2 million representing a tax rate of 19% compared to a tax rate of 38% in 2020. For information regarding additional matters related to our taxes, please see Note 5 — "Income Taxes" to the Consolidated Financial Statements included in this Annual Report.

 

Liquidity and Capital Resources

 

The Company had $4.8 million and $2.0 million of cash as of December 31, 2022, and 2021, respectively. The Company’s operating activities generated net cash of $4.9 and $0.4 million in 2022 and 2021, respectively. Investing activities used net cash of $0.2 million in both 2022 and 2021. Financing activities used net cash of $1.9 million and $1.0 million in 2022 and 2021, respectively.

 

Operating cash generated in operations of $4.9 million in 2022 primarily reflected the net loss of $1.1 million adjusted for depreciation and amortization of $2.4 million and stock compensation expense of $0.9 million. Cash generated in operations was also affected by the following changes in assets and liabilities: collection of a tax receivable of $2.3 million, accounts receivable of $0.4 million, prepaid expenses of $0.4 million, and an increase in accrued expenses of $0.7 million. The $4.5 million change in operating cash from a positive $0.4 million in 2021 to a positive $4.9 million in 2022 was primarily driven by the income tax receivable in 2022 and the forgiveness of the PPP loan in 2021.

 

15
 

 

Operating cash generated in operations of $0.4 million in 2021 primarily reflected the net loss of $0.7 million adjusted for PPP Loan forgiveness of $2.2 million, depreciation and amortization of $2.8 million and stock compensation expense of $0.7 million. Cash generated in operations was also affected by the following changes in assets and liabilities: an increase in accounts receivable of $0.8 million and an increase in accrued expenses of $1.4 million. The $4.5 million change in operating cash from a negative $4.1 million in 2020 to a positive $0.4 million in 2021 was primarily driven by improved operating results in 2021.

 

Cash used in investing activities primarily reflected the purchase of capital expenditures. Capital expenditures were $0.2 million and $0.2 million in 2022 and 2021, respectively. In both 2022 and 2021, the expenditures related principally to laboratory equipment, machinery, and computer software.

 

During 2022 and 2021, the Company did not repurchase any shares of common stock for treasury. The Company has authorized 750,000 shares for repurchase since June of 1998, of which 250,000 shares of common stock were authorized in March of 2008 for repurchase. Since 1998, a total of 550,684 shares have been repurchased. The Company distributed cash dividends to its shareholders of $1.2 million in 2022 and $0.3 million in 2021. Cash flows used in financing activities also reflected repayments under the Equipment Loan Arrangement of $0.7 million in both 2022 and 2021.

 

During the last three consecutive quarters of 2022, the Company’s Board of Directors declared a quarterly cash dividend of $0.07 per common share. In March 2023, the Company announced that the Board of Directors authorized a quarterly cash dividend of $0.07 per share, payable in April 2023. There can be no assurance that the Company will pay dividends in the future. The Company will continue to evaluate the dividend as it moves forward.

 

At December 31, 2022, the Company’s principal sources of liquidity included $4.8 million of cash on hand. Management currently believes that such funds, together with future operating profits, should be adequate to fund anticipated working capital requirements, including debt obligations, and capital expenditures for at least the next 12 months. Depending upon the Company’s results of operations, its future capital needs and available marketing opportunities, the Company may use various financing sources to raise additional funds. Such sources could include but are not limited to, issuance of common stock or debt financing, lines of credit, or equipment leasing; although there is no assurance that such financings will be available to the Company on terms it deems acceptable, if at all.

 

On May 4, 2020, the Company borrowed $2.2 million from Bank of America, N.A., pursuant to the PPP, established under the CARES Act. These funds were used to maintain operations, including the employment of both exempt and non-exempt employees, in order to meet the drug testing needs of our customers and adhere to strict quality standards in the midst of the worldwide COVID-19 pandemic.

 

During the third quarter of 2021, the PPP Loan and accrued interest was 100% forgiven by the SBA. The PPP Loan exceeded $2.0 million audit threshold established by the SBA, and therefore, could be subject to audit by the SBA in the future.

 

Purchase Commitment

 

Operating leases consist of rent obligations for the company’s facilities and corporate office. The Company has no significant contractual obligation for supply agreements as of December 31, 2022.

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles require the Company’s management to make judgments, assumptions and estimates that affect the amounts reported. Note 2, “Summary of Significant Accounting Policies,” of the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K describes the significant accounting policies and methods used in the preparation of the Company’s consolidated financial statements. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances. Actual results may differ from these estimates, and such differences may be material.

 

Recent Accounting Pronouncements

 

See Note 2 – “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements in Part II, Item 8 of this Form 10-K for further detail on recent accounting pronouncements.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

Not required.

 

16
 

 

 

Item 8. Financial Statements and Supplementary Data

 

 

(a)

Financial Statements:

 

 

Page

Report of Independent Registered Public Accounting Firm (BDO USA, LLP; Boston, Massachusetts; PCAOB ID# 243)

18

Consolidated Balance Sheets as of December 31, 2022 and 2021

19

Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2022, 2021 and 2020

20

Consolidated Statements of Shareholders’ Equity for the Years Ended December 31, 2022, 2021 and 2020

21

Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021 and 2020

22

Notes to Consolidated Financial Statements

23

 

 

 

 

 

 

 

 

 

 

 

 

 

17
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

Shareholders and Board of Directors

Psychemedics Corporation

Acton, Massachusetts

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Psychemedics Corporation (the “Company”) and subsidiaries as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company and subsidiaries at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

/s/ BDO USA, LLP

 

We have served as the Company's auditor since 2004.

 

Boston, Massachusetts

March 24, 2023

 

 

18
 

 

 

PSYCHEMEDICS CORPORATION
CONSOLIDATED BALANCE SHEETS

(in thousands, except par value)

 

  

December 31,

  

December 31,

 
  

2022

  

2021

 

ASSETS

        

Current Assets:

        

Cash

 $4,750  $1,992 

Accounts receivable, net of allowance for doubtful accounts of $87 and $89 at December 31, 2022 and 2021, respectively

  3,739   4,116 

Prepaid expenses and other current assets

  1,136   1,499 

Income tax receivable

  339   2,678 
         

Total Current Assets

  9,964   10,285 
         

Property and equipment:

        

Computer software

  4,648   4,521 

Office furniture and equipment

  2,247   2,195 

Laboratory equipment

  16,013   16,005 

Leasehold improvements

  3,629   3,629 
   26,537   26,350 

Accumulated depreciation and amortization

  ( 21,964)  ( 19,659)
   4,573   6,691 

Other assets

  823   864 

Deferred tax assets

  691   160 

Operating lease right-of-use assets

  2,681   3,552 
         

Total Assets

 $18,732  $21,552 
         

LIABILITIES AND SHAREHOLDERS' EQUITY

        
         

Current Liabilities:

        

Accounts payable

 $448  $994 

Accrued expenses

  3,939   3,188 

Current portion of long-term debt

  294   664 

Current portion of operating lease liabilities

  1,037   984 
         

Total Current Liabilities

  5,718   5,830 
         

Long-term debt

  305   599 

Long-term portion of operating lease liabilities

  1,938   2,880 

Total Liabilities

  7,961   9,309 
         

Commitments and Contingencies (Note 9)

          

Shareholders' Equity:

        

Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding

  -   - 

Common stock, $0.005 par value; 50,000 shares authorized 6,349 shares and 6,257 shares issued at December 31, 2022 and 2021, respectively, 5,681 shares outstanding and 5,589 shares outstanding at December 31, 2022 and 2021, respectively

  32   31 

Additional paid-in capital

  34,275   33,478 

Less - Treasury stock, at cost, 668 shares

  ( 10,082)  ( 10,082)

Accumulated deficit

  ( 11,820)  ( 9,550)

Accumulated other comprehensive loss

  ( 1,634)  ( 1,634)
         

Total Shareholders' Equity

  10,771   12,243 
         

Total Liabilities and Shareholders' Equity

 $18,732  $21,552 

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

19
 

 

 

PSYCHEMEDICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS AND

COMPREHENSIVE LOSS

(in thousands, except per share amounts)

 

   

Year Ended December 31,

  
   

2022

    

2021

    

2020

  

Revenues

   $ 25,240     $ 24,909     $ 21,360  

Cost of revenues

     15,949       14,645       16,474  

Gross profit

     9,291       10,264       4,886  
                         

Operating Expenses:

                        

General & administrative

     5,857       6,126       6,095  

Marketing & selling

     3,191       2,799       3,577  

Research & development

     1,326       1,130       1,280  

Total Operating Expenses

     10,374       10,055       10,952  

Operating (loss) income

     ( 1,083 )     209       ( 6,066 )
                         

Other Income (Expense):

                        

Gain on forgiveness of PPP Loan

     -       2,181       -  

Settlements

     -       ( 3,150 )     -  

Other income (expense)

     43       ( 61 )     ( 140 )

Total Other Income (Expense)

     43       ( 1,030 )     ( 140 )
                         

Net loss before provision for (benefit from) income taxes

     ( 1,040 )     ( 821 )     ( 6,206 )

Provision for (benefit from) income taxes

     44       ( 156 )     ( 2,347 )

Net loss

   $ (1,084 )   $ (665 )   $ (3,859 )
                         

Other Comprehensive Loss:

                        

Foreign currency translation, net of taxes

     -       -       ( 10 )

Total Comprehensive Loss

   $ (1,084 )   $ (665 )   $ (3,869 )
                         

Basic net loss per share

   $ (0.19 )   $ (0.12 )   $ (0.70 )
                         

Diluted net loss per share

   $ (0.19 )   $ (0.12 )   $ (0.70 )
                         

Dividends declared per share

   $ 0.21     $ 0.05     $ 0.18  
                         

Weighted average common shares outstanding:

                        

Basic

     5,626       5,549       5,524  

Diluted

     5,626       5,549       5,524  

 
 The accompanying notes are an integral part of these Consolidated Financial Statements.

 

 

20
 

 

 

PSYCHEMEDICS CORPORATION
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands, except per share amounts)

 

  

Common Stock

      

Treasury Stock

      

Accumulated Other

     
       $0.005  

Paid-In

          

Accumulated

  

Comprehensive

     
  

Shares

  

par Value

  

Capital

  

Shares

  

Cost

  

Deficit

  

Income (loss)

  

Total

 

BALANCE, December 31, 2019

  6,185  $31  $32,249   668  $( 10,082) $( 3,754) $( 1,624) $16,820 

Shares issued – vested

  20   -   -   -   -   -       - 

Tax withholding related to vested shares from employee stock plans

  -   -   ( 9)  -   -   -   -   ( 9)

Stock compensation expense

  -   -   563   -   -   -   -   563 

Cash dividends declared ($0.18 per share)

  -   -   -   -   -   ( 993)  -   ( 993)

Net loss

  -   -   -   -   -   ( 3,859)  -   ( 3,859)

Foreign currency translation, net of taxes

  -   -   -   -   -   -   ( 10)  ( 10)

BALANCE, December 31, 2020

  6,205   31   32,803   668   ( 10,082)  ( 8,606)  ( 1,634)  12,512 

Shares issued – vested

  51   -   -   -   -   -   -   - 

Exercise of stock options

  1   -   4   -   -   -   -   4 

Tax withholding related to vested shares from employee stock plans

  -   -   ( 72)  -   -   -   -   ( 72)

Stock compensation expense

  -   -   743   -   -   -   -   743 

Cash dividends declared ($0.05 per share)

  -   -   -   -   -   ( 279)  -   ( 279)

Net loss

  -   -   -   -   -   ( 665)  -   ( 665)

BALANCE, December 31, 2021

  6,257   31   33,478   668   ( 10,082)  ( 9,550)  ( 1,634)  12,243 

Shares issued – vested

  91   1   ( 1)  -   -   -   -   - 

Exercise of stock options

  1   -   4   -   -   -   -   4 

Tax withholding related to vested shares from employee stock plans

  -   -   ( 78)  -   -   -   -   ( 78)

Stock compensation expense

  -   -   872   -   -   -   -   872 

Cash dividends declared ($0.21 per share)

  -   -   -   -   -   ( 1,186)  -   ( 1,186)

Net loss

  -   -   -   -   -   ( 1,084)  -   ( 1,084)

BALANCE, December 31, 2022

  6,349  $32  $34,275   668  $( 10,082) $( 11,820) $( 1,634) $10,771 

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

21
 

 

 

PSYCHEMEDICS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Cash flows from operating activities:

            

Net loss

 $(1,084) $(665) $(3,859)

Adjustments to reconcile net loss to net cash provided by operating activities:

            

Forgiveness of PPP loan

  -   ( 2,181)  - 

Depreciation and amortization

  2,367   2,784   2,691 

ROU asset amortization

  949   906   935 

Deferred income taxes

  ( 531)  ( 371)  ( 339)

Loss on sale of fixed assets

  -   -   94 

Stock compensation expense

  872   743   563 

Changes in operating assets and liabilities:

            

Accounts receivable

  377   ( 760)  424 

Prepaid expenses and other current assets

  363   ( 585)  392 

Income tax receivable

  2,339   ( 183)  ( 2,013)

Accounts payable

  ( 546)  417   ( 281)

Operating lease liabilities

  ( 967)  ( 1,078)  ( 914)

Accrued expenses

  751   1,387   ( 1,776)

Net cash provided by (used in) operating activities

  4,890   414   ( 4,083)
             

Cash flows from investing activities:

            

Proceeds from sale of fixed assets

  -   -   140 

Other assets

  ( 21)  ( 38)  ( 7)

Purchases of property and equipment and capitalized software development costs

  ( 187)  ( 182)  ( 991)

Net cash used in investing activities

  ( 208)  ( 220)  ( 858)
             

Cash flows from financing activities:

            

Cash dividends paid

  ( 1,186)  ( 279)  ( 993)

Proceeds from stock options and tax withholding related to vested shares from employee stock plans

  ( 74)  ( 68)  ( 9)

Proceeds from PPP Loan

  -   -   2,181 

Payments of equipment financing

  ( 664)  ( 688)  ( 678)

Net cash (used in) provided by financing activities

  ( 1,924)  ( 1,035)  501 
             

Effect of exchange rate changes on cash

  -   -   ( 10)

Net increase (decrease) in cash

  2,758   ( 841)  ( 4,450)

Cash, beginning of year

  1,992   2,833   7,283 

Cash, end of year

 $4,750  $1,992  $2,833 
             

Supplemental disclosures of cash flow information:

            

Cash paid for income taxes

 $-  $405  $249 

Cash paid for interest

 $33  $50  $75 

Cash paid for operating leases

 $1,044  $1,151  $1,038 

Right-of-use assets acquired through operating leases

 $78  $172  $2,346 

Non-cash investing and financing activities:

            

Purchases of equipment through accounts payable and accrued liabilities

 $-  $-  $241 

 

The accompanying notes are an integral part of these Consolidated Financial Statements.

 

22
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2022

 

 

1. Nature of Business

 

Company Overview

 

Psychemedics Corporation (the “Company”) provides hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay and mass spectrometry to analyze hair to detect abused substances. The Company’s customers include Fortune 500 companies, as well as small to mid-size corporations, schools and governmental entities located in the United States and Internationally.

 

COVID-19 Pandemic

 

The outbreak of coronavirus (“COVID-19”) which was declared by the World Health Organization to be a pandemic, has, and is expected to continue to impact worldwide economic activity. COVID-19 has had a significant impact on our entire operations. Additionally, COVID-19’s effect on the overall economy has had an adverse impact on hiring, which is having a negative impact on our testing volume.

 

The Coronavirus Aid, Relieve and Economic Security Act (“CARES”) Act, enacted on March 27, 2020, and the Families First Coronavirus Response Act, in each case modified by the Consolidated Appropriations Act enacted in December 2020, were emergency economic stimulus packages that included spending provisions and tax cuts to strengthen the United States economy and to fund a nationwide effort to curtail the effect of COVID-19. The principal impact of the CARES Act and subsequent legislation was the adoption of the Paycheck Protection Program (“PPP”). The CARES Act, together with subsequent legislation, also provided sweeping tax changes in response to the COVID-19 pandemic, including amendments to certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company recognized a benefit of $2.6 million and $0.2 million for the years ended December 31, 2021, and December 31, 2020, respectively, as a reduction to cost of revenues and operating expenses related to the employee retention credit which was a tax provision in the CARES Act and subsequent legislation. Additionally, the CARES Act allowed the Company to fully carryback the 2020 net operating loss, for a refund of corporate income taxes previously paid.

 

Liquidity and Management’s Plans

 

At December 31, 2022, the Company’s principal sources of liquidity included $4.8 million of cash on hand. Management currently believes that such funds, together with future operating profits, should be adequate to fund anticipated working capital requirements, including debt obligations, and capital expenditures for at least the next 12 months. Depending upon the Company’s results of operations, its future capital needs and available marketing opportunities, the Company may use various financing sources to raise additional funds. Such sources could include but are not limited to, issuance of common stock or debt financing, lines of credit, or equipment leasing, although there is no assurance that such financings will be available to the Company on terms it deems acceptable, if at all.

 

 

2. Summary of Significant Accounting Policies

 

Risks and Uncertainties

 

The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not limited to, FDA regulations, proposed laws and regulations, and delays in implementation of laws and regulations), competition and general economic conditions.

 

Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. As of December 31, 2022, and 2021, there were no investments classified as cash equivalents.

 

Property and Equipment

 

Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are:

 

23
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2022

 

2. Summary of Significant Accounting Policies (continued)

 

Computer software

3 to 5 years

Office furniture and equipment

3 to 7 years

Laboratory equipment

5 to 7 years

Leasehold improvements

Lesser of estimated useful life or lease term

 

The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.4 million, $2.8 million, and $2.7 million in 2022, 2021 and 2020, respectively. The Company had $0.5 million of capitalized software and equipment that was not placed in service as of December 31, 2022, which is included as a component of computer software on the accompanying consolidated balance sheets.

 

Capitalized Software Development Costs

 

We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for three to five years. Costs incurred during the post-implementation/operation stage, including training costs and maintenance costs, are expensed as incurred. In accordance with Company policy, during the years ended December 31, 2022, and 2021, we capitalized internally developed software costs of $127 thousand and $99 thousand, respectively. Amortization expense related to software development costs was $282 thousand, $421 thousand and $293 thousand in 2022, 2021 and 2020, respectively. Determining whether particular costs incurred are more properly attributable to the preliminary or conceptual stage, and thus expensed, or to the application development phase, and thus capitalized and amortized, depends on subjective judgments about the nature of the development work, and our judgments in this regard may differ from those made by other companies. General and administrative costs related to developing or obtaining such software is expensed as incurred.

 

Other Assets

 

Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty years. As of December 31, 2022, the Company had capitalized legal costs relating to patent applications of $1.1 million with accumulated amortization of $0.5 million, for a net balance of $0.6 million. As of December 31, 2021, the Company had capitalized legal costs relating to patent applications of $1.1 million with accumulated amortization of $0.4 million, for a net balance of $0.7 million. Amortization expense was $62 thousand, $62 thousand, and $62 thousand in 2022, 2021 and 2020, respectively. Based on payments made as of December 31, 2022, remaining amortization expense is expected to be $62 thousand for each of the five years ending December 31, 2027 and $109 thousand thereafter.

 

Allowance for Doubtful Accounts

 

The allowance for doubtful accounts is based on management’s assessment of the ability to collect amounts owed to it by its customers. Management reviews its accounts receivable aging for doubtful accounts and uses a methodology based on calculating the allowance using a combination of factors including the age of the receivable along with management’s judgment to identify accounts that may not be collectible. The Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. Bad debt expense has been within management’s expectations.

 

Revenue Recognition

 

The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer.

 

Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration (none of which is variable) the Company expects to be entitled to in exchange for those services. The Company typically invoices customers monthly for services provided and payments are generally due within 30 to 60 days of the invoice date.

 

 

24
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2022

 

2. Summary of Significant Accounting Policies (continued)

 

The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 13 – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report.

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Consolidated Revenue:

            

Testing

 $21,608  $21,894  $19,068 

Shipping / Collection (hair)

  3,476   2,847   2,174 

Other

  156   168   118 

Total Revenue

 $25,240  $24,909  $21,360 

 

Testing Revenue

 

Drug and alcohol tests for drugs of abuse using hair, performed in the Company’s forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received.

 

Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue.

 

Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue.

 

Shipping and Hair Collection Revenue

 

Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third parties who have contracted with the Company. Shipping and hair collection revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of the Company’s service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test (associated with the shipping or hair collection charge) and availability of test results to the customer.

 

Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues.

 

Other Revenue

 

Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than 1% of total revenue. The amounts are generally billed to customers as services are performed, which occurs at a specific point-in-time.

 

Practical Expedients and Exemptions

 

The Company generally expenses sales commissions when incurred as they are typically not related to costs to fulfill customer contracts but relate to overall sales targets. These costs are recorded within marketing and selling expense on the accompanying consolidated statements of operations.

 

Research and Development Expenses

 

The Company expenses all research and development costs as incurred.

 

Contingencies

 

Loss contingencies from legal proceedings and claims may occur from government investigations, shareholder lawsuits, product liability, contractual claims, tax and other matters. Accruals are recognized when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. Legal fees are expensed as incurred.

 

25
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022

 

2. Summary of Significant Accounting Policies (continued)

 

Income Taxes

 

The Company accounts for income taxes using the liability method pursuant to ASC 740, “Income Taxes”. Under this method, the Company recognizes deferred tax assets and liabilities for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts using enacted tax rates in effect for the year the differences are expected to reverse. The Company evaluates uncertain tax positions annually and considers whether the amounts recorded for income taxes are adequate to address the Company’s tax risk profile. The Company analyzes the potential tax liabilities of specific transactions and tax positions based on management’s judgment as to the expected outcome.

 

Concentration of Credit Risk and Off-Balance Sheet Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and accounts receivable. The Company’s policy is to place its cash in high quality financial institutions. At times, these deposits may exceed or be exempt from federally insured limits. The Company does not believe significant credit risk exists with respect to these institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom the Company makes substantial sales. To reduce risk, the Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. The Company does not require collateral. The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.

 

Significant Customers and Concentration of Credit Risk

 

The Company had no customers that represented 10% or more of total revenue for the years ended December 31, 2022, 2021, and 2020, respectively. The Company had one customer that represented 11% and 12% of the total accounts receivable balance as of December 31, 2022 and 2021, respectively.

 

Stock-Based Compensation

 

The Company accounts for equity awards in accordance with ASC 718, “Compensation — Stock Compensation” (“ASC 718”). ASC 718 requires employee equity awards to be accounted for under the fair value method. It also requires the measurement of compensation cost at fair value on the date of grant and recognition of compensation expense over the service period for awards expected to vest. Accordingly, share-based compensation is measured at the grant date based on the fair value of the award. The Company uses the straight-line method to recognize share-based compensation over the service period of the award, which is generally equal to the vesting period. The Company uses the simplified approach to calculate the expected exercise date of options, which is one of the components used to determine the fair value of the options. This approach is used due to the small number of recipients receiving stock options not providing a reasonable basis for estimating expected term. In 2016, the Company adopted ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of related amounts within the statement of cash flows. As a result, we recognize the impact of forfeitures when they occur with no adjustment for estimated forfeitures and recognize excess tax benefits as a reduction of income tax expense regardless of whether the benefit reduces income taxes payable.

 

Stock compensation expense by statements of operations account is as follows (in thousands):

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Cost of revenues

 $63  $63  $50 

General & administrative

  626   503   380 

Marketing & selling

  113   114   74 

Research & development

  70   63   59 

Total stock compensation

 $872  $743  $563 

 

See Note 7 – “Stock-Based Awards” to the Consolidated Financial Statements included in this Annual Report for additional information relating to the Company’s stock plan.

 

26
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022

 

2. Summary of Significant Accounting Policies (continued)

 

Basic and Diluted Net Loss per Share

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”).

 

Basic and diluted weighted average common shares outstanding are as follows (in thousands):

 

  

2022

  

2021

  

2020

 

Weighted average common shares outstanding, basic

  5,626   5,549   5,524 

Dilutive common equivalent shares

  -   -   - 

Weighted average common shares outstanding, assuming dilution

  5,626   5,549   5,524 

 

For the years ended December 31, 2022, 2021 and 2020, options to purchase 508 thousand, 574 thousand and 588 thousand common shares were outstanding but not included in the dilutive common equivalent share calculation as their effect would have been anti-dilutive.

 

Fair Value Measurements

 

The fair values of the Company’s cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of the Company’s note payable approximates its fair value, as it is based on current market rates at which the Company could borrow funds with similar terms.

 

Basis of Preparation and Consolidation

 

The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated.

 

Segment Reporting

 

The Company manages its operations as one segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. See Note 14 – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report for geographic breakdown of revenue.

 

 

 

27
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022

 

 

2. Summary of Significant Accounting Policies (continued)

 

Recently Adopted Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which modifies the measurement of expected credit losses on certain financial instruments. The Company will adopt ASU 2016-13 in its first quarter of 2023. Based on the Company’s historical credit loss activity, the adoption of ASU 2016-13 will not have a material impact on its consolidated financial statements.

 

 

3. Accounts Receivable

 

The Company maintains an allowance for uncollectible accounts receivable based on management’s assessment of the collectability of its customer accounts by reviewing customer payment patterns and other relevant factors. The Company reviews the adequacy of the allowance for uncollectible accounts on a quarterly basis and adjusts the balance as determined necessary. Write-offs are recorded at the time a customer account is deemed uncollectable. The following is a rollforward of the Company’s allowance for doubtful accounts (in thousands):

 

  

As of December 31,

 
  

2022

  

2021

 

Balance, beginning of period

 $89  $37 

Provision for doubtful accounts

  9   55 

Write-offs

  ( 11)  ( 3)

Balance, end of period

 $87  $89 

 
 

4. Accrued Expenses

 

Accrued expenses consist of the following (in thousands):

 

  

As of December 31,

 
  

2022

  

2021

 

Accrued compensation and employee benefits

 $442  $507 

Accrued vacation expense

  409   373 

Accrued taxes

  771   200 

Accrued shipping expense

  338   488 

Accrued legal settlement

  1,150   1,150 

Other accrued expenses

  829   470 

Total Accrued Expenses

 $3,939  $3,188 

 

 

28
 
 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2022

 

 

5. Income Taxes

 

The income tax provision consists of the following (in thousands):

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Current

            

Federal

 $552  $131  $( 2,006)

State

  23   84   ( 2)

Total Current

  575   215   ( 2,008)

Federal

  ( 959)  ( 704)  ( 13)

State

  428   333   ( 326)

Total Deferred

  ( 531)  ( 371)  ( 339)

Income Tax Provision

 $44  $( 156) $( 2,347)

 

A reconciliation of the effective rate with the federal statutory rate is as follows:

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Federal statutory rate

  21.0%  21.0%  21.0%

State income taxes, net of federal benefit

  12.0%  10.4%  4.4%

Permanent differences

  (0.4%)  47.6%  0.0%

Stock based compensation

  0.5%  1.4%  (0.4%)

Federal R&D Credits

  8.9%  0.0%  1.6%

Foreign taxes, net of federal benefit

  0.0%  (10.9%)  (2.2%)

Difference in tax rate for carryback claim

  0.0%  0.0%  13.4%

Increase/(decrease) in valuation reserve

  (46.2%)  (50.5%)  0.0%

Effective tax rate

  -4.2%  19.0%  37.8%

 

The change in effective tax rate from 2021 to 2022 was primarily driven by the Company’s 2021 non-taxable debt forgiveness from the Paycheck Protection Plan in 2021 that was included in income for GAAP purposes partially offset by the decrease in foreign taxes in 2022. As of December 31, 2022, the Company had no federal net operating loss carryforwards. As of December 31, 2022, the Company had $1.3 million of state net operating loss carryforwards, of which $1.2 million expire at various dates between 2030 and 2040, and $0.1 million do not expire. As of December 31, 2022, the Company had no federal tax credit carryforwards and $1.4 million of California tax credit carryforwards relating to the years 2013 through 2022 which have an unlimited carryforward period. In 2022, the 12.0% state income tax effective rate primarily consisted of California research tax credits of 8.3%.

 

29
 
 

The components of the net deferred tax liabilities included in the accompanying balance sheets are as follows (in thousands):

 

  

As of December 31,

 
  

2022

  

2021

 

Deferred Tax Assets

        

Allowance for doubtful accounts

 $21  $21 

Accrued expenses

  414   129 

Stock-based compensation

  381   325 

R&D tax credits

  1,086   1,083 

Operating lease

  701   944 

Capitalized research expenses

  404   - 

NOL carryforward

  72   219 

Gross Deferred Tax Assets

  3,079   2,721 

Valuation Allowance

  ( 895)  ( 414)

Deferred Tax Assets After Valuation Allowance

  2,184   2,307 
         

Deferred Tax Liabilities

        

Excess of tax over book depreciation and amortization

  ( 783)  ( 1,249)

Prepaid expenses

  ( 78)  ( 61)

Operating lease

  ( 632)  ( 837)

Gross Deferred Tax Liabilities

  ( 1,493)  ( 2,147)
         

Net Deferred Tax Assets

 $691  $160 

 

 

30
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022

5. Income Taxes (continued)

 

Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. The Company adopted ASU 2019-12 as of January 1, 2021, with no material impact to the Company’s consolidated financial statements.

 

ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions (tax contingencies). The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company’s tax positions and tax benefits, which may require periodic adjustments and which may not accurately forecast actual outcomes. The Company had immaterial uncertain tax positions at December 31, 2022, and 2021, respectively.

 

The Company operates within multiple taxing jurisdictions and could be subject to audit in these jurisdictions. These audits may involve complex issues, which may require an extended period of time to resolve. The Company has provided for its estimated taxes payable in the accompanying financial statements. The Company’s policy is to recognize interest and penalties related to income tax matters as a general and administrative expense, when and if incurred. Interest and penalties for the years ended December 31, 2022, 2021 or 2020 were not material.

 

 
 

6. Preferred Stock

 

The Board of Directors has the authority to designate authorized preferred shares in one or more series and to fix the relative rights and preferences without vote or action by the stockholders. The Board of Directors has no present plans to designate or issue any shares of preferred stock.

 

 

7. Stock-Based Awards

 

The 2006 Incentive Plan initially adopted in 2006 provides for grants of options with terms of up to ten years, grants of restricted stock or stock unit awards (“SUAs”), issuances of stock bonuses or grants other stock-based awards plus cash-based awards, to officers, directors, employees, and consultants. Such shares are issuable out of the Company’s authorized but unissued common stock. In May 2021, the 2006 Incentive Plan was amended to increase the total number of shares issuable thereunder from 1.2 million to 1.6 million. As of December 31, 2022, 183 thousand shares remained available for future grant under the 2006 Incentive Plan.

 

The fair value of the SUAs is determined by the closing price on the date of grant. The fair value of options is determined using a Black-Scholes model. The SUAs and options vest over a period of two to four years and are convertible or exercisable into an equivalent number of shares of the Company’s common stock provided that the employee receiving the award remains continuously employed throughout the vesting period. The Company records stock compensation expense related to the SUAs and options on a straight-line basis over the vesting term. Employees are issued shares upon vesting of SUAs, net of tax withholdings. As a result of our adoption of ASU 2016-09 in 2016, we recognize the impact of forfeitures when they occur with no adjustment for estimated forfeitures and recognize excess tax benefits as a reduction of income tax expense regardless of whether the benefit reduces income taxes payable.

 

31
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022

 

7. Stock-Based Awards (continued)

 

On April 4, 2022, the Company granted SUAs covering two thousand shares of common stock. On May 20, 2022, the Company granted SUAs covering 126 thousand shares of common stock. On August 12, 2022, the Company granted SUAs covering 18 thousand shares of common stock.

 

The following table represents all shares granted by the Company under the 2006 Incentive Plan for the last three years (shares in thousands):

 

Grant Date

Type

 

Shares

  

Fair Value
Per Share (1)

 

August 12, 2022

SUA

  18  $6.65 

May 20, 2022

SUA

  126  $6.51 

April 4, 2022

SUA

  2  $7.04 

May 13, 2021

SUA

  116  $6.55 

March 16, 2021

SUA

  2  $7.04 

January 25, 2021

SUA

  2  $5.54 

December 16, 2020

SUA

  5  $4.71 

November 11, 2020

Options

  40  $1.13 

November 11, 2020

SUA

  190  $4.07 

 

 

(1)

The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 years. The options granted on November 11, 2020, have a fair value of $1.13 per share based on the $4.07 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 45% volatility, 0.9% interest rate and a 4.0% dividend yield rate. No options were granted during fiscal years ended December 31, 2022, and 2021. For options granted during fiscal year ended December 31, 2020, the weighted average grant date fair value was $3.47. For SUAs granted during fiscal years ended December 31, 2022, 2021 and 2020, the weighted average grant date fair values were $6.53, $6.55, and $4.89, respectively.

 

A summary of the Company’s stock option activity is as follows (in thousands, except price per share):

 

  

Number of
Shares

  

Weighted Average
Exercise Price Per
Share

 

Weighted
Average
Remaining
Contractual Life

 

Aggregate
Intrinsic Value (2)

 

Outstanding, December 31, 2021

  574  $14.23 

6.1 years

 $100 

Granted

  -  $-      

Exercised

  (1) $4.07      

Forfeited

  (1) $4.07      

Canceled

  (64) $15.03      

Outstanding, December 31, 2022

  508  $14.19 

5.1 years

 $25 
              

Exercisable, December 31, 2022

  467  $14.70 

4.9 years

 $14 

 

 

(2)

The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of December 31, 2022, and 2021 was $4.90 and $7.02, respectively.

 

32
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022

 

7. Stock-Based Awards (continued)

 

A summary of the Company’s stock unit award activity is as follows (in thousands, except price per share):

 

  

 

Number of

Shares

  

Weighted Average

Grant-Date Fair Value

per Share (3)

 

Outstanding & Unvested, December 31, 2021

  224  $5.48 

Granted

  146  $6.53 

Converted to common stock

  ( 90) $6.33 

Cancelled

  ( 12) $6.29 

Forfeited

  ( 30) $6.26 

Outstanding & Unvested, December 31, 2022

  238  $6.10 

 

 

(3)

Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares.

 

The fair value of stock unit award vesting was $548 thousand, $296 thousand and $274 thousand for the years ended December 31, 2022, 2021, and 2020, respectively. The intrinsic value of stock unit awards converted to common stock was based on the stock price on the vesting date and amounted to $650 thousand, $501 thousand and $115 thousand for the years ended December 31, 2022, 2021, and 2020, respectively.

 

As of December 31, 2022, a total of 1,032 thousand shares of common stock were reserved for issuance under 2006 Incentive Plan. As of December 31, 2022, the unamortized fair value of outstanding options and awards was $1.2 million to be amortized over a weighted average period of 2.3 years.

 

The Board of Directors approved the accelerated vesting of 35 thousand SUAs to certain directors upon retirement from the Board of the Company during the year ended December 31, 2022. The Company determined the value of the modifications to be $230 thousand, which is included in stock-based compensation in the accompanying consolidated financial statements, for the year ended December 31, 2022.

 

 

8. Employee Benefit Plan

 

The Psychemedics Corporation 401(k) Savings and Retirement Plan (the “401(k) Plan”) is a qualified defined contribution plan in accordance with Section 401(k) of the Internal Revenue Code. All employees over the age of 21 are eligible to make pre-tax contributions up to a specified percentage of their compensation. Under the 401(k) Plan, the Company may, but is not obligated to, match a portion of the employees’ contributions up to a defined maximum. Matching contributions of zero, zero, and $198 thousand were made in the years ended December 31, 2022, 2021 and 2020, respectively.

 

 

9. Commitments and Contingencies

 

Commitments

 

The Company leases certain of its facilities and equipment under operating lease agreements expiring on various dates through December 2026. Total minimum lease payments, including scheduled increases, are charged to operations on the straight-line basis over the life of the respective lease. Rent expense was $1.0 million, $1.1 million and $1.1 million in 2022, 2021 and 2020, respectively. See Note 10 – “Operating Leases” to the Consolidated Financial Statements included in this Annual Report for commitments remaining under lease agreements.

 

Contingencies

 

In the normal course of business, we are subject to contingencies, such as legal proceedings and claims arising out of our business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product liability, contractual claims and tax matters. We recognize accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. These estimates are subject to uncertainties that are difficult to predict and, as such, actual results could vary from these estimates.

 

Settlements

 

On December 6, 2021, the Company entered into a binding Memorandum of Understanding (the “MOU”) to settle a purported class action lawsuit against it related to certain California wage and hour laws. The lawsuit, Enma Sagastume v. Psychemedics Corporation, Case No. 2:20-CV-06624-DSF, is pending in the United States District Court for the Central District of California (the “California Lawsuit”) and is similar to numerous lawsuits filed against employers with operations in California.

 

In the binding MOU, the parties agreed to settle this matter for a payment by the Company of $1.2 million in exchange for the dismissal of the California Lawsuit and a customary release of liability, subject only to final court approval and the process described below. Factoring in that process, the Company estimates that the settlement funds will be dispersed in the second half of 2023, subject to the actual timing of final court approval.

 

33
 
 

Although the Company believes that the allegations in the California Lawsuit lack merit, it agreed at a mediation to enter into the binding MOU to settle the claims in the California Lawsuit in order to avoid potentially significant legal fees, other expenses, and management time that would have to be devoted to protracted litigation in California regarding its wage and hour laws. The foregoing was also impacted in part by new California case law in February 2021 regarding meal period compliance. The allegations in the California Lawsuit relate to alleged discrepancies in compliance with meal and rest periods required by California law and other alleged compliance discrepancies relating to the California wage and hour laws with respect to non-exempt hourly employees of the Company in California for a period since June 9, 2017. The California Lawsuit sought recovery of wages, penalties, interest, attorneys’ fees and other alleged damages. As part of the settlement, the Company continues to deny any liability or wrongdoing with respect to the claims made in the California Lawsuit.

 

The MOU assumes class certification for purposes of the settlement only. The settlement amount of $1.2 million, which includes plaintiff attorneys' fees and costs, is subject to potential increase based on any adjustments in the final class size and the exact period to be covered, as determined by the court’s final approval. However, the Company believes that such adjustments, if any, would likely be immaterial. Once court approved, in exchange for the settlement payment, the plaintiff and all class members who do not opt out of the settlement will provide a broad release of any liability relating to the subject matter of the California Lawsuit, including any claims of such persons under California’s Private Attorneys' General Act of 2004. Such release is for the benefit of the Company, its affiliates, and any successor to the Company. The Company has the right to revoke the settlement prior to court approval in the event opt-outs, if any, from the class membership exceed a specified level. While the settlement is subject to final court approval as is customary, the MOU expressly provides that it is binding on and enforceable by each of the parties thereto, including by any successor to the Company. There is a $1.2 million liability reserve in connection with the California Lawsuit as of December 31, 2022, and 2021 included in accrued expenses in the accompanying balance sheets.

 

 

34
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2022

 

 

10.         Operating Leases

 

The Company has five operating leases for office and laboratory space used to conduct business. The exercise of lease renewal options is at our discretion and there are no renewals to extend the lease terms included in our Right-Of-Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates the renewal options and when they are reasonably certain of exercise. As most of the Company’s leases do not provide an implicit rate, the Company uses the incremental borrowing rate based on the information available at the lease commencement date in determining the net present value (NPV) of the lease payments.

 

The weighted average discount rate used for leases as of December 31, 2022, is 3.8%. The weighted average lease term as of December 31, 2022, is 3.2 years. The operating lease expense for the twelve months ended December 31, 2022, and 2021, was $1.0 million and $1.1 million, respectively.

 

Maturities and balance sheet presentation of the Company’s lease liabilities for all operating leases as of December 31, 2022, is as follows (in thousands):

 

2023

   $ 1,134  

2024

     1,061  

2025

     553  

2026

     460  

Total lease payments

     3,208  

Less: interest

     ( 233 )

Present value of lease liabilities

   $ 2,975  
         

Current operating lease liabilities

   $ 1,037  

Long-term operating lease liabilities

     1,938  

Total

   $ 2,975  

 
 

11.         Debt and Other Financing Arrangements

 

On March 20, 2014, the Company entered into an equipment financing arrangement with Banc of America Leasing & Capital, LLC (the “Lender”), which it amended on various dates, most recently on March 23, 2021, including a Master Loan and Security Agreement and related documentation (collectively the “Equipment Loan Arrangement”) which provided the Company with the ability to finance, at its option, up to $16 million of new and used equipment purchases. Each such purchase financed under the Equipment Loan Arrangement was documented by the execution of an equipment note with a maturity date of 60 months from the applicable loan date. The loans bore interest at the then current 30-day LIBOR rate plus a premium ranging from 1.75% to 3.79%. Principal and interest were payable over the 60 month repayment period. Borrowings under the Equipment Loan Arrangement were secured by a first priority security interest in the equipment acquired with the proceeds of the equipment notes. Under the Equipment Loan Arrangement, the Company has been subject to a maximum quarterly funded debt to EBITDA ratio and a minimum fixed charge coverage ratio each of which was waived for certain quarters in 2020 and 2021. The Company was in compliance with all covenants under the Equipment Loan Arrangement as of December 31, 2022.

 

Under the Equipment Loan Arrangement, the Company executed notes on various dates between March 24, 2014, and December 4, 2019 in the aggregate amount of $12.2 million, of which $0.7 million and $0.7 million was repaid in 2022 and 2021, respectively. As of December 31, 2022, the aggregate amount outstanding under the equipment notes was $0.6 million. The weighted average interest rate for these notes for the year ended December 31, 2022, was 3.7% and represented $32 thousand of interest expense. As of December 31, 2022, weighted average interest rate was 3.8%.

 

On May 1, 2020, the Company entered into a term loan with Bank of America N.A. under the PPP administered by the United States Small Business Administration (“SBA”) under the CARES Act (the “PPP Loan”). The principal amount of the PPP Loan was $2.1 million, which was evidenced by a promissory note with a maturity date of May 4, 2022. The note bore interest on the unpaid balance at the rate of one percent (1%) per annum.

 

In July 2021, the PPP Loan was 100% forgiven by the SBA and recorded as a gain on forgiveness of the PPP Loan in the 2021 consolidated statement of operations and comprehensive loss.

 

 

 

 

35
 
 

The annual principal repayment requirements for debt obligations as of December 31, 2022, are as follows (in thousands):

 

2023

 $294 

2024

  305 

Long-term debt from equipment financing

  599 

Less current portion of long-term debt from equipment financing

  (294)

Long-term debt from equipment financing, net of current portion

 $305 

 

 

36
 

 

PSYCHEMEDICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2022

 

 

12. Other Income/(Expense)

 

Interest expense for the year ended December 31, 2022, 2021, and 2020 was $32 thousand, $49 thousand, and $75 thousand, respectively. There was no interest income for the years ended December 31, 2022, 2021, and 2020. Interest expense is included as a component of other income (expense) on the accompanying consolidated statements of operations and comprehensive loss.

 

 

13. Business Segment Reporting

 

The Company manages its operations as one segment, drug testing services. As a result, the financial information disclosed herein materially represents all the financial information related to the Company’s principal operating segment. The Company’s revenues by geographic region, based on the location of the customer, were as follows (in thousands):

 

   

Year Ended December 31,

  
   

2022

    

2021

    

2020

  

Consolidated Revenue:

                        

United States

   $ 24,509     $ 23,584     $ 19,486  

International

     731       1,325       1,874  

Total Revenue

   $ 25,240     $ 24,909     $ 21,360  

 
 

14. Subsequent Event

 

On March 21, 2023, the Company declared a quarterly cash dividend of $0.07 per share, payable on April 10, 2023 to shareholders of record on March 31, 2023.

 

37
 
 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

 

a)

Evaluation of Disclosure Controls and Procedures

 

The Company carried out an evaluation as of December 31, 2022, under the supervision and with the participation of our management, including our Chief Executive Officer and Controller as well as a third-party internal control firm, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act. Based upon that evaluation, our Chief Executive Officer and Controller have concluded that our disclosure controls and procedures were effective as of December 31, 2022, to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Controller, as appropriate to allow timely decisions regarding required disclosure.

 

 

b)

Management’s Report on Internal Control over Financial Reporting

 

The Company’s management is responsible for establishing and maintaining an adequate system of internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f) and 15d-15(f). The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance, as opposed to absolute assurance, of achieving their internal control objectives.

 

Management, including our Chief Executive Officer and Controller, conducted an assessment of the Company’s internal control over financial reporting as of December 31, 2022, based on criteria established in the 2013 Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on the assessment, management concluded that, as of December 31, 2022, the Company’s internal control over financial reporting is effective.

 

 

c)

Changes in Internal Control over Financial Reporting

 

There was no change the Company's internal control over financial reporting during the Company's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

 

38
 

 

Item 9B. Other Information

 

On March 21, 2023, the Board established August 17, 2023, as the scheduled date of the Company’s 2023 annual meeting of stockholders (the “2023 Annual Meeting”). The Company will publish additional details regarding the 2023 Annual Meeting, including its record date and the exact time, location and matters to be voted on at the 2023 Annual Meeting, in the Company’s proxy statement for the 2023 Annual Meeting when it is filed, which the Company currently expects will be in late June 2023.

 

On March 21, 2023, the Company entered into new change in control severance agreements with Raymond C. Kubacki, Chairman, Chief Executive and President, and Charles Doucot, Executive Vice President. The agreements each run until May 2, 2024.  They provide that if, during the term, the Company terminates the employee’s employment for any reason other than for Cause (as defined in the agreement), death or disability (as defined in the agreement) or if the employee terminates his employment for Good Reason (as defined below), in either case, within twelve months following a Change in Control (as defined in the agreement), he will be entitled to receive a continuation of base salary for a period of up to twelve months from the date of such termination, except that for Mr. Kubacki only, Good Reason termination solely on account of a change in location would give rise to a continuation of base salary for a period of up to six months rather than twelve months.  Good Reason includes a change in title, a reduction in base salary then in effect, a material decrease in duties or responsibilities, or, in the case of Mr. Kubacki, a change of location. The agreement also prohibits the employee from working for a competitor of the Company or from soliciting employees of the Company during the period he is eligible to receive salary continuation under the agreement.  Mr. Kubacki’s agreements was in replacement of an agreement executed in 2018, which had a five-year term and expired in February 2023. Mr. Doucot’s agreement was in replacement of his agreement executed in 2018, which had a five-year term and was due to expire in May 2023.

 

The foregoing summary of the change in control severance agreements with Messrs. Kubacki and Doucot does not purport to be complete and is qualified in its entirety by reference to the change in control severance agreements with such executives which are attached hereto as Exhibits and are incorporated by reference into this report.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

Not Applicable.

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

Following is a list that sets forth the names, ages and positions within the Company of all of the Executive Officers of the Company and the Directors of the Company, as well as Directors nominated or chosen to become directors, in each case, as of March 24, 2023.

 

Name

  

Age

  

Position

Raymond C. Kubacki

   78  

Chairman, Chief Executive Officer, President, Director

Charles M. Doucot

   57  

Executive Vice President

William B. Norris

   34  

Controller

Michael I. Schaffer, Ph.D.

   78  

Vice President, Laboratory Operations

Peter H. Kamin

   61  

Director, Compensation Committee Member, Nominating and Corporate Governance Committee Member

Darius G. Nevin

   65  

Director, Audit Committee Member, Compensation Committee Member

Robyn C. Davis

   61  

Director, Audit Committee Member, Compensation Committee Member, Nominating and Corporate Governance Committee Member

Fred J. Weinert

   75  

Director, Audit Committee Member, Compensation Committee Member, Nominating and Corporate Governance Committee Member, Lead Independent Director

Andrew M. Reynolds

   55  

Director, Audit Committee Member, Compensation Committee Member, Nominating and Corporate Governance Committee Member

 

All Directors hold office until the next annual meeting of stockholders or until their successors are elected. Officers serve at the discretion of the Board of Directors.

 

39
 

 

Raymond C. Kubacki has been the Company’s President and Chief Executive Officer since 1991. He has also served as Chairman of the Board of the Company since 2003. He is also a trustee of the Center for Excellence in Education based in Washington, D.C. and holds an Executive Masters Professional Director Certification from the American College of Corporate Directors, an organization that provides educational and other services to public and private company directors. Mr. Kubacki received an M.B.A. from Harvard Business School and an A.B. from Harvard University. Mr. Kubacki has been a director of the Company since 1991.  

 

Charles M. Doucot has served as Executive Vice President since January 2019. From May 2018 until January 2019, he served as Vice President Sales & Marketing. Prior to joining the Company, he served as Vice President Sales & GM of Burning Glass Technologies, a data analytics company, from January 2016 to December 2017. From April 2014 to January 2016, he served as Sr. VP and GM at Lumesse, an HR technology company, responsible for the Americas Business and starting a new business unit. From August 2009 to February 2014, he served as VP WW Sales and Marketing for Kalido, a big data and analytics company. Mr. Doucot began his career spending over 15 years at Hewlett-Packard Company with increasing levels of global responsibility. Mr. Doucot received a B.S. in Electrical Engineering from Northeastern University.

 

William B. Norris has served as Controller since December 2022. Most recently, he served as Assistant Controller for the Company since August 2022 and as Accounting Manager for the Company from April 2021 until August 2022. From February 2020 until April 2021, he served as a Senior Accountant at Vicinity Energy, a clean energy company that owns and operates a portfolio of district energy systems. From 2016 to 2019, he served as an external auditor at Warren Averett, a public accounting firm. Mr. Norris received a B.S. in Accounting from Birmingham-Southern College, his M.B.A. from Boston University, and is a Certified Public Accountant.

 

Michael I. Schaffer has served as Vice President of Laboratory Operations since 1999. From December 2016 – December 2020, Dr. Schaffer served as a member of the Drug Testing Advisory Board (DTAB) which advises the administrator of Substance Abuse and Mental Health Services Administration (SAMHSA) on drug testing activities and laboratory certification. From 1990 to 1999, Dr. Schaffer served as Director of Toxicology, Technical Manager and Responsible Person for the Leesburg, Florida laboratory of SmithKline Beecham Clinical Laboratories. From 1990 to 1999, Dr. Schaffer was also a member of the Board of Directors of the American Board of Forensic Toxicologists. He has been Board certified since 1977. Dr. Schaffer has also served as an inspector for the College of American Pathologists since 1990. Dr. Schaffer received a Ph. D from the University of Chicago in Pharmacology and Toxicology, a B.S. in Zoology from the University of Illinois Urbana-Champaign, a B.S. and M.S. in Pharmacy and Pharmacognosy from the University of Illinois, College of Pharmacy. He has served as Chairman of the Society of Forensic Toxicologists as well as the Toxicology section of the American Academy of Forensic Sciences. He was awarded the Alexander O. Gettler Award for outstanding contribution to the field of Forensic Toxicology.

 

Peter H. Kamin is the founder and Managing Partner of 3K Limited Partnership. Prior to the formation of 3K, Mr. Kamin was a founding member and Managing Partner of ValueAct Capital. Mr. Kamin has served on the Board of Directors of Tile Shop Holdings, Inc. (NASDAQ: TTSH) (“Tile Shop Holdings”), a specialty retailer of natural stone and man-made tiles, setting and maintenance materials, and related accessories, since 2012, and as Chairman since July 2018. Mr. Kamin previously served on the boards of directors of MAM Software Group, Inc. (formerly NASDAQ: MAM), a leading provider of cloud-based business and on-premise management solutions for the auto parts, tires and vertical distribution industries, from 2012 to October 2019, and IAA, Inc. (NYSE: IAA), a publicly traded multi-channel vehicle marketplace and former subsidiary of KAR Auction Services, Inc from June, 2019 until it was sold in March, 2023. Mr. Kamin holds a BA from Tufts University and an MBA from Harvard’s Graduate School of Business. Mr. Kamin has served as a member of our Board since August 2022.

 

40
 

 

Darius G. Nevin has served as a member of our Board since August 2022. Mr. Nevin has been a member of G3 Capital Partners LLC, an adviser to private equity firms in the fields of security, telecommunications, and recurring services, and of G3 Investment Holdings LLC, an affiliated investment holding company, since 2010. Mr. Nevin has served on the boards of directors of Alarm.com Holdings, Inc. (NASDAQ: ALRM), a provider of interactive security solutions for home and business owners, since 2016, and of Cohealo, Inc., a venture-backed technology and services company that develops products for health systems, also since 2016. Prior to co-founding G3 Capital Partners, LLC, Mr. Nevin served as chief financial officer of Protection One, Inc., a then publicly traded company, from 2001 until June 2010. He served as a director and chairman of the audit committee of WCI Communities, Inc., a then publicly traded community developer and luxury homebuilder, from July 2013 through its acquisition in February 2017. Mr. Nevin earned an A.B. from Harvard College and an M.B.A. from the University of Chicago Booth School of Business.

 

Robyn C. Davis has been managing director of Angel Healthcare Investors, LLC, an early-stage investment group focused on medical devices, life sciences and specialty pharmaceutical companies since 2000. Additionally, Ms. Davis is a global Executive Coach at The Leadership Consortium. Prior to Angel Healthcare, Ms. Davis was a director of the merchant banking services practices for Barents Group, LLC, a strategy consultant at Bain & Company and a consultant at Computer Sciences Corporation. She currently serves as a director of Azenta Life Sciences (AZTA:Nasdaq-GS), a provider of life sciences sample management solutions, and Akston Biosciences, an early-stage company developing a novel fusion-protein platform for multiple conditions. Ms. Davis holds a B.A. in International Relations from Tufts University and an M.B.A from Harvard Business School. She holds an Executive Masters Professional Director Certification from the American College of Corporate Directors. Ms. Davis has served as a member of our Board since March 2021.

 

Fred J. Weinert is an entrepreneur who currently serves as President of Barrington Services Group, an international business consulting company as well as the Managing Member of a commercial real estate development group. From 1989 to 1995, Mr. Weinert was President of MW Partners LP, a private partnership, focused on retail product and services sector in the UK and USA, and was also an early-stage equity investor in Psychemedics. From 1973 to 1989 Mr. Weinert had an expansive career with Waste Management (NYSE: WM) that included 6 years as President of Waste Management International with responsibility for business development, partner relations, and operations in Argentina, Saudi Arabia, Australia, New Zealand, Hong Kong and Europe. During his career at WM, Mr. Weinert held other positions including Vice President, Mobilization Director, Regional Controller and Financial Analyst for acquisitions and government tenders. Prior to his WM career, Mr. Weinert was an Accounting Manager and Controller for a private company, and a public auditor for Arthur Andersen & Co. Mr. Weinert received a B.S. in Accounting from the University of Dayton (UD) in 1969. Mr. Weinert served as a member of the UD School of Business Advisory Council for 22 years, and in 2002 Mr. Weinert was awarded the UD Alumni Lifetime Achievement Award, and in 1999 he was recognized as the Department of Accounting Alumnus of the year. Mr. Weinert has been a director of the Company since 1991. 

 

41
 

 

Andrew M. Reynolds serves as an independent director for AddSecure, Idle Smart, and Linxup. From June 2011 until December 2017, Mr. Reynolds served as Senior Vice President of Global Business Development at Fleetmatics, PLC, of Dublin, Ireland (FLTX). From July 2007 until January 2011, Mr. Reynolds served as Senior Vice President of Corporate Development at Art Technology Group (ARTG). From September 2002 until June 2007, Mr. Reynolds served as Vice President of Corporate Development for Hyperion Solutions (HYSL). Mr. Reynolds received an M.B.A. from Cornell University and an A.B. from Dartmouth College. Mr. Reynolds has served as a member of our Board since April 2022.

 

Our Common Stock is listed on the NASDAQ Stock Market LLC, or Nasdaq, and Nasdaq’s listing standards relating to director independence apply to us. The Board of Directors has determined that the following current directors are independent under applicable Nasdaq listing standards: Messrs. Weinert, Kamin, Nevin and Reynolds, as well as Ms. Davis.

 

The Company strives to have the members of its Board of Directors possess a diverse set of skills and background so as to best provide guidance to the management team and oversight to the Company. While the Nominating Committee does not have a formal policy in this regard, the Nominating Committee views diversity broadly to include a diversity of experience, skills and viewpoint, as well as diversity of gender and race. The Nominating Committee does not assign specific weights to particular criteria and no particular criterion is necessarily applicable to all prospective nominees. Skills sought include financial, capital markets, executive leadership, sales and marketing, domestic and international business development and strategic planning.

 

The Company recognizes that different board leadership structures may be appropriate for companies in different situations and believe that no one structure is suitable for all companies. We believe our current board leadership structure is optimal for us because it demonstrates to our employees, suppliers, customers, and other stakeholders that we are under strong leadership, with a single person setting the tone and having primary responsibility for managing our operations. A single leader for both the Company and the Board of Directors eliminates the potential for confusion or duplication of efforts and provides us with clear leadership.

 

Because the positions of Chairman of the Board and Chief Executive Officer are held by the same person, the Board also believes it is appropriate for the independent directors to elect one independent director to serve as a Lead Independent Director. In addition to presiding at executive sessions of independent directors, the Lead Independent Director has the responsibility to: (1) coordinate with the Chairman of the Board and Chief Executive Officer in establishing the agenda and topic items for Board meetings; (2) retain independent advisors on behalf of the Board as the Board may determine is necessary or appropriate; and (3) perform such other functions as the independent directors may designate from time to time. Mr. Weinert currently serves as the Lead Independent Director, a position he has held since March 2021.

 

Our overall leadership structure consists of a single individual serving as Chief Executive Officer and Chairman of the Board, with independent and experienced directors making up the majority of our Board. Having a single leader for both the Company and the Board eliminates the potential for confusion or duplication of efforts. We believe that this structure is beneficial to us and our stockholders.

 

The Company has a code of ethics that applies to all employees and non-employee directors. This code satisfies the requirements set forth in Item 406 of Regulation S-K and applies to all relevant persons set forth therein. The Company will mail to interested parties a copy of the Code of Ethics upon written request and without charge. Such request shall be made to our General Counsel, 289 Great Road, Acton, Massachusetts 01720.

 

The Audit Committee, whose members are Ms. Davis and Messrs. Nevin, Reynolds and Weinert, reviews the appropriateness, quality and acceptability of the Company’s accounting policies and the integrity of financial statements reported to the public, and compliance with legal and regulatory requirements. The Board has determined that each member of the Audit Committee is an “independent director” under the rules of the Nasdaq Stock Market governing the qualifications of the members of audit committees, and each member of the Audit Committee satisfies the requirements of the Nasdaq Stock Market regarding competency in financial matters. In addition, the Board of Directors has determined that Mr. Weinert, the Chairman of the Audit Committee, qualifies as an “Audit Committee Financial Expert” as defined by the Securities and Exchange Commission rules.

 

42
 

 

Item 11. Executive Compensation

 

Director Compensation

 

Mr. Kubacki receives no additional compensation for serving on the Company’s Board of Directors. Each of the Company’s outside (non-employee) directors received cash compensation of $12,500 per quarter served in 2022. Both Messrs. Kamin and Nevin received pro-rated cash compensation for the third quarter of 2022 since they were elected on August 12, 2022. In addition, Mr. Weinert received additional cash compensation of $15,000 in 2022 for serving as Chairman of the Audit Committee, and $40,300 for serving as Lead Independent Director and as the Board’s corporate governance representative overseeing the Corporation’s activities in Brazil. Each of the outside directors has also been granted from time-to-time equity awards under the Company’s equity compensation plans, most recently in August 2022. In each case the directors were granted stock unit awards or non-qualified stock options with an equivalent fair value, that in each case vest with respect to 50% of the number of shares covered thereunder on approximately the first anniversary of the date of grant, and with respect to the balance of 50% of the shares on approximately the second anniversary of the date of grant. Any unvested stock unit awards or options generally terminate upon the cessation of a recipient’s service as a member of the Board of Directors, subject to partial or full vesting in the case of termination on account of death or permanent disability. In the event of a change in control of the Company (as defined in the stock unit award or option agreement evidencing the award) the stock unit awards or options become fully vested immediately prior to the effective date of such change in control.

 

The following table shows, for the fiscal year ended December 31, 2022, the compensation paid by the Company or accrued for such year, to the Company’s non-employee directors. The compensation paid to Mr. Kubacki for his service as Chairman, Chief Executive Officer and President, is reported in the Summary Compensation Table under the caption “Executive Compensation” below.

 

Director Compensation for Fiscal Year Ended December 31, 2022

 

(a)

(b)

(c)

(d)

(e)

(f)

Name

Fees Earned or Paid in Cash

Stock Awards

(1)

Option Awards

(1)

All other Compensation (4)

(4)

Total

Robyn C. Davis

$         50,000

$    78,120

(2)

$             -

(3)

$                 -

  

$       128,120

Harry F. Connick*

$         12,500

$              -

(2)

$             -

(3)

$                 -

  

$         12,500

Peter H. Kamin

$         18,750

$    59,850

(2)

$             -

(3)

$                 -

  

$         78,600

Darius G. Nevin

$         18,750

$    59,850

(2)

$             -

(3)

$                 -

  

$         78,600

Andrew M. Reynolds

$         37,500

$    78,120

(2)

$             -

(3)

$                 -

  

$       115,620

Walter S. Tomenson, Jr.**

$         31,250

$    78,120

(2)

$             -

(3)

$                 -

  

$       109,370

Fred J. Weinert 

$       105,300

$    78,120

(2)

$             -

(3)

$                 -

  

$       183,420

 

* Director Harry F. Connick retired from the Board of Directors on April 4, 2022.

 

** Director Walter S. Tomenson, Jr. retired from the Board of Directors on August 12, 2022.

 

 

(1)

The amounts in columns (c) and (d) reflect the grant date fair values of awards and options to the named individuals in 2022.
     
  (2) As of December 31, 2022, the number of shares underlying unvested stock unit awards held by the non-employee directors was as follows: Mr. Connick: 5,500, which vest on April 30, 2023; Mr. Kamin: 9,000, of which 4,500 vest on August 12, 2023, and the balance vest on August 12, 2024; Mr. Nevin: 9,000, of which 4,500 vest on August 12, 2023, and the balance vest on August 12, 2024; Mr. Reynolds: 14,000, of which 1,000 vest on April 4, 2023, 6,000 vest on April 30, 2023, 1,000 vest on April 4, 2024 and 6,000 vest on April 30, 2024; Mr. Weinert: 17,500, of which 11,500 vest on April 30, 2023, and the balance vest on April 30, 2024; and Ms. Davis: 18,500, of which 1,000 shares vested on March 16, 2023, 11,500 vest on April 30, 2023, and the balance vest on April 30, 2024; Mr. Tomenson: 0.

 

 

43
 

 

 

(3)

As of December 31, 2022, the number of shares underlying non-qualified stock options held by the non-employee directors was as follows: Mr. Connick: 2,000; and Mr. Weinert: 81,500.

 

 

(4)

Any perquisites or other personal benefits received from the Company by the named director were less than the reporting thresholds established by the Securities and Exchange Commission ($10,000).

 

EXECUTIVE COMPENSATION

 

Overview of Compensation Program

 

The Compensation Committee of the Board has responsibility for establishing, implementing and continually monitoring adherence to the Company’s compensation philosophy. The Compensation Committee ensures that the total compensation paid to the executive officers is fair, reasonable and competitive.

 

Throughout this annual report the individual who served as the Company’s Chief Executive Officer during fiscal 2022, as well as those individuals who were the Company’s two most highly compensated executive officers other than the Chief Executive Officer are included in the Summary Compensation Table below and are referred to as the “named executive officers”.

 

Compensation Philosophy and Objectives

 

The Compensation Committee believes that the most effective executive compensation program is one that is designed to reward the achievement of specific annual performance goals by the Company, and which aligns executives’ interests with those of the stockholders by rewarding performance with the ultimate objective of improving stockholder value. The Compensation Committee evaluates both performance and compensation to ensure that the Company maintains its ability to attract and retain superior employees in key positions and that compensation provided to key employees remains competitive relative to the compensation paid to similarly situated executives of similarly sized public companies. To that end, the Compensation Committee believes executive compensation packages provided by the Company to its executives, including the named executive officers, should include both cash and stock-based compensation and that its executives’ performance should be rewarded as measured against established goals.

 

Role of Executive Officers in Compensation Decisions

 

The Compensation Committee makes all compensation decisions for the Chief Executive Officer but takes into account his recommendations when making compensation decisions with respect to the other executive officers.

 

The Chief Executive Officer annually reviews the performance of each other executive officer. The conclusions reached and recommendations based on these reviews, including with respect to salary adjustments and annual award amounts, are presented to the Compensation Committee. The Compensation Committee can exercise its discretion in modifying any recommended adjustments or awards to executives.

 

Setting Executive Compensation

 

Based on the foregoing objectives, the Compensation Committee has structured the Company’s annual and long-term incentive-based cash and non-cash executive compensation to motivate executives to achieve the business goals set by the Company and reward the executives for achieving such goals.

 

In making compensation decisions, the Compensation Committee compares each element of total compensation against what the Compensation Committee believes to be the average amount paid to similarly situated executives at comparably sized publicly-traded and privately-held companies.

 

A significant percentage of total compensation is allocated to incentives as a result of the philosophy mentioned above. The Compensation Committee determines the appropriate level and mix of incentive compensation. Income from such incentive compensation is realized as a result of the performance of the Company or the individual, depending on the type of award, compared to established goals. A significant portion of its total compensation payable to executive officers is in the form of cash bonus awards tied to achievement of performance goals and to the award of restricted stock units or stock options that would become vested over a period of time.

 

44
 

 

2022 Executive Compensation Components

 

For the fiscal year ended December 31, 2022, the principal components of compensation for named executive officers were:

 

 

●

base salary
 

●

performance-based cash incentive compensation; and
 

●

long-term equity incentive compensation

 

Base Salary

 

Base salary ranges for named executive officers are determined by the Compensation Committee for each executive based on his or her position and responsibility, a market competitive assessment of similar roles at other companies and a comparison of salaries paid to peers within the Company. Salary levels are typically considered annually as part of the Company’s performance review process as well as upon a promotion or other change in job responsibility. Merit based increases to salaries of executive officers are based on the Compensation Committee’s assessment of the individual’s performance.

 

In the third quarter of 2020, at the request of the Chief Executive Officer, each of the named executive officers took a 10% base salary reduction to curtail costs. During the first quarter of 2021, again at the request of the Chief Executive Officer, each of the named executive officers took an additional salary cut of 10% of his or her current base salary to curtail costs. The additional cuts from 2021 remained in place throughout the remainder of 2021 until the first quarter ended 2022 and are reflected in the Summary Compensation Table below. The initial 10% base salary reduction made during the third quarter of 2020 for executive officers remains in place.

 

Incentive Cash Bonus Compensation

 

The Company typically provides its named executive officers with the opportunity to earn cash incentive bonuses. For most years, bonuses are determined based on a combination of qualitative and quantitative, company and individual measures, the details of which are established annually in the form of business objectives. The business objectives may vary for each executive based upon his or her responsibilities and may include financial and/or strategic measures. The Compensation Committee typically retains the discretion to amend the bonus program including the ability to increase or decrease any bonus payment and make changes to any financial and/or strategic measures. In 2022, the named executive officers’ bonuses were computed as follows: (i) up to seven and one-half percent (7.5%) of base salary would be payable if the Company achieved pre-determined revenue targets; (ii) up to an additional seven and one-half percent (7.5%) of base salary would be payable if the Company achieved pre-determined earnings per share targets; and (iii) up to an additional ten percent (10%) of base salary would be payable based on achievement of individual written performance objectives for the fiscal year, as determined by Mr. Kubacki (for named executive officers other than himself) and as determined by the Compensation Committee (with respect to achievement by Mr. Kubacki of his performance objectives). The Compensation Committee retained sole discretion over all matters relating to the annual bonus payments, including, without limitation, the decision to pay any bonuses, the amount of each bonus, if any, the ability to increase or decrease any bonus payment and make changes to any financial and/or strategic measures.

 

Long-Term Equity Incentive Compensation

 

It is the philosophy of the Company to provide executives with incentives to receive equity in the Company and, thus, align their financial interests with those of the Company’s shareholders. The Company’s 2006 Incentive Plan provides long-term rewards and incentives to the Company’s named executive officers, as well as other participants.

 

Stock Unit Awards.

 

Stock unit awards (“Awards”) represent a right to receive shares of the Company’s Common Stock in varying amounts subject to satisfaction of certain time-based vesting requirements. The amount of stock unit awards granted to the named executive officers typically varies based upon their levels of responsibility, their individual performance and the Company’s performance for the year preceding the year of grant. Each of the units provides for vesting over the four-year period following the date of grant and are convertible into shares of Common Stock of the Company upon vesting.

 

Stock Options.

 

Stock options (“Option Awards”) represent a right to acquire shares of the Company’s Common Stock in varying amounts at a strike price equal to the closing price on the date of grant, subject to satisfaction of certain time-based vesting requirements. The number of Option Awards granted to the executive officers typically varies based upon their levels of responsibility and their individual performance. Each of the Option Awards provides for vesting over the four-year period following the date of grant.

 

45
 

 

Retirement and Other Benefits

 

The Company maintains a 401(k) plan for the benefit of all employees who have satisfied minimum age requirements. Employees have the opportunity to contribute to the plan on a before tax basis, subject to limits prescribed under the Internal Revenue Code. All employee contributions are 100% vested on the date of contribution. The Company does not maintain any separate non-qualified retirement plans.

 

Perquisites and Other Personal Benefits

 

Any perquisites or other personal benefits that the Company offers to its executive officers are below the threshold limit ($10,000 per executive, per annum) for reporting under Securities and Exchange Commission rules.

 

The Company has entered into Change of Control Severance Agreements with Messrs. Kubacki and Doucot. The Change of Control Severance Agreements are designed to promote stability and continuity of senior management. Information regarding applicable payments under such agreements for Messrs. Kubacki and Doucot is provided under the heading “Potential Payments upon Termination and Change in Control” below.

 

Tax and Accounting Implications

 

As part of its role, the Compensation Committee reviews and considers the deductibility of executive compensation under Section 162(m) of the Internal Revenue Code, which provides that the Company may not deduct compensation of more than $1,000,000 per year to named executive officers except, in the case of equity awards granted prior to 2018, to the extent they constituted performance-based compensation. Depending on future stock prices, it is possible that a portion of the payments that might be payable to Mr. Kubacki under the agreement with him described under the heading “Potential Payments upon Termination and Change in Control” below may not be fully deductible. Subject to the foregoing, the Company believes that all compensation paid to its executive officers is, or will be when paid, fully deductible for federal income tax purposes.

 

Summary of Cash and Certain Other Compensation

 

The following tables show, the total compensation earned by the named executive officers during the years ended December 31, 2022 and 2021, and outstanding equity awards held by the named executive officers as of December 31, 2022.

 

46
 

 

Summary Compensation Table

 

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

Name and Position

Year

Salary

Bonus (1)

Stock Awards

Option Awards

Non-Equity Incentive Plan Compensation

Change in Pension Value and Nonqualified Deferred Compensation Earnings

All Other Compensation (2)

Total

Raymond C. Kubacki

2022

$  470,138

$              -

$  130,200

$            -

$                   -

$                            -

$                 -

$     600,338

Chairman, CEO, & President

2021

$  430,702

$    42,500

$  150,650

$            -

$                   -

$                            -

$                 -

$     623,852

Charles M. Doucot

2022

$  282,896

$    15,000

$    71,610

$            -

$                   -

$                            -

$                 -

$     369,506

Executive Vice President

2021

$  238,750

$    24,000

$    78,600

$            -

$                   -

$                            -

$                 -

$     341,350

Michael I. Schaffer 

2022

$  258,456

$      2,700

$    32,550

$            -

$                   -

$                            -

$                 -

$     293,706

Vice President, Labortory Operations

2021

$  236,024

$    12,000

$    29,475

$            -

$                   -

$                            -

$                 -

$     277,499

 

(1)        

The amounts in column (d) reflect cash bonus awards made to the named executive officers based on achievement of certain financial and individual objectives, as described in more detail below under the heading “Incentive Cash Bonus Compensation”.
   

(2)        

The amounts shown in column (i) reflect for each named executive officer matching contributions allocated by the Company to each of the named executive officers during the applicable year pursuant to the Company’s 401(k) Plan (which is more fully described below under the heading “Retirement and Other Benefits”); the amount of perquisites attributable to each named executive officer did not exceed $10,000 in either 2021 or 2022.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

47
 

 

Outstanding Equity Awards at Fiscal Year-End

 

 

Option Awards

Stock Awards

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

Name

Number of Securities Underlying Unexercised Options Exercisable

Number of Securities Underlying Unexercised Options Unexercisable

Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options

Option Exercise Price

Option Expiration Date

Number of Shares or Units of Stock That Have Not Vested

Market Value of Shares or Units of Stock That Have Not Vested (1)

Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested

Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested

Raymond C. Kubacki

 22,000

 -   

  

$10.20

9/15/2025

        
 

 42,000

 -   

  

$13.82

5/12/2026

        
 

 40,000

 -   

  

$18.87

5/4/2027

        
 

 28,000

 -   

  

$21.04

5/3/2028

        
 

 45,000

 15,000

  

$10.60

5/3/2029

        
 

 7,500

 7,500

  

$4.07

11/11/2030

 17,500

$85,750

    
 

 -   

 -   

  

 -   

 -   

 17,250

$84,525

    
 

 -   

 -   

  

 -   

 -   

 20,000

$98,000

    

Charles M. Doucot

 18,000

 -   

  

$21.04

5/3/2028

        
 

 22,500

 7,500

  

$10.60

5/3/2029

        
 

 3,500

 3,500

  

$4.07

11/11/2030

 9,000

$44,100

    
 

 -   

 -   

  

 -   

 -   

 9,000

$44,100

    
 

 -   

 -   

  

 -   

 -   

 11,000

$53,900

    

Michael I. Schaffer 

 7,500

 -   

  

$13.82

5/12/2026

        
 

 8,000

 -   

  

$18.87

5/4/2027

        
 

 5,000

 -   

  

$21.04

5/3/2028

        
 

 7,500

 2,500

  

$10.60

5/3/2029

        
 

 1,000

 1,000

  

$4.07

11/11/2030

 3,500

$17,150

    
 

 -   

 -   

  

 -   

 -   

 3,375

$16,538

    
 

 -   

 -   

  

 -   

 -   

 5,000

$24,500

    

 

(1) Based on closing price of $4.90 per share on December 31, 2022 on the Nasdaq Stock Market.

 

Potential Payments upon Termination and Change in Control

 

The Company has change-in-control severance agreements in place with each of Messrs. Kubacki and Doucot providing for severance benefits for a period of up to 12 months in the event of termination within 12 months following a change in control (as defined in the agreements). The agreements provide for severance benefits only if (1) the Company undergoes a change in control (as defined in the agreement) and (2) within 12 months thereafter either (a) the Company (or its successor) terminates the employee (other than termination for “cause”), or (b) the employee terminates his employment for “good reason” (as defined in his agreement). The agreements do not provide for severance benefits in the event of an employee’s death or disability, or in the event of his voluntary termination without good reason. The agreements provide that the employee shall not compete with the Company during the period in which he is entitled to receive severance payments. Except for such change-in-control severance agreements, and except for the separate employment severance agreement with Mr. Doucot described below, none of the named executive officers has an employment agreement with the Company.

 

48
 

 

Each of the stock unit award and option agreements with Messrs. Kubacki, Doucot and Schaffer described in the Summary Compensation Table above provides that the vesting would accelerate upon a change in control. In the event the Company had incurred a change in control on December 31, 2022, and terminated the employment of Messrs. Kubacki, Doucot and Schaffer on such date, the amounts paid out to such named executive officers: (i) the Change in Control agreements with Messrs. Kubacki and Doucot in effect on the date of filing this Report and (ii) the existing equity award agreements with Messrs. Kubacki, Doucot and Schaffer would have been as follows:

 

Payments and Benefits Upon Termination and Change in Control

 

(a)

(b)

(c)

(d)

(e)

(f)

Name

Salary (1)

Accrued Vacation (2)

Health Benefits (3)

Acceleration of Equity Awards (4)

Total

Raymond C. Kubacki (5)

          

12 Month

$      486,500

$     18,718

$    33,325

$     268,275

$     806,818

6 Month (change of location only)

$      243,250

$     18,718

$    16,663

$     268,275

$     546,906

Charles Doucot (6)

          

12 Month

$      355,000

$     11,489

$    29,136

$     142,100

$     537,725

Michael I. Schaffer

          

12 Month

$              -   

$     11,764

$            -

$       58,188

$       69,952

 

(1)

 The amounts in column (b) reflect current base salary in effect on December 31, 2022 for Mr. Kubacki and on August 1, 2020 for Mr. Doucot.
   

(2)

Accrued vacation is payable upon separation of service whether or not in connection with a change in control.
   

(3)

The amounts in column (d) represent the amount payable by the Company during the applicable period for continuation of health benefits. 
   

(4)

The amounts in column (e) reflect: (i) the acceleration of the vesting under stock unit awards granted under the Company’s 2006 Incentive Plan triggered by a change in control, as provided in each executive officer’s respective stock unit award agreement with the Company, the valuation of which is determined by multiplying the number of stock unit awards that would have become vested on December 31, 2022, pursuant to such acceleration provision, times the closing price of the Company stock on such date ($4.90 per share); plus (ii) the acceleration of the vesting under in-the-money unvested stock options granted under the Company’s 2006 Incentive Plan triggered by a change in control, as provided in each executive officer’s respective stock option agreement with the Company, the valuation of which is determined by assuming a net exercise of all unvested stock options having an exercise price that is less than the closing price of the Company stock on such date ($4.90 per share).
   

(5)

 Mr. Kubacki’s arrangement provides for up to 12 months of salary in the event of a termination by the Company without cause (as defined in his agreement) or a termination by him for good reason (as defined in his agreement) in either case, within a 12 month period following a change in control of the Company (as such term is defined in the agreement), provided, however, that in the event of termination by Mr. Kubacki for good reason solely on account of a change in his required place of employment, following a change in control, then in lieu of 12 months of salary and bonus compensation, his benefits would be limited up to 6 months of salary and bonus compensation.
   

(6)

 Mr. Doucot’s arrangement provides for 12 months of salary (at the rate that was in effect for the 12-month period preceding August 1, 2020, or any higher rate thereafter in effect) and bonus continuation, in the event of a termination by the Company without cause (as defined in his agreement) or a termination by him for good reason (as defined in his agreement) in either case, within a 12 month period following a change in control of the Company (as such term is defined in the agreement).

 

49
 

 

Employment Severance Agreement

 

In addition to a change-in-control severance agreement, the Company also entered into an employment severance agreement with Mr. Doucot providing for severance benefits for a period of up to 6 months. The agreement provides for severance benefits if (a) the Company (or its successor) terminates Mr. Doucot (other than termination for “cause”), or (b) Mr. Doucot terminates his employment for “good reason” (as defined in his agreement). The agreement does not provide for severance benefits in the event of his death or disability, or in the event of his voluntary termination without good reason. Any payments under the severance agreement are reduced by the amount of any payments received by him under his change-in-control severance agreement.

 

Equity Compensation Plan Information

 

The following table provides information as of December 31, 2022, with respect to shares of the Company’s common stock that were issuable under the Company’s 2006 Incentive Plan (the “2006 Incentive Plan”).

 

 

Plan Category

  

Number of Securities to Be Issued Upon Exercise of Outstanding Options, Warrants and Rights

    

Weighted Average Exercise Price of Outstanding Options, Warrants and Rights

    

Number of Securities that Remained Available for Future Issuance

  

Equity compensation plans approved by security holders

     745,375 (1)   $ 14.19 (2)     182,992  

Equity compensation plans not approved by security holders

     -       -       -  

Total

     745,375     $ 14.19       182,992  

 

 

(1)

This amount includes 508,500 shares subject to outstanding stock options with a weighted average remaining contractual term of 4.9 years and 238,000 shares subject to outstanding stock unit awards.
 

(2)

 The weighted-average exercise price information does not include any outstanding stock unit awards.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following table shows, as of March 15, 2023, the number of shares beneficially owned (i) by those stockholders who are known to the Company to own beneficially more than five percent of the outstanding Common Stock of the Company, (including their addresses) (ii) by each director and nominee for director of the Company, (iii) by each named executive officer, and (iv) by all directors and executive officers as a group.

 

 

 

50
 

 

Name

Amount and Nature of Beneficial Ownership

(1)

Percentage Owned (2)
       

Peter H. Kamin

 624,737

(3)

11.0%

289 Great Road, Suite 200

      

Acton, MA 01720

      
       

Raymond C. Kubacki

 400,462

(4)(6)

6.8%

289 Great Road, Suite 200

      

Acton, MA 01720

      
       

Renaissance Technologies LLC 

 290,463

(5)

5.1%

800 Third Avenue

      

New York, NY 10022

      
       

Fred J. Weinert

 260,064

(4)(6)(7)

4.5%

Robyn C. Davis

 19,000

(6)

*

Andrew M. Reynolds

 7,000

(6)

*

Darius G. Nevin

 25,181

  

*

Michael I. Schaffer

 57,951

(4)(6)

1.0%

Charles M. Doucot

 63,175

(4)(6)

1.1%
       

All Executive Officers and Directors (9 persons)

 1,123,296

(8)

23.9%

 

* Denotes ownership of less than 1%.

 

 

(1)

Shares are considered beneficially owned, for the purpose of this table only, if held by the person indicated as beneficial owner, or if such person, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares the power to vote, to direct the voting of and/or to dispose of or to direct the disposition of such security, or if the person has the right to acquire beneficial ownership within sixty (60) days, unless otherwise indicated in these footnotes.

 

 

(2)

Pursuant to the rules of the Securities and Exchange Commission, shares of Common Stock which an individual or group has a right to acquire within 60 days pursuant to the exercise of options or pursuant to the vesting of stock unit awards are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group, but with respect to options and stock unit awards, are not deemed outstanding for the purpose of computing the percentage ownership of any other person shown in this table.

 

 

(3)

Based on a Statement of Changes in Beneficial Ownership on Form 4 filed by Mr. Kamin on June 9, 2022. Includes 365,726 shares held by Mr. Kamin as trustee of certain trusts and 44,980 shares held by a limited partnership of which Mr. Kamin serves as general partner.

 

 

(4)

Includes the following number of shares of Common Stock which the individual had a right to acquire within 60 days pursuant to the exercise of options: Mr. Kubacki – 199,500; Mr. Weinert – 81,500; Dr. Schaffer – 31,500; and Mr. Doucot – 51,500.

 

 

(5)

Based on the statement on Schedule 13G/A filed on February 13, 2023, each of Renaissance Technologies, LLC, a registered investment adviser, and Renaissance Technologies Holding Company has sole voting and dispositive power over 290,463 shares of Common Stock.

 

 

(6)

Includes the following number of shares of Common Stock which the individual had the right to receive within 60 days pursuant to the vesting of stock unit awards: Mr. Kubacki – 5,750; Mr. Weinert – 11,500; Mr. Reynolds – 7,000; Ms. Davis – 12,500; Dr. Schaffer – 1,125; and Mr. Doucot – 3,000.

 

 

(7)

Includes 108,381 shares held by Mr. Weinert as trustee of a trust and 1,600 shares held by Mr. Weinert’s spouse.

 

 

(8)

Includes 364,000 shares which the executive officers and directors had the right to acquire within 60 days pursuant to the exercise of options, and 34,875 shares which were issuable to the executive officers and directors within 60 days pursuant to the vesting of stock unit awards.

 

51
 

 

Item 13. Certain Relationships and Related Transactions and Director Independence

 

Under the rules of the Nasdaq Stock Market, a majority of the directors and all of the members of the Audit Committee must qualify as independent directors. The Board of Directors of the Company conducts an annual review of the independence of the members of the Board and its committees. Five of our six directors are nonemployee directors (all except Mr. Kubacki). Although the Board has not adopted categorical standards of materiality for independence purposes (other than those set forth in Securities and Exchange Commission Regulations and the Nasdaq Stock Market listing standards), information provided by the directors and the Company did not indicate any relationships (e.g., commercial, industrial, banking, consulting, legal, accounting, charitable, or familial), which would impair the independence of any of the nonemployee directors.

 

The Board of Directors has adopted a policy whereby the Company’s Audit Committee is responsible for reviewing any proposed related party transaction. The types of transactions covered by the policy include payments for products or services to or indebtedness to or from, related parties, as defined in Item 404(b) of Regulation S-K under the federal securities laws. The Audit Committee has determined that there were no related party transactions with any related party in fiscal 2022 that would require disclosure under Item 404(a) of Regulation S-K.

 

Item 14. Principal Accounting Fees and Services

 

The following table presents fees paid or payable to BDO USA, LLP for services attributable to fiscal years 2022 and 2021:

 

   

Fiscal Year

  
   

2022

    

2021

  

Audit Fees (1)

   $ 440,861     $ 392,309  

Audit-Related Fees (2)

     23,873       15,950  

Tax Fees (3)

     57,593       182,275  

Total

   $ 522,327     $ 590,534  

 

 

(1)

Audit Fees – Fees for professional services rendered to the Company (or estimates of fees for services to be rendered) in connection with auditing the Company’s annual financial statements and reviewing the interim financial information included in the Company’s Quarterly Reports on Form 10-Q and consents and assistance with the review of documents filed with the Securities and Exchange Commission.

 

 

(2)

Audit-Related Fees – Fees billed to the Company or to the Company’s employee retirement plan for services related to the audit of the Company’s financial statements that are not reported under Audit Fees, which include audit work performed on certain of the Company’s benefit plans.

 

 

(3)

Tax Fees – Fees billed to the Company related to tax compliance and consultation.

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules

 

(a) (1) Financial Statements required by Item 15 are included and indexed in Part II, Item 8.

(a) (2) Financial Statement Schedules included in Part IV of this report. Schedule II is omitted because information is included in Notes to Financial Statements. All other schedules under the accounting regulations of the SEC are not required under the related instructions and are inapplicable and, thus have been omitted.

(a) (3) See “Exhibit Index” included elsewhere in this Report.

 

Item 16. Form 10-K Summary

 

None.

 

52
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

PSYCHEMEDICS CORPORATION
   

Date: March 27, 2023

By: /s/ RAYMOND C. KUBACKI
Raymond C. Kubacki
Chairman, President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

  /s/ RAYMOND C. KUBACKI
  Raymond C. Kubacki

Chairman, President and Chief Executive Officer, Director
(Principal Executive Officer)

 March 27, 2023
     

  /s/ WILLIAM B. NORRIS
  William B. Norris

Controller
(Principal Financial and Accounting Officer)

 March 27, 2023
     

  PETER H. KAMIN*
  Peter H. Kamin

Director

  
     

  DARIUS G. NEVIN*
  Darius G. Nevin

Director

  
     

  ANDREW M. REYNOLDS*
  Andrew M. Reynolds

Director

  
     

  FRED J. WEINERT*
  Fred J. Weinert

Director

  
     

  ROBYN C. DAVIS*
  Robyn C. Davis

Director

  
     

*By: /s/ RAYMOND C. KUBACKI
   Raymond C. Kubacki

Attorney-in-Fact

 March 27, 2023

 

 

 

 

53
 

EXHIBIT INDEX

 

     

Exhibit
Number

  

Description

3.1

  

Amended and Restated Certificate of Incorporation filed with the State of Delaware on August 1, 2002 — (Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended September 30, 2002).

3.2

  

Amended and Restated By-Laws of the Company — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on July 31, 2015).

4.1

  

Specimen Stock Certificate — (Incorporated by reference from the Registrant’s Registration Statement on Form 8-A filed on July 31, 2002).

10.2.1P

  

Lease dated October 6, 1992, with Mitchell H. Hersch, et. Al with respect to premises in Culver City, California — (Incorporated by reference from the Registrant’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 1992).

10.2.2P

  

Security Agreement dated October 6, 1992, with Mitchell H. Hersch et. Al — (Incorporated by reference from the Registrant’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 1992).

10.2.3

  

First Amendment to Lease dated with Mitchell H. Hersch, et.al California — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1997).

10.2.4

  

Second Amendment to Lease dated with Mitchell H. Hersch, et.al. California — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1997).

10.2.5

  

Third Amendment to Lease dated December 31, 1997, with Mitchell H. Hersch, et.al. California — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1997).

10.2.6

  

Fourth Amendment to Lease dated May 24, 2005, with Mitchell H. Hersch, et.al. California — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005).

10.2.7

  

Sixth Amendment to Lease dated October 13, 2015, with Mitchell H. Hersch, et.al. California — Supersedes the Fifth amendment in its entirety (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015)
10.2.8   Eighth Amendment to Lease dated March 20, 2022, with Mitchell H. Hersch, et.al. California — Supersedes the Seventh amendment in its entirety.
     
     

 

54
 

 

TABLE OF CONTENTS

 

     

Exhibit
Number

  

Description

10.3*

  

2006 Incentive Plan, as amended — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 17, 2021).

10.4*

  

Form of Stock Unit Award used with employees and consultants under the 2006 Incentive Plan — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 19, 2016).

10.5*

  

Form of Stock Unit Award used with non-employee directors under the 2006 Equity Incentive Plan — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 19, 2016).

10.6*

  

Form of Incentive Stock Option Agreement used with employees under the 2006 Incentive Plan (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 19, 2016)

10.7*

  

Form of Non Qualified Stock Option Agreement used with employees and consultants under the 2006 Incentive Plan (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 19, 2016)

10.8*

  

Form of Non Qualified Stock Option Agreement used with non-employee directors under the 2006 Incentive Plan (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 19, 2016)

10.9*

  

Change in control severance agreement with Ray Kubacki dated March 21, 2023

10.10*

  

Severance agreement with Charles Doucot dated February 26, 2019 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019)
10.11   Amendment dated September 3, 2020 to Change in Control Severance Agreement between Psychemedics Corporation and Charles Doucot (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on September 10, 2020)

10.12

  

Lease dated July 29, 2019, with Culver City/Hannum, LLC with respect to 5750 Hannum premises in Culver City, CA — (Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019)

10.13

  

Loan agreement dated March 20, 2014, with Banc of America Leasing and Capital, LLC — (Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014)

10.13.1

  

Letter Agreement dated September 15, 2015, with Banc of America Leasing and Capital, LLC, together with Equipment Security Note dated September 15, 2015 and Proposal Letter dated August 19, 2015 — (Incorporated by reference from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015)

10.13.2

  

Letter Agreement dated October 30, 2017, with Banc of America Leasing and Capital, LLC, together with Equipment Security Note dated November 10, 2017 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2017)

10.13.3

  

Letter Agreement dated December 3, 2019, with Banc of America Leasing and Capital, LLC, together with Equipment Security Note dated December 4, 2019 — (Incorporated by reference from the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019)

10.13.4

  

Conditional Waiver and Amendment No 1. To Master Loan and Security Agreement dated November 4, 2020, with Banc of America Leasing & Capital, LLC — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on November 9, 2020)

10.13.5

  

Conditional Waiver dated March 19, 2021, and Amendment Number 002 dated March 23, 2021 to Master Loan and Security Agreement Amendment dated March 19, 2014 between Banc of America Leasing & Capital, LLC and Psychemedics Corporation LLC — (Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on March 23, 2021)

10.14

  

Form of Indemnification Agreement with Directors and Executive Officers of the Company*

 

 

55
 

 

21.1

  

Subsidiaries of the Registrant

23.1

  

Consent of BDO USA, LLP, Independent Registered Public Accounting Firm

24

  

Power of Attorney

31.1

  

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

  

Certification of Controller Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

  

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2

  

Certification of Controller Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS

  

Inline XBRL Instance Document

101.SCH

  

Inline XBRL Taxonomy Extension Schema

101.CAL

  

Inline XBRL Taxonomy Extension Calculation Linkbase

101.DEF

  

Inline XBRL Taxonomy Extension Definition Linkbase

101.LAB

  

Inline XBRL Taxonomy Extension Label Linkbase

101.PRE

  

Inline XBRL Taxonomy Extension Presentation Linkbase

104

  

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

*

Management compensation plan or arrangement

 

56
EX-10.28 2 ex_492590.htm EXHIBIT 10.2.8 ex_492590.htm
 

Exhibit 10.2.8

 

EIGHTH AMENDMENT TO LEASE

 

This EIGHTH AMENDMENT TO LEASE (the "Amendment") is made and entered into as of the 20th day of March 2022, by and between UPLANDER LLC(“Lessor") and PSYCHEMEDICS CORPORATION, a Delaware corporation ("Lessee"), with respect to that Standard Industrial Lease dated October 6, 1992, and amended January 1, 1993, December 16, 1994, December 31, 1997, May 24, 2005, November 22, 2011, October 13, 2015 and June 26, 2020 (as amended, the “Lease"), pursuant to which Lessee leases from Lessor those certain premises located at 5830 Uplander Way, Los Angeles County, California and 5832 Uplander Way, Los Angeles County, California (collectively the "Premises"). Unless otherwise defined herein, all capitalized terms used in this Amendment shall have the same meanings as are ascribed to such terms in the Lease. Lessor and Lessee hereby acknowledge the following:

 

RECITALS

 

A. Lessee herewith exercises the first Option to Extend Term provided in the Seventh Amendment to Lease dated June 26, 2020. Said Lease Extension shall commence January 1, 2023 and shall terminate December 31, 2024.

 

B. Lessor and Lessee desire to modify the Lease as provided herein.

 

C. Except as amended and modified, all terms of the Lease, as amended, shall remain in full force and effect.

 

NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, and other good and valuable consideration, receipt of which is hereby acknowledged, Lessor and Lessee agree as follows:

 

AGREEMENT

 

1. Option to Extend Term. Lessee shall have the option to extend the Lease term for (1) additional Period of two years, which option period shall commence on January 1, 2025 and shall terminate on December 31, 2026. Lessee may exercise this option strictly in accordance with the procedures set forth in Paragraph 9 of the Addendum to Standard Industrial Lease dated September 16, 1992 (the "Addendum"), except that the rent for all years of this option period shall be determined pursuant to the C.P.I. adjustment outlined in

Paragraph 2 below. Such option is not assignable notwithstanding anything to the contrary in the Lease.

 

1
 

 

2. Rent Adjustment. Commencing January 1, 2023 and thereafter annually on each subsequent January 1st, the Base Monthly Rental shall be readjusted by a percentage equal to the increase in the Consumer Price Index (U.S. Department of Labor for all Urban Consumers, Los Angeles-Anaheim-Riverside California {1967=100) hereinafter 'C.P.I. Index") for the previous calendar year period of January 1st through December 31st; provided, however, notwithstanding the C.P.I. Index, the Base Monthly Rental for calendar year 2023 and for each subsequent calendar year shall increase by no less than two percent (2%) nor more than four percent (4%) per year. If the Bureau of Labor Statistics discontinues publication of the C.P.I. Index, publishes the C.P.I. Index less frequently, or alters the C.P.I. Index in a material manner, then Lessor, in its sole discretion, may adopt a substitute index or procedure with reasonably reflects and monitors consumer prices.

 

3. Security Deposit. At such time that the rent is adjusted in accordance with Paragraph 2 above, the security deposit then in effect will be adjusted in a like amount.

 

4. Incorporation. Except as otherwise expressly set

forth herein, and to the extent necessary to give effect to the provisions hereof, all terms and conditions of the Lease shall remain unmodified and in full force and effect.

 

5. Counterparts. This Amendment may be executed in one or more counterpart copies, and each of which, so executed, irrespective of the date of execution and delivery, shall be deemed' to be an original, and all such counterparts together shall constitute one and the same instrument. The signature pages of one or more of the counterpart copies may be removed from such counterpart copies and be attached to the same copy of this Amendment, which, with all signatures attached, shall be deemed to be an original Agreement.

 

2
 

 

IN WITHNESS WHEREOF, the parties hereto have entered into this Eighth Amendment as of the date first set forth above.

 

LESSOR LESSEE
   
   
UPLANDER LLC PSYCHEMEDICS CORPORATION, a Delaware corporation
   
   
herschsig.jpg
limbeklogo.jpg

 

 

3
 EX-10.9 3 ex_492591.htm EXHIBIT 10.9 ex_492591.htm

Exhibit 10.9

 

 

 

March 21, 2023

 

 

CONFIDENTIAL

 

Mr. Raymond C. Kubacki

c/o Psychemedics Corporation

289 Great Road

Suite 200

Acton, MA 01720

 

Dear Ray:

 

This letter sets forth the agreements we have made regarding your employment with Psychemedics Corporation (the “Company”). Definitions not defined in the text below shall have the meanings set forth in Paragraph 14.

 

 

1.

If at any time after the effective date hereof and prior to May 2, 2024 your employment is terminated by the Company without Cause, or you voluntarily terminate your employment for Good Reason, in either case at the time of, or within twelve (12) months following a Change of Control of the Company, then you will continue to be paid monthly, through the first anniversary of the effective date of the Change of Control of the Company, an amount (“Termination Pay”) equal to one twelfth of your annual base salary in effect immediately prior to such termination, provided that in the case of your voluntary termination of your employment solely on account of the “Good Reason” factor described in clause (iv) of paragraph 14(d) below, then such Termination Pay shall continue until the date that is six (6) months following the effective date of the Change of Control of the Company. The Company agrees to continue to make health insurance available to you, under such health insurance plan as the Company has in effect, for so long as you are receiving Termination Pay and so long as you contribute such portion of the premiums for such insurance as is required of employees under such plan. You agree, however, that if you obtain health insurance coverage through another employer while you are eligible to receive health insurance under this Agreement, the Company shall no longer be required to make health insurance available to you under this Agreement. You agree to give the Company at least fourteen (14) days prior written notice of the termination of your employment in the event of your voluntary termination without Good Reason.  You shall not be entitled to Termination Pay as a result of termination by reason of your death or Disability following a Change of Control of the Company.  
     

 

 
 

Raymond C. Kubacki

March 21, 2023

Page 2

 

  2. Notwithstanding any other provision of this Agreement, the Termination Pay contemplated to be paid to you under certain circumstances set forth in this Agreement shall only be paid in consideration of the execution and delivery by you of a release reasonably satisfactory to the Company waiving all claims you, your heirs, or legal representatives have or may have against the Company or any of its shareholders, officers, directors, employees or agents with respect to your employment or the termination thereof, or any other claim.
     
  3. You acknowledge that, as the Company’s Chief Executive Officer, you are in possession of specialized information concerning the total operations, conduct, management, and strategy of the Company, as well as proprietary information concerning the Company’s products and services and that the applicability of your knowledge of these matters is applicable to all geographic areas in which the Company does business. You further acknowledge that the Company has a legitimate business interest in protecting its hair testing business from unfair competition.
     
  4. In addition to any other confidentiality obligations you may have as an employee of the Company, you shall not, without the prior and express written approval of the Company, either during or subsequent to the term of your employment, disclose or use or enable another to disclose or use any secret, private or confidential information, trade secret or other proprietary knowledge of the Company, or its subsidiaries, divisions, employees or agents. Upon termination of your employment with the Company, you shall deliver to the Company all equipment, records and copies of records, notes, data, memoranda, prototypes, designs, customer lists and other information which is embodied in physical media and documents belonging to the Company which are then in your possession. You agree that all such information and documents shall be the property of the Company and that the obligations set forth in this paragraph shall survive termination of your employment.

 

 

5.

You agree that in addition to any other covenant not to compete with the Company following termination of your employment to which you may be bound, if you or the Company shall terminate your employment in such a manner as to entitle you to Termination Pay under paragraph 1, above, you shall not, for so long as you are entitled to receive such Termination Pay:
     
    (a)       directly or indirectly own, manage, operate or control, or participate in the ownership, management, operation or control of, or become associated in any capacity with any business enterprise, firm, corporation or company related to the field of testing for the detection of drug use, which is in competition with the business of the Company, or directly or indirectly accept employment with or render services on behalf of a competitor of the Company, or any other third party, in any capacity which may reasonably be considered to be useful to the competitor or such other third party to become a competitor, without receiving the Company’s prior written approval; or
     

 

 
 

Raymond C. Kubacki

March 21, 2023

Page 3

 

    (b)       induce or attempt to induce any employee, officer, consultant, or agent of the Company to leave the employ thereof or in any way interfere with the relationship between the Company and any employee, officer, consultant, or agent thereof; hire directly or through another entity any person who was an employee of the Company at any time during the six (6) months prior to the date such person is to be so hired; or induce or attempt to induce any customer, client, supplier, licensee, or other business relation of the Company to cease doing business with the Company or in any way interfere with the relationship between any such customer, client, supplier, licensee, or business relation and the Company (including, without limitation, making any negative statements or communications concerning the Company).
     
  6.  You agree that your obligations under paragraphs 4 and 5 are special, unique, and extraordinary and that any breach by you of such obligations shall be deemed material, and shall be deemed to cause irreparable injury not properly compensable by damages in an action at law, and the rights and remedies of the Company under paragraphs 4 and 5 may, therefore, be enforced both at law and in equity, by injunction or otherwise. For purposes of paragraphs 4, and 5, the term “Company” shall include any and all subsidiaries or divisions of the Company.
     
  7. The periods set forth in paragraph 1 above may be extended only with the mutual written agreement of the parties.
     
  8.  If at any time a controversy between you and the Company arises as to the meaning or operation of this Agreement, such controversy shall be submitted to arbitration by either party in Boston, Massachusetts, before an arbitrator to be named by the President of the Boston Branch of the American Arbitration Association, provided however, that the Company shall also have the rights set forth in paragraph 6 above. Such arbitration proceedings shall be conducted in accordance with the rules and procedures then in effect of the American Arbitration Association. The decision of the arbitrator shall be binding upon the parties and judgment on any award made by the arbitrator may be entered in any court having jurisdiction thereof. The costs of the arbitrator shall be borne equally by you and the Company. Each party will bear his or its own legal costs.
     

 

 
 

Raymond C. Kubacki

March 21, 2023

Page 4

 

  9. This Agreement shall be governed by and interpreted in accordance with the laws of the Commonwealth of Massachusetts without reference to principles of conflict of laws.
     
  10. This Agreement contains the entire agreement of the parties in respect of this transaction and supersedes any prior agreement or understanding relating to your employment by the Company, other than any existing nondisclosure or confidentiality agreements you may have with the Company and any prior stock unit award agreements with the Company. No amendment or modification of any provision of this Agreement will be valid unless in writing signed by both parties. Any waiver must be in writing and signed by you or an authorized officer of the Company, as the case may be.
     
  11. This Agreement shall be binding upon and inure to the benefit of:
    (a) the Company, and any successors or assigns of the Company, whether by way of a merger or consolidation, or liquidation of the Company, or by way of the Company selling all or substantially all of the assets and business of the Company to a successor entity; and, subject to the Company's right to terminate your employment at any time, the Company agrees to require any successor entity to expressly assume or unconditionally guarantee the Company's obligations under this Agreement (unless such obligations are assumed by operation of law); and (b) you and your heirs, executors and administrators.
     
  12. Any notice or other communication required hereunder shall be in writing, shall be deemed to have been given and received when delivered in person, or, if mailed, shall be deemed to have been given when deposited in the United States mail, first class, registered or certified, return receipt requested, with proper postage prepaid, and shall be deemed to have been received on the third business day thereafter, and shall be addressed as follows:
     

 

                       If to the Company, addressed to:

 

Psychemedics Corporation

289 Great Road

Suite 200

Acton, MA 01720

Attn: General Counsel

 

 
 

Raymond C. Kubacki

March 21, 2023

Page 5

 

                       If to you, addressed to:

 

Raymond C. Kubacki, Jr.

Psychemedics Corporation

289 Great Road

Suite 200

Acton, MA 01720

 

                       or such other address as to which any party hereto may have notified the other in writing.

 

     
  13. Section 409A.
     
    (a) Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations thereunder (the “Code”), following a Change in Control of the Company, you are a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement would be considered deferred compensation subject to the twenty percent (20%) additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i) six (6) months and one (1) day after your separation from service, or (ii) your death.
     
    (b) This Agreement is intended to be in compliance with the provisions of Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with said Section. The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.
     
    (c) Solely for the purposes of Section 409A of the Code, each installment payment of Termination Pay shall be considered a separate payment.
     
    (d) The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, said Section.
     

 

 
 

Raymond C. Kubacki

March 21, 2023

Page 6

 

  14. Definitions.
     
    (a)    . “Cause” shall mean: (i) theft or embezzlement, or attempted theft or embezzlement, by you of money or property of the Company, your perpetration or attempted perpetration of fraud, or your participation in a fraud or attempted fraud upon the Company; (ii) your unauthorized appropriation of, or attempt to misappropriate, any tangible or intangible assets or property of the Company, or your appropriation of, or attempt to appropriate, a business opportunity of the Company, including but not limited to attempting to secure or securing any profit for yourself or any of your family members or personal associates in connection with any transaction entered into on behalf of the Company; (iii) any act or acts of disloyalty, misconduct, or moral turpitude by you, including but not limited to violation of the Company’s sexual harassment or non-harassment policy, any of which the Board of Directors of the Company determines in good faith has been or is likely to be materially injurious to the interest, property, operations, business, or reputation of the Company, or its directors, employees or shareholders; (iv) any act or omission constituting gross negligence in connection with the performance of your duties on behalf of the Company which is materially injurious to the interest, property, operations, business, or reputation of the Company; (v) your conviction of a crime other than minor traffic violations or other similar minor offenses (including pleading guilty or entering a plea of no contest), or your indictment for a felony or its equivalent, or your being charged with a violent crime, a crime involving moral turpitude, or any other crime for which imprisonment is a possible punishment; (vi) your willful refusal or material failure (other than by reason of Disability) to carry out reasonable and lawful instructions and directives from the Board of Directors and your failure to cure or correct such refusal or failure within ten (10) days after receiving written notice from the Board of Directors describing such refusal or failure; or (vii) the material breach by you of your obligations under paragraphs 4, or 5 hereof or under any other confidentiality, non-compete, non-solicitation, non-disparagement or similar agreement with the Company.
     
    (b)“    Change in Control of the Company” shall mean
     
      (i) any person or group as defined in Rule 13d-3 under the Securities Exchange Act of 1934 (the “Exchange Act”) shall own more than 30% of the then outstanding shares of the outstanding Common Stock of the Company; or
       

 

 
 

Raymond C. Kubacki

March 21, 2023

Page 7

 

 

      (ii) the consummation of a reorganization, merger or consolidation or sale or disposition of all or substantially all of the assets of the Company (a “Business Combination”), unless, in each case following such Business Combination, (A) all or substantially all of the individuals and entities who were the beneficial owners of the Common Stock of the Company immediately before the consummation of such Business Combination beneficially own, directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation that as a result of the transaction owns the Company or all or substantially all of the assets of the Company either directly or indirectly through one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination, of the Common Stock of the Company; and (B) no person or group (as defined in Section 13(d) of the Exchange Act) of the Company or the corporation resulting from the Business Combination) beneficially owns, directly or indirectly, more than 30% of the then outstanding shares of the common stock of the corporation resulting from the Business Combination or of the combined voting power of the then outstanding voting securities of the corporation; or
       
      (iii) Individuals who, as of the date of this Agreement, constitute the Board of Directors of the Company (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board of Directors of the Company, provided, however, that any individual's becoming a director after the date of this Agreement whose election, or nomination for election by the stockholders of the Company, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board will be considered as though the individual were a member of the Incumbent Board, but excluding, for this purpose, any individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board.
       

 

 
 

Raymond C. Kubacki

March 21, 2023

Page 8

 

 

    (c)“    Disability” shall mean your inability because of physical or mental incapacity to perform your usual duties at the Company for a period of one hundred eighty (180) days in any consecutive twelve (12) month period.
     
    (d)“    Good Reason” shall mean: (i) payment of base salary following the Change of Control at a rate below $486,675 per annum, or at such higher base salary rate as may be in effect immediately prior to such Change of Control; (ii) removal from your position as President and Chief Executive Officer of the Company, or failure to re‑elect or reappoint you to such position or, if the Company shall no longer exist as a result of the Change of Control, failure to elect or appoint you to the position of President and Chief Executive Officer of the division or separate entity succeeding to the business of the Company; (iii) a material decrease in your duties or responsibilities or the assignment to you of duties and responsibilities, which are materially inconsistent with such position; or (iv) the Company's requiring you to relocate your work location outside the Greater Boston, Massachusetts or Chicago, Illinois areas at any time during the six month period following the effective date of a Change in Control of the Company.

 

 

 

 

 

 

 

 

 

 
 

Raymond C. Kubacki

March 21, 2023

Page 9

 

If this letter correctly sets forth our understanding and agreement, please indicate your acceptance by signing both copies of this letter and returning one copy.

 

  Very truly yours,
   
  PSYCHEMEDICS CORPORATION
   
   
  By: /s/ William Norris                  
       William Norris, Controller

 

 

Agreed to: March 21, 2023

 

 

 

/s/ Raymond C. Kubacki            

Raymond C. Kubacki

 

 

 

 

 

 

 

 

 

 

 
 EX-10.14 4 ex_492598.htm EXHIBIT 10.14 ex_492598.htm

Exhibit 10.14

 

INDEMNIFICATION AGREEMENT

 

THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made as of November 12, 2021 by and between PSYCHEMEDICS CORPORATION, a Delaware corporation (the “Company”), and [●] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.

 

RECITALS

 

WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;

 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The certificate of incorporation of the Company (as the same may be amended from time to time, the “Certificate of Incorporation”) requires indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the “DGCL”). The Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;

 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;

 

WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;

 

 
 

 

WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and

 

WHEREAS, Indemnitee does not regard the protection available under the Certificate of Incorporation and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified.

 

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

 

Section 1.    Services to the Company. Indemnitee agrees to serve as a[n] [director] [and] [officer] of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that Indemnitee’s employment with the Company (or of its subsidiaries or any Enterprise), if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company (or of its subsidiaries or any Enterprise), other applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company, by the Certificate of Incorporation, the Company’s Bylaws, and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as a[n] [director] [or] [officer] of the Company, as provided in Section 16 hereof.

 

Section 2.    Definitions. As used in this Agreement:

 

(a)    References to “agent” shall mean any person who is or was a director, officer, or employee of the Company or a subsidiary of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company.

 

(b)    A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

 

i.    Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing forty percent (40%) or more of the combined voting power of the Company’s then outstanding securities unless the change in relative Beneficial Ownership of the Company’s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors;

 

2
 

 

ii.   Change in Board of Directors. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;

 

iii.   Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its ultimate parent, as applicable) more than 51% of the combined voting power of the voting securities of the surviving entity or its ultimate parent, as applicable, outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity or its ultimate parent, as applicable;

 

iv.    Liquidation or Sale of Assets. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and

 

v.     Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.

 

For purposes of this Section 2(b), the following terms shall have the following meanings:

 

(A)     “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time.

 

(B)      “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 

(C)     “Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity.

 

3
 

 

(D)     “Corporate Status” describes the status of a person as a current or former director or officer of the Company or as a current or former director, manager, partner, officer, employee, agent, or trustee of any other entity or enterprise that such person is or was serving at the request of the Company.

 

(E)     “Disinterested Director” shall mean a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.

 

(F)     “Enterprise” shall mean the Company and any other corporation, limited liability company, partnership, joint venture, trust or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, employee, agent or fiduciary.

 

(G)     “Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii) for purposes of Section 14(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement, by litigation or otherwise. The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee’s counsel as being reasonable shall be presumed conclusively to be reasonable. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.

 

(H)     “Independent Counsel” shall mean a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

 

4
 

 

(I)    The term “Proceeding” shall include any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by him (or a failure to take action by him) or of any action (or failure to act) on his part while acting pursuant to his Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.

 

(J)    Reference to “other enterprise” shall include employee benefit plans; references to “fines” shall include any excise tax assessed with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in manner “not opposed to the best interests of the Company” as referred to in this Agreement.

 

Section 3.    Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding had no reasonable cause to believe that his conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification provided by the Certificate of Incorporation, the Bylaws, vote of its stockholders or disinterested directors or applicable law.

 

5
 

 

Section 4.    Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the “Delaware Court”) or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such Expenses as the Delaware Court or other court shall deem proper.

 

Section 5.    Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

 

Section 6.    Indemnification For Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of his Corporate Status, a witness or otherwise asked to participate in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.

 

Section 7.    Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.

 

Section 8.    Additional Indemnification.

 

(a)    Notwithstanding any limitation in Sections 3, 4, or 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with the Proceeding.

 

6
 

 

(b)    For purposes of Section 8(a), the meaning of the phrase “to the fullest extent permitted by applicable law” shall include, but not be limited to:

 

i.    to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and

 

ii.    to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.

 

Section 9.     Exclusions. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification payment in connection with any claim made against Indemnitee:

 

(a)     (for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or

 

(b)     for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in Section 2(b) hereof) or similar provisions of state statutory law or common law, or (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act); or

 

(c)     except as provided in Section 14(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.

 

Section 10.   Advances of Expenses. Notwithstanding any provision of this Agreement to the contrary (other than Section 14(d)), the Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding (or any part of any Proceeding) not initiated by Indemnitee, and such advancement shall be made within twenty (20) days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. In accordance with Section 14(d), advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. The Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing that the Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required other than the execution of this Agreement. This Section 10 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 9.

 

7
 

 

Section 11.    Procedure for Notification and Defense of Claim.

 

(a)      Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. The omission by Indemnitee to notify the Company hereunder will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification.

 

(b)     The Company will be entitled to participate in the Proceeding at its own expense.

 

Section 12.    Procedure Upon Application for Indemnification.

 

(a)      Upon written request by Indemnitee for indemnification pursuant to Section 11(a), a determination, if required by applicable law, with respect to Indemnitee’s entitlement thereto shall be made in the specific case: (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Board, by the stockholders of the Company; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied.

 

8
 

 

(b)      In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) hereof, the Independent Counsel shall be selected as provided in this Section 12(b). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising him of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section 11(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

 

Section 13.    Presumptions and Effect of Certain Proceedings.

 

9
 

 

(a)      In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(a) of this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

 

(b)      Subject to Section 14(e), if the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 13(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 12(a) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) of this Agreement.

 

(c)      The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.

 

10
 

 

(d)      For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with the reasonable care by the Enterprise. The provisions of this Section 13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.

 

(e)      The knowledge and/or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.

 

Section 14.    Remedies of Indemnitee.

 

(a)      Subject to Section 14(e), in the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12(a) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5, 6 or 7 or the last sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment of indemnification pursuant to Section 3, 4 or 8 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 14(a); provided, however, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under Section 5 of this Agreement. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.

 

(b)     In the event that a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 14, the Company shall have the burden of proving Indemnitee is not not entitled to indemnification or advancement of expenses, as the case may be.

 

11
 

 

(c)      If a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 14, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.

 

(d)      The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder. The Company shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company if, in the case of indemnification, Indemnitee is wholly successful on the underlying claims; if Indemnitee is not wholly successful on the underlying claims, then such indemnification shall be only to the extent Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater.

 

(e)      Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.

 

Section 15.    Non-exclusivity; Survival of Rights; Insurance; Subrogation.

 

(a)      The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Certificate of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

 

12
 

 

(b)      To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents of the Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.

 

(c)      In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

(d)      The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

 

(e)       The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, limited liability company, partnership, joint venture, trust or other enterprise.

 

Section 16.      Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a [director] [or] [officer] of the Company or (b) one (1) year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement relating thereto. The indemnification and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or of any other Enterprise, and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.

 

13
 

 

Section 17.    Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

 

Section 18.    Enforcement.

 

(a)      The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.

 

(b)      This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof, including without limitation any previous indemnification agreements, which are hereby terminated in full; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the Bylaws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.

 

Section 19.    Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.

 

Section 20.    Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise.

 

Section 21.    Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:

 

14
 

 

(a)      If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide to the Company.

 

(b)      If to the Company to:

 

  Psychemedics Corporation

  289 Great Road

  Acton, MA 02170

  Attention: Chief Executive Officer

 

or to any other address as may have been furnished to Indemnitee by the Company.

 

Section 22.    Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company, on the one hand, and Indemnitee, on the other hand, as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its other directors, officers, employees and agents), on the one hand, and Indemnitee, on the other hand, in connection with such event(s) and/or transaction(s).

 

Section 23.    Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably the Corporation Trust Center as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.

 

15
 

 

Section 24.    Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

 

Section 25.    Miscellaneous. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

[The remainder of this page is intentionally left blank.]

 

 

 

 

 

 

 

16
 

 

The parties executed this Agreement as of the day and year first set forth above.

 

 

 

  PSYCHEMEDICS CORPORATION
   
   
  By:    
  Name:    
  Title:    
   
   
  INDEMNITEE
   
   
     
  Name:
   
   
  Address:
   
   
     
     

 

 

 

 
 EX-21.1 5 ex_490005.htm EXHIBIT 21.1 HTML Editor

EXHIBIT 21.1

 

PSYCHEMEDICS CORPORATION

 

Subsidiaries

 

Psychemedics Corporation wholly-owns the following companies:

 

Name        Country of Incorporation
   
1. Psychemedics International, LLC      Delaware, USA
   
2. Psychemedics Laboratórios Ltda      Brazil
(owned jointly by Psychemedics Corporation  
and Psychemedics International, LLC)  

 

 

 

 

 

 

 

 
 EX-23.1 6 ex_490004.htm EXHIBIT 23.1 HTML Editor

EXHIBIT 23.1
 

Consent of Independent Registered Public Accounting Firm
 

Psychemedics Corporation
Acton, Massachusetts
 
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-134974, 333-174531, 333-211745, 333-233238 and 333-256467) of Psychemedics Corporation (the “Corporation”) of our report dated March 24, 2023, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K. 

 

/s/ BDO USA, LLP
Boston, Massachusetts
March 27, 2023 

 

 

 

 

 

 

 

 
 EX-24 7 ex_490006.htm EXHIBIT 24 HTML Editor

EXHIBIT 24

 

Power of Attorney

 

KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned, being a director or officer, or both, of Psychemedics Corporation, a Delaware corporation (hereinafter called the “Corporation”), does hereby constitute and appoint Raymond C. Kubacki and William B. Norris, with full power to each of them to act alone, as the true and lawful attorneys and agents of the undersigned, with full power of substitution and resubstitution to each of said attorneys, to execute, file or deliver any and all instruments and to do all acts and things which said attorneys and agents, or any of them, deem advisable to enable the Corporation to comply with the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and any requirements of the Securities and Exchange Commission in respect thereof, in connection with the filing under said Securities Exchange Act of the Corporation's Annual Report on Form 10-K for the year ended December 31, 2021, including specifically, but without limitation of the general authority hereby granted, the power and authority to sign his or her name as a director or officer, or both, of the Corporation, as indicated below opposite his or her signature, to the Annual Report on Form 10-K, or any amendment, post-effective amendment, or papers supplemental thereto to be filed in respect of said Annual Report on Form 10-K; and each of the undersigned does hereby fully ratify and confirm all that said attorneys and agents, or any of them, or the substitute of any of them, shall do or cause to be done by virtue hereof.

 

IN WITNESS WHEREOF, each of the undersigned has subscribed these presents, as of the 21st day of March, 2023.

 

 

  Signature

 Title 

/s/ RAYMOND C. KUBACKI
Raymond C. Kubacki

 

Chairman, President and Chief Executive Officer, Director
(Principal Executive Officer)

/s/ WILLIAM B. NORRIS
Andrew Limbek

 

Controller
(Principal Financial and Accounting Officer)

/s/ PETER H. KAMIN
Peter H. Kamin

 

Director

/s/ DARIUS G. NEVIN
Darius G. Nevin

 

Director

/s/ ANDREW M. REYNOLDS
Andrew M. Reynolds

 

Director

/s/ ROBYN C. DAVIS
Robyn C. Davis

 

Director

/s/ FRED J. WEINERT
Fred J. Weinert

Director

 

 

 

 

 
 EX-31.1 8 ex_490007.htm EXHIBIT 31.1 HTML Editor

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO

SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Raymond C. Kubacki, certify that:

 

1.

I have reviewed this annual report on Form 10-K of Psychemedics Corporation (the “registrant”);

 

2.

Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

4.

The registrant's other certifying officer and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

 

 

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

 

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
 

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 27, 2023

 

 

By:    /s/ Raymond C. Kubacki

Raymond C. Kubacki

President and Chief Executive Officer

(principal executive officer)

 

 

 

 
 EX-31.2 9 ex_490008.htm EXHIBIT 31.2 HTML Editor

EXHIBIT 31.2

 

CERTIFICATION PURSUANT TO

SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

 

I, William B. Norris, certify that:

 

1.

I have reviewed this annual report on Form 10-K of Psychemedics Corporation (the “registrant”);

 

2.

Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

4.

The registrant's other certifying officer and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

 

 

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

 

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
 

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: March 27, 2023

 

 

By:     /s/ William B. Norris

William B. Norris

Controller

(principal financial and accounting officer)

 

 

 
 EX-32.1 10 ex_490009.htm EXHIBIT 32.1 HTML Editor

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Raymond C. Kubacki, President and Chief Executive Officer of Psychemedics Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 24, 2022 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 27, 2023

 

 

By: /s/ Raymond C. Kubacki

Raymond C. Kubacki

President and Chief Executive Officer

(principal executive officer)

 

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

 

 

 

 

 
 EX-32.2 11 ex_490010.htm EXHIBIT 32.2 HTML Editor

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, William B. Norris, Controller of Psychemedics Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 24, 2023 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 27, 2023

 

 

By: /s/ William B. Norris

William B. Norris

Controller

(principal financial and accounting officer)

 

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

 

 

 

 

 

 

 
 EX-101.SCH 12 pmd-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Nature of Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Accounts Receivable link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Preferred Stock link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Stock-based Awards link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Employee Benefit Plan link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Operating Leases link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Debt and Other Financing Arrangements link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Other Income (Expense) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - Business Segment Reporting link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 14 - Subsequent Event link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Accounts Receivable (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 7 - Stock-based Awards (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 10 - Operating Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 11 - Debt and Other Financing Arrangements (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 13 - Business Segment Reporting (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 1 - Nature of Business (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 5 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 5 - Income Taxes - Summary of Income Tax Provision (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 7 - Stock-based Awards (Details Textual) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 7 - Stock-based Awards - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 7 - Stock-based Awards - Nonvested Award Activity (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 8 - Employee Benefit Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 10 - Operating Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 10 - Operating Leases - Maturities of Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 11 - Debt and Other Financing Arrangements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 12 - Other Income (Expense) (Details Textual) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 13 - Business Segment Reporting (Details Textual) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 13 - Business Segment Reporting - Revenue by Major Source (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 14 - Subsequent Event (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 13 pmd-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 14 pmd-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 15 pmd-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Note 3 - Accounts Receivable Note 4 - Accrued Expenses Note 5 - Income Taxes Paycheck Protection Program CARES Act [Member] Represents loan designed to provide funds for small businesses to keep their employees on the payroll. Note 7 - Stock-based Awards Note 10 - Operating Leases Note 11 - Debt and Other Financing Arrangements Note 13 - Business Segment Reporting Income Tax Disclosure [Text Block] Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details) Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details) Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details) Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details) us-gaap_LiabilitiesCurrent Total Current Liabilities Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details) Note 5 - Income Taxes - Summary of Income Tax Provision (Details) Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year) Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details) Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details) Note 7 - Stock-based Awards - Stock Option Activity (Details) Note 7 - Stock-based Awards - Nonvested Award Activity (Details) Note 10 - Operating Leases - Maturities of Lease Liabilities (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Shares issued – vested Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) Note 13 - Business Segment Reporting - Revenue by Major Source (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] us-gaap_LitigationSettlementAmountAwardedToOtherParty Litigation Settlement, Amount Awarded to Other Party Share-Based Payment Arrangement, Option, Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) Foreign currency translation, net of taxes Foreign currency translation, net of taxes us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Outstanding & Unvested at beginning of period (in shares) Outstanding & Unvested at end of period (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) Shares issued – vested (in shares) Current portion of long-term debt Less current portion of long-term debt from equipment financing Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Exercisable, weighted average exercise price (in dollars per share) Exercisable, weighted average remaining contractual life (Year) Exercisable, aggregate intrinsic value us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Exercisable (in shares) pmd_LegalCostCapitalizedNet Legal Cost Capitalized, Net Represents the legal cost capitalized, net. Outstanding, weighted average remaining contractual life (Year) Outstanding, aggregate intrinsic value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) pmd_LegalCostCapitalizedAmortization Legal Cost Capitalized, Amortization Represents amortization related to legal cost capitalized. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Forfeited, weighted average exercise price (in dollars per share) Canceled (in dollars per share) Fair value per share (in dollars per share) Fair value per share (in dollars per share) Accrued taxes Exercised, weighted average exercise price (in dollars per share) Accrued expenses Total Accrued Expenses Accrued legal settlement Lessee, Operating Leases [Text Block] Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding (in shares) Outstanding (in shares) Loans, Notes, Trade and Other Receivables Disclosure [Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Canceled (in shares) Credit Facility [Axis] Proceeds from sale of fixed assets Accrued compensation and employee benefits Credit Facility [Domain] Other accrued expenses us-gaap_PolicyTextBlockAbstract Accounting Policies Accrued vacation expense us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost Share-Based Payment Arrangement, Accelerated Cost us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares) us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment and capitalized software development costs pmd_IncomeTaxBenefitCARESAct Income Tax Benefit CARES Act Amount of income tax benefit related to the CARES Act. Non-cash investing and financing activities: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Weighted average common shares outstanding: us-gaap_LossContingencyAccrualAtCarryingValue Loss Contingency Accrual, Ending Balance Current Liabilities: Supplemental disclosures of cash flow information: us-gaap_Assets Total Assets Patents [Member] Preferred Stock [Text Block] Plan Name [Axis] Plan Name [Domain] Compensation and Employee Benefit Plans [Text Block] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total us-gaap_OperatingLeaseExpense Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) pmd_OperatingLossCarryforwardsSubjectToExpiration Operating Loss Carryforwards, Subject to Expiration The amount of operating loss carryforwards subject to expiration. pmd_OperatingLossCarryforwardsNotSubjectToExpiration Operating Loss Carryforwards, Not Subject to Expiration The amount of operating loss carryforwards not subject to expiration. May 13, 2021 [Member] Related to date. Computer Software, Intangible Asset [Member] March 16, 2021 [Member] Related to date. Deferred tax assets Finite-Lived Intangible Assets by Major Class [Axis] Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Tax withholding related to vested shares from employee stock plans pmd_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent Federal R&D Credits Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credit (expense). January 25, 2021 [Member] Related to date. Enma Sagastume v. Psychemedics Corporation [Member] Related to Enma Sagastume v. Psychemedics Corporation. Award Type [Domain] Award Date [Axis] Award Date [Domain] Award Type [Axis] Net loss Net loss pmd_OtherNonoperatingExpenseSettlement Settlements Amount of expense related to nonoperating activities, classified as settlement. Share-Based Payment Arrangement, Option [Member] pmd_IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes Accrued expenses The increase (decrease) during the reporting period in the aggregate amount of expenses and income taxes incurred but not yet paid. Computer software pmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeriod Converted to common stock (in shares) The number of equity-based payment instruments, excluding stock (or unit) options, that were converted to common stock during the reporting period. pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod Cancelled (in shares) The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period. pmd_PaymentsOfEquipmentFinancing Payments of equipment financing The cash outflow in relating to equity financing during the year. pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAndNonvestedWeightedAverageExercisePrice Outstanding & Unvested at beginning of period, weighted average price per share (in dollars per share) Outstanding & Unvested at end of period, weighted average price per share (in dollars per share) Weighted average price at which grantees can acquire the shares reserved for issuance under the equity instrument other than option. pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice Granted, weighted average price per share (in dollars per share) Weighted average per share amount at which grantees can acquire shares of common stock by exercise of equity instrument other than option. Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization us-gaap_PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Total Stock Unit Award [Member] Related to stock unit awards. pmd_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. us-gaap_PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross, Ending Balance Office furniture and equipment Leasehold improvements California Franchise Tax Board [Member] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Property and equipment: Laboratory equipment Carrying amount as of the balance sheet date of laboratory equipment held for productive use pmd_LegalCostCapitalized Legal Cost Capitalized The amount of legal costs capitalized. Customer One [Member] Information related to customer one. pmd_SoftwareDevelopmentCostCapitalized Software Development Cost Capitalized The software development cost capitalized as of the balance sheet date. Schedule of Stock Based Compensation Expense [Table Text Block] Laboratory Equipment [Member] Information related to laboratory equipment. Cash flows from investing activities: Accrued shipping expense Carrying value as of the balance sheet date of accrued shipping obligations. Provision for doubtful accounts Represents the provision for (recoveries of) doubtful accounts. Basis of Presentation and Consolidation, Policy [Policy Text Block] Disclosure of accounting policy for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). In addition, discloses the accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. Permanent differences The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent differences. Line of Credit [Member] pmd_DeferredTaxLiabilitiesExcessOfTaxOverBookDepreciationAndAmortization Excess of tax over book depreciation and amortization Amount of deferred tax liability attributable to taxable temporary differences from excess of tax over book depreciation and amortization. Provision for (benefit from) income taxes Income Tax Provision Incentive Plan 2006 [Member] Information related to the 2006 incentive plan. us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Testing [Member] Represents testing services. Other Revenue [Member] Represents other revenue sources not otherwise disclosed. Converted to common stock, weighted average price per share (in dollars per share) Weighted average price at which the instruments, excluding stock (or unit) options, that were converted to common stock during the reporting period Forfeited, weighted average price per share (in dollars per share) Weighted average price at which grantees could have acquired the underlying shares with respect to equity instrument other than stock options that were forfeited. us-gaap_OperatingExpenses Total Operating Expenses Cancelled, weighted average price per share (in dollars per share) Weighted average price at which grantees could have acquired the underlying shares with respect to equity instrument other than stock options that were cancelled. us-gaap_DebtInstrumentTerm Debt Instrument, Term (Month) us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount General & administrative us-gaap_CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value, Total Cash Cash and Cash Equivalents, at Carrying Value, Total Equipment Loan Arrangement [Member] Information related to the Equipment Loan Arrangement. us-gaap_AllocatedShareBasedCompensationExpense Stock compensation expense Banc of America Leasing and Capital [Member] Informaiton related to an equipment financing agreement with Banc of America Leasing and Capital LLC. Amendment Flag Other Comprehensive Loss: us-gaap_ComprehensiveIncomeNetOfTax Total Comprehensive Loss City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) us-gaap_LongTermDebtWeightedAverageInterestRateOverTime Long-Term Debt, Weighted Average Interest Rate, over Time Preferred stock, shares outstanding (in shares) us-gaap_DebtWeightedAverageInterestRate Debt, Weighted Average Interest Rate Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent Document Fiscal Period Focus Document Fiscal Year Focus us-gaap_IncreaseDecreaseInDeferredIncomeTaxes Deferred income taxes Document Period End Date Right-of-use assets acquired through operating leases us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Operating Lease, Weighted Average Remaining Lease Term (Year) Entity File Number Entity Emerging Growth Company Document Type Gain on forgiveness of PPP Loan Forgiveness of PPP loan Entity Small Business Entity Shell Company us-gaap_DividendsCommonStockCash Cash dividends declared Document Information [Line Items] Document Information [Table] Entity Public Float Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Entity Voluntary Filers Entity Well-known Seasoned Issuer London Interbank Offered Rate (LIBOR) [Member] Variable Rate [Domain] Schedule of Long-Term Debt Instruments [Table Text Block] us-gaap_IncreaseDecreaseInIncomeTaxesReceivable Income tax receivable Variable Rate [Axis] us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Entity Tax Identification Number Entity Central Index Key us-gaap_DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction, Total Entity Registrant Name us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Stock compensation expense Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Entity Address, Address Line One Exercise of stock options Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Concentration Risk Type [Axis] Concentration Risk Type [Domain] Operating lease liabilities Amount of increase (decrease) in operating lease liabilities during the period. us-gaap_TreasuryStockValue Less - Treasury stock, at cost, 668 shares Entity Common Stock, Shares Outstanding Revenue Benchmark [Member] Accounts Receivable [Member] Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Risks and Uncertainties [Policy Text Block] Disclosure of accounting policy for risks and uncertainties. Local Phone Number Other Assets [Policy Text Block] Disclosure of accounting policy for other assets. Exercise of stock options (in shares) Exercised (in shares) August 12, 2022 [Member] Relating to August 12, 2022. us-gaap_GainLossOnDispositionOfAssets Loss on sale of fixed assets us-gaap_TableTextBlock Notes Tables May 20, 2022 [Member] Relating to May 20, 2022 April 4, 2022 [Member] Relating to April 4, 2022. Depreciation and amortization Amount of depreciation and amortization expense, excluding amortization expense for right-of-use asset from operating lease. Capitalized research expenses Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development. Shares granted (in shares) Shares granted (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited (in shares) Marketing & selling Line of Credit Facility, Lender [Domain] Foreign taxes, net of federal benefit Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total Liabilities and Shareholders' Equity Stock based compensation Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs. UNITED STATES Contingent Liability Reserve Estimate, Policy [Policy Text Block] Research & development Accumulated deficit Accumulated other comprehensive loss Debt Disclosure [Text Block] us-gaap_InterestExpense Interest Expense, Total Changes in operating assets and liabilities: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] Long-term portion of operating lease liabilities Long-term operating lease liabilities Present value of lease liabilities Total Subsequent Event Type [Axis] Current portion of operating lease liabilities Current operating lease liabilities Subsequent Event Type [Domain] Subsequent Events [Text Block] Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: interest us-gaap_DeferredIncomeTaxExpenseBenefit Total Deferred us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Finite-Lived Intangible Asset, Expected Amortization, after Year Five us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2025 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2026 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Finite-Lived Intangible Asset, Expected Amortization, Year Two Fair Value of Financial Instruments, Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Finite-Lived Intangible Asset, Expected Amortization, Year Three us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Finite-Lived Intangible Asset, Expected Amortization, Year Four us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2023 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Finite-Lived Intangible Asset, Expected Amortization, Year Five us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2024 Segment Reporting, Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Asset, Expected Amortization, Year One Lessee, Operating Lease, Liability, Maturity [Table Text Block] Stock compensation expense Other assets us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) Earnings Per Share, Policy [Policy Text Block] us-gaap_AdjustmentForAmortization Amortization, Total Operating Expenses: Income Tax, Policy [Policy Text Block] Research, Development, and Computer Software, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] us-gaap_ConversionOfStockAmountIssued1 Conversion of Stock, Amount Issued us-gaap_AssetsCurrent Total Current Assets Share-Based Payment Arrangement [Policy Text Block] Income tax receivable Treasury stock, shares (in shares) us-gaap_InterestIncomeOther Interest Income, Other Common stock, $0.005 par value; 50,000 shares authorized 6,349 shares and 6,257 shares issued at December 31, 2022 and 2021, respectively, 5,681 shares outstanding and 5,589 shares outstanding at December 31, 2022 and 2021, respectively Adjustments to reconcile net loss to net cash provided by operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Purchases of equipment through accounts payable and accrued liabilities Common stock, par value (in dollars per share) us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) us-gaap_DeferredTaxAssetsValuationAllowance Valuation Allowance Statistical Measurement [Domain] Cash paid for operating leases Maximum [Member] Minimum [Member] Product and Service [Axis] us-gaap_DeferredTaxAssetsNet Deferred Tax Assets After Valuation Allowance Product and Service [Domain] Statistical Measurement [Axis] Litigation Case [Axis] Litigation Case [Domain] Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding us-gaap_DeferredTaxAssetsLiabilitiesNet Net Deferred Tax Assets Preferred stock, shares issued (in shares) Cash paid for interest Cash paid for income taxes Geographical [Axis] Property, Plant and Equipment [Table Text Block] us-gaap_DeferredTaxAssetsGross Gross Deferred Tax Assets Geographical [Domain] Preferred stock, shares authorized (in shares) us-gaap_DeferredIncomeTaxLiabilities Gross Deferred Tax Liabilities Preferred stock, par value (in dollars per share) Revenues Revenues R&D tax credits Customer [Axis] Customer [Domain] us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Accrued expenses Property, plant and equipment, useful life (Year) Property, Plant and Equipment, Useful Life (Year) Cash flows from operating activities: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts Allowance for doubtful accounts Revenue [Policy Text Block] Statement [Line Items] Allowance for doubtful accounts Balance, beginning of period Balance, end of period us-gaap_NumberOfOperatingSegments Number of Operating Segments Accounts receivable, net of allowance for doubtful accounts of $87 and $89 at December 31, 2022 and 2021, respectively Stock-based compensation Additional paid-in capital AOCI Attributable to Parent [Member] Shareholders' Equity: Property, Plant and Equipment, Policy [Policy Text Block] Other income (expense) Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total Other Income (Expense) Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] NOL carryforward Other Income (Expense): Current Assets: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, beginning of year Cash, end of year Deferred Tax Assets us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash (used in) provided by financing activities us-gaap_Liabilities Total Liabilities Commitments and Contingencies (Note 9) Effect of exchange rate changes on cash us-gaap_OperatingIncomeLoss Operating (loss) income us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by (used in) operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Prepaid expenses and other current assets us-gaap_GrossProfit Gross profit Cost of revenues Concentration Risk, Credit Risk, Policy [Policy Text Block] Major Customers, Policy [Policy Text Block] us-gaap_DeferredTaxLiabilitiesPrepaidExpenses Prepaid expenses Deferred Tax Liabilities us-gaap_PaymentsOfDividendsCommonStock Cash dividends paid Other Income and Other Expense Disclosure [Text Block] Retained Earnings [Member] Proceeds from stock options and tax withholding related to vested shares from employee stock plans State Treasury Stock [Member] us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit State Total Current Additional Paid-in Capital [Member] Common Stock [Member] Federal us-gaap_DeferredFederalIncomeTaxExpenseBenefit Federal Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Long-Term Debt, Total Long-term debt from equipment financing us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Net loss before provision for (benefit from) income taxes ICFR Auditor Attestation Flag State and Local Jurisdiction [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Internal Revenue Service (IRS) [Member] Income Tax Authority [Axis] Capitalized Software and Equipment [Member] Information related to capitalized software and equipment. Income Tax Authority [Domain] Disaggregation of Revenue [Table Text Block] Domestic Tax Authority [Member] us-gaap_RepaymentsOfLongTermDebt Repayments of Long-term Debt, Total Office Equipment [Member] Document Annual Report Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Software Development [Member] Entity Incorporation, State or Country Code General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Entity Interactive Data Current Selling and Marketing Expense [Member] Dividends declared, per share (in dollars per share) Common Stock, Dividends, Per Share, Declared (in dollars per share) Security Exchange Name Title of 12(b) Security us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs Write-offs Proceeds from long term det Proceeds from Issuance of Long-term Debt, Total Cost of Sales [Member] Shipping/Collection (Hair) [Member] Information pertaining to shipping and hair collection services. Research and Development Expense [Member] Income Statement Location [Axis] Income Statement Location [Domain] Auditor Name Difference in tax rate for carryback claim Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in tax rate for carryback claim. Auditor Firm ID Auditor Location Dilutive common equivalent shares (in shares) us-gaap_TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount us-gaap_SharePrice Share Price (in dollars per share) December 16, 2020 [Member] Related to December 16, 2020. us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) November 11, 2020 [Member] Related to November 11, 2020. Diluted (in shares) Weighted average common shares outstanding, assuming dilution (in shares) Non-US [Member] us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards Statement [Table] Statement of Financial Position [Abstract] Diluted net loss per share (in dollars per share) Basic (in shares) Weighted average common shares outstanding, basic (in shares) Accounts Payable and Accrued Liabilities Disclosure [Text Block] us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective tax rate Basic net loss per share (in dollars per share) Increase/(decrease) in valuation reserve Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Revenue from External Customers by Geographic Areas [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2023 Financing Receivable, Current, Allowance for Credit Loss [Table Text Block] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2024 pmd_DeferredTaxLiabilitiesOperatingLease Operating lease Amount of deferred tax consequences attributable to taxable temporary differences derived from operating lease. Operating lease pmd_DeferredTaxAssetsOperatingLease Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease. Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total State income taxes, net of federal benefit us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Cash flows from financing activities: Federal statutory rate ROU asset amortization pmd_PaymentsForProceedsFromOtherAssets Other assets The net cash outflow or inflow from other assets. us-gaap_StockholdersEquity Total Shareholders' Equity Balance Balance Class of Stock [Axis] Long-term debt us-gaap_LongTermDebtNoncurrent Long-term debt from equipment financing, net of current portion Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] EX-101.PRE 16 pmd-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 17 herschsig.jpg begin 644 herschsig.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#T17AI9@ 34T *@ @ ! $[ ( M . (2H=I 0 ! (6)R= $ < 0T.H< < @, /@ M FMC.60G/SX-"CQX.GAM M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS M.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z M#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K M970@96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5 M&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @* M"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ*BHJ_\ $0@ 3 #1 P$B (1 0,1 ?_$ !\ $% 0$! M 0$! ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" M P $$042(3%!!A-180'EZ@X2% MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ M ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,082 M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3 ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C MY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ J)+B*2> M2%'5I(L;U!Y7/3-+B@#)-@12RQ^9K&KS%XX M'4C#N/E# 9(5$"ACZ*>YJE&Y+E8ZJBLWP]/E)JSL-.ZN+13!-&9S")%\U5#%-WS '@''IP?RIS,%4D\ =32&+16/; M:O'-87&L7#^58)EH68<-&/\ EI[[NWMCUIPN4N6C&HHL)A'VEP9,"(9.S=S@ MG&3W *^P-5RM$J29K44@(*Y!R.QJM=70BDB@0CSIR50'M@9+?0?SP.]):C;L M6J*;N ;:2-V,XJDUS]HUI;:/.+>/S92&(P6R$!]> YP?13Z46N#=B_1112&% M%%% !1110 4444 %%%% !1110 44?2N?TOQ1]NNA#/# C,DC[;:X,[)L;:=R M[01STZYZ=<9 .@HJC;ZQ97:9<+Z_=7<-M%(3I^FR32!%"Y^>7)XP7!.>ZQKZU'KNJ[H_$&H0/AT\O2+ M1UY(E8C>R@ M<#H"JJ/;)[BM3PCXCLK'0(;.-=7U*8-([3C39_WNZ1B'W,H'((/6J^KZ8^GV M>@^';+"W=[>>=E#\L*Q1]1ZA,1@>NWU-3IJ.E>'/$>LSW$B1+865M:6L .7* M*C/M5>IZC\O05I*,)1M!>?Z?G3\OU$TC7[^[\0:S?VNBW=PA\N*,2 MR11")4W*P.6R#O#YXXQ^<.I:SKOB2.UT=+&TL$U7S 2UR\CB*-OWA("@ -PO M7/S?DD$-YI?@"SA<;]3UZ= ZKD;3+\[J._"[R3ZEC5W+:;X[@M+93=7*:,L< M0)QN)E^9V(X4?*"3^ R2 3W4[I;;?+K]X>\U9O??YD>OB^EO]+T*[U2V2.64 M3SK;6WE^7#$"^269Q]Y5&. 1GK@UL^'-/@GLQJERK3RW+F:)[C+,J=$.#P#M M /&.37.ZQI;7GCS3M'DS.)[*::^DSC*M)'O_ (C6,#^Z<=JTO'^K/::1;Z) MIB&6_P!4D%O%;Q/L;R^KG/\ ",#&>V<]JCE#XM=\00_P#"2:A>K!.R MM%:QK&K(4+%FW9&<;L*"""1&#DYK$U^Q$>F6/A2PDW3ZG?)%>WJ+A3M^8HG^ MS& HQT '4G'I-Q/9>'/#[2/M@M+*#"KG'"C 4>YP *NHXQII16KV]/^"_R( M@G*;SG@TH MW5^FR]OY##$NKW4FL7P_OJI#@$>[-% MG/IBN\U/6M.T:%9-1NDAW?<0\O(?15'+'V K.LK2Y8_U;3\S2D[KFE_5]2_4 M<]S#:PM+Z[K<;-;6O]C6QX26[7?.X]1&#A._WB>G*U MHV>BVUJRRRM)>7*\BXNFWN#WQV7Z* *YW&VYT*5]BW;7,=W LT._8W0NA4GW MP0#CW[U-24M24%%%% !1110 4444 %%%% "')4X.#V/I6':^'Y+/[/))>27? MV,R20QB-$W,P8$$_\"/<#IGI6[10!@>&-*FLEO)[RW>"6:9EBB9U810!B412 MO& 68X[9QT JS#)+HFFQQZK>W6IS%V_?I9DL022 5B7 &!G'./4UK5A^*;N M^LK&VETQV\X7"YB55/GJ%8F/D<;L8R,$4 <'/I=SIATV]0:GK+6%_P"%"LS&/, MA #;B!W&T=2=J+5-5O\ 3=?NVNY;(VQ\VTC2),I&(]R[@R$_,,,0>1G QBM+ M6(]4M8;8VVJ2K$'CBDDV1F21I)HU'&S;@*S= .<=:W]O+=J^_P")A[%+1/\ MI',Z?*MO\0[:YU6>]O+LZ?-([_V?,NTET4(B;,A >?4DDY-;>OC1]8TZ^C^ MR7<5Y!#$LCNRN>02 =HZYQFE*;; M4D]AQ@E=,SS96M^!'?$UKJ5K;ZO):RVSV]_=7.FW.\-N#+*[-&,C@J?0;>,#C=34+YO$UU:F\N MDAAG&'DBC%N%Q"?*+;=V\^:=HS_#WK0TZXD^T:E'=Z@\BK=BW@+A 5)C5L#" MC)RQZYZ#WS/M)=1^SCT/.]6U749OB"-5\+2NZZE:&RCN9;&X(M]I5V(4QX<_ M*< 9ZG/ K2D\,PG6K2_AU'55?:XOIVTRX\^U:O$3LN732W]?(S5"-W?OU33;&46NFF: M$QSVTUO%'YB!58L8S@#![$\UD^)]>77-&G=KN>59-D"2BTD2%A(ZJRP@KDC: M2"[KGMT%4?&,2RKH5KT M635[?Y0.H3=)C_QRBG4O*/E_PX5(:2\_^&,K6+F*[U2UOM!U@:?-';M:N9=/ MD<",L#E00,'*_3I5OP_9^&]!W3+=27=^_P#KKZY5WE<]^2.![#BM;5M3EL=8 MM( \BP36TS$16CSL'5HPI^4$@?.>W;K6*FNZS.UG%%=PQW%WI\,\9:Q=XA(R M2,=[!OD7]V,9YY(&:R]I+EY>AK[.*ES'0_\ "0Z6.MT!_P ;_"HF\6:$K;6 MU*%6]#D?TK*O/$6IVOB![.)[:=&NX(88?LS@NC@%SYN[:"J[V QSMP.M6/[6 MU9=?2&:2UM[9KLQ"*6VD^>,*2I28'87)Q\I XR.HR2^^%&C+( V_#D,4! MX&1DC'%,\-Z]>:O+;_:-FR2PCGQ\_K6QBDH RE\4^'Y "FN::V>F+N/_&M2.198UDC8.C ,K*< M@@]Q3J* "BBB@ HHHH *I:C;Z?<.R'\* )+JV\.QME>4+.Y:,+"/M C>;!4 YW]2UN%O=.@N8TN'&T2N&CV[N>%D M1&R#G!/J : .@N8="U26W2:>VFEEC*P[+C#RQGJ 0Z:<2-"+]CF12,$Q[L$C:.,<;1Z4^VT?1Y)VEMI9)7\SS&VWTCC> M1C<1O(SC@'MCCI6=Y$J^(;B=TO)H9+A=ENT.(\_N?WH<#(V['."2#[54T32; MBTUN&_DAQ;FXNT14MO+>+?*S*6.-S(5QZ!3MR#U4 Z.ST#3[&X6:!)BZ%BOF M7$D@4L,[MO_ @"O_ JN#M(BI\)=N-,M[F[ M6YE\X3)$\2LD[IA6QNX! SP.>O ]*J)X8TV-0(UNE40I!A;R8#RU!"KC=T&3 M^9K1M+J*]LXKFW"X19R5F:=8GN)&C61B2SA"=N26)Z<'D8K6HH RXO#MA#- MOC^T@ ,$C^U2;(LC!*+NPAP2!C&,G&,FI;'1++3I(GM%F4PP"W0/<2.!&#D# M#$C\>OO6ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HQ110 4444 %%%% M !1110 E!I<44 06ME;62R+9V\< DIZ*#0 4444 %%%% 3!1110 4444 %%%% !1110!__V0$! end GRAPHIC 18 limbeklogo.jpg begin 644 limbeklogo.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#T17AI9@ 34T *@ @ ! $[ ( M . (2H=I 0 ! (6)R= $ < 0T.H< < @, /@ M FMC.60G/SX-"CQX.GAM M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS M.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z M#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K M970@96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5 M&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @* M"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ*BHJ_\ $0@ .P#L P$B (1 0,1 ?_$ !\ $% 0$! M 0$! ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" M P $$042(3%!!A-180'EZ@X2% MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ M ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,082 M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3 ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C MY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*AN[RVL+5[F^N(K:! M/ORRN%5?J3P*;9ZA9ZA&SV%W!=(C;6:"0.%/7!([\T 6**** "BBC..M !17 M*+X^L[OQ1;Z1I5G/>QR7!MI+]"H@1PC.54YRY 0YP, X!.3BNKH **!7*^*- M?NS?0^'?#4JIK%T5+SLF];.+J9"#P6P#M!XSU[ @'544B JBAF+$#!)[TM ! M1110 45!>WD&GV,]Y>2K#;V\;222-T50,DU5T*[OK_18+O5+46D\^9!!WC0D ME%;_ &@NW=VSG% &C14%S<2020+':RSK+)L=XRH$(P3N;)!(R .,G)'&,D3T M %%1W%Q#:6TEQ=2K%#$A>21S@*H&22:R_#FKW6N6,E_/9-9VDKYLA(<2218& M'=?X:KJRP:(D?V&WEVW=])RK$=8X@/O'L6Z+R.3 MD W:*** "BBB@ HHHH **** ,[7X9KCP]?V]K"\TTUN\2(A4'+ C.6('&_U32&U!F/E QOAU !%Y()E4HAB>^<.P'=][",1ZA2>U,D_LR-GW:%<^5%:0W4\D=VYU!EUN=+:,RO';: MQ<*Y49 M,9P&"Y8\78O&<,5KI.BC4-0@,,"2SWLT#&XU )A<0QMF5_,?/S;?NJV.H8;= MQH=E#HG]H&V\2.V/,:U379_-4?CG. U48;'1KF;25NK?Q+:2ZFDC0^=KM MQF,*%.&*7!QN!&,9]\$T 4[GQ5KMYJ>LV%K)]DU)XDM-,TQ LDD$C1JYN9R M0JKYB#J5!5@-QQGN-.DU?][+K2V$$84;([:1Y"OJ2[!<]OX17%6T>DWC1-IV MG>+;N.X65HY8]?F =8WV,WS70/5ACC."..PM7?\ 9:%Q;6?B6^MUM4N?-AUB M3:\;AB,*]P&)PC<8SQ0!6E\=>%_$VLQB\U6WMM#LL3(]Z3!'?3 G:07P&1,$ M^[8/1O:M<:5HMK;W&H7][=_;WF"O:6\,43!MB$@.T08("[##Y;;G@"O/XO\ $$EQ MON]=%EI%QJHMXKX0JAF6-291$N"=A*,J\L[%EP0 <^BKX.M4E,B:GK(8C&3J M4IX].6J=?#D:C"ZEJ@^MXQ_G0!Y]XDUNV\;?:;:\U8:'I-G.BK;W2LMQ=SKM M90T(*R&-@XPHPY*#ITIVH^(?$/ACP;I-OK5[Y$M_/(([D1^4\40),<+O*[JC ML"HW.?E ;EF )[H>$K471N5OK]9V&&E$PW$>F<9["I/^$;R#G6-5.?6YS_2@ M#SW5_&M]/X6U MX]M;7(UE6\M':TD!L[)!N/$@54)PU'_OF#_XU1_9- MYCC7]1'/]RW_ /C5 &I164=(O2YT^XEADMF6 M9Q$J,9(U.73YE/)7.,8.<4 90\'3OI[6EUJ,<@%G';0R):E7B:,L8W!+GD;L M$=\>YJQ<>'+R6:=8]1ACM;FSCLYD-J3)L3?RK[P 3YC-)H9Y7N2D7F MNRE-J#*;,8=C]W/RCWR 1?\ ")J-3GU%);5+S[4D]M.MI\T*B-8S&3N^=2BX M[8)SC(&$TSPS=Z=?/.+NR_TBXDFNVAL2DEP&:1E1F,AX4R=<=!BLJ^N]:C\0 M:?IVG:M=7\4\,WG36Z6P\K;<*F]LH<[0Y4A>I3H.:Z_3)#+I-G(;H7F^!&^T MA HFRH^? X&>N/>@#!\->#/^$>NK.;[=]I-O8M:OF+;YC&3<'ZG&!E<<\=^U M;6N6,VIZ'>6%M,D#W4+0^8Z%PH88)P",G!]:Q+N[U<^)KBWT^2ZE6.2W/EA8 M?)C1C^\+$@/T!(P2F*6[NXO/G2 0NL;R*JQ[/F\P;5/ MS#!"N<=* -=M-U=H[T->6[&>!((D$;!(P-^6QN/)##_OD5!/X:EU".Q@U,P2 MVT-L]O,B;D+#=&RLI!R"#$OYU2T74]2>&2ZU/4)K>*-) AOQ (YR 3O4H 0J MA23DYQG(%6=%FU.:XFL]4O;R"Y-NK!9(X#R#AI(W0$%@SDT/-NX$ \ ?*PX)H NIX=O4UJXU426PO6: M+9,%.YE4;71NGRL.<#@-@\[173#I7)7^KW^F:A8I]M-W:-!9\W;"-QGBF6]UK5[IN@7(U.2$ZC;Q!@L#M!)R#@X"T =#17* M:GJVJZ7IHN'O(+A[BSEF7RH/*HWFD.P/<-&NY0?[PSCF@#JJ*Y+^T=:3PS;:G-?1D3BT;,5J78>8 MX5P%&2)TA:Z6XD^T/#@[(G5 #&3\CDOR#R-I!4'A M0#J**YR/4]1FN-,#7$2"2]FMIPD/ROY8D)*Y)*Y\L<9.,GKBK3ZC*VOVJ07D M#6$UK+.S _<9%X;.,?/D_0>] &S17-'6KZ369K:WN+EQP-##IUK'$TOG,D<*J#)G._ '7/.:OBB@#*C\,Z M+$I1-,M@K*R%?+&"K AACW!(_&GVWA[2K*&:*TL8HDF4)(%&,J,X7/91DX X M&3BM*B@#+'AS2%L39"QC^S%Q(8N<;@<@_4'FG-X>TIH(H?L,2QPLSQA1MPS= M3QW/R+NVC=G M.1O;G.>>M7** ,L>'M/73HK$"Y^SPNKQI]KE^4KC;SNS@8! Z<4^?0=/N"Y> M.16>7SB\4SQLK[=I92I!7(X.,9[UHT4 97_".:=MM55)T6TYA"74JX)SECAO MF8[FR3DG)S2'PSIA2-0EPJQQ&%0MW*N$.,CAN GRAPHIC 19 perf_graph.jpg begin 644 perf_graph.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# 8$!08%! 8&!08'!P8("A *"@D) M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_ MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P 1" #V B\# 2( A$! Q$!_\0 M' ! ,! 0$! 0 ,%!@0' @$(_\0 4A 0,# 00$"@<&!0 ( M! < 0(#! %$082%"$Q$T%3D@<5(E%288&1L=$R-'%SDZ'2%C5"5'+!%R,S M8K(D)C:"HK/"X3=T==-#8X24P_#Q_\0 &0$! 0$! 0$ (! M P0%_\0 .1$! ( @8'!@,( P $" Q$$$A,QD:$4(3)!<8'10E%2 ML<'A%5-A!2(C,V*"\/&2HN+_V@ , P$ A$#$0 _ /Z>B1F%1&5*9:*BA))* M!QX5+ND?L&NX*0OJ;'W:?A4U!#ND?L&NX*;I'[!KN"IJ4$.Z1^P:[@IND?L& MNX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*;I'[!KN"IJ4$.Z1^P:[@IND? ML&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*;I'[!KN"IJ4$.Z1^P:[@IN MD?L&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*;I'[!KN"IJ4$.Z1^P:[@ MIND?L&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*;I'[!KN"IJ4$.Z1^P: M[@IND?L&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*;I'[!KN"IJ4$.Z1^ MP:[@IND?L&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*;I'[!KN"IJ4$.Z M1^P:[@IND?L&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*;I'[!KN"IJ4$ M.Z1^P:[@IND?L&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*;I'[!KN"IJ M4$.Z1^P:[@IND?L&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*;I'[!KN" MIJ4$.Z1^P:[@IND?L&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*;I'[!K MN"IJ4$.Z1^P:[@IND?L&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*Y+JP MRW =4VTVE0Q@I2 1Q%6-<=X_=KWL^(H)H7U-C[M/PJ:H87U-C[M/PJ:@4I2@ M4I2@5EO"?=Y-CT/8CU@X(^R@R6F=!V>W,VZ[H5+7=T-I>=F;RLJ?)3DA0)P4G/FK.Z'TQ;] M>6F3?]4%^9-DR'$M8?6D1D@X"4 $#U\<]7KSJ;%I&\VQZ&R[JR7(M,10+<3= MD(40.25. Y4GU=8KE1H*X6V1,3IC4TBTV^4X75Q-U0\$J//842"GV>KS4&!G MS)4WP7S[;.DN240;VF$AU:LJ6V%<,GKY_#S5=P-0R-/:(OVG]M2[O;I1MT(< MUK2Z3T2AZ\;1'V"M7+\'L0Z/8L$&4MA#@X< M_7L+4RW]E<=(VXX;X.K2"$K*L]7#J_A%!YM;+:+-HSPC6U*U+3%+2,D\SCB? M::DT4BU_M;IQS0^\I0B.3>E#I0R/)X[6WPSG/+AG&*]"DZ&Z:+JMGQCL^/7$ MKST&>@QU?2\K\JO)=G==TDJS1YI8=,011)#>2/)V2K9SYL]=!XS&OL4:HB:Q M-RC&1(NJXRXH>3TB89&P@E&^%EN ]X0=/INMMF72&8CI7%AI4IQ M?/! 20>!X\^0K5RO!M8GM)^*&X<-J4&$M"X"*GI=L8\LGGQ(XC/7BNEC2+J; M[I^Z2+ETSMJB&*H=!CIR4D;6=KR>?+C0>:V]"_\ "?6$J&MQNR/N_P#0(SCW M2+90%C(5Q.SG(X9ZO7DZCP46ZPI>9DV_3-XML],1.W,EH<2T]D)VM@E9!R>/ M(<*M'_!\%1M3Q(]S+,&]*#H8Z#(CN9!*@=H9!\W#J\U66E;!?K.\RFX:F\8P M&F>B1&W!MG& D[8)/ "@Q'A"TY(N=)V?2UE<+Z[=!D,D1F5MN.E(0=E0)2%[;G,;EYZ/;V]G/D\QC.>=<^M] M*R-1OVJ1"NGBV5;GB\V[NX>XG'42!U>N@H8LNTZ4\'5XNECL\^RCRMEB>E:7 M%.D!*584I7#)'7U&J7P5.Q+%JQ5GBW&--:N4!N2I3+Z70F2D?YB<@G!/$^RM M3,T9=+O"AQ=1:C\9,,S$2G$& AH.H2.#9"3C&<\>/.I[OH*W/W*T3[*W$L\J MWR \51XB0'D]:%!)3S\_'&3YZ#R;40LJ=2ZV>O-GN,UY#^(TJ-E+<99! *U; M0 R=G&0>5>AW.X7?3/@83(?E!ZZHC(0'TKV]G;4 "%=9"5#CYQS-7D+1C+4G M5"Y4G>&+Z?+:Z/9Z(8(QG)R>// Y5]VK22&=$?LU=Y9N,;HRUTO1]&H(SE( MR>*>&#ZA05VEM V>"W;;JA4M=W2A+KLS>5E3Q(R0H$X*3GS53^"__P"&E]^_ ME_\ &KVPZ1O-L>A-.ZMER+3$4"W$W9"%$#Z*5. Y*?5UBN)_P>3&G+BQ9M2R M;=:+@M3C\(1TN'*OI;*R6EI+' M@G2P@GHVM0["+?<-1ZAD7A5OR8K9CI92A7I*P3M'EQ/FH(/!W_VO MUU_\\C_B:R?A5DQKWJ2XQ';E&B>)(/2QTN/I;+DI1"L)R1GR0!ZB:U_[%WJ+ M?[I<;-JG<&[@^'G6/%Z'>7(;2E?;R KLLN@[9%7<'[TS#O,V9)7(4_)B()2# MC" #G %!E]<0;/JKP;'5;\4.7),!/1NAQ8Z,A7$;(.#A15S%5VJ--VJQ^#2! M(M<7H'IKT)C+OIQ%S*HTQQ:V%ECC'2H@[ M.-KRN7/AS-6&H=)^.-*P;+OO0[JID]-T6UM=&,?1VAC/V\*"@84-,^%N:EU> MQ OD0R03R2ZT#M?^$$^VL/?V3)\&LF^RD+6Y>KRE\I'TBT"I*$^X''VUZIX0 M-(#5L2&AJLFG+M9%JV4."X(6@NCB1LA2UPUZ/IJV7RWNOJO>H?&Z%@!M.Y(C]&>LY M2>.:_)VG=ZUE;;]O6QN;#C'0='G;VL\=K/#&?,:#$(LL34NOI^G[CTOB&QQ& M6X\!#RTI42D84H@Y)'+GYO7GXMECA0]=W31A#K^G)<%,O0ZGJVD*P"> X^H>:NG2FE!99TRYS MY[UTO$P!+TMU 1Y(Y)2D<$CEP]0H,+H'1NGSJ[4JG((Q:9S9B$O.#HL J]+C MQ YYJAC7V*-41-8FY1C(D75<9<4/)Z1,,C802C.1C&>76*]01H]UE.JMWN9: M=OBMH+#&3'X$'^+RN!/'A7/*\&UB>TGXH;APVI082T+@(J>EVQCRR>?$CB,] M>*#GM/\ \:+Y_P#3&O\ DFH?#O@Z$(4DJ3O;64CF>)X5]G0EZ8NJ+C;=5[I+ M,-J(ZOQ>ASI @ ;7E*.,X!J[U;IAW4FF8]KDW'8?0MIQR3T /2*1S.P" ,GU M\*# >#Z/$/A$5^R\&=9;?&B'?X-/X-K=8ITH&Y: M:O$V>;@O8N+*'-W;PH$;2@L 8/$\.NO6+AI?I]96[4,288ST=E4=]H-;0D-G MD":J33^A[[85EJVZMZ*WJD%]<;Q:VK:R02-LJ)&0,9H,U=M!Z;: M\)EEM;=MQ!E17G7FNG<\I0S@YVLCV&KS2L1B!X7;U#B(Z..Q:V&FT9)V4@( M&3Q/#SUJIVG=ZUE;;]O6QN;#C'0='G;VL\=K/#&?,:K]1:/D3;^B]V.\NV>Y MEKH'7 PE]#J.H%*B!GU^H4&!N'U3PL?>-_$U7Z,C0UZJTLUIJWW"SST-!^X. M2W"VF4ULC)0E2CM@X5C Z^K(]'8T"TUI:\VPW%YV==E%OG4URT7O+>FEQK@8TZR;"42 SM=*@) 4DC:& <>>@'.8[@QM8_VJ /_P#E;30*DKUAK=2"%)5+9((Y$='5M:=*,PYN MHW9+PE,7ES;<9+>R$)V2"G.3G.>?"N?0.COV2%Q'C!R=O2T%)6WLE"4C92DG M)SPZ^'+E08'PJR8U[U)<8CMRC1/$D'I8Z7'TMER4HA6$Y(SY( ]1-6OA%N:- M0>">V30?)F/1^D /(DX4/80?=6GLNA+9&7<'[RQ#O$V9*7(4_)B()2#R0 %!00-0R-/:(OVG]M2[O;I1 MMT(880X3Q2I0V2L>OB2/97H]S MT'#GZ]A:F6_LKCI&W'#?!U:00E95GJX=7\(J1G1,52M3(GO[S&OC@<6V&]@M M8!Q@Y.2#@@X'*@R%[T':[7H5V]Q'I:+]'C"7XQ$E>VXO&T<\<8/+EGEQJKU* MF?JF[Z/?8WU5K/\/;F_;V[3<-63)%A1A.Z",A M"U(!X)+NRM"[I=HZJM%W8?#+-NBKBHBI;X%)&!Y6>&/-@T& O>J-YO6G] M016_\]NTS7%,G^!U"#M)(]2@:X%VRPQM+6Z_ZL@7Z^3I[6\NSHRE*$;D0"0M M*4@9&,YY'[*W:?!]$3K-Z];R3#>0Z%V]3>4%3B=E9VL\ KF1CG5:[X-YR+=( ML]OU3*8L#VSXBN MRN.\?NU[V?$4$T+ZFQ]VGX5-4,+ZFQ]VGX5-0*4I0*4I0*4I0*JG]1V./+5% M?O-M:DI5L*97*0E85YBDG.:M:\%N3;$N^:[@C3D(Z1EL/)V MG4^DD9XCUBO*KGH^]P&]/7-RW0]0&!;Q%DVZ2H*X\3E&<@D XZ^7 '/#HN8@ MW?P>6[4>E8VXR+(M4EEE7 H"5$NM$^B>)]W+E0>GBX0C-=AB7',MI'2.,!U. MVA/I%.<@<1QKGAWRTS5/)AW2!(4RDJ=#4A"R@#F58/ ?;7BMW9D?L2W>9[@; M?U1 MW-!?)ND!5N\8)G13 QM;R'D]%C.,[6<<_74$V_6> &3.NMOC!Y'2-]-)0C;3 MZ215?#O#]YTM:M#NK)NN_&WS0#@ICLJRI7V;( ]>#0>N>/;1XOW_P : MP-QVMC>-X1T>UYMK.,^JOB/J*R267WH]XMKK3"0IU:)2%);!Y%1!X#[:\-E- MI:\$CC3325)3J!24M=1 Y)X^ZMG?HSC7@ZU.Y(TE"TXZ6$I CN-.%X9ZRV!C M'K\]!Z%;[[:+D\6;==8$MT#)0Q(0XK'GP#74B;%7-9XYY5W3ITF)K?5 MLY@%$MK3Z74X&=E8 /Y&@](;9&G( MA2;C"9F+QLL./I2XK/+"2(@4K@./' ) X$?;U4'LRE!*2I M1 2!DD]5<-OO-KN+SC-ON4*6ZV,K0P^EQ2>KB >%8GPS32O2EM::>4W!N,UE ME]Q)Q_E*!5S]@JVO-AM.GK!/N=CMD2)/A0G2R\RV$J^@>9'TN77F@O9%^L\: M9NDB[6]J7G'0N24)7G^DG-37*ZV^UH0NYSXD-#APA4AY+84?5DC->[0KK;I\9R1!GQ),=O.VZR\E:4XXG)!P*@@:ALMPD"/ M N]NE/D$AMF2A:B!Z@Z@]VN5WMMKV/&=PAP M]OZ.\/);VOLVB,U]FXPDP#.5,C"$$[1D%U/1X\^UG&*\WT/;+?J/5>KYM^BQ MY\MB:8K:)+8<2TTG(3A*L@? -33[G MY9$^;%BEY6RV'W4HVSYD MY/$\1RKQ/3L;?-4Z,C/66)IYYED2D26U!2[@D)'#* !DX)(420"?L/UX4+O9 M[IJJ]1+K/Z#Q=!Z&"G86H*DDA94"D''().<4'L,[45D@25QYUXML:0C&TT]* M0A24ZQ,(>X&=O;:'MEOU'JO5\V_18\^6Q-,5M$EL.)::3D)PE60.7/U>LUG7VD M6^V>$ZU6_*;5'Z-;+0R4MK5](#W8QZJ#VE%S@+MQN")L54 )*MY#J2W@<"=K M.,5TM.(>:0XTM*VU@*2I)R% \B#UBO$W2O3VC[Q9'CB#E_^S5I_^49_X"@Z%7. FXIMZIL43U)VDQBZGI".>0G.<<#4B9D9 M4U<-,ADRT(#BF L;:4GDHIYX]=>1:KMDJ=X3;S*M?"Z6V$Q-C?[E)(RC[%)) M'NJYTO>(MT\(TZ[,K"8KMD:>)/\ !Y?E ^L8(/V4'H N< W$V\38IGA.T8W2 MIZ4#GG9SG%+EIC-S>UW9;C M[!;6"F(H; 3M8V3A(Y9ZZ]%\(-@N$C4<'4<"V0[_ V8Q907B79[[;M &VP4LVU=S+2H;J=H(.T-I!!R",D^P]7*K>\PK? MI?PHZ<=LK+,%$QE],QED!""VE.0HI' 8P3P]&@]'%S@&XFWB;%,\)VC&Z5/2 M@<\[.6FIS$"(T(C#R=ML)4 2K9/ \_SH/2 M84R+/CI?@R69+"N3C+@6D^T<*^+C<85M9#MQF1HC1. M]U+:2?-DFO/=+QF; M1X8;U;;0A+-N<@H?=CM<&VW!XGK\_J%!Z,W/ANP1-;EQUPRG:Z=+@+>//M9QBH;;>;7=%+3; M+E"F*0,J$=]+A'VX)KSK7UJM\>]Z1T\TPB+9)TUQY^.WE*'%C9P/4"3R'GK] M\(%IMVG]0:1FV"''@3G+BA@IBMAOI&S](%*>!YXSCKH/1FKK;GK@Y :GQ%SF MQE<=+R2XG[4YR.8K]GW6WVYQENX3XD5;QPTE]Y*"L\."03QYCEYZ\0N(5:]7 MZ@U0P#TEJO#0>V>984<_1'5M#CQJN%GFPK=H/36HR M41)S6V\VNZ*6FV7*%,4@94([Z7"/MP37ZF\V MQ=Q,!-QA*G X,8/I+@_[NS..?TJ#U>3?K1&#QDW M6 R&7 TZ7)"$]&L@D)5D\#@'@?-4<;4UAE.AJ->[6\Z02$-RVU' &2< ]0!/ MLK&Z,MT*YZHUPS2^! MZ,ZNVV=QW1T%MD-K4F]=(R75'*L'9V=L'^'G7K5 I2E I2E I2E KCO'[M>] MGQ%=E<=X_=KWL^(H)H7U-C[M/PJ:H87U-C[M/PJ:@4I2@4I2@4I2@546:P1; M1>#B@4I(!'DX P./7FK>E!FM0Z/C7J>9GC.\6]Y2 VYN,LM M!U(S@*&".LUUL:9ML;2SE@B-K8@.,K9.P?+PH'*LG/'CS-75*"B.E;8YI1K3 MTEM1R ./K%5MKT%"@.*4NZ7J: RMAI$N7TB6$J3LG83@ ' M'#CFM?2@SC6D(#6BSIA+TK<"V6^D*D]+@JVN>SCGZJX[QH*#S/KK[:T,QXKN5OEWR_3F)S8:7ODL.EL YRC*< ^^M=6 M9=UI;FF-0.K9E[-D4$2/(3E9/H>5Q]N*"OMW@WM463$=F3KO=&XA!CL3Y72- M-$P/,,9SP\]<,+6ELFZ0D:B81 M),..%EUHI2'4E)XI(SC/(\^NN:\Z\@VMZV,BVW::_<8XDLM0V$N+V<9XC:!S MCS9H.=GP:VF.\1&GWEBWESI%6YJ84QE'.<%.,XY==?5;E3"8Q45;7T,9Y\>==UEUK:KO#N#K(E,/V]LN28DAKHWFP 3Q2>'5U&N*P M:_8OCT9,+3^H@Q(SL27(8#/ '^/:QU8^V@T5[LL"]6EVVW%A+D-P ; \G9QR M(QR(JFL6B(=IFMR%7*\7#HD*;9:G2NE;:!&#LIP!RX<<\*A;\(5G7IE^\AN8 M$,R!%7$+:=X#I( 3L[6,\<\^6?LK7-++C2%E"D%20=E7-/J/KH,,KP867'2=MF^)$@.QVK0ZEV,VP0$Y&,!60L&-.2$R4S'@G M9=V!T0*@2E).,DI0IT@J())XD #K\UNLW%\*EG=89E2+;?(=N=.RF=(A_Y&"\O.*.,J*B#QX>;%6M M\O,:SV*1=GPMV*PWTIZ'"BI/#ED@'GYZSMH\(MLN%Q@Q'[?=[:J=]5/4$J!. MGXE@:FIBN/O+F2%RGG'U!2E+5SX@#A7Y8]0Q+S<+M#BMOH=MKP8>+B0 I7'B MG!.1PZ\54I\(-F\0R+LM$M#+4I4)+1;!<=='\*$@G.?610?"?!Y:4V1^THD3 MDPG9HG!(6C_+7Z*?)X)X.<\A7Y9M;0[FU+6JW7:#N\=MTGH2[CTN!J9G1-H8TO,L M4<4<945$'CP\V*Y=.Z]CWZ3%1#L.H41Y)(1+=A@, <>)6%$8 MX8JZTQ?XNHX+TJ$V^VVT^N.H/) .TGF1@GAQH.'46C+9?]/Q+3-5(2S%"0T\ MVI(=3LIV>9!'$<^%1Z>TNNW:EFW1]Q!&[M08B$*)*6$ <5D@>42.K@*LM,7^ M+J."]*A-OMMM/KCJ#R0#M)YD8)X<:Y-4:LB:>6&W85SG.]'TRT08Q=Z-OCY: MCD #@>N@ZX]@BL:GEWU#CYER6$QUH*AL!*2""!C.>'GJE;\'EH9D7MZ,]-8- MV:4RZEMQ(2VE1RH-C9X9.>>>9KK_ &WLG[*)U#O"]P4=A*=C_,*\XV-GTL^S MKSCC7SI_6UMO$B9&<8G6R7%:Z=QBX,]"OH_3QD\*#ME:9M\G2?[.K2X+?T"8 MXV2-L!.,*SC&UD YQSJJEZ"AOMQ4M7>^Q5LQT15+C3.C+R$#"0L 8/ ]0%1V MSPCV>?V>5:+7;H[LZWLVYPNL+ANA#FV>:BH@G.>.:^( M_@[M33$\.R[I*F3&3'7.DR.D?2V>:4J(P,CARJ^NM^A6[3CM\45OP4,A\%D ME:#C!&2/.*IKQK^T6B19VIK2[[%BZB@69Q#QE36W'6UI V $<\G.<^PUE4^%*UJ#[GBF_;FPZI MIV8(@4RV0<'*@H_.@FT[HJ7IC4:IEIN.\P9F-^3/&W() .%)< XG)&0>'.K/ M4FC+=?;BU<%2)]ON+:.C$N _T3A3Z).#7Q?=<6NTPK5*;9F7%NYG$5,%H.*7 MP!Y$@]?+G7._K^)$M(N-QLU]@1=Y3&4944-E&T,A9!5G8ZLC/'JH)G]!V>38 M!:I:ID@!XR!*=?*I'2G^/;\_LQZJ670MOMMU:N4B;=+K-9!2R[<9/3%D'GL\ M !5BUJ.&]J8&.1JZH,ZC2%N2G4"5+D.)O M9S)2I2<)X$>1PX<^O-<@T#:4Z3C:?0Y+1#8>#X6%IZ12PHG*CLXZ_-6MI05$ M>P16-3R[ZAQ\RY+"8ZT%0V E)!! QG/#SU^:HTY;]2V],2YMK*4+#C;C:ME; M:A_$D]1JXI09&TZ"ML*XIG2YEUNTMM!0TY<91=+0(P=G@,SA5]2@QVG=!1[#)BKAW[ M4*X\8DHB.S 6"./ H"0,<] MGQ%!-"^IL?=I^%35#"^IL?=I^%34"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4 M"O%KC^[/"M]^BO::XE6FW*3+2J!$*99S(!93AX^=?#RO;0>/:H0K3>FGWDA7 MBS4%K0ESK#PGS#(X#U M4'F,R4Q?-=ZCN=F6E^WQK$['?DM\6UN$$@ ]?#'+T:D\#\IQNVVA#VLH*V"V MM*;,6V4N).58&UM;9]+E7J4:!#BPS$C1([,4@CH6VPE&#S&R!BN!C2]@CNAR M/8[6TX,@+1$;21D8/$#S&@\7D/-.:V7K-,?_ *KHNR&EC:.%N!)3O&SRP%'. M?7]M>PZZO2;%I&Y7%*P'$,D,G/-Q7!./:0:LO%-N-M\7;A$\7\MVZ%/1<\_0 MQCGQYVW>F2[DDJ2GBGB5'C]E:*]65.H?"/J2"'"V\;8P['=!_TW4J!0H> MW\B:]1G0HMPC*CSXS$J.H@J:>;"TG'$9!X5\M0(;,M4IJ)';DJ0&U/); 64# MDDJQG \U!Y+IV[KO6I]029+9:FMV$L2FB,%#R%$+'O&?;7/:]0V:/X#Q;GYL M9V>[&=91#0X%.E:EJV?('$W(DR$08J7Y(V7W RD*='F4<94/MKF MAZ5_" 2?[Y]HEQF)D=R/+9:? M8<&%MNH"DJ'F(/ U#(M<"3'8CR(,5UA@A33:V4J2V0, I!&!CJQ0>\+" X@A1RG//F. JCTS!L]Q\'RDWZX&U-3+L[)@2RKH MR%@<% G@!P5SQ]N<5Z]<;-:[FXARY6V%+<0,(4^PEPI^PD'%32K?#EQ!%EQ( M[\48'0NMI4CAR\DC%!Y1;+PU>+;J/3^L+S'N%GCEEMN\,80%*41L@J&4Y! X M\>1R2*^;5>9\>1>M.)O3&HK4BTNO-S&L*4QA) 0I220?:2>7+E7JS-JM[$%4 M)F!$;AJYL(92&S]J<8K\A6BVP([C$&WPXS#O!;;+*4)7]H P:#S+P/2746VS MMNZQ@N,EM:4V7HV0ZDY5@;6UMD_Q+9&M,R#(N,-J:Y/6/8=(UIJQ-2DR6K+;$24KVPZF*V%A6 MX MV^WW=ER;(CN!Q&T/5YJ]7BV>V1(3L.+;H;$1TDN,-L)2A9(P0K[MUM@VQI35MA1H; M:CDHCM);!/GP *#QR9<[?>=$Z#M-JDLNW),N-M1VU!2V]A)"RH/.I+; M=[=:;!X1+==)+,>X.2Y10TZK"W0M.$;(/%7'S>?->N1;/;(DQ=M MYMA*5JSSRH#)I+L]LF2T2I=NA/RF\;#SK"5+3CEA1&108*YQGH?@%+$I)2\B MW(VDD8(R0<'WU6SK-4:0MTP$QY5A6VL#G@M\QZP<$>L5ZQ+C,3([D>6RT M^PX,+;=0%)4/,0>!J)-NA)D,/IAQ@_'1T;+@:3M-HY;*3C('J%!Y1IR=)=\( MVG;7/GK[VBW-=&YTJ-B,A.POTA@<#PY\Z#S_P.QW+!=KQ8+PD M>.=EJ3TI65%UG8 "03U(/#V^JO5*YEP(:YZ)RXD=4UM.PB06P7$IX\ K&0.) MX>NNF@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@5QWC]VO>SXBNRN.\?NU[V? M$4$T+ZFQ]VGX5-4,+ZFQ]VGX5QZ@*D6U;HN+MN;;\M;S2$*7C' #;2H<3CJ) M/(>J0G=BV@(9V"=DI(&T>"2#M$Y)R,1%<=X_=KWL^(H)H7U-C[M/PKFO%HAW=ME$Y+Q#+@=;+3[C*DK (!RA0/6: MZ87U-C[M/PJ&Z/3&(X5;XK,E[/%+S_0H2,9R5!*C^77U4'*K3UO6ZPM[?'N@ MV2A#TUYQ!*3D%2%+*5$'CD@G('F%20K';X4]R9'96E]>V?*=6I*=L[2MA))2 MC:/$[(&>NJ=.JW78[,J-;MJ&&6'Y2G']A;0=/ )3LG;*1Q/%/#ED\*[+;?GY M=Q9;)3#6/3< K-_LG*D?O"]2W@>:4Y _,G MX5T1]%V=K&VV\]]XX?[8IM,>VZF7C/H9S[D<76<%^ZB+T:T,J5L(?4>!/K'4 M/76H!! (((/(BLT=%V@R%N;#VRH<&PYY*?6.O\ZYSI>; )58KJZT.?1.\4_+ M\JYTOI-,]I76\"-:-[6TK(^.[[;.%VMG3M#F]'\WG.,CX58V_55IFX&\= L_ MPOC9_/E^==:Z5AS.4SE/NGJ;K0O:5^)4E:0I!"DGB"#D&OVO0TI2E I2E I2 ME I2E I2E KCO'[M>]GQ%=E<=X_=KWL^(H)H7U-C[M/PK@U);IET@IC0IK45 M)6"]TC!=#J,'*#A:2 >&<'U===\+ZFQ]VGX5#=;G#M,0R;@^&60<9P5$G!. M!DG@"> Y GD*"GDZ>F275%RXQTLR$-)F-MQ".DZ-1(Z,E9V,C@<[7 <,'C4U MLL+\2>TX]-0]$C%U49E+&PI'2')VU[1VL D# 3SXY/&NZ1=XC%R;@JWE4E:4 MJPU%=<2D*) *EI24IX@\R.5?,.^6^9<5P8[RU2$;?-I:4*V"$JV5D;*MDD [ M).#SH+*OAQEIT@N-H61UJ2#7W2@AW2/V#7<%-TC]@UW!4U*"'=(_8-=P4W2/ MV#7<%34H(=TC]@UW!3=(_8-=P5-2@AW2/V#7<%-TC]@UW!4U*"'=(_8-=P4W M2/V#7<%34H(=TC]@UW!3=(_8-=P5-2@AW2/V#7<%-TC]@UW!4U*"'=(_8-=P M4W2/V#7<%34H(=TC]@UW!3=(_8-=P5-2@AW2/V#7<%-TC]@UW!4U*"'=(_8- M=P4W2/V#7<%34H(=TC]@UW!3=(_8-=P5-2@AW2/V#7<%-TC]@UW!4U*"'=(_ M8-=P4W2/V#7<%34H(=TC]@UW!3=(_8-=P5-0D $D@ =9H(=TC]@UW!3=(_8- M=P5PS-06J'GIIS.T/X4';/N&:J'-9M/+*+9;Y4M?J3@?EDUPOI.%3JFS-:(: M7=(_8-=P4W2/V#7<%9C>-5S_ /1C1X#9Y*7@G\\_"G[*S9G&[WB0ZD\VV^ _ M/A^51TBUNQ29\>KYLS]T+>9<++#SO#L-*AS2 %*]PXUEK]JN)T0;LS#?2$^4 MZMD8 ]0/]ZT4/2=GBX.[=,H=;JBK\N7Y5:F#$,([_"7E("0H^?F!75XIU'*_P!5Z!%0>:4-IS^2 M3\:V+3:&FTMM(2AM(PE*1@ >H5]5M=&G*->\SYY&K[Y8Y&BW'>,ZZON9YI0G M _,GX5VQ]%V=K&VV\]]XX?[8K24JHT3!CKU<_'K^9JPKF+':V!AN!&^U384? M>:ZA#C 8$=D#U(%3TKO6E:]F,E(=TC]@UW!3=(_8-=P5-2J$.Z1^P:[@IND? ML&NX*FI00[I'[!KN"FZ1^P:[@J:E!#ND?L&NX*XYUBMDU)#\)G)_B0G95[Q5 ME2IM6MXRM&8Q[VCG(RRY9YZVCS#;PVDG_P#OV&H][O-KX7*SL3&AS=80,_;P M']A6TI7GZ+%?Y@HGLCFXQ]+\OE79 U?:Y)V'E MKBN\BEY.!G[1P]^*VNE8;I'[!KN"FZ1^P:[@K\,R*EE+QDL MAI1P%EP;)/VU..(R.5>B)B=RD.Z1^P:[@IND?L&NX*FI6B'=(_8-=P4W2/V# M7<%34H Y 5QWC]VO>SXBNRN.\?NU[V?$4$T+ZFQ]VGX56:O1)>T[-C MP83TQ^0VIE*&E(3LY2?*)6I(Q]F3QY59POJ;'W:?A7[*DL1&%ORWFF&4?2<= M4$I'5Q)X4&8ND>9,GQ),*UW2+/(9"I)F(0RA"5Y4AQM+I"S@J'T%?2X$I(']P:^Z4$/0K_ )EWW)_33H5_S+ON3^FIJ4$/0K_F7?1> M)_N!3_K?)ZH43/V''_*LZ56>S69\O5FLTW0K_F7?WGB:1C1$33#XS'JJ(O;LUS;:9J"V1,A=V4M0_A:"5_!.*JCJEZ42FTP M[A*/+:*4@#W)/]JM&8.G+8 2(#9'':><23]N5&I'M5:>C#"[S;ALY&RE]*L8 M]0-5,8UNU:*^'W]&UPL2VZ.2J;1JZ;S<8A-GTMDG'L!_M7V-(.2CM7:ZRI)Y M[*3@#WY^ K[?\(6EF3Y=W;/]#:U_!)JO?\*FF6_H/2G?Z&"/CBIV.%/\RVMX MS]':N@X]O8GA*\B:3M<4@MM%2O.X$K^(JV;C%M 2V\XA(Y!*4 ?\:P1\+%L= M.(-KND@\1P;2,GV*-/\ $.Z/?4='71X'&"=H#CU\$&NU)PJ=5.KPAT_#\>/9 MR\XCZM_T*_YEWW)_33H5_P R[[D_IKS_ /:K6L@?]%TD&^O_ #EG^Y33??"5 M(X"V6J+U9*P?_6JKVL=T3P;T*T=JU8_NAZ!T*_YEWW)_344E2(K*GI,XLM)Y MK<*$I'VDBL)XO\),GZ5WM<5)YA* 3_P/QJEU7HC65RMZ=ZNS=T4A84(P5T8S MRR,X&?MQUUDXDY=59530\.;1%\6L<'%?1: M6D$F4Z .))"/TUY?I_P:W0VEE%ROTV&<',1A9*6^.<9VL9SQX"K(>":TN*"I MEQNDA6<\7$C[?X32+WF.R6P-'K,QM>$-F]/A,?Z]W:;_ *W6Q\15<_JBPL_3 MU'%/]#S:_@#52QX+=,MXVV)+O];Y'PQ5@QX/M+,_0M#1_K<6OXJ-;GB>Z$ZN MBQOM:?*/5S/Z^TRSG:ORU'CP0R59]R*KWO"=IUOZ$VX._P!$=(^(%:EC2M@8 MQT=EMP(Y$QTDCVD5WL6Z$QCH(<9O'H-)3\!3+$]\&MHL;JVGSCT>>_XHPGOJ M,*]2#]TT/AFG[>7I[ZEI6\N@\E*& /-R:/QKTRE-6_Q MNI'U73;C8/;*3_<)K]2_X37^<2W1OM*#_P"HUZ72FSGOM)TJL=G#KSGZO!8- MKUZSJ]V2TS+-P!*EO.?Z#@\VT?)(Y8 Y>K'#6_M!KV#^\-/&0!UQ5).?=M5Z M;2IKA:NZ9=,33XQ9C7PZSQ]7F7^)2HO[XLUZA$<_(0<=Y*:L(?A)TW((#ESF M1R>UCC_TI-;VJ^99+5-SO=MA/YZW&$J/O(JM6\=[GM-&MOI,>$^L*V'J:QS, M=!J&,2>25.MH)]A -7+.'D;;,U;B/204$?"L[,\'FEY62JUH;4>MIQ:,>P'' MY53O>"BSI7TD";<8CG44. @?EG\Z9XD=QJ:+;=:8\8S^4M[T*_YEWW)_33H5 M_P R[[D_IKS[]A]20OW7K"64CDA\*('_ (B/RINWA)@?1EVRXI'($!)QZ_)3 M\:;28WUDZ+2W8Q8\\X^A7_,N^Y/Z:XY]FBSP1,!=/I%"-KW[.:Q7[5:V MA?O'20?QSW51/P*Z_1X4F(QQ=[%=(1Z_(!QWMGU5-KTM&5N<'0,:>S$3X3$I M;_HIUM;:K,E3J#P6VM8!2?."<<*UMCM\B%:8T=^4X7&TX.SLD#CR&1UMQ0 M]"O^9=]R?TTZ%?\ ,N^Y/Z:FI0 , DGUFN.\?NU[V?$5V5QWC]VO>SXB@FA M?4V/NT_"J770:5IJ8E<5V2\IM:6$M1EOJ#A0H @)22G@2-K@.//C5U"^IL?= MI^%34&'NQ5)DSDM09KCEQ:B[JX8C@"=E9)VR4_Y92?*\K'/AD\*FL#3OC*W1 M]SDM/05RS(=<84A!"UG&RLC"]HD*X$\N.#6RI0*^'"Z".C0A0_W+(_L:^Z4$ M.U([)K\0_IIM2.R:_$/Z:FI00[4CLFOQ#^FFU([)K\0_IJ:E!YMK2ZW6/?5- MA]Z,TA*2TEI9"5 @$D\MKCD)/NK?TKR=%MKVMK MSULR>+86\<]J*\GXUS?XG['!UF.%#F#M)_(UZ?7RM"'!AQ*5#GA M0S5='M^9/+T;E'^?Z>9?XI-]E%[ZJ#PIM9&6XO?(K?O66U/C#]L@N#_>P@_$ M5P/Z.TZ]G;L\,9S]!&Q\,5O1[?FSPAN=?=/'_P LI_BC'[&-^/\ ^U/\48_8 MQOQ__:KQ_P '.EW3GQ;L'SH><'Y;6*KWO!3IUSZ)FM?T.@_%)K>C7_.G_C#8 MFG?$\8]',WX4(ISM,1S_ /J@/[5]_P")\/\ EX__ .\'Z:YG_!!;%9Z"XRD> M;;0E7P KA=\#Q3DQ[P@YZG(O]]JMZ+B]V/R^S=;"[XM_U]86CWA)1(:4U"98 M1(4/)5O 9E+ M:&0AA*DN'[!CB?SKGL.CM1J95,=L;$Q2C@(N*BE?#_:5)./MJ.@:5-\]K&7O MSB/I]#6T;?-K>&77X]4Y9<_T:5_PAO+X+NUNB_T-J<^"555R=;H#F ]L\RRV%^[Z=6#&MH,#Z[H^5 QSV(Z>'GYI35_A6- M;?;6\_28;TC08WQ;SG+Z,NG4MIDJ\J-?)ZP<<%) )_,U81KPT<&)H2Z2O,I; MCG+V(Q6MB^%#3CH 6J7''_YC.<=TFK6-KG34C'1W9@?>!2/^0%9^%VIUS3EG MZJC2M"]G#CSM/V8]BZ:CP-PT''9/474\?><5VB=X2'QANT6N(CJRH' /_?/P MK'[&'7G/U><[EX2I''QG M:HO7C9!]GT%5\*TOKI_ZQJMM'W0(^"17I-*W91WS/%O3;1V:UC^V'F?^'U^> M/_3=6SW@>:0XL#U\R:II'@BG.75*_&++D)1!<4XI73>O^'!^VO9:5DX-)[E5 M_:6D4W3RCT>?,^"VQ-_3BNN_URU#X)%6#'@^T\SC9LD91_WR75?&MC2JC#I' M8 MY00:OK5!%JM[$*#&9;CLIV4)#I^TGZ/,G)JPI4Q6(G.(=+8U[5BEIZH0[4CL MFOQ#^FFU([)K\0_IJ:E4YH=J1V37XA_33:D=DU^(?TU-2@#.!G /7BN.\?NU M[V?$5V5QWC]VO>SXB@FA?4V/NT_"IJAA?4V/NT_"IJ#+:C1(AWIBZ/!;EN3T M#.RBXNLE"RX1GHD^0YG;1P4>KD>5[ B+G(&$25,I+B?L5C(YFON/;8,:6_+C0XS4I M_P#U7FVDI6Y_4H#)]M!U5\..I;("@L_TH*O@*^Z4$.\H]%W\)7RIO*/1=_"5 M\JFI00[RCT7?PE?*F\H]%W\)7RJ:E!#O*/1=_"5\J;RCT7?PE?*IJ4$.\H]% MW\)7RIO*/1=_"5\JFI00[RCT7?PE?*F\H]%W\)7RJ:E!#O*/1=_"5\J;RCT7 M?PE?*IJ4$.\H]%W\)7RIO*/1=_"5\JFI00[RCT7?PE?*F\H]%W\)7RJ:E!#O M*/1=_"5\J;RCT7?PE?*IJ4'!)9@2L[S#2]GM(I5\4U52=+Z:D?ZEE8'W<92/ M^(%:2E5%[5W2F:5G?#"R?![I9[.Q#EL9[,N_^H&N$^#B PK"2<>Y M(]5>D4KK&DXL>TYS@8<^R\W_ &6U%%^H:NGK Y)?8<('JXE7PIT?A!B?0N$* M8D<@I@@_^6/C7I%*WI-I[41/E!L*QNF8\WG"=0Z\C<).GH\A(_B:!!/_ (C\ M*ST[PE:A8OZ4.PDQVVU!*X*D>4K[5$9R>K'JX'K]HKE$'3#N,71*3Y ME,N)^*:ZVM9:==QL7>)Q])6S\:F?TM87\])9[?DYR4L)2?>!7"]H'3#WT[4V M/Z'%I^"A3^!/OY'\;].:V9OEM?\ ]&6VY_1D_"NL2FR,@.D?=*^58Y[P8:;< M'D-26OZ'C_?-'W-;%CV8X_9N]Y1Z+ MOX2OE3>4>B[^$KY5@_\ #^YL_4M77-D#J.T?@L4_9?63'U;5?2?>H/\ ?--E MASNO'"3:7C?2>3>;RCT7?PE?*F\H]%W\)7RK![EX18_$7.V2AYBD#_T"J/6- MWUW;[3F>AF-'*P%28GTAZB0> /V#E[ZKHNM,1%HXIMI&K&CM;/ MG&0\H]%W\)7RIO*/1=_"5\JP>X^$9W(\:VM MGU[(/_\ &:_?$>OG"DO:DAI/([#8X?\ @%9L([[QS]&[:?AG_/-N]Y1Z+OX2 MOE3>4>B[^$KY5@_V3U:X"'=6N)'5L)/S%/V%OSA!>UI<>/TDH"P/_,_M38X? M?>.$^AM+]U)Y-YO*/1=_"5\J;RCT7?PE?*L'_AQ(6,2-3W-P=7$\/>HT_P + M8+GUB[71S/TO+3Q]X--GA?'RDU\3X.;>DF M-IV>>UD8K(M^"BP)SM/W%?\ 4ZGA[DUTM^##3B<;34E>/2>/'W4U,&/:GA]S M6Q?ACC]G4QX0M//754%,M22"0'E(PTH^8'_VQ5ZW>KYX+].*!V6Y2,^B]R]XJ[UT;V;3P16V/[ M41Q;!N:RX,MEQ0Y92VH_VKZWE'HN_A*^585SP3V%1RF1<4>I+J/[HKY_POB( MXL7FYMJZCMCE[ *C9X/Q\ONO7Q?AYMYO*/1=_"5\J;RCT7?PE?*L%_AS*1P8 MU1$!OBUJ*$HGGMH&/\ RS385[KQ MS]#:V[Z3R]6]WE'HN_A*^5-Y1Z+OX2OE6"W/PCMV>O92-K_P _M3I M?",U_P#@6Q[/K2,?F*='_KCB;;^F>#>[RCT7?PE?*F\H]%W\)7RKQS6U_P!; MPV8R;F@6YLJ.RY#..D/F*@HX^SA[:]1TA(GR]-0'[N@HG+;RX",$\3@D=1(P M?;3%T><.D7F8G/W&'C1>TUB)ZEEO*/1=_"5\J;RCT7?PE?*IJ5YW9#O*/1=_ M"5\J;RCT7?PE?*IJ4 '(!&>/GKCO'[M>]GQ%=E<=X_=KWL^(H)H7U-C[M/PJ M:H87U-C[M/PJ:@5S>,(?C#<=[C[]L=)N_2)Z39]+9SG'KKII0*^''FFB XXA M!/4I0%?=*"'>X_;M=\4WN/V[7?%34H(=[C]NUWQ3>X_;M=\5-2@AWN/V[7?% M-[C]NUWQ4U*"'>X_;M=\4WN/V[7?%34H(=[C]NUWQ3>X_;M=\5-2@AWN/V[7 M?%-[C]NUWQ4U*"'>X_;M=\4WN/V[7?%34H(=[C]NUWQ3>X_;M=\5-2@AWN/V M[7?%-[C]NUWQ4U*"'>X_;M=\4WN/V[7?%34H(=[C]NUWQ3>X_;M=\5-2@AWN M/V[7?%-[C]NUWQ4U*"'>X_;M=\4WN/V[7?%34H(=[C]NUWQ3>X_;M=\5-2@A MWN/V[7?%-[C]NUWQ4U*"'>X_;M=\4WN/V[7?%34H(=[C]NUWQ3>X_;M=\5-2 M@AWN/V[7?%-[C]NUWQ4U*"'>X_;M=\4WN/V[7?%34H(=[C]NUWQ3>X_;M=\5 M-2@AWN/V[7?%-[C]NUWQ4U*"'>X_;M=\4WN/V[7?%34H(=[C]NUWQ3>X_;M= M\5-2@AWN/V[7?%-[C]NUWQ4U*"'>X_;M=\4WN/V[7?%34H(=[C]NUWQ3>X_; MM=\5-2@AWN/V[7?%-[C]NUWQ4U*"'>X_;M=\4WN/V[7?%34H(=[C]NUWQ3>X M_;M=\5-2@AWN/V[7?%-[C]NUWQ4U*"'>X_;M=\4WN/V[7?%34H ((!!!!Y$5 MQWC]VO>SXBNRN.\?NU[V?$4$T+ZFQ]VGX5-4,+ZFQ]VGX5-0*4I0*4I0*4I0 M*H+K<;C;[M'VMU=@/%?^2AM73)2ELJ+A7M8QM )QL_Q#CU5?U2JL.;T_<3=)MSNRM+PKK#D0&G7(S:U,NQ5N=(ZL#92DAU.SE2@..>==4/ M3:8D=U#5TN)=4TF.V^LM*6RTDY"$Y1LGUE0)/#CP%30["U'A6R*N9+D-V]86 MT72@%6$E*0K92 0,Y'#F 3F@MF=OHD=,4ES9&T4C SUX]5?5*4"E*4"E*4"H M)PE&,L05LHD' 2MY)4E/'B2D$$\.K(^VIZX;U;Q=;:]#,J3%2[@*'.K>@4I2@4I2@4I2@R]TO-TM\PK;> YXN?F0 '>E2VMMM M3905?0VE':R"/I 8(/\ MKJ3I=&W<>FNEQ?9G;?2M.=%@9Y84&PL;/\ #Y7" MOU_3*7[;+BN76XER8?\ I$G_ ">D<3L[.Q_I[(3CS)!SQSQ.0X=0:G=MEXZ MR+>PV@,D1Y /32MM>RKHCM#Z(_VJR>'"M=52[9EOKB[U)' UQ&\W$W(+"8HMPF"$65(5TVT4_3V]K9QM$#9V>7'/55A> M[*;I(B/"XS8:HQ*D)8#125'^(AQ"@2.H]6340TZT+AO1FS5)Z0/F.2CHR\$; M/28VYO) M+B7D..=#TC;H5M=(%!L%2LCCM;0(X8JWM4!%NBEE#KKRU+4XXZZ05N+4+Q'D2H;I@.R-N.VT^VTM+;2W%*RE M8*R5%*0%<"G.T/HYS6K4,I(!()',=59V+I5+$%R*J[W-Y)<2\AQSH>D;="MK MI H-@J5D<=K:!'#%!S2KM>F[++DH7;MY@N.MN@LK(D*21L);&WE!4"!Q*L$X MP:M4SIHU(W#=;81$=C+>1@DN;22@')Y#Z9&!GD#GC@F+DJZ3E*:;+09*6>C*3L[6?\O:XE(/ M/GRP.%!;4I2@4I2@4I2@52WZ9?8U2[PS<472?'<:1L):;#2FP,Y) 6VH@GD2"#@4%?"O%UD2658@ M[O-#Z8R-A86TI!\DK5M$*! ). ,@W *DVQMV'(4@S51U]"M"4 M!2B$=)D$*)2?+P-D_94R=,,H6\47"X(2I+J6$I6@"*7#E1;.SG/FVBK'(8J) M6E-JU-6\WFY] TXEQ.$QQRSY) :V5#/$Y!R1F@N+-)>F6B%)E,]!(>90XXUZ M"B 2*[*BBM+9CMMN/N2%I&"ZZ$A2O6=D >X"I:!2E*!7'>/W:][/B*[*X[Q^ M[7O9\1030OJ;'W:?A4U0POJ;'W:?A4U I2E I2E I7XE:5YV5!6#@X.<&OV@ M4JD=U&PU=78;L26EIIT,*EX06@X6PL)X*V^1''9QGAFOF-J5EV B:[!G1XCB MFMAUU*"E2'#A+GDJ.$\LYP1D$C%!>TJC6,\ "<'GQ\]!>4JCDZA2Q*N#8MLYUB #T\E!:Z-)#8

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end XML 20 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2022
Mar. 15, 2023
Jun. 30, 2022
Document Information [Line Items]      
Entity Central Index Key 0000806517    
Entity Registrant Name PSYCHEMEDICS CORP    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Document Transition Report false    
Entity File Number 1-13738    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 58-1701987    
Entity Address, Address Line One 289 Great Road    
Entity Address, City or Town Acton    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 01720    
City Area Code 978    
Local Phone Number 206-8220    
Title of 12(b) Security Common stock. $0.005 par value    
Trading Symbol PMD    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 26,900,000
Entity Common Stock, Shares Outstanding   5,684,647  
Auditor Firm ID 243    
Auditor Name BDO USA, LLP    
Auditor Location Boston, Massachusetts    

XML 21 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current Assets:    
Cash $ 4,750 $ 1,992
Accounts receivable, net of allowance for doubtful accounts of $87 and $89 at December 31, 2022 and 2021, respectively 3,739 4,116
Prepaid expenses and other current assets 1,136 1,499
Income tax receivable 339 2,678
Total Current Assets 9,964 10,285
Property and equipment:    
Computer software 4,648 4,521
Office furniture and equipment 2,247 2,195
Laboratory equipment 16,013 16,005
Leasehold improvements 3,629 3,629
Property, Plant and Equipment, Gross, Ending Balance 26,537 26,350
Accumulated depreciation and amortization (21,964) (19,659)
Property, Plant and Equipment, Net, Total 4,573 6,691
Other assets 823 864
Deferred tax assets 691 160
Operating lease right-of-use assets 2,681 3,552
Total Assets 18,732 21,552
Current Liabilities:    
Accounts payable 448 994
Accrued expenses 3,939 3,188
Current portion of long-term debt 294 664
Current portion of operating lease liabilities 1,037 984
Total Current Liabilities 5,718 5,830
Long-term debt 305 599
Long-term portion of operating lease liabilities 1,938 2,880
Total Liabilities 7,961 9,309
Commitments and Contingencies (Note 9)
Shareholders' Equity:    
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding 0 0
Common stock, $0.005 par value; 50,000 shares authorized 6,349 shares and 6,257 shares issued at December 31, 2022 and 2021, respectively, 5,681 shares outstanding and 5,589 shares outstanding at December 31, 2022 and 2021, respectively 32 31
Additional paid-in capital 34,275 33,478
Less - Treasury stock, at cost, 668 shares (10,082) (10,082)
Accumulated deficit (11,820) (9,550)
Accumulated other comprehensive loss (1,634) (1,634)
Total Shareholders' Equity 10,771 12,243
Total Liabilities and Shareholders' Equity $ 18,732 $ 21,552
XML 22 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
shares in Thousands, $ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Allowance for doubtful accounts $ 87 $ 89
Preferred stock, par value (in dollars per share) $ 0.005 $ 0.005
Preferred stock, shares authorized (in shares) 873 873
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.005 $ 0.005
Common stock, shares authorized (in shares) 50,000 50,000
Common stock, shares issued (in shares) 6,349 6,257
Common stock, shares outstanding (in shares) 5,681 5,589
Treasury stock, shares (in shares) 668 668
XML 23 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues $ 25,240 $ 24,909 $ 21,360
Cost of revenues 15,949 14,645 16,474
Gross profit 9,291 10,264 4,886
Operating Expenses:      
General & administrative 5,857 6,126 6,095
Marketing & selling 3,191 2,799 3,577
Research & development 1,326 1,130 1,280
Total Operating Expenses 10,374 10,055 10,952
Operating (loss) income (1,083) 209 (6,066)
Other Income (Expense):      
Gain on forgiveness of PPP Loan (0) 2,181 (0)
Settlements 0 (3,150) 0
Other income (expense) 43 (61) (140)
Total Other Income (Expense) 43 (1,030) (140)
Net loss before provision for (benefit from) income taxes (1,040) (821) (6,206)
Provision for (benefit from) income taxes 44 (156) (2,347)
Net loss (1,084) (665) (3,859)
Other Comprehensive Loss:      
Foreign currency translation, net of taxes 0 0 (10)
Total Comprehensive Loss $ (1,084) $ (665) $ (3,869)
Basic net loss per share (in dollars per share) $ (0.19) $ (0.12) $ (0.70)
Diluted net loss per share (in dollars per share) (0.19) (0.12) (0.70)
Dividends declared, per share (in dollars per share) $ 0.21 $ 0.05 $ 0.18
Weighted average common shares outstanding:      
Basic (in shares) 5,626 5,549 5,524
Diluted (in shares) 5,626 5,549 5,524
XML 24 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Shareholders' Equity - USD ($)
shares in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balance (in shares) at Dec. 31, 2019 6,185   668      
Balance at Dec. 31, 2019 $ 31,000 $ 32,249,000 $ (10,082,000) $ (3,754,000) $ (1,624,000) $ 16,820,000
Shares issued – vested (in shares) 20          
Tax withholding related to vested shares from employee stock plans $ 0 (9,000) 0 0 0 (9,000)
Stock compensation expense   563,000       563,000
Cash dividends declared 0 0 0 (993,000) 0 (993,000)
Net loss 0 0 0 (3,859,000) 0 (3,859,000)
Foreign currency translation, net of taxes $ 0 0 $ 0 0 (10,000) (10,000)
Balance (in shares) at Dec. 31, 2020 6,205   668      
Balance at Dec. 31, 2020 $ 31,000 32,803,000 $ (10,082,000) (8,606,000) (1,634,000) 12,512,000
Shares issued – vested (in shares) 51   0      
Tax withholding related to vested shares from employee stock plans $ 0 (72,000) $ 0 0 0 (72,000)
Stock compensation expense 0 743,000 0 0 0 743,000
Cash dividends declared 0 0 0 (279,000) 0 (279,000)
Net loss $ 0 0 $ 0 (665,000) 0 (665,000)
Foreign currency translation, net of taxes           0
Exercise of stock options (in shares) 1   0      
Exercise of stock options $ 0 4,000 $ 0 0 0 4,000
Balance (in shares) at Dec. 31, 2021 6,257   668      
Balance at Dec. 31, 2021 $ 31,000 33,478,000 $ (10,082,000) (9,550,000) (1,634,000) 12,243,000
Shares issued – vested (in shares) 91   0      
Tax withholding related to vested shares from employee stock plans $ 0 (78,000) $ 0 0 0 (78,000)
Stock compensation expense 0 872,000 0 0 0 872,000
Cash dividends declared 0 0 0 (1,186,000) 0 (1,186,000)
Net loss $ 0 0 $ 0 (1,084,000) 0 (1,084,000)
Foreign currency translation, net of taxes           $ 0
Exercise of stock options (in shares) 1   0     1
Exercise of stock options $ 0 4,000 $ 0 0 0 $ 4,000
Shares issued – vested $ 1 (1)        
Balance (in shares) at Dec. 31, 2022 6,349   668      
Balance at Dec. 31, 2022 $ 32,000 $ 34,275,000 $ (10,082,000) $ (11,820,000) $ (1,634,000) $ 10,771,000
XML 25 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Shareholders' Equity (Parentheticals) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dividends declared, per share (in dollars per share) $ 0.21 $ 0.05 $ 0.18
XML 26 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:      
Net loss $ (1,084) $ (665) $ (3,859)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Forgiveness of PPP loan 0 (2,181) 0
Depreciation and amortization 2,367 2,784 2,691
ROU asset amortization 949 906 935
Deferred income taxes (531) (371) (339)
Loss on sale of fixed assets 0 0 94
Stock compensation expense 872 743 563
Changes in operating assets and liabilities:      
Accounts receivable 377 (760) 424
Prepaid expenses and other current assets 363 (585) 392
Income tax receivable 2,339 (183) (2,013)
Accounts payable (546) 417 (281)
Operating lease liabilities (967) (1,078) (914)
Accrued expenses 751 1,387 (1,776)
Net cash provided by (used in) operating activities 4,890 414 (4,083)
Cash flows from investing activities:      
Proceeds from sale of fixed assets 0 0 140
Other assets (21) (38) (7)
Purchases of property and equipment and capitalized software development costs (187) (182) (991)
Net cash used in investing activities (208) (220) (858)
Cash flows from financing activities:      
Cash dividends paid (1,186) (279) (993)
Proceeds from stock options and tax withholding related to vested shares from employee stock plans (74) (68) (9)
Payments of equipment financing (664) (688) (678)
Net cash (used in) provided by financing activities (1,924) (1,035) 501
Effect of exchange rate changes on cash 0 0 (10)
Net increase (decrease) in cash 2,758 (841) (4,450)
Cash, beginning of year 1,992 2,833 7,283
Cash, end of year 4,750 1,992 2,833
Supplemental disclosures of cash flow information:      
Cash paid for income taxes 0 405 249
Cash paid for interest 33 50 75
Cash paid for operating leases 1,044 1,151 1,038
Right-of-use assets acquired through operating leases 78 172 2,346
Non-cash investing and financing activities:      
Purchases of equipment through accounts payable and accrued liabilities   0 241
Paycheck Protection Program CARES Act [Member]      
Cash flows from financing activities:      
Proceeds from long term det $ 0 $ 0 $ 2,181
XML 27 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Note 1 - Nature of Business
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. Nature of Business

 

Company Overview

 

Psychemedics Corporation (the “Company”) provides hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay and mass spectrometry to analyze hair to detect abused substances. The Company’s customers include Fortune 500 companies, as well as small to mid-size corporations, schools and governmental entities located in the United States and Internationally.

 

COVID-19 Pandemic

 

The outbreak of coronavirus (“COVID-19”) which was declared by the World Health Organization to be a pandemic, has, and is expected to continue to impact worldwide economic activity. COVID-19 has had a significant impact on our entire operations. Additionally, COVID-19’s effect on the overall economy has had an adverse impact on hiring, which is having a negative impact on our testing volume.

 

The Coronavirus Aid, Relieve and Economic Security Act (“CARES”) Act, enacted on March 27, 2020, and the Families First Coronavirus Response Act, in each case modified by the Consolidated Appropriations Act enacted in December 2020, were emergency economic stimulus packages that included spending provisions and tax cuts to strengthen the United States economy and to fund a nationwide effort to curtail the effect of COVID-19. The principal impact of the CARES Act and subsequent legislation was the adoption of the Paycheck Protection Program (“PPP”). The CARES Act, together with subsequent legislation, also provided sweeping tax changes in response to the COVID-19 pandemic, including amendments to certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company recognized a benefit of $2.6 million and $0.2 million for the years ended December 31, 2021, and December 31, 2020, respectively, as a reduction to cost of revenues and operating expenses related to the employee retention credit which was a tax provision in the CARES Act and subsequent legislation. Additionally, the CARES Act allowed the Company to fully carryback the 2020 net operating loss, for a refund of corporate income taxes previously paid.

 

Liquidity and Management’s Plans

 

At December 31, 2022, the Company’s principal sources of liquidity included $4.8 million of cash on hand. Management currently believes that such funds, together with future operating profits, should be adequate to fund anticipated working capital requirements, including debt obligations, and capital expenditures for at least the next 12 months. Depending upon the Company’s results of operations, its future capital needs and available marketing opportunities, the Company may use various financing sources to raise additional funds. Such sources could include but are not limited to, issuance of common stock or debt financing, lines of credit, or equipment leasing, although there is no assurance that such financings will be available to the Company on terms it deems acceptable, if at all.
XML 28 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Note 2 - Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

2. Summary of Significant Accounting Policies

 

Risks and Uncertainties

 

The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not limited to, FDA regulations, proposed laws and regulations, and delays in implementation of laws and regulations), competition and general economic conditions.

 

Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. As of December 31, 2022, and 2021, there were no investments classified as cash equivalents.

 

Property and Equipment

 

Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are:

 

 

Computer software

3 to 5 years

Office furniture and equipment

3 to 7 years

Laboratory equipment

5 to 7 years

Leasehold improvements

Lesser of estimated useful life or lease term

 

The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.4 million, $2.8 million, and $2.7 million in 2022, 2021 and 2020, respectively. The Company had $0.5 million of capitalized software and equipment that was not placed in service as of December 31, 2022, which is included as a component of computer software on the accompanying consolidated balance sheets.

 

Capitalized Software Development Costs

 

We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for three to five years. Costs incurred during the post-implementation/operation stage, including training costs and maintenance costs, are expensed as incurred. In accordance with Company policy, during the years ended December 31, 2022, and 2021, we capitalized internally developed software costs of $127 thousand and $99 thousand, respectively. Amortization expense related to software development costs was $282 thousand, $421 thousand and $293 thousand in 2022, 2021 and 2020, respectively. Determining whether particular costs incurred are more properly attributable to the preliminary or conceptual stage, and thus expensed, or to the application development phase, and thus capitalized and amortized, depends on subjective judgments about the nature of the development work, and our judgments in this regard may differ from those made by other companies. General and administrative costs related to developing or obtaining such software is expensed as incurred.

 

Other Assets

 

Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty years. As of December 31, 2022, the Company had capitalized legal costs relating to patent applications of $1.1 million with accumulated amortization of $0.5 million, for a net balance of $0.6 million. As of December 31, 2021, the Company had capitalized legal costs relating to patent applications of $1.1 million with accumulated amortization of $0.4 million, for a net balance of $0.7 million. Amortization expense was $62 thousand, $62 thousand, and $62 thousand in 2022, 2021 and 2020, respectively. Based on payments made as of December 31, 2022, remaining amortization expense is expected to be $62 thousand for each of the five years ending December 31, 2027 and $109 thousand thereafter.

 

Allowance for Doubtful Accounts

 

The allowance for doubtful accounts is based on management’s assessment of the ability to collect amounts owed to it by its customers. Management reviews its accounts receivable aging for doubtful accounts and uses a methodology based on calculating the allowance using a combination of factors including the age of the receivable along with management’s judgment to identify accounts that may not be collectible. The Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. Bad debt expense has been within management’s expectations.

 

Revenue Recognition

 

The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer.

 

Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration (none of which is variable) the Company expects to be entitled to in exchange for those services. The Company typically invoices customers monthly for services provided and payments are generally due within 30 to 60 days of the invoice date.

 

The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 13 – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report.

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Consolidated Revenue:

            

Testing

 $21,608  $21,894  $19,068 

Shipping / Collection (hair)

  3,476   2,847   2,174 

Other

  156   168   118 

Total Revenue

 $25,240  $24,909  $21,360 

 

Testing Revenue

 

Drug and alcohol tests for drugs of abuse using hair, performed in the Company’s forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received.

 

Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue.

 

Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue.

 

Shipping and Hair Collection Revenue

 

Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third parties who have contracted with the Company. Shipping and hair collection revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of the Company’s service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test (associated with the shipping or hair collection charge) and availability of test results to the customer.

 

Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues.

 

Other Revenue

 

Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than 1% of total revenue. The amounts are generally billed to customers as services are performed, which occurs at a specific point-in-time.

 

Practical Expedients and Exemptions

 

The Company generally expenses sales commissions when incurred as they are typically not related to costs to fulfill customer contracts but relate to overall sales targets. These costs are recorded within marketing and selling expense on the accompanying consolidated statements of operations.

 

Research and Development Expenses

 

The Company expenses all research and development costs as incurred.

 

Contingencies

 

Loss contingencies from legal proceedings and claims may occur from government investigations, shareholder lawsuits, product liability, contractual claims, tax and other matters. Accruals are recognized when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. Legal fees are expensed as incurred.

 

Income Taxes

 

The Company accounts for income taxes using the liability method pursuant to ASC 740, “Income Taxes”. Under this method, the Company recognizes deferred tax assets and liabilities for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts using enacted tax rates in effect for the year the differences are expected to reverse. The Company evaluates uncertain tax positions annually and considers whether the amounts recorded for income taxes are adequate to address the Company’s tax risk profile. The Company analyzes the potential tax liabilities of specific transactions and tax positions based on management’s judgment as to the expected outcome.

 

Concentration of Credit Risk and Off-Balance Sheet Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and accounts receivable. The Company’s policy is to place its cash in high quality financial institutions. At times, these deposits may exceed or be exempt from federally insured limits. The Company does not believe significant credit risk exists with respect to these institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom the Company makes substantial sales. To reduce risk, the Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. The Company does not require collateral. The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.

 

Significant Customers and Concentration of Credit Risk

 

The Company had no customers that represented 10% or more of total revenue for the years ended December 31, 2022, 2021, and 2020, respectively. The Company had one customer that represented 11% and 12% of the total accounts receivable balance as of December 31, 2022 and 2021, respectively.

 

Stock-Based Compensation

 

The Company accounts for equity awards in accordance with ASC 718, “Compensation — Stock Compensation” (“ASC 718”). ASC 718 requires employee equity awards to be accounted for under the fair value method. It also requires the measurement of compensation cost at fair value on the date of grant and recognition of compensation expense over the service period for awards expected to vest. Accordingly, share-based compensation is measured at the grant date based on the fair value of the award. The Company uses the straight-line method to recognize share-based compensation over the service period of the award, which is generally equal to the vesting period. The Company uses the simplified approach to calculate the expected exercise date of options, which is one of the components used to determine the fair value of the options. This approach is used due to the small number of recipients receiving stock options not providing a reasonable basis for estimating expected term. In 2016, the Company adopted ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of related amounts within the statement of cash flows. As a result, we recognize the impact of forfeitures when they occur with no adjustment for estimated forfeitures and recognize excess tax benefits as a reduction of income tax expense regardless of whether the benefit reduces income taxes payable.

 

Stock compensation expense by statements of operations account is as follows (in thousands):

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Cost of revenues

 $63  $63  $50 

General & administrative

  626   503   380 

Marketing & selling

  113   114   74 

Research & development

  70   63   59 

Total stock compensation

 $872  $743  $563 

 

See Note 7 – “Stock-Based Awards” to the Consolidated Financial Statements included in this Annual Report for additional information relating to the Company’s stock plan.

 

Basic and Diluted Net Loss per Share

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”).

 

Basic and diluted weighted average common shares outstanding are as follows (in thousands):

 

  

2022

  

2021

  

2020

 

Weighted average common shares outstanding, basic

  5,626   5,549   5,524 

Dilutive common equivalent shares

  -   -   - 

Weighted average common shares outstanding, assuming dilution

  5,626   5,549   5,524 

 

For the years ended December 31, 2022, 2021 and 2020, options to purchase 508 thousand, 574 thousand and 588 thousand common shares were outstanding but not included in the dilutive common equivalent share calculation as their effect would have been anti-dilutive.

 

Fair Value Measurements

 

The fair values of the Company’s cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of the Company’s note payable approximates its fair value, as it is based on current market rates at which the Company could borrow funds with similar terms.

 

Basis of Preparation and Consolidation

 

The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated.

 

Segment Reporting

 

The Company manages its operations as one segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. See Note 14 – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report for geographic breakdown of revenue.

 

Recently Adopted Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which modifies the measurement of expected credit losses on certain financial instruments. The Company will adopt ASU 2016-13 in its first quarter of 2023. Based on the Company’s historical credit loss activity, the adoption of ASU 2016-13 will not have a material impact on its consolidated financial statements.
XML 29 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Note 3 - Accounts Receivable
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

3. Accounts Receivable

 

The Company maintains an allowance for uncollectible accounts receivable based on management’s assessment of the collectability of its customer accounts by reviewing customer payment patterns and other relevant factors. The Company reviews the adequacy of the allowance for uncollectible accounts on a quarterly basis and adjusts the balance as determined necessary. Write-offs are recorded at the time a customer account is deemed uncollectable. The following is a rollforward of the Company’s allowance for doubtful accounts (in thousands):

 

  

As of December 31,

 
  

2022

  

2021

 

Balance, beginning of period

 $89  $37 

Provision for doubtful accounts

  9   55 

Write-offs

  ( 11)  ( 3)

Balance, end of period

 $87  $89 

 
XML 30 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Note 4 - Accrued Expenses
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

4. Accrued Expenses

 

Accrued expenses consist of the following (in thousands):

 

  

As of December 31,

 
  

2022

  

2021

 

Accrued compensation and employee benefits

 $442  $507 

Accrued vacation expense

  409   373 

Accrued taxes

  771   200 

Accrued shipping expense

  338   488 

Accrued legal settlement

  1,150   1,150 

Other accrued expenses

  829   470 

Total Accrued Expenses

 $3,939  $3,188 

 

 
XML 31 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Note 5 - Income Taxes
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

5. Income Taxes

 

The income tax provision consists of the following (in thousands):

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Current

            

Federal

 $552  $131  $( 2,006)

State

  23   84   ( 2)

Total Current

  575   215   ( 2,008)

Federal

  ( 959)  ( 704)  ( 13)

State

  428   333   ( 326)

Total Deferred

  ( 531)  ( 371)  ( 339)

Income Tax Provision

 $44  $( 156) $( 2,347)

 

A reconciliation of the effective rate with the federal statutory rate is as follows:

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Federal statutory rate

  21.0%  21.0%  21.0%

State income taxes, net of federal benefit

  12.0%  10.4%  4.4%

Permanent differences

  (0.4%)  47.6%  0.0%

Stock based compensation

  0.5%  1.4%  (0.4%)

Federal R&D Credits

  8.9%  0.0%  1.6%

Foreign taxes, net of federal benefit

  0.0%  (10.9%)  (2.2%)

Difference in tax rate for carryback claim

  0.0%  0.0%  13.4%

Increase/(decrease) in valuation reserve

  (46.2%)  (50.5%)  0.0%

Effective tax rate

  -4.2%  19.0%  37.8%

 

The change in effective tax rate from 2021 to 2022 was primarily driven by the Company’s 2021 non-taxable debt forgiveness from the Paycheck Protection Plan in 2021 that was included in income for GAAP purposes partially offset by the decrease in foreign taxes in 2022. As of December 31, 2022, the Company had no federal net operating loss carryforwards. As of December 31, 2022, the Company had $1.3 million of state net operating loss carryforwards, of which $1.2 million expire at various dates between 2030 and 2040, and $0.1 million do not expire. As of December 31, 2022, the Company had no federal tax credit carryforwards and $1.4 million of California tax credit carryforwards relating to the years 2013 through 2022 which have an unlimited carryforward period. In 2022, the 12.0% state income tax effective rate primarily consisted of California research tax credits of 8.3%.

 

The components of the net deferred tax liabilities included in the accompanying balance sheets are as follows (in thousands):

 

  

As of December 31,

 
  

2022

  

2021

 

Deferred Tax Assets

        

Allowance for doubtful accounts

 $21  $21 

Accrued expenses

  414   129 

Stock-based compensation

  381   325 

R&D tax credits

  1,086   1,083 

Operating lease

  701   944 

Capitalized research expenses

  404   - 

NOL carryforward

  72   219 

Gross Deferred Tax Assets

  3,079   2,721 

Valuation Allowance

  ( 895)  ( 414)

Deferred Tax Assets After Valuation Allowance

  2,184   2,307 
         

Deferred Tax Liabilities

        

Excess of tax over book depreciation and amortization

  ( 783)  ( 1,249)

Prepaid expenses

  ( 78)  ( 61)

Operating lease

  ( 632)  ( 837)

Gross Deferred Tax Liabilities

  ( 1,493)  ( 2,147)
         

Net Deferred Tax Assets

 $691  $160 

 

 

Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. The Company adopted ASU 2019-12 as of January 1, 2021, with no material impact to the Company’s consolidated financial statements.

 

ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions (tax contingencies). The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company’s tax positions and tax benefits, which may require periodic adjustments and which may not accurately forecast actual outcomes. The Company had immaterial uncertain tax positions at December 31, 2022, and 2021, respectively.

 

The Company operates within multiple taxing jurisdictions and could be subject to audit in these jurisdictions. These audits may involve complex issues, which may require an extended period of time to resolve. The Company has provided for its estimated taxes payable in the accompanying financial statements. The Company’s policy is to recognize interest and penalties related to income tax matters as a general and administrative expense, when and if incurred. Interest and penalties for the years ended December 31, 2022, 2021 or 2020 were not material.

 

 
XML 32 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Note 6 - Preferred Stock
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Preferred Stock [Text Block]

6. Preferred Stock

 

The Board of Directors has the authority to designate authorized preferred shares in one or more series and to fix the relative rights and preferences without vote or action by the stockholders. The Board of Directors has no present plans to designate or issue any shares of preferred stock.
XML 33 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Note 7 - Stock-based Awards
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

7. Stock-Based Awards

 

The 2006 Incentive Plan initially adopted in 2006 provides for grants of options with terms of up to ten years, grants of restricted stock or stock unit awards (“SUAs”), issuances of stock bonuses or grants other stock-based awards plus cash-based awards, to officers, directors, employees, and consultants. Such shares are issuable out of the Company’s authorized but unissued common stock. In May 2021, the 2006 Incentive Plan was amended to increase the total number of shares issuable thereunder from 1.2 million to 1.6 million. As of December 31, 2022, 183 thousand shares remained available for future grant under the 2006 Incentive Plan.

 

The fair value of the SUAs is determined by the closing price on the date of grant. The fair value of options is determined using a Black-Scholes model. The SUAs and options vest over a period of two to four years and are convertible or exercisable into an equivalent number of shares of the Company’s common stock provided that the employee receiving the award remains continuously employed throughout the vesting period. The Company records stock compensation expense related to the SUAs and options on a straight-line basis over the vesting term. Employees are issued shares upon vesting of SUAs, net of tax withholdings. As a result of our adoption of ASU 2016-09 in 2016, we recognize the impact of forfeitures when they occur with no adjustment for estimated forfeitures and recognize excess tax benefits as a reduction of income tax expense regardless of whether the benefit reduces income taxes payable.

 

On April 4, 2022, the Company granted SUAs covering two thousand shares of common stock. On May 20, 2022, the Company granted SUAs covering 126 thousand shares of common stock. On August 12, 2022, the Company granted SUAs covering 18 thousand shares of common stock.

 

The following table represents all shares granted by the Company under the 2006 Incentive Plan for the last three years (shares in thousands):

 

Grant Date

Type

 

Shares

  

Fair Value
Per Share (1)

 

August 12, 2022

SUA

  18  $6.65 

May 20, 2022

SUA

  126  $6.51 

April 4, 2022

SUA

  2  $7.04 

May 13, 2021

SUA

  116  $6.55 

March 16, 2021

SUA

  2  $7.04 

January 25, 2021

SUA

  2  $5.54 

December 16, 2020

SUA

  5  $4.71 

November 11, 2020

Options

  40  $1.13 

November 11, 2020

SUA

  190  $4.07 

 

 

(1)

The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 years. The options granted on November 11, 2020, have a fair value of $1.13 per share based on the $4.07 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 45% volatility, 0.9% interest rate and a 4.0% dividend yield rate. No options were granted during fiscal years ended December 31, 2022, and 2021. For options granted during fiscal year ended December 31, 2020, the weighted average grant date fair value was $3.47. For SUAs granted during fiscal years ended December 31, 2022, 2021 and 2020, the weighted average grant date fair values were $6.53, $6.55, and $4.89, respectively.

 

A summary of the Company’s stock option activity is as follows (in thousands, except price per share):

 

  

Number of
Shares

  

Weighted Average
Exercise Price Per
Share

 

Weighted
Average
Remaining
Contractual Life

 

Aggregate
Intrinsic Value (2)

 

Outstanding, December 31, 2021

  574  $14.23 

6.1 years

 $100 

Granted

  -  $-      

Exercised

  (1) $4.07      

Forfeited

  (1) $4.07      

Canceled

  (64) $15.03      

Outstanding, December 31, 2022

  508  $14.19 

5.1 years

 $25 
              

Exercisable, December 31, 2022

  467  $14.70 

4.9 years

 $14 

 

 

(2)

The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of December 31, 2022, and 2021 was $4.90 and $7.02, respectively.

 

A summary of the Company’s stock unit award activity is as follows (in thousands, except price per share):

 

  

 

Number of

Shares

  

Weighted Average

Grant-Date Fair Value

per Share (3)

 

Outstanding & Unvested, December 31, 2021

  224  $5.48 

Granted

  146  $6.53 

Converted to common stock

  ( 90) $6.33 

Cancelled

  ( 12) $6.29 

Forfeited

  ( 30) $6.26 

Outstanding & Unvested, December 31, 2022

  238  $6.10 

 

 

(3)

Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares.

 

The fair value of stock unit award vesting was $548 thousand, $296 thousand and $274 thousand for the years ended December 31, 2022, 2021, and 2020, respectively. The intrinsic value of stock unit awards converted to common stock was based on the stock price on the vesting date and amounted to $650 thousand, $501 thousand and $115 thousand for the years ended December 31, 2022, 2021, and 2020, respectively.

 

As of December 31, 2022, a total of 1,032 thousand shares of common stock were reserved for issuance under 2006 Incentive Plan. As of December 31, 2022, the unamortized fair value of outstanding options and awards was $1.2 million to be amortized over a weighted average period of 2.3 years.

 

The Board of Directors approved the accelerated vesting of 35 thousand SUAs to certain directors upon retirement from the Board of the Company during the year ended December 31, 2022. The Company determined the value of the modifications to be $230 thousand, which is included in stock-based compensation in the accompanying consolidated financial statements, for the year ended December 31, 2022.
XML 34 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Note 8 - Employee Benefit Plan
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Compensation and Employee Benefit Plans [Text Block]

8. Employee Benefit Plan

 

The Psychemedics Corporation 401(k) Savings and Retirement Plan (the “401(k) Plan”) is a qualified defined contribution plan in accordance with Section 401(k) of the Internal Revenue Code. All employees over the age of 21 are eligible to make pre-tax contributions up to a specified percentage of their compensation. Under the 401(k) Plan, the Company may, but is not obligated to, match a portion of the employees’ contributions up to a defined maximum. Matching contributions of zero, zero, and $198 thousand were made in the years ended December 31, 2022, 2021 and 2020, respectively.
XML 35 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Note 9 - Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

9. Commitments and Contingencies

 

Commitments

 

The Company leases certain of its facilities and equipment under operating lease agreements expiring on various dates through December 2026. Total minimum lease payments, including scheduled increases, are charged to operations on the straight-line basis over the life of the respective lease. Rent expense was $1.0 million, $1.1 million and $1.1 million in 2022, 2021 and 2020, respectively. See Note 10 – “Operating Leases” to the Consolidated Financial Statements included in this Annual Report for commitments remaining under lease agreements.

 

Contingencies

 

In the normal course of business, we are subject to contingencies, such as legal proceedings and claims arising out of our business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product liability, contractual claims and tax matters. We recognize accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. These estimates are subject to uncertainties that are difficult to predict and, as such, actual results could vary from these estimates.

 

Settlements

 

On December 6, 2021, the Company entered into a binding Memorandum of Understanding (the “MOU”) to settle a purported class action lawsuit against it related to certain California wage and hour laws. The lawsuit, Enma Sagastume v. Psychemedics Corporation, Case No. 2:20-CV-06624-DSF, is pending in the United States District Court for the Central District of California (the “California Lawsuit”) and is similar to numerous lawsuits filed against employers with operations in California.

 

In the binding MOU, the parties agreed to settle this matter for a payment by the Company of $1.2 million in exchange for the dismissal of the California Lawsuit and a customary release of liability, subject only to final court approval and the process described below. Factoring in that process, the Company estimates that the settlement funds will be dispersed in the second half of 2023, subject to the actual timing of final court approval.

 

Although the Company believes that the allegations in the California Lawsuit lack merit, it agreed at a mediation to enter into the binding MOU to settle the claims in the California Lawsuit in order to avoid potentially significant legal fees, other expenses, and management time that would have to be devoted to protracted litigation in California regarding its wage and hour laws. The foregoing was also impacted in part by new California case law in February 2021 regarding meal period compliance. The allegations in the California Lawsuit relate to alleged discrepancies in compliance with meal and rest periods required by California law and other alleged compliance discrepancies relating to the California wage and hour laws with respect to non-exempt hourly employees of the Company in California for a period since June 9, 2017. The California Lawsuit sought recovery of wages, penalties, interest, attorneys’ fees and other alleged damages. As part of the settlement, the Company continues to deny any liability or wrongdoing with respect to the claims made in the California Lawsuit.

 

The MOU assumes class certification for purposes of the settlement only. The settlement amount of $1.2 million, which includes plaintiff attorneys' fees and costs, is subject to potential increase based on any adjustments in the final class size and the exact period to be covered, as determined by the court’s final approval. However, the Company believes that such adjustments, if any, would likely be immaterial. Once court approved, in exchange for the settlement payment, the plaintiff and all class members who do not opt out of the settlement will provide a broad release of any liability relating to the subject matter of the California Lawsuit, including any claims of such persons under California’s Private Attorneys' General Act of 2004. Such release is for the benefit of the Company, its affiliates, and any successor to the Company. The Company has the right to revoke the settlement prior to court approval in the event opt-outs, if any, from the class membership exceed a specified level. While the settlement is subject to final court approval as is customary, the MOU expressly provides that it is binding on and enforceable by each of the parties thereto, including by any successor to the Company. There is a $1.2 million liability reserve in connection with the California Lawsuit as of December 31, 2022, and 2021 included in accrued expenses in the accompanying balance sheets.

 

 
XML 36 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Note 10 - Operating Leases
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

10.         Operating Leases

 

The Company has five operating leases for office and laboratory space used to conduct business. The exercise of lease renewal options is at our discretion and there are no renewals to extend the lease terms included in our Right-Of-Use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates the renewal options and when they are reasonably certain of exercise. As most of the Company’s leases do not provide an implicit rate, the Company uses the incremental borrowing rate based on the information available at the lease commencement date in determining the net present value (NPV) of the lease payments.

 

The weighted average discount rate used for leases as of December 31, 2022, is 3.8%. The weighted average lease term as of December 31, 2022, is 3.2 years. The operating lease expense for the twelve months ended December 31, 2022, and 2021, was $1.0 million and $1.1 million, respectively.

 

Maturities and balance sheet presentation of the Company’s lease liabilities for all operating leases as of December 31, 2022, is as follows (in thousands):

 

2023

   $ 1,134  

2024

     1,061  

2025

     553  

2026

     460  

Total lease payments

     3,208  

Less: interest

     ( 233 )

Present value of lease liabilities

   $ 2,975  
         

Current operating lease liabilities

   $ 1,037  

Long-term operating lease liabilities

     1,938  

Total

   $ 2,975  

 
XML 37 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Note 11 - Debt and Other Financing Arrangements
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Debt Disclosure [Text Block]

11.         Debt and Other Financing Arrangements

 

On March 20, 2014, the Company entered into an equipment financing arrangement with Banc of America Leasing & Capital, LLC (the “Lender”), which it amended on various dates, most recently on March 23, 2021, including a Master Loan and Security Agreement and related documentation (collectively the “Equipment Loan Arrangement”) which provided the Company with the ability to finance, at its option, up to $16 million of new and used equipment purchases. Each such purchase financed under the Equipment Loan Arrangement was documented by the execution of an equipment note with a maturity date of 60 months from the applicable loan date. The loans bore interest at the then current 30-day LIBOR rate plus a premium ranging from 1.75% to 3.79%. Principal and interest were payable over the 60 month repayment period. Borrowings under the Equipment Loan Arrangement were secured by a first priority security interest in the equipment acquired with the proceeds of the equipment notes. Under the Equipment Loan Arrangement, the Company has been subject to a maximum quarterly funded debt to EBITDA ratio and a minimum fixed charge coverage ratio each of which was waived for certain quarters in 2020 and 2021. The Company was in compliance with all covenants under the Equipment Loan Arrangement as of December 31, 2022.

 

Under the Equipment Loan Arrangement, the Company executed notes on various dates between March 24, 2014, and December 4, 2019 in the aggregate amount of $12.2 million, of which $0.7 million and $0.7 million was repaid in 2022 and 2021, respectively. As of December 31, 2022, the aggregate amount outstanding under the equipment notes was $0.6 million. The weighted average interest rate for these notes for the year ended December 31, 2022, was 3.7% and represented $32 thousand of interest expense. As of December 31, 2022, weighted average interest rate was 3.8%.

 

On May 1, 2020, the Company entered into a term loan with Bank of America N.A. under the PPP administered by the United States Small Business Administration (“SBA”) under the CARES Act (the “PPP Loan”). The principal amount of the PPP Loan was $2.1 million, which was evidenced by a promissory note with a maturity date of May 4, 2022. The note bore interest on the unpaid balance at the rate of one percent (1%) per annum.

 

In July 2021, the PPP Loan was 100% forgiven by the SBA and recorded as a gain on forgiveness of the PPP Loan in the 2021 consolidated statement of operations and comprehensive loss.

 

The annual principal repayment requirements for debt obligations as of December 31, 2022, are as follows (in thousands):

 

2023

 $294 

2024

  305 

Long-term debt from equipment financing

  599 

Less current portion of long-term debt from equipment financing

  (294)

Long-term debt from equipment financing, net of current portion

 $305 

 

 
XML 38 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Note 12 - Other Income (Expense)
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Other Income and Other Expense Disclosure [Text Block]

12. Other Income/(Expense)

 

Interest expense for the year ended December 31, 2022, 2021, and 2020 was $32 thousand, $49 thousand, and $75 thousand, respectively. There was no interest income for the years ended December 31, 2022, 2021, and 2020. Interest expense is included as a component of other income (expense) on the accompanying consolidated statements of operations and comprehensive loss.
XML 39 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Note 13 - Business Segment Reporting
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

13. Business Segment Reporting

 

The Company manages its operations as one segment, drug testing services. As a result, the financial information disclosed herein materially represents all the financial information related to the Company’s principal operating segment. The Company’s revenues by geographic region, based on the location of the customer, were as follows (in thousands):

 

   

Year Ended December 31,

  
   

2022

    

2021

    

2020

  

Consolidated Revenue:

                        

United States

   $ 24,509     $ 23,584     $ 19,486  

International

     731       1,325       1,874  

Total Revenue

   $ 25,240     $ 24,909     $ 21,360  

 
XML 40 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Note 14 - Subsequent Event
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Subsequent Events [Text Block]

14. Subsequent Event

 

On March 21, 2023, the Company declared a quarterly cash dividend of $0.07 per share, payable on April 10, 2023 to shareholders of record on March 31, 2023.

 
XML 41 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Risks and Uncertainties [Policy Text Block]

Risks and Uncertainties

 

The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not limited to, FDA regulations, proposed laws and regulations, and delays in implementation of laws and regulations), competition and general economic conditions.

 
Use of Estimates, Policy [Policy Text Block]

Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.

 
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. As of December 31, 2022, and 2021, there were no investments classified as cash equivalents.

 
Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

 

Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are:

 

 

Computer software

3 to 5 years

Office furniture and equipment

3 to 7 years

Laboratory equipment

5 to 7 years

Leasehold improvements

Lesser of estimated useful life or lease term

 

The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.4 million, $2.8 million, and $2.7 million in 2022, 2021 and 2020, respectively. The Company had $0.5 million of capitalized software and equipment that was not placed in service as of December 31, 2022, which is included as a component of computer software on the accompanying consolidated balance sheets.

 
Research, Development, and Computer Software, Policy [Policy Text Block]

Capitalized Software Development Costs

 

We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for three to five years. Costs incurred during the post-implementation/operation stage, including training costs and maintenance costs, are expensed as incurred. In accordance with Company policy, during the years ended December 31, 2022, and 2021, we capitalized internally developed software costs of $127 thousand and $99 thousand, respectively. Amortization expense related to software development costs was $282 thousand, $421 thousand and $293 thousand in 2022, 2021 and 2020, respectively. Determining whether particular costs incurred are more properly attributable to the preliminary or conceptual stage, and thus expensed, or to the application development phase, and thus capitalized and amortized, depends on subjective judgments about the nature of the development work, and our judgments in this regard may differ from those made by other companies. General and administrative costs related to developing or obtaining such software is expensed as incurred.

 
Other Assets [Policy Text Block]

Other Assets

 

Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty years. As of December 31, 2022, the Company had capitalized legal costs relating to patent applications of $1.1 million with accumulated amortization of $0.5 million, for a net balance of $0.6 million. As of December 31, 2021, the Company had capitalized legal costs relating to patent applications of $1.1 million with accumulated amortization of $0.4 million, for a net balance of $0.7 million. Amortization expense was $62 thousand, $62 thousand, and $62 thousand in 2022, 2021 and 2020, respectively. Based on payments made as of December 31, 2022, remaining amortization expense is expected to be $62 thousand for each of the five years ending December 31, 2027 and $109 thousand thereafter.

 
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]

Allowance for Doubtful Accounts

 

The allowance for doubtful accounts is based on management’s assessment of the ability to collect amounts owed to it by its customers. Management reviews its accounts receivable aging for doubtful accounts and uses a methodology based on calculating the allowance using a combination of factors including the age of the receivable along with management’s judgment to identify accounts that may not be collectible. The Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. Bad debt expense has been within management’s expectations.

 
Revenue [Policy Text Block]

Revenue Recognition

 

The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer.

 

Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration (none of which is variable) the Company expects to be entitled to in exchange for those services. The Company typically invoices customers monthly for services provided and payments are generally due within 30 to 60 days of the invoice date.

 

The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 13 – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report.

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Consolidated Revenue:

            

Testing

 $21,608  $21,894  $19,068 

Shipping / Collection (hair)

  3,476   2,847   2,174 

Other

  156   168   118 

Total Revenue

 $25,240  $24,909  $21,360 

 

Testing Revenue

 

Drug and alcohol tests for drugs of abuse using hair, performed in the Company’s forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received.

 

Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue.

 

Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue.

 

Shipping and Hair Collection Revenue

 

Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third parties who have contracted with the Company. Shipping and hair collection revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of the Company’s service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test (associated with the shipping or hair collection charge) and availability of test results to the customer.

 

Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues.

 

Other Revenue

 

Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than 1% of total revenue. The amounts are generally billed to customers as services are performed, which occurs at a specific point-in-time.

 

Practical Expedients and Exemptions

 

The Company generally expenses sales commissions when incurred as they are typically not related to costs to fulfill customer contracts but relate to overall sales targets. These costs are recorded within marketing and selling expense on the accompanying consolidated statements of operations.

 
Research and Development Expense, Policy [Policy Text Block]

Research and Development Expenses

 

The Company expenses all research and development costs as incurred.

 
Contingent Liability Reserve Estimate, Policy [Policy Text Block]

Contingencies

 

Loss contingencies from legal proceedings and claims may occur from government investigations, shareholder lawsuits, product liability, contractual claims, tax and other matters. Accruals are recognized when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. Legal fees are expensed as incurred.

 
Income Tax, Policy [Policy Text Block]

Income Taxes

 

The Company accounts for income taxes using the liability method pursuant to ASC 740, “Income Taxes”. Under this method, the Company recognizes deferred tax assets and liabilities for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts using enacted tax rates in effect for the year the differences are expected to reverse. The Company evaluates uncertain tax positions annually and considers whether the amounts recorded for income taxes are adequate to address the Company’s tax risk profile. The Company analyzes the potential tax liabilities of specific transactions and tax positions based on management’s judgment as to the expected outcome.

 
Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk and Off-Balance Sheet Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and accounts receivable. The Company’s policy is to place its cash in high quality financial institutions. At times, these deposits may exceed or be exempt from federally insured limits. The Company does not believe significant credit risk exists with respect to these institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom the Company makes substantial sales. To reduce risk, the Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has not experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. The Company does not require collateral. The Company has no significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.

 
Major Customers, Policy [Policy Text Block]

Significant Customers and Concentration of Credit Risk

 

The Company had no customers that represented 10% or more of total revenue for the years ended December 31, 2022, 2021, and 2020, respectively. The Company had one customer that represented 11% and 12% of the total accounts receivable balance as of December 31, 2022 and 2021, respectively.

 
Share-Based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

 

The Company accounts for equity awards in accordance with ASC 718, “Compensation — Stock Compensation” (“ASC 718”). ASC 718 requires employee equity awards to be accounted for under the fair value method. It also requires the measurement of compensation cost at fair value on the date of grant and recognition of compensation expense over the service period for awards expected to vest. Accordingly, share-based compensation is measured at the grant date based on the fair value of the award. The Company uses the straight-line method to recognize share-based compensation over the service period of the award, which is generally equal to the vesting period. The Company uses the simplified approach to calculate the expected exercise date of options, which is one of the components used to determine the fair value of the options. This approach is used due to the small number of recipients receiving stock options not providing a reasonable basis for estimating expected term. In 2016, the Company adopted ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of related amounts within the statement of cash flows. As a result, we recognize the impact of forfeitures when they occur with no adjustment for estimated forfeitures and recognize excess tax benefits as a reduction of income tax expense regardless of whether the benefit reduces income taxes payable.

 

Stock compensation expense by statements of operations account is as follows (in thousands):

 

  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Cost of revenues

 $63  $63  $50 

General & administrative

  626   503   380 

Marketing & selling

  113   114   74 

Research & development

  70   63   59 

Total stock compensation

 $872  $743  $563 

 

See Note 7 – “Stock-Based Awards” to the Consolidated Financial Statements included in this Annual Report for additional information relating to the Company’s stock plan.

 
Earnings Per Share, Policy [Policy Text Block]

Basic and Diluted Net Loss per Share

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”).

 

Basic and diluted weighted average common shares outstanding are as follows (in thousands):

 

  

2022

  

2021

  

2020

 

Weighted average common shares outstanding, basic

  5,626   5,549   5,524 

Dilutive common equivalent shares

  -   -   - 

Weighted average common shares outstanding, assuming dilution

  5,626   5,549   5,524 

 

For the years ended December 31, 2022, 2021 and 2020, options to purchase 508 thousand, 574 thousand and 588 thousand common shares were outstanding but not included in the dilutive common equivalent share calculation as their effect would have been anti-dilutive.

 
Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value Measurements

 

The fair values of the Company’s cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of the Company’s note payable approximates its fair value, as it is based on current market rates at which the Company could borrow funds with similar terms.

 
Basis of Presentation and Consolidation, Policy [Policy Text Block]

Basis of Preparation and Consolidation

 

The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated.

 
Segment Reporting, Policy [Policy Text Block]

Segment Reporting

 

The Company manages its operations as one segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. See Note 14 – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report for geographic breakdown of revenue.

 
New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which modifies the measurement of expected credit losses on certain financial instruments. The Company will adopt ASU 2016-13 in its first quarter of 2023. Based on the Company’s historical credit loss activity, the adoption of ASU 2016-13 will not have a material impact on its consolidated financial statements.
XML 42 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Note 2 - Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Property, Plant and Equipment [Table Text Block]

Computer software

3 to 5 years

Office furniture and equipment

3 to 7 years

Laboratory equipment

5 to 7 years

Leasehold improvements

Lesser of estimated useful life or lease term
Disaggregation of Revenue [Table Text Block]
  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Consolidated Revenue:

            

Testing

 $21,608  $21,894  $19,068 

Shipping / Collection (hair)

  3,476   2,847   2,174 

Other

  156   168   118 

Total Revenue

 $25,240  $24,909  $21,360 
Schedule of Stock Based Compensation Expense [Table Text Block]
  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Cost of revenues

 $63  $63  $50 

General & administrative

  626   503   380 

Marketing & selling

  113   114   74 

Research & development

  70   63   59 

Total stock compensation

 $872  $743  $563 
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

2022

  

2021

  

2020

 

Weighted average common shares outstanding, basic

  5,626   5,549   5,524 

Dilutive common equivalent shares

  -   -   - 

Weighted average common shares outstanding, assuming dilution

  5,626   5,549   5,524 
XML 43 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Note 3 - Accounts Receivable (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]
  

As of December 31,

 
  

2022

  

2021

 

Balance, beginning of period

 $89  $37 

Provision for doubtful accounts

  9   55 

Write-offs

  ( 11)  ( 3)

Balance, end of period

 $87  $89 
XML 44 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Note 4 - Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
  

As of December 31,

 
  

2022

  

2021

 

Accrued compensation and employee benefits

 $442  $507 

Accrued vacation expense

  409   373 

Accrued taxes

  771   200 

Accrued shipping expense

  338   488 

Accrued legal settlement

  1,150   1,150 

Other accrued expenses

  829   470 

Total Accrued Expenses

 $3,939  $3,188 
XML 45 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Note 5 - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Current

            

Federal

 $552  $131  $( 2,006)

State

  23   84   ( 2)

Total Current

  575   215   ( 2,008)

Federal

  ( 959)  ( 704)  ( 13)

State

  428   333   ( 326)

Total Deferred

  ( 531)  ( 371)  ( 339)

Income Tax Provision

 $44  $( 156) $( 2,347)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

Year Ended December 31,

 
  

2022

  

2021

  

2020

 

Federal statutory rate

  21.0%  21.0%  21.0%

State income taxes, net of federal benefit

  12.0%  10.4%  4.4%

Permanent differences

  (0.4%)  47.6%  0.0%

Stock based compensation

  0.5%  1.4%  (0.4%)

Federal R&D Credits

  8.9%  0.0%  1.6%

Foreign taxes, net of federal benefit

  0.0%  (10.9%)  (2.2%)

Difference in tax rate for carryback claim

  0.0%  0.0%  13.4%

Increase/(decrease) in valuation reserve

  (46.2%)  (50.5%)  0.0%

Effective tax rate

  -4.2%  19.0%  37.8%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

As of December 31,

 
  

2022

  

2021

 

Deferred Tax Assets

        

Allowance for doubtful accounts

 $21  $21 

Accrued expenses

  414   129 

Stock-based compensation

  381   325 

R&D tax credits

  1,086   1,083 

Operating lease

  701   944 

Capitalized research expenses

  404   - 

NOL carryforward

  72   219 

Gross Deferred Tax Assets

  3,079   2,721 

Valuation Allowance

  ( 895)  ( 414)

Deferred Tax Assets After Valuation Allowance

  2,184   2,307 
         

Deferred Tax Liabilities

        

Excess of tax over book depreciation and amortization

  ( 783)  ( 1,249)

Prepaid expenses

  ( 78)  ( 61)

Operating lease

  ( 632)  ( 837)

Gross Deferred Tax Liabilities

  ( 1,493)  ( 2,147)
         

Net Deferred Tax Assets

 $691  $160 
XML 46 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Note 7 - Stock-based Awards (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

Grant Date

Type

 

Shares

  

Fair Value
Per Share (1)

 

August 12, 2022

SUA

  18  $6.65 

May 20, 2022

SUA

  126  $6.51 

April 4, 2022

SUA

  2  $7.04 

May 13, 2021

SUA

  116  $6.55 

March 16, 2021

SUA

  2  $7.04 

January 25, 2021

SUA

  2  $5.54 

December 16, 2020

SUA

  5  $4.71 

November 11, 2020

Options

  40  $1.13 

November 11, 2020

SUA

  190  $4.07 
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
  

Number of
Shares

  

Weighted Average
Exercise Price Per
Share

 

Weighted
Average
Remaining
Contractual Life

 

Aggregate
Intrinsic Value (2)

 

Outstanding, December 31, 2021

  574  $14.23 

6.1 years

 $100 

Granted

  -  $-      

Exercised

  (1) $4.07      

Forfeited

  (1) $4.07      

Canceled

  (64) $15.03      

Outstanding, December 31, 2022

  508  $14.19 

5.1 years

 $25 
              

Exercisable, December 31, 2022

  467  $14.70 

4.9 years

 $14 
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]
  

 

Number of

Shares

  

Weighted Average

Grant-Date Fair Value

per Share (3)

 

Outstanding & Unvested, December 31, 2021

  224  $5.48 

Granted

  146  $6.53 

Converted to common stock

  ( 90) $6.33 

Cancelled

  ( 12) $6.29 

Forfeited

  ( 30) $6.26 

Outstanding & Unvested, December 31, 2022

  238  $6.10 
XML 47 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Note 10 - Operating Leases (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Lessee, Operating Lease, Liability, Maturity [Table Text Block]

2023

   $ 1,134  

2024

     1,061  

2025

     553  

2026

     460  

Total lease payments

     3,208  

Less: interest

     ( 233 )

Present value of lease liabilities

   $ 2,975  
         

Current operating lease liabilities

   $ 1,037  

Long-term operating lease liabilities

     1,938  

Total

   $ 2,975  
XML 48 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Note 11 - Debt and Other Financing Arrangements (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Long-Term Debt Instruments [Table Text Block]

2023

 $294 

2024

  305 

Long-term debt from equipment financing

  599 

Less current portion of long-term debt from equipment financing

  (294)

Long-term debt from equipment financing, net of current portion

 $305 
XML 49 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Note 13 - Business Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Revenue from External Customers by Geographic Areas [Table Text Block]
   

Year Ended December 31,

  
   

2022

    

2021

    

2020

  

Consolidated Revenue:

                        

United States

   $ 24,509     $ 23,584     $ 19,486  

International

     731       1,325       1,874  

Total Revenue

   $ 25,240     $ 24,909     $ 21,360  
XML 50 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Note 1 - Nature of Business (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2022
Income Tax Benefit CARES Act $ 2,600 $ 200  
Cash and Cash Equivalents, at Carrying Value, Total $ 1,992   $ 4,750
XML 51 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Note 2 - Summary of Significant Accounting Policies (Details Textual)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Cash Equivalents, at Carrying Value, Total $ 0 $ 0  
Depreciation, Depletion and Amortization, Nonproduction, Total 2,400 2,800 $ 2,700
Property, Plant and Equipment, Net, Ending Balance 4,573 $ 6,691  
Finite-Lived Intangible Asset, Expected Amortization, Year One 62    
Finite-Lived Intangible Asset, Expected Amortization, Year Two 62    
Finite-Lived Intangible Asset, Expected Amortization, Year Three 62    
Finite-Lived Intangible Asset, Expected Amortization, Year Four 62    
Finite-Lived Intangible Asset, Expected Amortization, Year Five 62    
Finite-Lived Intangible Asset, Expected Amortization, after Year Five $ 109    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 508 574 588
Customer Concentration Risk [Member] | Revenue Benchmark [Member]      
Number of Major Customers 0 0 0
Customer Concentration Risk [Member] | Accounts Receivable [Member]      
Number of Major Customers 1 1 1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]      
Concentration Risk, Percentage 11.00% 12.00%  
Patents [Member]      
Amortization, Total $ 62 $ 62 $ 62
Finite-Lived Intangible Asset, Useful Life (Year) 20 years    
Legal Cost Capitalized $ 1,100 1,100  
Legal Cost Capitalized, Amortization 500 400  
Legal Cost Capitalized, Net 600   700
Capitalized Software and Equipment [Member]      
Property, Plant and Equipment, Net, Ending Balance 500    
Software Development [Member]      
Software Development Cost Capitalized 127 99  
Amortization, Total $ 282 $ 421 $ 293
Software Development [Member] | Minimum [Member]      
Property, Plant and Equipment, Useful Life (Year) 3 years    
Software Development [Member] | Maximum [Member]      
Property, Plant and Equipment, Useful Life (Year) 5 years    
XML 52 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details)
 12 Months Ended
Dec. 31, 2022
Minimum [Member] | Office Equipment [Member]  
Property, plant and equipment, useful life (Year) 3 years
Minimum [Member] | Laboratory Equipment [Member]  
Property, plant and equipment, useful life (Year) 5 years
Minimum [Member] | Computer Software, Intangible Asset [Member]  
Property, plant and equipment, useful life (Year) 3 years
Maximum [Member] | Office Equipment [Member]  
Property, plant and equipment, useful life (Year) 7 years
Maximum [Member] | Laboratory Equipment [Member]  
Property, plant and equipment, useful life (Year) 7 years
Maximum [Member] | Computer Software, Intangible Asset [Member]  
Property, plant and equipment, useful life (Year) 5 years
XML 53 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues $ 25,240 $ 24,909 $ 21,360
Testing [Member]      
Revenues 21,608 21,894 19,068
Shipping/Collection (Hair) [Member]      
Revenues 3,476 2,847 2,174
Other Revenue [Member]      
Revenues $ 156 $ 168 $ 118
XML 54 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Stock compensation expense $ 872 $ 743 $ 563
Cost of Sales [Member]      
Stock compensation expense 63 63 50
General and Administrative Expense [Member]      
Stock compensation expense 626 503 380
Selling and Marketing Expense [Member]      
Stock compensation expense 113 114 74
Research and Development Expense [Member]      
Stock compensation expense $ 70 $ 63 $ 59
XML 55 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Weighted average common shares outstanding, basic (in shares) 5,626 5,549 5,524
Dilutive common equivalent shares (in shares) 0 0 0
Weighted average common shares outstanding, assuming dilution (in shares) 5,626 5,549 5,524
XML 56 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Balance, beginning of period $ 89 $ 37
Provision for doubtful accounts 9 55
Write-offs (11) (3)
Balance, end of period $ 87 $ 89
XML 57 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Accrued compensation and employee benefits $ 442 $ 507
Accrued vacation expense 409 373
Accrued taxes 771 200
Accrued shipping expense 338 488
Accrued legal settlement 1,150 1,150
Other accrued expenses 829 470
Total Accrued Expenses $ 3,939 $ 3,188
XML 58 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Note 5 - Income Taxes (Details Textual)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]  
Operating Loss Carryforwards $ 0
Tax Credit Carryforward, Amount 0
State and Local Jurisdiction [Member]  
Operating Loss Carryforwards 1,300
Operating Loss Carryforwards, Subject to Expiration 1,200
Operating Loss Carryforwards, Not Subject to Expiration 100
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member]  
Tax Credit Carryforward, Amount $ 1,400
Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total 12.00%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 8.30%
XML 59 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Note 5 - Income Taxes - Summary of Income Tax Provision (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Federal $ 552 $ 131 $ (2,006)
State 23 84 (2)
Total Current 575 215 (2,008)
Federal (959) (704) (13)
State 428 333 (326)
Total Deferred (531) (371) (339)
Income Tax Provision $ 44 $ (156) $ (2,347)
XML 60 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Federal statutory rate 21.00% 21.00% 21.00%
State income taxes, net of federal benefit 12.00% 10.40% 4.40%
Permanent differences (0.40%) 47.60% 0.00%
Stock based compensation 0.50% 1.40% (0.40%)
Federal R&D Credits 8.90% 0.00% 1.60%
Foreign taxes, net of federal benefit 0.00% (10.90%) (2.20%)
Difference in tax rate for carryback claim 0.00% 0.00% 13.40%
Increase/(decrease) in valuation reserve (46.20%) (50.50%) 0.00%
Effective tax rate (4.20%) 19.00% 37.80%
XML 61 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Deferred Tax Assets    
Allowance for doubtful accounts $ 21 $ 21
Accrued expenses 414 129
Stock-based compensation 381 325
R&D tax credits 1,086 1,083
Operating lease 701 944
Capitalized research expenses 404 0
NOL carryforward 72 219
Gross Deferred Tax Assets 3,079 2,721
Valuation Allowance (895) (414)
Deferred Tax Assets After Valuation Allowance 2,184 2,307
Deferred Tax Liabilities    
Excess of tax over book depreciation and amortization (783) (1,249)
Prepaid expenses (78) (61)
Operating lease (632) (837)
Gross Deferred Tax Liabilities (1,493) (2,147)
Net Deferred Tax Assets $ 691 $ 160
XML 62 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Note 7 - Stock-based Awards (Details Textual) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Aug. 12, 2022
May 20, 2022
Apr. 04, 2022
Nov. 11, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2006
May 31, 2021
Jan. 31, 2019
Share Price (in dollars per share)       $ 1.13 $ 4.90 $ 7.02        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)           $ 3.47        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value         $ 548 $ 296 $ 274      
Conversion of Stock, Amount Issued         650 $ 501 $ 115      
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total         $ 1,200          
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)         2 years 3 months 18 days          
Stock Unit Award [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 18 126 2,000   146          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)         $ 6.53 $ 6.55 $ 4.89      
Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares)         35          
Share-Based Payment Arrangement, Accelerated Cost         $ 230          
Share-Based Payment Arrangement, Option [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)       $ 4.07            
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate       45.00%            
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate       0.90%            
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate       4.00%            
Minimum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)         2 years          
Minimum [Member] | Share-Based Payment Arrangement, Option [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)       5 years 9 months            
Maximum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)         4 years          
Maximum [Member] | Share-Based Payment Arrangement, Option [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)       6 years 3 months            
Incentive Plan 2006 [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)               10 years    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)         183       1,600 1,200
Common Stock, Capital Shares Reserved for Future Issuance (in shares)         1,032          
XML 63 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details)
shares in Thousands
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
November 11, 2020 [Member]  
Shares granted (in shares) | shares 40
Fair value per share (in dollars per share) | $ / shares $ 1.13
Shares granted (in shares) | shares 40
Fair value per share (in dollars per share) | $ / shares $ 1.13
Stock Unit Award [Member] | August 12, 2022 [Member]  
Shares granted (in shares) | shares 18
Fair value per share (in dollars per share) | $ / shares $ 6.65 [1]
Shares granted (in shares) | shares 18
Fair value per share (in dollars per share) | $ / shares $ 6.65 [1]
Stock Unit Award [Member] | May 20, 2022 [Member]  
Shares granted (in shares) | shares 126
Fair value per share (in dollars per share) | $ / shares $ 6.51 [1]
Shares granted (in shares) | shares 126
Fair value per share (in dollars per share) | $ / shares $ 6.51 [1]
Stock Unit Award [Member] | April 4, 2022 [Member]  
Shares granted (in shares) | shares 2
Fair value per share (in dollars per share) | $ / shares $ 7.04 [1]
Shares granted (in shares) | shares 2
Fair value per share (in dollars per share) | $ / shares $ 7.04 [1]
Stock Unit Award [Member] | May 13, 2021 [Member]  
Shares granted (in shares) | shares 116
Fair value per share (in dollars per share) | $ / shares $ 6.55 [1]
Shares granted (in shares) | shares 116
Fair value per share (in dollars per share) | $ / shares $ 6.55 [1]
Stock Unit Award [Member] | March 16, 2021 [Member]  
Shares granted (in shares) | shares 2
Fair value per share (in dollars per share) | $ / shares $ 7.04 [1]
Shares granted (in shares) | shares 2
Fair value per share (in dollars per share) | $ / shares $ 7.04 [1]
Stock Unit Award [Member] | January 25, 2021 [Member]  
Shares granted (in shares) | shares 2
Fair value per share (in dollars per share) | $ / shares $ 5.54 [1]
Shares granted (in shares) | shares 2
Fair value per share (in dollars per share) | $ / shares $ 5.54 [1]
Stock Unit Award [Member] | December 16, 2020 [Member]  
Shares granted (in shares) | shares 5
Fair value per share (in dollars per share) | $ / shares $ 4.71 [1]
Shares granted (in shares) | shares 5
Fair value per share (in dollars per share) | $ / shares $ 4.71 [1]
Stock Unit Award [Member] | November 11, 2020 [Member]  
Shares granted (in shares) | shares 190
Fair value per share (in dollars per share) | $ / shares $ 4.07
Shares granted (in shares) | shares 190
Fair value per share (in dollars per share) | $ / shares $ 4.07
[1] The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 years. The options granted on May 3, 2019, have a fair value of $2.99 per share based on the $10.60 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 41% volatility, 2.4% interest rate and a 3.9% dividend yield rate. The options granted on November 11, 2020, have a fair value of $1.13 per share based on the $4.07 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 45% volatility, 0.9% interest rate and a 4.0%dividend yield rate. No options were granted during fiscal year ended December 31, 2021. For options granted during fiscal years ended December 31, 2020, and 2019, the weighted average grant date fair values were $3.47, and $3.40,respectively. For SUAs granted during fiscal years ended December 31, 2021, 2020 and 2019, the weighted average grant date fair values were $6.55, $4.89, and $12.01, respectively.
XML 64 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Note 7 - Stock-based Awards - Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Outstanding (in shares) 574  
Outstanding, weighted average exercise price (in dollars per share) $ 14.23  
Outstanding, weighted average remaining contractual life (Year) 5 years 1 month 6 days 6 years 1 month 6 days
Outstanding, aggregate intrinsic value $ 25 [1] $ 100
Exercised (in shares) (1)  
Exercised, weighted average exercise price (in dollars per share) $ 4.07  
Forfeited (in shares) (1)  
Forfeited, weighted average exercise price (in dollars per share) $ 4.07  
Canceled (in shares) (64)  
Canceled (in dollars per share) $ 15.03  
Outstanding (in shares) 508 574
Outstanding, weighted average exercise price (in dollars per share) $ 14.19 $ 14.23
Exercisable (in shares) 467  
Exercisable, weighted average exercise price (in dollars per share) $ 14.70  
Exercisable, weighted average remaining contractual life (Year) 4 years 10 months 24 days  
Exercisable, aggregate intrinsic value $ 14  
[1] The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of December 31, 2021, and 2020 was $7.02 and $5.09, respectively.
XML 65 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Note 7 - Stock-based Awards - Nonvested Award Activity (Details) - Stock Unit Award [Member] - $ / shares
shares in Thousands
 12 Months Ended
Aug. 12, 2022
May 20, 2022
Apr. 04, 2022
Dec. 31, 2022
Outstanding & Unvested at beginning of period (in shares)       224
Outstanding & Unvested at beginning of period, weighted average price per share (in dollars per share) [1]       $ 5.48
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 18 126 2,000 146
Granted, weighted average price per share (in dollars per share) [1]       $ 6.53
Converted to common stock (in shares)       (90)
Converted to common stock, weighted average price per share (in dollars per share) [1]       $ 6.33
Cancelled (in shares)       (12)
Cancelled, weighted average price per share (in dollars per share) [1]       $ 6.29
Forfeited (in shares)       (30)
Forfeited, weighted average price per share (in dollars per share) [1]       $ 6.26
Outstanding & Unvested at end of period (in shares)       238
Outstanding & Unvested at end of period, weighted average price per share (in dollars per share) [1]       $ 6.10
[1] Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares.
XML 66 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Note 8 - Employee Benefit Plan (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Defined Contribution Plan, Employer Discretionary Contribution Amount $ 0 $ 0 $ 198
XML 67 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Note 9 - Commitments and Contingencies (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Dec. 06, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating Lease, Expense   $ 1.0 $ 1.1 $ 1.1
Enma Sagastume v. Psychemedics Corporation [Member]        
Litigation Settlement, Amount Awarded to Other Party $ 1.2      
Loss Contingency Accrual, Ending Balance     $ 1.2  
XML 68 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Note 10 - Operating Leases (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating Lease, Weighted Average Discount Rate, Percent 3.80%    
Operating Lease, Weighted Average Remaining Lease Term (Year) 3 years 2 months 12 days    
Operating Lease, Expense $ 1.0 $ 1.1 $ 1.1
XML 69 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Note 10 - Operating Leases - Maturities of Lease Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
2023 $ 1,134  
2024 1,061  
2025 553  
2026 460  
Total lease payments 3,208  
Less: interest (233)  
Present value of lease liabilities 2,975  
Current operating lease liabilities 1,037 $ 984
Long-term operating lease liabilities 1,938 $ 2,880
Total $ 2,975  
XML 70 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Note 11 - Debt and Other Financing Arrangements (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended 68 Months Ended
May 01, 2020
Dec. 02, 2019
Oct. 30, 2017
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 04, 2019
Interest Expense, Total       $ 32 $ 49 $ 75  
Paycheck Protection Program CARES Act [Member]              
Proceeds from Issuance of Long-term Debt, Total $ 2,100     0 0 $ 2,181  
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member]              
Interest Expense, Total   $ 16,000   32      
Debt Instrument, Term (Month)   60 months          
Debt Instrument, Interest Rate, Stated Percentage   3.79%          
Proceeds from Issuance of Long-term Debt, Total             $ 12,200
Repayments of Long-term Debt, Total       700 $ 700    
Long-Term Debt, Total       $ 600      
Long-Term Debt, Weighted Average Interest Rate, over Time       3.70%      
Debt, Weighted Average Interest Rate       3.80%      
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]              
Debt Instrument, Basis Spread on Variable Rate     1.75%        
XML 71 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Less current portion of long-term debt from equipment financing $ (294) $ (664)
Long-term debt from equipment financing, net of current portion 305 $ 599
Equipment Loan Arrangement [Member]    
2023 294  
2024 305  
Long-term debt from equipment financing 599  
Less current portion of long-term debt from equipment financing (294)  
Long-term debt from equipment financing, net of current portion $ 305  
XML 72 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Note 12 - Other Income (Expense) (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Interest Expense, Total $ 32 $ 49 $ 75
Interest Income, Other $ 0 $ 0  
XML 73 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Note 13 - Business Segment Reporting (Details Textual)
 12 Months Ended
Dec. 31, 2022
Number of Operating Segments 1
XML 74 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Note 13 - Business Segment Reporting - Revenue by Major Source (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues $ 25,240 $ 24,909 $ 21,360
UNITED STATES      
Revenues 24,509 23,584 19,486
Non-US [Member]      
Revenues $ 731 $ 1,325 $ 1,874
XML 75 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Note 14 - Subsequent Event (Details Textual) - $ / shares
 12 Months Ended
Mar. 21, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Common Stock, Dividends, Per Share, Declared (in dollars per share)   $ 0.21 $ 0.05 $ 0.18
Subsequent Event [Member]        
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 0.07      
XML 76 pmd20221231_10k_htm.xml IDEA: XBRL DOCUMENT 0000806517 2022-01-01 2022-12-31 0000806517 2022-06-30 0000806517 2023-03-15 0000806517 2022-12-31 0000806517 2021-12-31 0000806517 2021-01-01 2021-12-31 0000806517 2020-01-01 2020-12-31 0000806517 us-gaap:CommonStockMember 2019-12-31 0000806517 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000806517 us-gaap:TreasuryStockMember 2019-12-31 0000806517 us-gaap:RetainedEarningsMember 2019-12-31 0000806517 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000806517 2019-12-31 0000806517 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000806517 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000806517 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0000806517 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000806517 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000806517 us-gaap:CommonStockMember 2020-12-31 0000806517 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000806517 us-gaap:TreasuryStockMember 2020-12-31 0000806517 us-gaap:RetainedEarningsMember 2020-12-31 0000806517 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000806517 2020-12-31 0000806517 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000806517 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0000806517 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000806517 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000806517 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000806517 us-gaap:CommonStockMember 2021-12-31 0000806517 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000806517 us-gaap:TreasuryStockMember 2021-12-31 0000806517 us-gaap:RetainedEarningsMember 2021-12-31 0000806517 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000806517 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000806517 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000806517 us-gaap:TreasuryStockMember 2022-01-01 2022-12-31 0000806517 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000806517 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000806517 us-gaap:CommonStockMember 2022-12-31 0000806517 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000806517 us-gaap:TreasuryStockMember 2022-12-31 0000806517 us-gaap:RetainedEarningsMember 2022-12-31 0000806517 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000806517 pmd:PaycheckProtectionProgramCaresActMember 2022-01-01 2022-12-31 0000806517 pmd:PaycheckProtectionProgramCaresActMember 2021-01-01 2021-12-31 0000806517 pmd:PaycheckProtectionProgramCaresActMember 2020-01-01 2020-12-31 0000806517 srt:MinimumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2022-01-01 2022-12-31 0000806517 srt:MaximumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2022-01-01 2022-12-31 0000806517 srt:MinimumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0000806517 srt:MaximumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0000806517 srt:MinimumMember pmd:LaboratoryEquipmentMember 2022-01-01 2022-12-31 0000806517 srt:MaximumMember pmd:LaboratoryEquipmentMember 2022-01-01 2022-12-31 0000806517 pmd:CapitalizedSoftwareAndEquipmentMember 2022-12-31 0000806517 srt:MinimumMember us-gaap:SoftwareDevelopmentMember 2022-01-01 2022-12-31 0000806517 srt:MaximumMember us-gaap:SoftwareDevelopmentMember 2022-01-01 2022-12-31 0000806517 us-gaap:SoftwareDevelopmentMember 2022-12-31 0000806517 us-gaap:SoftwareDevelopmentMember 2021-12-31 0000806517 us-gaap:SoftwareDevelopmentMember 2022-01-01 2022-12-31 0000806517 us-gaap:SoftwareDevelopmentMember 2021-01-01 2021-12-31 0000806517 us-gaap:SoftwareDevelopmentMember 2020-01-01 2020-12-31 0000806517 us-gaap:PatentsMember 2022-01-01 2022-12-31 0000806517 us-gaap:PatentsMember 2022-12-31 0000806517 us-gaap:PatentsMember 2021-12-31 0000806517 us-gaap:PatentsMember 2020-12-31 0000806517 us-gaap:PatentsMember 2021-01-01 2021-12-31 0000806517 us-gaap:PatentsMember 2020-01-01 2020-12-31 0000806517 pmd:TestingMember 2022-01-01 2022-12-31 0000806517 pmd:TestingMember 2021-01-01 2021-12-31 0000806517 pmd:TestingMember 2020-01-01 2020-12-31 0000806517 pmd:ShippingCollectionHairMember 2022-01-01 2022-12-31 0000806517 pmd:ShippingCollectionHairMember 2021-01-01 2021-12-31 0000806517 pmd:ShippingCollectionHairMember 2020-01-01 2020-12-31 0000806517 pmd:OtherRevenueMember 2022-01-01 2022-12-31 0000806517 pmd:OtherRevenueMember 2021-01-01 2021-12-31 0000806517 pmd:OtherRevenueMember 2020-01-01 2020-12-31 0000806517 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000806517 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000806517 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000806517 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000806517 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000806517 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000806517 pmd:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000806517 pmd:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000806517 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000806517 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000806517 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000806517 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0000806517 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0000806517 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0000806517 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0000806517 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0000806517 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0000806517 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000806517 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000806517 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000806517 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2022-12-31 0000806517 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0000806517 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember 2022-12-31 0000806517 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember 2022-01-01 2022-12-31 0000806517 pmd:IncentivePlan2006Member 2006-01-01 2006-12-31 0000806517 pmd:IncentivePlan2006Member 2019-01-31 0000806517 pmd:IncentivePlan2006Member 2021-05-31 0000806517 pmd:IncentivePlan2006Member 2022-12-31 0000806517 srt:MinimumMember 2022-01-01 2022-12-31 0000806517 srt:MaximumMember 2022-01-01 2022-12-31 0000806517 pmd:StockUnitAwardMember 2022-04-04 2022-04-04 0000806517 pmd:StockUnitAwardMember 2022-05-20 2022-05-20 0000806517 pmd:StockUnitAwardMember 2022-08-12 2022-08-12 0000806517 pmd:August122022Member pmd:StockUnitAwardMember 2022-01-01 2022-12-31 0000806517 pmd:May202022Member pmd:StockUnitAwardMember 2022-01-01 2022-12-31 0000806517 pmd:April42022Member pmd:StockUnitAwardMember 2022-01-01 2022-12-31 0000806517 pmd:May132021Member pmd:StockUnitAwardMember 2022-01-01 2022-12-31 0000806517 pmd:March162021Member pmd:StockUnitAwardMember 2022-01-01 2022-12-31 0000806517 pmd:January252021Member pmd:StockUnitAwardMember 2022-01-01 2022-12-31 0000806517 pmd:December162020Member pmd:StockUnitAwardMember 2022-01-01 2022-12-31 0000806517 pmd:November112020Member 2022-01-01 2022-12-31 0000806517 pmd:November112020Member pmd:StockUnitAwardMember 2022-01-01 2022-12-31 0000806517 2020-11-11 0000806517 us-gaap:EmployeeStockOptionMember 2020-11-11 2020-11-11 0000806517 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-11-11 2020-11-11 0000806517 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-11-11 2020-11-11 0000806517 pmd:StockUnitAwardMember 2022-01-01 2022-12-31 0000806517 pmd:StockUnitAwardMember 2021-01-01 2021-12-31 0000806517 pmd:StockUnitAwardMember 2020-01-01 2020-12-31 0000806517 pmd:StockUnitAwardMember 2021-12-31 0000806517 pmd:StockUnitAwardMember 2022-12-31 0000806517 pmd:EnmaSagastumeVPsychemedicsCorporationMember 2021-12-06 2021-12-06 0000806517 pmd:EnmaSagastumeVPsychemedicsCorporationMember 2021-12-31 0000806517 us-gaap:LineOfCreditMember pmd:EquipmentLoanArrangementMember pmd:BancOfAmericaLeasingAndCapitalMember 2019-12-02 2019-12-02 0000806517 us-gaap:LineOfCreditMember pmd:EquipmentLoanArrangementMember pmd:BancOfAmericaLeasingAndCapitalMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-10-30 2017-10-30 0000806517 us-gaap:LineOfCreditMember pmd:EquipmentLoanArrangementMember pmd:BancOfAmericaLeasingAndCapitalMember 2019-12-02 0000806517 us-gaap:LineOfCreditMember pmd:EquipmentLoanArrangementMember pmd:BancOfAmericaLeasingAndCapitalMember 2014-03-25 2019-12-04 0000806517 us-gaap:LineOfCreditMember pmd:EquipmentLoanArrangementMember pmd:BancOfAmericaLeasingAndCapitalMember 2022-01-01 2022-12-31 0000806517 us-gaap:LineOfCreditMember pmd:EquipmentLoanArrangementMember pmd:BancOfAmericaLeasingAndCapitalMember 2021-01-01 2021-12-31 0000806517 us-gaap:LineOfCreditMember pmd:EquipmentLoanArrangementMember pmd:BancOfAmericaLeasingAndCapitalMember 2022-12-31 0000806517 pmd:PaycheckProtectionProgramCaresActMember 2020-05-01 2020-05-01 0000806517 pmd:EquipmentLoanArrangementMember 2022-12-31 0000806517 country:US 2022-01-01 2022-12-31 0000806517 country:US 2021-01-01 2021-12-31 0000806517 country:US 2020-01-01 2020-12-31 0000806517 us-gaap:NonUsMember 2022-01-01 2022-12-31 0000806517 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000806517 us-gaap:NonUsMember 2020-01-01 2020-12-31 0000806517 us-gaap:SubsequentEventMember 2023-03-21 2023-03-21 iso4217:USD shares thunderdome:item iso4217:USD shares utr:Y pure utr:M 0000806517 PSYCHEMEDICS CORP false --12-31 FY 2022 87000 89000 21964000 19659000 0.005 0.005 873000 873000 0 0 0 0 0.005 0.005 50000000 50000000 6349000 6257000 5681000 5589000 668000 668000 10082000 10082000 -11820000 -9550000 -1634000 -1634000 -1083000 209000 -6066000 -0 3150000 -0 43000 -61000 -140000 43000 -1030000 -140000 -1040000 -821000 -6206000 44000 -156000 -2347000 -1084000 -665000 -3859000 0 0 -10000 -1084000 -665000 -3869000 -0.19 -0.12 -0.70 -0.19 -0.12 -0.70 -10082000 -3754000 -1624000 9000 9000 0.18 993000 993000 -3859000 -3859000 -10000 -10000 -10082000 -8606000 -1634000 72000 72000 0.05 279000 279000 -665000 -665000 -10082000 -9550000 -1634000 1 78000 78000 0.21 1186000 1186000 -1084000 -1084000 -10082000 -11820000 -1634000 -1084000 -665000 -3859000 -0 2181000 -0 531000 371000 339000 -377000 760000 -424000 -363000 585000 -392000 -2339000 183000 2013000 -546000 417000 -281000 -967000 -1078000 -914000 751000 1387000 -1776000 4890000 414000 -4083000 21000 38000 7000 187000 182000 991000 -208000 -220000 -858000 1186000 279000 993000 -74000 -68000 -9000 664000 688000 678000 -1924000 -1035000 501000 0 0 -10000 2758000 -841000 -4450000 0 P3Y P5Y P3Y P7Y P5Y P7Y P3Y P5Y P20Y 62000 62000 62000 62000 62000 0 0 1 1 1 11000 3000 552000 131000 -2006000 23000 84000 -2000 -2008000 -959000 -704000 -13000 428000 333000 -326000 -531000 -371000 -339000 44000 -156000 -2347000 -0.004 0.476 0.000 0.005 0.014 -0.004 0.000 -0.109 -0.022 -0.462 -0.505 0.000 895000 414000 783000 1249000 78000 61000 632000 837000 1493000 2147000 P10Y P2Y P4Y 2000000 P6Y1M6D 1000 1000 64000 P5Y1M6D P4Y10M24D 90000 12000 30000 0 0 233000 294000 0 1 10-K true 2022-12-31 false 1-13738 DE 58-1701987 289 Great Road Acton MA 01720 978 206-8220 Common stock. $0.005 par value PMD NASDAQ No No Yes Yes Non-accelerated Filer true false false false 26900000 5684647 243 BDO USA, LLP Boston, Massachusetts 4750000 1992000 3739000 4116000 1136000 1499000 339000 2678000 9964000 10285000 4648000 4521000 2247000 2195000 16013000 16005000 3629000 3629000 26537000 26350000 4573000 6691000 823000 864000 691000 160000 2681000 3552000 18732000 21552000 448000 994000 3939000 3188000 294000 664000 1037000 984000 5718000 5830000 305000 599000 1938000 2880000 7961000 9309000 0 0 32000 31000 34275000 33478000 10771000 12243000 18732000 21552000 25240000 24909000 21360000 15949000 14645000 16474000 9291000 10264000 4886000 5857000 6126000 6095000 3191000 2799000 3577000 1326000 1130000 1280000 10374000 10055000 10952000 0 2181000 0 0.21 0.05 0.18 5626000 5549000 5524000 5626000 5549000 5524000 6185000 31000 32249000 668000 16820000 20000 -0 -0 -0 -0 563000 563000 -0 -0 -0 -0 0 0 0 0 0 0 0 0 6205000 31000 32803000 668000 12512000 51000 0 1000 0 4000 0 0 0 0 4000 -0 -0 -0 -0 0 743000 0 0 0 743000 -0 -0 -0 -0 0 0 0 0 6257000 31000 33478000 668000 12243000 91000 -1 0 1000 0 4000 0 0 0 0 4000 -0 -0 -0 -0 0 872000 0 0 0 872000 -0 -0 -0 -0 0 0 0 0 6349000 32000 34275000 668000 10771000 2367000 2784000 2691000 949000 906000 935000 -0 -0 -94000 872000 743000 563000 0 0 140000 0 0 2181000 1992000 2833000 7283000 4750000 1992000 2833000 0 405000 249000 33000 50000 75000 1044000 1151000 1038000 78000 172000 2346000 0 241000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">1.</em> Nature of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Company Overview</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">Psychemedics Corporation (the “Company”) provides hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay and mass spectrometry to analyze hair to detect abused substances. The Company’s customers include Fortune <em style="font: inherit;">500</em> companies, as well as small to mid-size corporations, schools and governmental entities located in the United States and Internationally.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>COVID-<em style="font: inherit;">19</em> Pandemic</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">The outbreak of coronavirus (“COVID-<em style="font: inherit;">19”</em>) which was declared by the World Health Organization to be a pandemic, has, and is expected to continue to impact worldwide economic activity. COVID-<em style="font: inherit;">19</em> has had a significant impact on our entire operations. Additionally, COVID-<em style="font: inherit;">19’s</em> effect on the overall economy has had an adverse impact on hiring, which is having a negative impact on our testing volume.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">The Coronavirus Aid, Relieve and Economic Security Act (“CARES”) Act, enacted on <em style="font: inherit;"> March 27, 2020, </em>and the Families First Coronavirus Response Act, in each case modified by the Consolidated Appropriations Act enacted in <em style="font: inherit;"> December 2020, </em>were emergency economic stimulus packages that included spending provisions and tax cuts to strengthen the United States economy and to fund a nationwide effort to curtail the effect of COVID-<em style="font: inherit;">19.</em> The principal impact of the CARES Act and subsequent legislation was the adoption of the Paycheck Protection Program (“PPP”). The CARES Act, together with subsequent legislation, also provided sweeping tax changes in response to the COVID-<em style="font: inherit;">19</em> pandemic, including amendments to certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company recognized a benefit of $2.6 million and $0.2 million for the years ended <em style="font: inherit;"> December 31, 2021, </em>and <em style="font: inherit;"> December 31, 2020, </em>respectively, as a reduction to cost of revenues and operating expenses related to the employee retention credit which was a tax provision in the CARES Act and subsequent legislation. Additionally, the CARES Act allowed the Company to fully carryback the <em style="font: inherit;">2020</em> net operating loss, for a refund of corporate income taxes previously paid.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Liquidity and Management</i></b>’<b><i>s Plans</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">At <em style="font: inherit;"> December 31, 2022, </em>the Company’s principal sources of liquidity included $4.8 million of cash on hand. Management currently believes that such funds, together with future operating profits, should be adequate to fund anticipated working capital requirements, including debt obligations, and capital expenditures for at least the next <em style="font: inherit;">12</em> months. Depending upon the Company’s results of operations, its future capital needs and available marketing opportunities, the Company <em style="font: inherit;"> may </em>use various financing sources to raise additional funds. Such sources could include but are <em style="font: inherit;">not</em> limited to, issuance of common stock or debt financing, lines of credit, or equipment leasing, although there is <em style="font: inherit;">no</em> assurance that such financings will be available to the Company on terms it deems acceptable, if at all.</p> 2600000 200000 4800000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">2.</em> Summary of Significant Accounting Policies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Risks and Uncertainties</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but <em style="font: inherit;">not</em> limited to, FDA regulations, proposed laws and regulations, and delays in implementation of laws and regulations), competition and general economic conditions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company considers all highly liquid investments with original maturities at the date of purchase of <em style="font: inherit;">90</em> days or less as cash equivalents. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> there were no investments classified as cash equivalents.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Property and Equipment</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">Property &amp; equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b/></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 98%; margin-left: 27pt; margin-right: auto;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;">Computer software</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95779577">3</span> to <span style="-sec-ix-hidden:c95779578">5</span> years</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;">Office furniture and equipment</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95779579">3</span> to <span style="-sec-ix-hidden:c95779580">7</span> years</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;">Laboratory equipment</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95779581">5</span> to <span style="-sec-ix-hidden:c95779582">7</span> years</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;"><em style="font: inherit;">Leasehold improvements</em></p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Lesser of estimated useful life or lease term</em></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.4 million, $2.8 million, and $2.7 million in <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. The Company had $0.5 million of capitalized software and equipment that was <em style="font: inherit;">not</em> placed in service as of <em style="font: inherit;"> December 31, 2022, </em>which is included as a component of computer software on the accompanying consolidated balance sheets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Capitalized Software Development Costs </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for <span style="-sec-ix-hidden:c95773456">three</span> to <span style="-sec-ix-hidden:c95773459">five</span> years. Costs incurred during the post-implementation/operation stage, including training costs and maintenance costs, are expensed as incurred. In accordance with Company policy, during the years ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> we capitalized internally developed software costs of $127 thousand and $99 thousand, respectively. Amortization expense related to software development costs was $282 thousand, $421 thousand and $293 thousand in <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. Determining whether particular costs incurred are more properly attributable to the preliminary or conceptual stage, and thus expensed, or to the application development phase, and thus capitalized and amortized, depends on subjective judgments about the nature of the development work, and our judgments in this regard <em style="font: inherit;"> may </em>differ from those made by other companies. General and administrative costs related to developing or obtaining such software is expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Other Assets</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is <span style="-sec-ix-hidden:c95773472">twenty</span> years. As of <em style="font: inherit;"> December 31, 2022, </em>the Company had capitalized legal costs relating to patent applications of $1.1 million with accumulated amortization of $0.5 million, for a net balance of $0.6 million. As of <em style="font: inherit;"> December 31, 2021, </em>the Company had capitalized legal costs relating to patent applications of $1.1 million with accumulated amortization of $0.4 million, for a net balance of $0.7 million. Amortization expense was $62 thousand, $62 thousand, and $62 thousand in <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. Based on payments made as of <em style="font: inherit;"> December 31, 2022, </em>remaining amortization expense is expected to be <em style="font: inherit;"><span style="-sec-ix-hidden:c95773486"><span style="-sec-ix-hidden:c95773487"><span style="-sec-ix-hidden:c95773488"><span style="-sec-ix-hidden:c95773489"><span style="-sec-ix-hidden:c95773490">$62</span></span></span></span></span></em> thousand for each of the <em style="font: inherit;">five</em> years ending <em style="font: inherit;"> December 31, 2027 </em>and $109 thousand thereafter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b><i>Allowance for Doubtful Accounts</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">The allowance for doubtful accounts is based on management’s assessment of the ability to collect amounts owed to it by its customers. Management reviews its accounts receivable aging for doubtful accounts and uses a methodology based on calculating the allowance using a combination of factors including the age of the receivable along with management’s judgment to identify accounts that <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be collectible. The Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has <em style="font: inherit;">not</em> experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. Bad debt expense has been within management’s expectations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:1pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:1pt;"><b><i>Revenue Recognition</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration (<em style="font: inherit;">none</em> of which is variable) the Company expects to be entitled to in exchange for those services. The Company typically invoices customers monthly for services provided and payments are generally due within <em style="font: inherit;">30</em> to <em style="font: inherit;">60</em> days of the invoice date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note <em style="font: inherit;">13</em> – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 96%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 40pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Consolidated Revenue:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Testing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,894</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Shipping / Collection (hair)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,174</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">118</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,240</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;"><span style="text-decoration: underline; ">Testing Revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Drug and alcohol tests for drugs of abuse using hair, performed in the Company’s forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;"><span style="text-decoration: underline; ">Shipping and Hair Collection Revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by <em style="font: inherit;">third</em> parties who have contracted with the Company. Shipping and hair collection revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of the Company’s service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test (associated with the shipping or hair collection charge) and availability of test results to the customer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;"><span style="text-decoration: underline; ">Other Revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than <em style="font: inherit;">1%</em> of total revenue. The amounts are generally billed to customers as services are performed, which occurs at a specific point-in-time.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;"><span style="text-decoration: underline; ">Practical Expedients and Exemptions</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">The Company generally expenses sales commissions when incurred as they are typically <em style="font: inherit;">not</em> related to costs to fulfill customer contracts but relate to overall sales targets. These costs are recorded within marketing and selling expense on the accompanying consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Research and Development Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:15pt;">The Company expenses all research and development costs as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;"><b><i>Contingencies</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Loss contingencies from legal proceedings and claims <em style="font: inherit;"> may </em>occur from government investigations, shareholder lawsuits, product liability, contractual claims, tax and other matters. Accruals are recognized when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. Legal fees are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company accounts for income taxes using the liability method pursuant to ASC <em style="font: inherit;">740,</em> “<i>Income Taxes</i>”. Under this method, the Company recognizes deferred tax assets and liabilities for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts using enacted tax rates in effect for the year the differences are expected to reverse. The Company evaluates uncertain tax positions annually and considers whether the amounts recorded for income taxes are adequate to address the Company’s tax risk profile. The Company analyzes the potential tax liabilities of specific transactions and tax positions based on management’s judgment as to the expected outcome.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Concentration of Credit Risk and Off-Balance Sheet Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and accounts receivable. The Company’s policy is to place its cash in high quality financial institutions. At times, these deposits <em style="font: inherit;"> may </em>exceed or be exempt from federally insured limits. The Company does <em style="font: inherit;">not</em> believe significant credit risk exists with respect to these institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom the Company makes substantial sales. To reduce risk, the Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has <em style="font: inherit;">not</em> experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. The Company does <em style="font: inherit;">not</em> require collateral. The Company has <em style="font: inherit;">no</em> significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Significant Customers and Concentration of Credit Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">The Company had no customers that represented <em style="font: inherit;">10%</em> or more of total revenue for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively. The Company had <span style="-sec-ix-hidden:c95773517"><span style="-sec-ix-hidden:c95773518"><span style="-sec-ix-hidden:c95773519">one</span></span></span> customer that represented 11% and 12% of the total accounts receivable balance as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">The Company accounts for equity awards in accordance with ASC <em style="font: inherit;">718,</em> “<i>Compensation</i> — <i>Stock Compensation</i>”<i> </i>(“ASC <em style="font: inherit;">718”</em>). ASC <em style="font: inherit;">718</em> requires employee equity awards to be accounted for under the fair value method. It also requires the measurement of compensation cost at fair value on the date of grant and recognition of compensation expense over the service period for awards expected to vest. Accordingly, share-based compensation is measured at the grant date based on the fair value of the award. The Company uses the straight-line method to recognize share-based compensation over the service period of the award, which is generally equal to the vesting period. The Company uses the simplified approach to calculate the expected exercise date of options, which is <em style="font: inherit;">one</em> of the components used to determine the fair value of the options. This approach is used due to the small number of recipients receiving stock options <em style="font: inherit;">not</em> providing a reasonable basis for estimating expected term. In <em style="font: inherit;">2016,</em> the Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">09,</em> <i>Improvements to Employee Share-Based Payment Accounting</i>, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of related amounts within the statement of cash flows. As a result, we recognize the impact of forfeitures when they occur with <em style="font: inherit;">no</em> adjustment for estimated forfeitures and recognize excess tax benefits as a reduction of income tax expense regardless of whether the benefit reduces income taxes payable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;">Stock compensation expense by statements of operations account is as follows (in thousands):</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General &amp; administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketing &amp; selling</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">114</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">872</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">See Note <em style="font: inherit;">7</em> – “Stock-Based Awards” to the Consolidated Financial Statements included in this Annual Report for additional information relating to the Company’s stock plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Basic and Diluted Net Loss per Share</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">Basic and diluted weighted average common shares outstanding are as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average common shares outstanding, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common equivalent shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average common shares outstanding, assuming dilution</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">For the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> options to purchase 508 thousand, 574 thousand and 588 thousand common shares were outstanding but <em style="font: inherit;">not</em> included in the dilutive common equivalent share calculation as their effect would have been anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b><i>Fair Value Measurements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">The fair values of the Company’s cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of the Company’s note payable approximates its fair value, as it is based on current market rates at which the Company could borrow funds with similar terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Basis of Preparation and Consolidation</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Segment Reporting</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">The Company manages its operations as <em style="font: inherit;">one</em> segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. See Note <em style="font: inherit;">14</em> – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report for geographic breakdown of revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments </i>–<i> Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i> (“ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13”</em>), which modifies the measurement of expected credit losses on certain financial instruments. The Company will adopt ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> in its <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2023.</em> Based on the Company’s historical credit loss activity, the adoption of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> will <em style="font: inherit;">not</em> have a material impact on its consolidated financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Risks and Uncertainties</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company’s sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but <em style="font: inherit;">not</em> limited to, FDA regulations, proposed laws and regulations, and delays in implementation of laws and regulations), competition and general economic conditions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company considers all highly liquid investments with original maturities at the date of purchase of <em style="font: inherit;">90</em> days or less as cash equivalents. As of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> there were no investments classified as cash equivalents.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Property and Equipment</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">Property &amp; equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b/></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 98%; margin-left: 27pt; margin-right: auto;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;">Computer software</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95779577">3</span> to <span style="-sec-ix-hidden:c95779578">5</span> years</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;">Office furniture and equipment</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95779579">3</span> to <span style="-sec-ix-hidden:c95779580">7</span> years</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;">Laboratory equipment</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95779581">5</span> to <span style="-sec-ix-hidden:c95779582">7</span> years</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;"><em style="font: inherit;">Leasehold improvements</em></p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Lesser of estimated useful life or lease term</em></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.4 million, $2.8 million, and $2.7 million in <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. The Company had $0.5 million of capitalized software and equipment that was <em style="font: inherit;">not</em> placed in service as of <em style="font: inherit;"> December 31, 2022, </em>which is included as a component of computer software on the accompanying consolidated balance sheets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 98%; margin-left: 27pt; margin-right: auto;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;">Computer software</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95779577">3</span> to <span style="-sec-ix-hidden:c95779578">5</span> years</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;">Office furniture and equipment</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95779579">3</span> to <span style="-sec-ix-hidden:c95779580">7</span> years</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;">Laboratory equipment</p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c95779581">5</span> to <span style="-sec-ix-hidden:c95779582">7</span> years</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 408px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt;"><em style="font: inherit;">Leasehold improvements</em></p> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: top; width: 1312px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">Lesser of estimated useful life or lease term</em></p> </td></tr> </tbody></table> 2400000 2800000 2700000 500000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Capitalized Software Development Costs </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for <span style="-sec-ix-hidden:c95773456">three</span> to <span style="-sec-ix-hidden:c95773459">five</span> years. Costs incurred during the post-implementation/operation stage, including training costs and maintenance costs, are expensed as incurred. In accordance with Company policy, during the years ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> we capitalized internally developed software costs of $127 thousand and $99 thousand, respectively. Amortization expense related to software development costs was $282 thousand, $421 thousand and $293 thousand in <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. Determining whether particular costs incurred are more properly attributable to the preliminary or conceptual stage, and thus expensed, or to the application development phase, and thus capitalized and amortized, depends on subjective judgments about the nature of the development work, and our judgments in this regard <em style="font: inherit;"> may </em>differ from those made by other companies. General and administrative costs related to developing or obtaining such software is expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 127000 99000 282000 421000 293000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Other Assets</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is <span style="-sec-ix-hidden:c95773472">twenty</span> years. As of <em style="font: inherit;"> December 31, 2022, </em>the Company had capitalized legal costs relating to patent applications of $1.1 million with accumulated amortization of $0.5 million, for a net balance of $0.6 million. As of <em style="font: inherit;"> December 31, 2021, </em>the Company had capitalized legal costs relating to patent applications of $1.1 million with accumulated amortization of $0.4 million, for a net balance of $0.7 million. Amortization expense was $62 thousand, $62 thousand, and $62 thousand in <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. Based on payments made as of <em style="font: inherit;"> December 31, 2022, </em>remaining amortization expense is expected to be <em style="font: inherit;"><span style="-sec-ix-hidden:c95773486"><span style="-sec-ix-hidden:c95773487"><span style="-sec-ix-hidden:c95773488"><span style="-sec-ix-hidden:c95773489"><span style="-sec-ix-hidden:c95773490">$62</span></span></span></span></span></em> thousand for each of the <em style="font: inherit;">five</em> years ending <em style="font: inherit;"> December 31, 2027 </em>and $109 thousand thereafter.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1100000 500000 600000 1100000 400000 700000 62000 62000 62000 109000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b><i>Allowance for Doubtful Accounts</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">The allowance for doubtful accounts is based on management’s assessment of the ability to collect amounts owed to it by its customers. Management reviews its accounts receivable aging for doubtful accounts and uses a methodology based on calculating the allowance using a combination of factors including the age of the receivable along with management’s judgment to identify accounts that <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be collectible. The Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has <em style="font: inherit;">not</em> experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. Bad debt expense has been within management’s expectations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:1pt;"><b><i>Revenue Recognition</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company is in the business of performing drug testing services and reporting the results thereof. The Company’s services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration (<em style="font: inherit;">none</em> of which is variable) the Company expects to be entitled to in exchange for those services. The Company typically invoices customers monthly for services provided and payments are generally due within <em style="font: inherit;">30</em> to <em style="font: inherit;">60</em> days of the invoice date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note <em style="font: inherit;">13</em> – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 96%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 40pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Consolidated Revenue:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Testing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,894</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Shipping / Collection (hair)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,174</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">118</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,240</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;"><span style="text-decoration: underline; ">Testing Revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Drug and alcohol tests for drugs of abuse using hair, performed in the Company’s forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;"><span style="text-decoration: underline; ">Shipping and Hair Collection Revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (collectively called the “sample”) to the Company’s laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by <em style="font: inherit;">third</em> parties who have contracted with the Company. Shipping and hair collection revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of the Company’s service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test (associated with the shipping or hair collection charge) and availability of test results to the customer.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;"><span style="text-decoration: underline; ">Other Revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Other revenue represents several items including: urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all these items is less than <em style="font: inherit;">1%</em> of total revenue. The amounts are generally billed to customers as services are performed, which occurs at a specific point-in-time.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;"><span style="text-decoration: underline; ">Practical Expedients and Exemptions</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">The Company generally expenses sales commissions when incurred as they are typically <em style="font: inherit;">not</em> related to costs to fulfill customer contracts but relate to overall sales targets. These costs are recorded within marketing and selling expense on the accompanying consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 96%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 40pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Consolidated Revenue:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Testing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,894</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Shipping / Collection (hair)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,174</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">168</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">118</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,240</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 21608000 21894000 19068000 3476000 2847000 2174000 156000 168000 118000 25240000 24909000 21360000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Research and Development Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:15pt;">The Company expenses all research and development costs as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;"><b><i>Contingencies</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 45pt;text-indent:15pt;">Loss contingencies from legal proceedings and claims <em style="font: inherit;"> may </em>occur from government investigations, shareholder lawsuits, product liability, contractual claims, tax and other matters. Accruals are recognized when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. Legal fees are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company accounts for income taxes using the liability method pursuant to ASC <em style="font: inherit;">740,</em> “<i>Income Taxes</i>”. Under this method, the Company recognizes deferred tax assets and liabilities for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts using enacted tax rates in effect for the year the differences are expected to reverse. The Company evaluates uncertain tax positions annually and considers whether the amounts recorded for income taxes are adequate to address the Company’s tax risk profile. The Company analyzes the potential tax liabilities of specific transactions and tax positions based on management’s judgment as to the expected outcome.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Concentration of Credit Risk and Off-Balance Sheet Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and accounts receivable. The Company’s policy is to place its cash in high quality financial institutions. At times, these deposits <em style="font: inherit;"> may </em>exceed or be exempt from federally insured limits. The Company does <em style="font: inherit;">not</em> believe significant credit risk exists with respect to these institutions. Concentration of credit risk with respect to accounts receivable is limited to certain customers to whom the Company makes substantial sales. To reduce risk, the Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. The Company maintains an allowance for potential credit losses but historically has <em style="font: inherit;">not</em> experienced any significant losses related to individual customers or groups of customers in any particular industry or geographic area. The Company does <em style="font: inherit;">not</em> require collateral. The Company has <em style="font: inherit;">no</em> significant off-balance-sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Significant Customers and Concentration of Credit Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">The Company had no customers that represented <em style="font: inherit;">10%</em> or more of total revenue for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively. The Company had <span style="-sec-ix-hidden:c95773517"><span style="-sec-ix-hidden:c95773518"><span style="-sec-ix-hidden:c95773519">one</span></span></span> customer that represented 11% and 12% of the total accounts receivable balance as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0 0.11 0.12 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">The Company accounts for equity awards in accordance with ASC <em style="font: inherit;">718,</em> “<i>Compensation</i> — <i>Stock Compensation</i>”<i> </i>(“ASC <em style="font: inherit;">718”</em>). ASC <em style="font: inherit;">718</em> requires employee equity awards to be accounted for under the fair value method. It also requires the measurement of compensation cost at fair value on the date of grant and recognition of compensation expense over the service period for awards expected to vest. Accordingly, share-based compensation is measured at the grant date based on the fair value of the award. The Company uses the straight-line method to recognize share-based compensation over the service period of the award, which is generally equal to the vesting period. The Company uses the simplified approach to calculate the expected exercise date of options, which is <em style="font: inherit;">one</em> of the components used to determine the fair value of the options. This approach is used due to the small number of recipients receiving stock options <em style="font: inherit;">not</em> providing a reasonable basis for estimating expected term. In <em style="font: inherit;">2016,</em> the Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">09,</em> <i>Improvements to Employee Share-Based Payment Accounting</i>, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification of related amounts within the statement of cash flows. As a result, we recognize the impact of forfeitures when they occur with <em style="font: inherit;">no</em> adjustment for estimated forfeitures and recognize excess tax benefits as a reduction of income tax expense regardless of whether the benefit reduces income taxes payable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;">Stock compensation expense by statements of operations account is as follows (in thousands):</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General &amp; administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketing &amp; selling</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">114</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">872</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">See Note <em style="font: inherit;">7</em> – “Stock-Based Awards” to the Consolidated Financial Statements included in this Annual Report for additional information relating to the Company’s stock plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General &amp; administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketing &amp; selling</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">114</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">74</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">872</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 63000 63000 50000 626000 503000 380000 113000 114000 74000 70000 63000 59000 872000 743000 563000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Basic and Diluted Net Loss per Share</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">Basic and diluted weighted average common shares outstanding are as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average common shares outstanding, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common equivalent shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average common shares outstanding, assuming dilution</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">For the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> options to purchase 508 thousand, 574 thousand and 588 thousand common shares were outstanding but <em style="font: inherit;">not</em> included in the dilutive common equivalent share calculation as their effect would have been anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average common shares outstanding, basic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilutive common equivalent shares</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average common shares outstanding, assuming dilution</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 5626000 5549000 5524000 0 0 0 5626000 5549000 5524000 508000 574000 588000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b><i>Fair Value Measurements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">The fair values of the Company’s cash, accounts receivable and accounts payable approximate their carrying values due to their short maturities. The carrying value of the Company’s note payable approximates its fair value, as it is based on current market rates at which the Company could borrow funds with similar terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Basis of Preparation and Consolidation</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Segment Reporting</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">The Company manages its operations as <em style="font: inherit;">one</em> segment, drug testing services. As a result, the financial information disclosed herein materially represents all of the financial information related to the Company’s principal operating segment. See Note <em style="font: inherit;">14</em> – “Business Segment Reporting” to the Consolidated Financial Statements included in this Annual Report for geographic breakdown of revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments </i>–<i> Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i> (“ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13”</em>), which modifies the measurement of expected credit losses on certain financial instruments. The Company will adopt ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> in its <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2023.</em> Based on the Company’s historical credit loss activity, the adoption of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> will <em style="font: inherit;">not</em> have a material impact on its consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">3.</em> Accounts Receivable</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company maintains an allowance for uncollectible accounts receivable based on management’s assessment of the collectability of its customer accounts by reviewing customer payment patterns and other relevant factors. The Company reviews the adequacy of the allowance for uncollectible accounts on a quarterly basis and adjusts the balance as determined necessary. Write-offs are recorded at the time a customer account is deemed uncollectable. The following is a rollforward of the Company’s allowance for doubtful accounts (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>As of December 31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance, beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Provision for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Write-offs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773612">( 11</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773613">( 3</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance, end of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 27pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>As of December 31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance, beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Provision for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Write-offs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773612">( 11</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773613">( 3</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance, end of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 89000 37000 9000 55000 87000 89000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">4.</em> Accrued Expenses</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:16pt;">Accrued expenses consist of the following (in thousands):</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:16pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b>As of December 31,</b> </b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b><b><b>2022</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b><b><b>2021</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued compensation and employee benefits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">507</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued vacation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">409</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">373</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">771</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued shipping expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">338</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">488</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued legal settlement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">829</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">470</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Accrued Expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,188</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"/></b></p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b>As of December 31,</b> </b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b><b><b>2022</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b><b><b>2021</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued compensation and employee benefits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">507</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued vacation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">409</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">373</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">771</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued shipping expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">338</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">488</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued legal settlement</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,150</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">829</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">470</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Accrued Expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,939</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,188</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 442000 507000 409000 373000 771000 200000 338000 488000 1150000 1150000 829000 470000 3939000 3188000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">5.</em> Income Taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:1pt;">The income tax provision consists of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Year Ended December 31,</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>2022</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>2021</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>2020</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773674">552</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773675">131</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773676">( 2,006</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773677">23</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773678">84</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773679">( 2</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">575</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773682">( 2,008</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773684">( 959</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773686">( 704</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773688">( 13</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773689">428</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773690">333</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773691">( 326</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773692">( 531</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773693">( 371</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773694">( 339</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Income Tax Provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773695">44</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773696">( 156</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773697">( 2,347</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">A reconciliation of the effective rate with the federal statutory rate is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State income taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773704">(0.4%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773705">47.6</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773706">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773707">0.5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773708">1.4</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773709">(0.4%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal R&amp;D Credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773713">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773714">(10.9%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773715">(2.2%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Difference in tax rate for carryback claim</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Increase/(decrease) in valuation reserve</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773719">(46.2%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773720">(50.5%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773721">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-4.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The change in effective tax rate from <em style="font: inherit;">2021</em> to <em style="font: inherit;">2022</em> was primarily driven by the Company’s <em style="font: inherit;">2021</em> non-taxable debt forgiveness from the Paycheck Protection Plan in <em style="font: inherit;">2021</em> that was included in income for GAAP purposes partially offset by the decrease in foreign taxes in <em style="font: inherit;">2022.</em> As of <em style="font: inherit;"> December 31, 2022, </em>the Company had no federal net operating loss carryforwards. As of <em style="font: inherit;"> December 31, 2022, </em>the Company had $1.3 million of state net operating loss carryforwards, of which $1.2 million expire at various dates between <em style="font: inherit;">2030</em> and <em style="font: inherit;">2040,</em> and $0.1 million do <em style="font: inherit;">not</em> expire. As of <em style="font: inherit;"> December 31, 2022, </em>the Company had no federal tax credit carryforwards and $1.4 million of California tax credit carryforwards relating to the years <em style="font: inherit;">2013</em> through <em style="font: inherit;">2022</em> which have an unlimited carryforward period. In <em style="font: inherit;">2022,</em> the 12.0% state income tax effective rate primarily consisted of California research tax credits of 8.3%.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The components of the net deferred tax liabilities included in the accompanying balance sheets are as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred Tax Assets</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">414</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">129</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">381</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">325</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">R&amp;D tax credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,086</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,083</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">701</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">944</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized research expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">404</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">NOL carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross Deferred Tax Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,079</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,721</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation Allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773742">( 895</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773743">( 414</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred Tax Assets After Valuation Allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,184</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,307</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred Tax Liabilities</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Excess of tax over book depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773747">( 783</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773748">( 1,249</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773749">( 78</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773750">( 61</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773751">( 632</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773752">( 837</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross Deferred Tax Liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773753">( 1,493</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773754">( 2,147</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td style="border-bottom: 1px solid black;"> </td><td style="border-bottom: 1px solid black;"> </td><td style="border-bottom: 1px solid black;"> </td><td> </td><td style="border-bottom: 1px solid black;"> </td><td style="border-bottom: 1px solid black;"> </td><td style="border-bottom: 1px solid black;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net Deferred Tax Assets</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">160</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">Income taxes are recorded in accordance with FASB ASC Topic <em style="font: inherit;">740,</em> Income Taxes (“ASC <em style="font: inherit;">740”</em>), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided, if, based upon the weight of available evidence, it is more likely than <em style="font: inherit;">not</em> that some or all of the net deferred tax assets will <em style="font: inherit;">not</em> be realized. The Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> as of <em style="font: inherit;"> January 1, 2021, </em>with <em style="font: inherit;">no</em> material impact to the Company’s consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">ASC <em style="font: inherit;">740</em> contains a <em style="font: inherit;">two</em>-step approach to recognizing and measuring uncertain tax positions (tax contingencies). The <em style="font: inherit;">first</em> step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than <em style="font: inherit;">not</em> that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The <em style="font: inherit;">second</em> step is to measure the tax benefit as the largest amount which is more than <em style="font: inherit;">50%</em> likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating the Company’s tax positions and tax benefits, which <em style="font: inherit;"> may </em>require periodic adjustments and which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> accurately forecast actual outcomes. The Company had immaterial uncertain tax positions at <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company operates within multiple taxing jurisdictions and could be subject to audit in these jurisdictions. These audits <em style="font: inherit;"> may </em>involve complex issues, which <em style="font: inherit;"> may </em>require an extended period of time to resolve. The Company has provided for its estimated taxes payable in the accompanying financial statements. The Company’s policy is to recognize interest and penalties related to income tax matters as a general and administrative expense, when and if incurred. Interest and penalties for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> or <em style="font: inherit;">2020</em> were <em style="font: inherit;">not</em> material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Year Ended December 31,</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>2022</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>2021</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>2020</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Current</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773674">552</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773675">131</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773676">( 2,006</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773677">23</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773678">84</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773679">( 2</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">575</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">215</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773682">( 2,008</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773684">( 959</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773686">( 704</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773688">( 13</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773689">428</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773690">333</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773691">( 326</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total Deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773692">( 531</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773693">( 371</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773694">( 339</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Income Tax Provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773695">44</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773696">( 156</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c95773697">( 2,347</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> </tbody></table> 575000 215000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State income taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773704">(0.4%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773705">47.6</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773706">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773707">0.5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773708">1.4</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773709">(0.4%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal R&amp;D Credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign taxes, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773713">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773714">(10.9%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773715">(2.2%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Difference in tax rate for carryback claim</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Increase/(decrease) in valuation reserve</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773719">(46.2%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773720">(50.5%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773721">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-4.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">19.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td></tr> </tbody></table> 0.210 0.210 0.210 0.120 0.104 0.044 -0.089 -0.000 -0.016 0.000 0.000 0.134 -0.042 0.190 0.378 0 1300000 1200000 100000 0 1400000 0.120 0.083 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred Tax Assets</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Allowance for doubtful accounts</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">414</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">129</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">381</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">325</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">R&amp;D tax credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,086</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,083</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">701</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">944</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized research expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">404</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">NOL carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">219</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross Deferred Tax Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,079</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,721</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation Allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773742">( 895</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773743">( 414</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred Tax Assets After Valuation Allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,184</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">2,307</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Deferred Tax Liabilities</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Excess of tax over book depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773747">( 783</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773748">( 1,249</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773749">( 78</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773750">( 61</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773751">( 632</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773752">( 837</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross Deferred Tax Liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773753">( 1,493</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773754">( 2,147</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td style="border-bottom: 1px solid black;"> </td><td style="border-bottom: 1px solid black;"> </td><td style="border-bottom: 1px solid black;"> </td><td> </td><td style="border-bottom: 1px solid black;"> </td><td style="border-bottom: 1px solid black;"> </td><td style="border-bottom: 1px solid black;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net Deferred Tax Assets</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">691</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">160</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 21000 21000 414000 129000 381000 325000 1086000 1083000 701000 944000 404000 0 72000 219000 3079000 2721000 2184000 2307000 691000 160000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">6.</em> Preferred Stock</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Board of Directors has the authority to designate authorized preferred shares in <em style="font: inherit;">one</em> or more series and to fix the relative rights and preferences without vote or action by the stockholders. The Board of Directors has <em style="font: inherit;">no</em> present plans to designate or issue any shares of preferred stock.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">7.</em> Stock-Based Awards</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The <em style="font: inherit;">2006</em> Incentive Plan initially adopted in <em style="font: inherit;">2006</em> provides for grants of options with terms of up to <span style="-sec-ix-hidden:c95773763">ten</span> years, grants of restricted stock or stock unit awards (“SUAs”), issuances of stock bonuses or grants other stock-based awards plus cash-based awards, to officers, directors, employees, and consultants. Such shares are issuable out of the Company’s authorized but unissued common stock. In <em style="font: inherit;"> May 2021, </em>the <em style="font: inherit;">2006</em> Incentive Plan was amended to increase the total number of shares issuable thereunder from 1.2 million to 1.6 million. As of <em style="font: inherit;"> December 31, 2022, </em>183 thousand shares remained available for future grant under the <em style="font: inherit;">2006</em> Incentive Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The fair value of the SUAs is determined by the closing price on the date of grant. The fair value of options is determined using a Black-Scholes model. The SUAs and options vest over a period of <span style="-sec-ix-hidden:c95773769">two</span> to <span style="-sec-ix-hidden:c95773770">four</span> years and are convertible or exercisable into an equivalent number of shares of the Company’s common stock provided that the employee receiving the award remains continuously employed throughout the vesting period. The Company records stock compensation expense related to the SUAs and options on a straight-line basis over the vesting term. Employees are issued shares upon vesting of SUAs, net of tax withholdings. As a result of our adoption of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">09</em> in <em style="font: inherit;">2016,</em> we recognize the impact of forfeitures when they occur with <em style="font: inherit;">no</em> adjustment for estimated forfeitures and recognize excess tax benefits as a reduction of income tax expense regardless of whether the benefit reduces income taxes payable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">On <em style="font: inherit;"> April 4, 2022, </em>the Company granted SUAs covering <span style="-sec-ix-hidden:c95773777">two thousand</span> shares of common stock. On <em style="font: inherit;"> May 20, 2022, </em>the Company granted SUAs covering 126 thousand shares of common stock. On <em style="font: inherit;"> August 12, 2022, </em>the Company granted SUAs covering 18 thousand shares of common stock.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">The following table represents all shares granted by the Company under the <em style="font: inherit;">2006</em> Incentive Plan for the last <em style="font: inherit;">three</em> years (shares in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 40pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Grant Date</span></p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 24.1%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">Type</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">Fair Value<br/> Per Share (1)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">August 12, 2022</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">May 20, 2022</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">April 4, 2022</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">May 13, 2021</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">March 16, 2021</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">January 25, 2021</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.54</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">December 16, 2020</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">November 11, 2020</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">Options</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">November 11, 2020</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:41pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">1</em>)</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of <em style="font: inherit;">10</em> years. The options granted on <em style="font: inherit;"> November 11, 2020, </em>have a fair value of $1.13 per share based on the $4.07 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 45% volatility, 0.9% interest rate and a 4.0% dividend yield rate. <em style="font: inherit;">No</em> options were granted during fiscal years ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021.</em> For options granted during fiscal year ended <em style="font: inherit;"> December 31, 2020, </em>the weighted average grant date fair value was $3.47. For SUAs granted during fiscal years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> the weighted average grant date fair values were $6.53, $6.55, and $4.89, respectively.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:16pt;">A summary of the Company’s stock option activity is as follows (in thousands, except price per share):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 40pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of<br/> Shares</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted Average<br/> Exercise Price Per<br/> Share</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12.1%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual Life</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Aggregate<br/> Intrinsic Value</b><b><sup style="vertical-align:top;line-height:120%;font-size:pt"> (2)</sup></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 30.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95773854">6.1 years</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773860">(1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773864">(1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773868">(64</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.03</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">508</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95773874">5.1 years</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">467</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95773878">4.9 years</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:65pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">2</em>)</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on <em style="font: inherit;"> December 31 </em>of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021</em> was $4.90 and $7.02, respectively.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">A summary of the Company’s stock unit award activity is as follows (in thousands, except price per share):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 50pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> <b>Number of</b> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b style="font-size: 10pt;">Weighted Average</b></p> <b>Grant-Date Fair Value</b> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>per Share</b><b><sup style="vertical-align:top;line-height:120%;font-size:pt"> (3)</sup></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding &amp; Unvested, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">224</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Converted to common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773884">( 90</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773886">( 12</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773888">( 30</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">6.26</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding &amp; Unvested, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">238</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">6.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"><tbody><tr><td style="width:65pt;"> </td><td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">3</em>)</p> </td><td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The fair value of stock unit award vesting was $548 thousand, $296 thousand and $274 thousand for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively. The intrinsic value of stock unit awards converted to common stock was based on the stock price on the vesting date and amounted to $650 thousand, $501 thousand and $115 thousand for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">As of <em style="font: inherit;"> December 31, 2022, </em>a total of 1,032 thousand shares of common stock were reserved for issuance under <em style="font: inherit;">2006</em> Incentive Plan. As of <em style="font: inherit;"> December 31, 2022, </em>the unamortized fair value of outstanding options and awards was $1.2 million to be amortized over a weighted average period of 2.3 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 15pt;">The Board of Directors approved the accelerated vesting of 35 thousand SUAs to certain directors upon retirement from the Board of the Company during the year ended <em style="font: inherit;"> December 31, 2022. </em>The Company determined the value of the modifications to be $230 thousand, which is included in stock-based compensation in the accompanying consolidated financial statements, for the year ended <em style="font: inherit;"> December 31, 2022.</em></p> 1200000 1600000 183000 126000 18000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 40pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Grant Date</span></p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 24.1%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">Type</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">Fair Value<br/> Per Share (1)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">August 12, 2022</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">May 20, 2022</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">April 4, 2022</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">May 13, 2021</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.55</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">March 16, 2021</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">January 25, 2021</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.54</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">December 16, 2020</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">November 11, 2020</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">Options</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1.13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">November 11, 2020</p> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><em style="font: inherit;">SUA</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 18000 6.65 126000 6.51 2000 7.04 116000 6.55 2000 7.04 2000 5.54 5000 4.71 40000 1.13 190000 4.07 1.13 4.07 P6Y3M P5Y9M 0.45 0.009 0.040 3.47 6.53 6.55 4.89 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 40pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of<br/> Shares</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted Average<br/> Exercise Price Per<br/> Share</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12.1%; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual Life</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Aggregate<br/> Intrinsic Value</b><b><sup style="vertical-align:top;line-height:120%;font-size:pt"> (2)</sup></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 30.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95773854">6.1 years</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773860">(1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c95773864">(1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="-sec-ix-hidden:c95773868">(64</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.03</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">508</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14.19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95773874">5.1 years</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">467</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14.70</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95773878">4.9 years</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 574000 14.23 100000 4.07 4.07 15.03 508000 14.19 25000 467000 14.70 14000 4.90 7.02 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 50pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"> </p> <b>Number of</b> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b style="font-size: 10pt;">Weighted Average</b></p> <b>Grant-Date Fair Value</b> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>per Share</b><b><sup style="vertical-align:top;line-height:120%;font-size:pt"> (3)</sup></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding &amp; Unvested, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">224</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.48</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Converted to common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773884">( 90</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c95773886">( 12</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6.29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773888">( 30</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">6.26</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding &amp; Unvested, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">238</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">6.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 224000 5.48 146000 6.53 6.33 6.29 6.26 238000 6.10 548000 296000 274000 650000 501000 115000 1032000 1200000 P2Y3M18D 35000 230000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">8.</em> Employee Benefit Plan</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Psychemedics Corporation <em style="font: inherit;">401</em>(k) Savings and Retirement Plan (the <em style="font: inherit;">“401</em>(k) Plan”) is a qualified defined contribution plan in accordance with Section <em style="font: inherit;">401</em>(k) of the Internal Revenue Code. All employees over the age of <em style="font: inherit;">21</em> are eligible to make pre-tax contributions up to a specified percentage of their compensation. Under the <em style="font: inherit;">401</em>(k) Plan, the Company <em style="font: inherit;"> may, </em>but is <em style="font: inherit;">not</em> obligated to, match a portion of the employees’ contributions up to a defined maximum. Matching contributions of <span style="-sec-ix-hidden:c95773902">zero</span>, <span style="-sec-ix-hidden:c95773903">zero</span>, and $198 thousand were made in the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively.</p> 198000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">9.</em> Commitments and Contingencies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><i>Commitments</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The Company leases certain of its facilities and equipment under operating lease agreements expiring on various dates through <em style="font: inherit;"> December 2026. </em>Total minimum lease payments, including scheduled increases, are charged to operations on the straight-line basis over the life of the respective lease. Rent expense was $1.0 million, $1.1 million and $1.1 million in <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. See Note <em style="font: inherit;">10</em> – “Operating Leases” to the Consolidated Financial Statements included in this Annual Report for commitments remaining under lease agreements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;"><b><i>Contingencies</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">In the normal course of business, we are subject to contingencies, such as legal proceedings and claims arising out of our business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product liability, contractual claims and tax matters. We recognize accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. These estimates are subject to uncertainties that are difficult to predict and, as such, actual results could vary from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;"><b><i>Settlements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">On <em style="font: inherit;"> December 6, 2021, </em>the Company entered into a binding Memorandum of Understanding (the “MOU”) to settle a purported class action lawsuit against it related to certain California wage and hour laws. The lawsuit, Enma Sagastume v. Psychemedics Corporation, Case <em style="font: inherit;">No.</em> <em style="font: inherit;">2:20</em>-CV-<em style="font: inherit;">06624</em>-DSF, is pending in the United States District Court for the Central District of California (the “California Lawsuit”) and is similar to numerous lawsuits filed against employers with operations in California.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">In the binding MOU, the parties agreed to settle this matter for a payment by the Company of $1.2 million in exchange for the dismissal of the California Lawsuit and a customary release of liability, subject only to final court approval and the process described below. Factoring in that process, the Company estimates that the settlement funds will be dispersed in the <em style="font: inherit;">second</em> half of <em style="font: inherit;">2023,</em> subject to the actual timing of final court approval.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">Although the Company believes that the allegations in the California Lawsuit lack merit, it agreed at a mediation to enter into the binding MOU to settle the claims in the California Lawsuit in order to avoid potentially significant legal fees, other expenses, and management time that would have to be devoted to protracted litigation in California regarding its wage and hour laws. The foregoing was also impacted in part by new California case law in <em style="font: inherit;"> February 2021 </em>regarding meal period compliance. The allegations in the California Lawsuit relate to alleged discrepancies in compliance with meal and rest periods required by California law and other alleged compliance discrepancies relating to the California wage and hour laws with respect to non-exempt hourly employees of the Company in California for a period since <em style="font: inherit;"> June 9, 2017. </em>The California Lawsuit sought recovery of wages, penalties, interest, attorneys’ fees and other alleged damages. As part of the settlement, the Company continues to deny any liability or wrongdoing with respect to the claims made in the California Lawsuit.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;">The MOU assumes class certification for purposes of the settlement only. The settlement amount of <em style="font: inherit;">$1.2</em> million, which includes plaintiff attorneys' fees and costs, is subject to potential increase based on any adjustments in the final class size and the exact period to be covered, as determined by the court’s final approval. However, the Company believes that such adjustments, if any, would likely be immaterial. Once court approved, in exchange for the settlement payment, the plaintiff and all class members who do <em style="font: inherit;">not</em> opt out of the settlement will provide a broad release of any liability relating to the subject matter of the California Lawsuit, including any claims of such persons under California’s Private Attorneys' General Act of <em style="font: inherit;">2004.</em> Such release is for the benefit of the Company, its affiliates, and any successor to the Company. The Company has the right to revoke the settlement prior to court approval in the event opt-outs, if any, from the class membership exceed a specified level. While the settlement is subject to final court approval as is customary, the MOU expressly provides that it is binding on and enforceable by each of the parties thereto, including by any successor to the Company. There is a $1.2 million liability reserve in connection with the California Lawsuit as of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021</em> included in accrued expenses in the accompanying balance sheets.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:15pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 24pt;"><b><em style="font: inherit;"/></b></p> 1000000.0 1100000 1100000 1200000 1200000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">10.</em></b>         <b>Operating Leases</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:9pt;">The Company has <em style="font: inherit;">five</em> operating leases for office and laboratory space used to conduct business. The exercise of lease renewal options is at our discretion and there are <em style="font: inherit;">no</em> renewals to extend the lease terms included in our Right-Of-Use (“ROU”) assets and lease liabilities as they are <em style="font: inherit;">not</em> reasonably certain of exercise. The Company regularly evaluates the renewal options and when they are reasonably certain of exercise. As most of the Company’s leases do <em style="font: inherit;">not</em> provide an implicit rate, the Company uses the incremental borrowing rate based on the information available at the lease commencement date in determining the net present value (NPV) of the lease payments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:9pt;">The weighted average discount rate used for leases as of <em style="font: inherit;"> December 31, 2022, </em>is 3.8%. The weighted average lease term as of <em style="font: inherit;"> December 31, 2022, </em>is 3.2 years. The operating lease expense for the <em style="font: inherit;">twelve</em> months ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021,</em> was $1.0 million and $1.1 million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:9pt;">Maturities and balance sheet presentation of the Company’s lease liabilities for all operating leases as of <em style="font: inherit;"> December 31, 2022, </em>is as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,134</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,061</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">553</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">2026</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">460</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Total lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,208</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Less: interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773945">( 233</span></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Present value of lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,975</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Current operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,037</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Long-term operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">1,938</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,975</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.038 P3Y2M12D 1000000.0 1100000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,134</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,061</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">553</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">2026</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">460</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Total lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,208</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Less: interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773945">( 233</span></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Present value of lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,975</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Current operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,037</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Long-term operating lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">1,938</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,975</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody> </table> 1134000 1061000 553000 460000 3208000 2975000 1037000 1938000 2975000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">11.</em></b>         <b>Debt and Other Financing Arrangements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:16pt;">On <em style="font: inherit;"> March 20, 2014, </em>the Company entered into an equipment financing arrangement with Banc of America Leasing &amp; Capital, LLC (the “Lender”), which it amended on various dates, most recently on <em style="font: inherit;"> March 23, 2021, </em>including a Master Loan and Security Agreement and related documentation (collectively the “Equipment Loan Arrangement”) which provided the Company with the ability to finance, at its option, up to $16 million of new and used equipment purchases. Each such purchase financed under the Equipment Loan Arrangement was documented by the execution of an equipment note with a maturity date of 60 months from the applicable loan date. The loans bore interest at the then current <em style="font: inherit;">30</em>-day LIBOR rate plus a premium ranging from 1.75% to 3.79%. Principal and interest were payable over the <em style="font: inherit;">60</em> month repayment period. Borrowings under the Equipment Loan Arrangement were secured by a <em style="font: inherit;">first</em> priority security interest in the equipment acquired with the proceeds of the equipment notes. Under the Equipment Loan Arrangement, the Company has been subject to a maximum quarterly funded debt to EBITDA ratio and a minimum fixed charge coverage ratio each of which was waived for certain quarters in <em style="font: inherit;">2020</em> and <em style="font: inherit;">2021.</em> The Company was in compliance with all covenants under the Equipment Loan Arrangement as of <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">Under the Equipment Loan Arrangement, the Company executed notes on various dates between <em style="font: inherit;"> March 24, 2014, </em>and <em style="font: inherit;"> December 4, 2019 </em>in the aggregate amount of $12.2 million, of which $0.7 million and $0.7 million was repaid in <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively. As of <em style="font: inherit;"> December 31, 2022, </em>the aggregate amount outstanding under the equipment notes was $0.6 million. The weighted average interest rate for these notes for the year ended <em style="font: inherit;"> December 31, 2022, </em>was 3.7% and represented $32 thousand of interest expense. As of <em style="font: inherit;"> December 31, 2022, </em>weighted average interest rate was 3.8%.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">On <em style="font: inherit;"> May 1, 2020, </em>the Company entered into a term loan with Bank of America N.A. under the PPP administered by the United States Small Business Administration (“SBA”) under the CARES Act (the “PPP Loan”). The principal amount of the PPP Loan was $2.1 million, which was evidenced by a promissory note with a maturity date of <em style="font: inherit;"> May 4, 2022. </em>The note bore interest on the unpaid balance at the rate of <em style="font: inherit;">one</em> percent (<em style="font: inherit;">1%</em>) per annum.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 24pt;text-indent:13pt;">In <em style="font: inherit;"> July 2021, </em>the PPP Loan was <em style="font: inherit;">100%</em> forgiven by the SBA and recorded as a gain on forgiveness of the PPP Loan in the <em style="font: inherit;">2021</em> consolidated statement of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 24pt; text-indent: 13pt;">The annual principal repayment requirements for debt obligations as of <em style="font: inherit;"> December 31, 2022, </em>are as follows (in thousands):</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">305</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term debt from equipment financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">599</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less current portion of long-term debt from equipment financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773981">(294</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term debt from equipment financing, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">305</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"/></b></p> 16000000 P60M 0.0175 0.0379 12200000 700000 700000 600000 0.037 32000 0.038 2100000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">305</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term debt from equipment financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">599</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less current portion of long-term debt from equipment financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c95773981">(294</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term debt from equipment financing, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">305</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 294000 305000 599000 305000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">12.</em> Other Income/(Expense)</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 10pt;">Interest expense for the year ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020</em> was $32 thousand, $49 thousand, and $75 thousand, respectively. There was no interest income for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020.</em> Interest expense is included as a component of other income (expense) on the accompanying consolidated statements of operations and comprehensive loss.</p> 32000 49000 75000 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">13.</em> Business Segment Reporting</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:10pt;">The Company manages its operations as <span style="-sec-ix-hidden:c95773994">one</span> segment, drug testing services. As a result, the financial information disclosed herein materially represents all the financial information related to the Company’s principal operating segment. The Company’s revenues by geographic region, based on the location of the customer, were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Consolidated Revenue:</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">United States</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24,509</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">23,584</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,486</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">International</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">731</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,325</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,874</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,240</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,909</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,360</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 40%; margin-left: 27pt; width: 60%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Consolidated Revenue:</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">United States</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24,509</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">23,584</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,486</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">International</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">731</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,325</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,874</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,240</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,909</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,360</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody> </table> 24509000 23584000 19486000 731000 1325000 1874000 25240000 24909000 21360000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;"><b><em style="font: inherit;">14.</em> Subsequent Event</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 10pt;">On <em style="font: inherit;"> March 21, 2023, </em>the Company declared a quarterly cash dividend of $0.07 per share, payable on <em style="font: inherit;"> April 10, 2023 </em>to shareholders of record on <em style="font: inherit;"> March 31, 2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.07 Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares. The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company’s stock on December 31 of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of December 31, 2021, and 2020 was $7.02 and $5.09, respectively. The fair value for the SUA’s is the closing price of the Company’s stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 years. The options granted on May 3, 2019, have a fair value of $2.99 per share based on the $10.60 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 41% volatility, 2.4% interest rate and a 3.9% dividend yield rate. The options granted on November 11, 2020, have a fair value of $1.13 per share based on the $4.07 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 45% volatility, 0.9% interest rate and a 4.0%dividend yield rate. No options were granted during fiscal year ended December 31, 2021. For options granted during fiscal years ended December 31, 2020, and 2019, the weighted average grant date fair values were $3.47, and $3.40,respectively. For SUAs granted during fiscal years ended December 31, 2021, 2020 and 2019, the weighted average grant date fair values were $6.55, $4.89, and $12.01, respectively. EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

,WWO![*;0]+GFZ;?7&3DV,*K>B *+>(6XN 2U+Y.RE'#W?# MON.@X$1ZD-43 E0V$[_8(56_F!&H>(7?5D4NU%Q_4#_Z@!92HKQ-"TD,]V@# ME<:I1L#Q]O 8=CME&?W:!5D^USKC*#REY.;Y'LO6Z?^1+EUM MJY!'.->/;X#4#-@QQ/'101]N1I16\ :%/^*]=S<8#(HHZ*2[ONF\@50I71?3 M87O+NG2< %EX+%9FUU=*%G!/HJ&&%7+N[DIF[..!(&)YVG'F#J]JXK2_I M>*FHO&5BV-HA$4Y/KH>A5^1638+-.%0>I': M6!][_V#"?5D_3>BN ./-E00-P$KPXW@"N^%8+Q/=W#"&^ I#MOEJ[C3KM^??2],/CL%'YPN7W)U3 /VS*,DJ/#J?M3^W5$?__0+T0.R:MK%YD. M]G>\O>:6@R4M\:L-0<(GV4F\J'ZVT+ZCIR0RPBTKOY())UNOV,](Z8OC 4,F M)MJ99-KF[FMEQFG7E3(=;DOY16Z5/^N'9^_\.UI2NM4>:48L,T@)/MQT&B^DELAF&RU%"RN;J_5^S6W8W4 M-=02>"X/SY3;=[0V;+, =.NM+X6^Q>+PG%:^HV-[&4 M4Y54_I2 -;8 ]4Z$ZV.]5=E=)+)LS*9I_\=]_C]-K_K+I'EZ[D!O>C;UTJG)($N./,E%N_7 MX:RFD[\.7G/ M"@8VUVZ&+R&G';7^=/A^_Q;ZF2!'E.&<:,W[ VNNCNU;Y;Q M=USEWS:@YI>^[C71[$C&^"UIJB,$JZ$ C0V00[%&)*F%Z-M>KS0]BL, M\D$Y?60QD\;.)M.S$?]5DTL 6_^R&P;S'L%\N3%D[SNDUK4QX=AES7YO4'#% M%)[UNGY1L>SEM]>UI)X2P]<7ZNPX_#F=J+])?.5[ M)G1*=YR.-1O>^6QVAC''ZOABHC[&)D 9ZA )TM-T>HS_3^ %5(Q*9$0_N#B? MT(JGE[[:Y9Y*YH6Z.)_A[_D)0WN F./JK AY)!!76=A2^DO:S?A@*=2:W/D^+0 MKDC GB//(4J>2IT:A#B^'7'-K=84'5,B@;RK:SGMSZ*"7L,%-R[!]R[/?6=8 MV,3_"UXYA"6&2%G#5ZQ:IM=U]94=$=)T"_R'Y(#XV(8Q1>P8\%6A1R E22=G MTYM#62.T!UW+PMV28;?]&^$^<\B"6I8J7TI(H$Q-E1-;[]? ?FQ[A&&_?S/A M$2?EB3H=,72-3D\NZ>_L1/2V=ZY/Q7O(_SUG+>[Q9#5@XACU=-T/I92 -T!& MI\QNO'[2<#2$=UTOPW2XF>$#E2'^I;.6]:"+27_I8M)G ^!W-#OTV/@HY:,\ M-D,NZ#MJJS6/F[-CM$IAZ6CW?6\_Z*WT1EY6<-]U50H<;$_9QUE!OFG'NG)#W6UMQ$EULW5G'BJATOJN:FF7;;J> MV%[ABWIOYV5-Y[]H82"^XA1^$""7(D,_%.G:&6;#[0QDTWP0-Q*?=AUYW?48 ME\B>IS7#J^YWFX&5V%#^A!,YK?[5W9Z&F:RH5\,44X[PTO,?^IV&N80T(4,OM[7^[NKKI\/8JRZ1) M+@F98E>S%$2?2R+:9\XWO#5?*>;,NL:!V7#CP*V17H5/X0K^V;KP':T$3Q;= MR@ZDI4*,KA]%.X[H$9D.;;RK^LV&JWZ_F?76;[WJLBCI%SK?!:-?68OZA8H& MRG*5EJPK>Q<&EJM_M-BF)"V_E6-)7*;'H]V 'S)5BC])WSZ7%=SE,9R6GQ*1GY<%]_&WR9>R2_RNN'R MPT8D&TM;4.EX@:F3\?GI@:KEMX+RT)05_SYO7C;(K/GCRF@$D30 WR]*@+-_ MH 7B+S;?_B]02P,$% @ $%![5DM[W5TB! (0H !D !X;"]W;W)K M&ULI59K;]LV%/TK%UI1M( :/2W;J6T@KSV =37B M;,4P[ ,M74E$)%$E*3O]][ND9#7;7"'#$(0FQ?LX/(>7Y.HHY*,J$34\U56C MUDZI=7OI>2HML6;J0K38T$PN9,TT#67AJ58BRZQ377FA[R=>S7CC;%;VVU9N M5J+3%6]P*T%U=)M5RPK6.4C-?8 M*"X:D)BOG:O@\GIN[*W!;QR/ZED?S$KV0CR:P4_9VO$-(*PPU28"HY\#WF!5 MF4 $X_,0TQE3&L?G_5/T[^W::2U[IO!&5)]XILNULW @PYQUE;X7QQ]Q6,_, MQ$M%I6P+Q]XV63J0=DJ+>G F!#5O^E_V-/#PS&'A?\,A'!Q"B[M/9%'>,LTV M*RF.((TU13,=NU3K3>!X8T39:4FSG/STYA>A$4)X![M>%1 Y['C1\)RGK-%P ME::B:S1O"MB*BJ<<%;QY8/L*U=N5IPF!B>.E0[;K/EOXC6Q!"!]$HTL%=TV& MV=\#> 1]Q!^>\%^'DQ%O,;V *' A],-P(EXT\A'9>-$$'PKZ!9Y;7^\=G_?Q2*8%;:"O$S,S@50RI:@RX'4KQ0'-C*+/BM@QFPV5YE1< MF$&G,.\JJ'B.("14QA,(3#U!W6RD;C:YL%NN6%%(+)@]"RCO/1ZPZ?"%M$U& M/R_[[\ADO\V!-BG6>UKO::.:)C"-#S>B4518F:5@ '5)<)2MN5<0!F[B+_K. M8AE3)UBZ?K* 7)Y Z"[B.;7!/(:/NB0 P2R! M@)R#8 $/0K-JY($2S-PP]DTG=I?^LD\9)3Y,\)^,_">3_._H,LDZXMD<+YI8 MAFM2-P.SX>B$[U6Y>S+]ETHRF?!_2J*T 2I[:A0QD42G9N;##]B@).I>L[I] M#RRC8YDK3=N?[A=(PH1L(H@6/GQ@\A&MCKTI74:5&05!1/\QD"SWA(W)M!PL M,DI9B;Y\YK[).%L.0BE+6_JPF(?4SF.+C*PGI)J/4LU?+-4=HY)O"@5; M8FI7TH'@&N%X:H^ 6UYU9M>^3*_)K.?U^HK?><\)XSV[MFN4A7V<*+ 7;G^#CU_']\]5?^U_->\?3[33"MXH.C1S M" @ @@4 !D !X;"]W;W)K&UL?51A3]LP$/TKIVR:F%1(D[046!NI+4.;-*8*V/@P[8.;7!H+Q\YL MIV7_?F-FXXYO2NHTPG=9L@_=H?]0K35'8H^2\0FFXDJ"QF 7SZ&HQ"-<+>J=T7[/2,'5ZFA/$C[-KP47PS<*XJX@]KS;1I[E-;,LG6JU ^VR"2X=)=R;S6= M8(=^RM4 X>7"3^3@-+;5R!6'6P2Y:V/@-V"B& M6R5M:>"SS#%_#1 2QYYH_$)T$1]%O,;L#))H /$PCH_@);WPQ.,E1X0;: 4> MTM=6CPY7.ZM U1IU?P]NB&#!A&,S@#5NN)2.-R77J+G*X3U<7-*03&"EU99[,SO:N6K6 MMF@$^;+[\2YA/(9'S2V>JJ(P< )1!!]I2FCL>Z#,7Z-/VA:'/GNXYXL*]<:[ MWX#OUUJDW^T?F'GKJ__I[>MTRS1I,R"PH-+AV60<@&X=WP96U=YE:V7)LWY9 MTB.)VB70>:'HA^L"UZ!_=M-_4$L#!!0 ( !!0>U9HA)SDI ( -L% 9 M >&PO=V]R:W-H965T\Y):HKH^L6QG7OOWK-]-]DH_6@J M1 O;6D@S#2IKFXLP-$6%-3-GJD%)?Y9*U\S24J]"TVAD90NJ19A$T7E8,RZ# M?-+NW>I\HM96<(FW&LRZKIE^GJ-0FVD0![N-.[ZJK-L(\TG#5GB/]EMSJVD5 M>I:2UR@-5Q(T+J?!++Z89RZ^#?C.<6/VYN"<+)1Z=(M/Y32(G" 46%C'P.CS MA) MV$*@>3L)+>5QT6'1<\X[SN0%SCB!&R5M9>!:EEC^2Q"20*\RV:F<)T<9K[ X M@S0^A21*DB-\J7>=MGSI$=<&.H.'_'7H[##:UZJY<"P2U])?RF;,%%]QR4OVSE0T/N+4P%ZIX_'7(P=$< MAQW,C$M)1XWU K4_;C?$7DFA:O<^6%=2L@2L&Z&>$6&!$I?<&CB!+$MH'$1# M#WMB10?![GE!%HTA':8^P+(M>1L.8TH7^5U3\:;ACM-Q^XTIU:$K M#?<*KD:]:MN*H<-92]O5GM_UG6O6%>S?\*[MW3"]XM*0DR5!H[/A( #=M9)N M8573EN]"66H&[;2B[HO:!=#_I:+'W"]< M_/\S]02P,$% @ $%![5I0: MSU'?! T0L !D !X;"]W;W)K&ULC599;]LX M$/XK V]:.(!CZ_21)@9R=;= CR#)=K%8[ ,MC6(BDNB2=)STU^\,*2MNH7KS MPDN<;TY^FI.-T@]FB6CAJ2IK<]I;6KLZ'HU,ML1*F*%:84U?"J4K86FK[T=F MI5'D3J@J1U$0C$>5D'5O?N+.KO7\1*UM*6N\UF#6527T\SF6:G/:"WO;@QMY MO[1\,)J?K,0]WJ+] M+)1ZX,V'_+07L$%88F890=#TB!=8E@Q$9GQK,'NM2A;<76_1WSO?R9>%,'BA MRK]D;I>GO6D/ITK@1-O[N).E!MC9658TP65#)VL_B MJ8G#CL T^(5 U A$SFZOR%EY*:R8GVBU P2[_O'32 M+0-W^&3AO%39P[]=CNU7_3<*[7,&%'&L M%JC;J/,0\A# Q5IKL@G>8XY:E' :1K1&,8AC7V(!L0&< BW5E!A13%,$SZE MDSMEZ?Y6/IVD$(5I(S&E[UO$/LS2&>W[, D2-X=Q"YA$4XCCF [C:-R"7F*! M!)O3<4IVL$P\:>:8L7:B=ZW5HW24<@!)XFP.4X;RUL?)! [W9#)M,YF^.I-7 M18&.?';MN&%W;C!3=29+*1Q%O2Z/^Q6_,H_;:!L*Z]HJ_0S:)2P0DPF"8T)2X\1J)/;F0(9<4"4I_QA1#5]Y0 MV)/)<$R7@D83.>U8-@?2QG7N(Q,,4X9U>%O)K0LW;T6U>G<)%U0!DE[+=#AK M 4,'3OQ-[%S_C^U>HD^VSQB^'PTCGB];HRD$#.$C1?]#R(36SPM!)F>ED%6# MT&B.G;&4]:0"/23L=?73\E97GB#*[5V4VG M9\:;T%F]79:=E=1;",X09R57ZX4MUB7]\3.U9OX\H$KVPUF6Z34)H^=0 TF8 M4-'.?.4==51>/ V):]*VRC@+65-IX2"8CMT8PY<5%9.5]3V4G&4BKQ!F1# 7 M8B6)H^1W F8/A/OI;(_(W0.4S(V7 &OVME3*?'\2"8S(BN M)N33U[:67N+0A^DL=03(#AYV1ZVP%-TNZ6@0$FT3&0:3'R5WTW_U1,_898I# MHAX)BYLO:HDHDUG#:%PSHE+:RN_^@%A]&GM6'T0)<_.UQI60.RGA*^[&F"G\ MY[C2<1RYS].8J+HK1KM6LIYDYC626\SN\)G>?U= #F \XSJAGSETO:?13IM5 MH;YWS:0!5V2^XVI/VW[US+=I+]=]L_M)Z'M9&_*I(-%@."%2U[Z!]!NK5JYI M6RA++:!;+JGG1LT7Z'NAJ(UI-JR@[>+G_P%02P,$% @ $%![5I&BAUD" M! 40H !D !X;"]W;W)K&ULE59M<]HX$/XK M.[Z;3C(3P))M2%)@!M+V7F::9O+2?KBY#\)>C">VY4H"PK^_E6P,S7&^] M8 MN_NL]N712N.M5,]ZA6C@IQ.3<=R;?*LQ#L%>ET40NWFF,OMQ&/>7G"?I2MC M!8/IN!(I/J!YJNX4K0:MER0KL-29+$'A*/9.+Y-B#,,3;6@Z"_#=Y@GEM'%,;WQJ?7;FF!Q]][[Y]<[I3+0FB\D?FW M+#&KB7?I08)+L<[-O=S^CDT^D?47RUR[7]@VMKX'\5H;631@BJ#(ROI?O#1U M> N -P#NXJXW6NH$SR57XT.3Z/M M2;G6E8AQXM%1T*@VZ$W?_<*&_ON.V,(VMK#+^_1A)13VYJX5-[*@\Z>%H_!, M*5&F2&?"P&('QW9W8N?$KG47\*6R 'T!OQ'":,A*N$.525)]Q0*&TEOE]3FQSV:-V#CR^HXLS6X(S!^;Z\--R7F)E7TAM1QG1UD' 8 M.BF+^G[0'0N'R+^L8V%7Q(]#+#S:;VZK>@H9#D'+,*N_@_;_@^[ M^T]W>;*F?E+9;V6Y06WSO:<_E<7VTTU_>"HSFA4_R8'.G?^/ \WA/SV3>J]G M4D4@AX"SX =>P#M15.\I_CJS4S3A/'2'-KQL6<'"9@($-&8)JJS02(AE4="T MU:XF9T G\=S9!4%#"\<+FCN-G%\=DPB"O3W-I9^)D0,/ZBG'_)--'QQ=\P6J MU#UF-(6[+DU]X[?2]KTTJY\)!_/ZL443+\UH#.6X)*C?']%)5O4#IEX86;E' MPT(:>H*XSQ6]^5!9 ](O)5V@S<)NT+XBI_\ 4$L#!!0 ( !!0>U9I#[1] MF0( +\% 9 >&PO=V]R:W-H965T="2#/Q-M:6HR P^08+9LY4B9).5DH7S-)2KP-3:F3+ M&E2(( [#05 P+KUL7._-=396E15)'WNG'+UQOK-H)L M7+(UWJ']7LXUK8*.9%LS@E1(_^=)N)M[0 M@R6N6"7LK=I^QM9/W_'E2ICZ%[9-[B#U(*^,544+)@4%E\V7/;?WL ,8AF\ MXA80U[J;0K7*:V99-M9J"]IE$YL+:JLUFL1QZ1[ESFHZY82SV5=E$:(03N%; MB9I9+M+02:DW%@J9!+#_*6=-J0QF^01C'<*&DW!C[*)2[_)0A( M82=8% _H9>]?Q<-P@\'M*6=MO00>S9#8Q#]_Q_$AQEG"RZX??'AAME*4P2_ M:@]PC\\6ID+E#[_WV3E8<+\=NN@$CB#RHR3MT2*E,!Q$+NQ#OY^X8 #I(.S= M*\L$"*<12O9"'6L-)'X<#GO.R@BXM$B\%HXA3A(XZU;L$$@+ M>P( *X% 9 >&PO=V]R:W-H965T6G+@+61* P-"38$;/LP[8.;7!(+QPZV0[M_O[,3LFXJ%5\2O]SS MX-&MC<)DLE'ITDZM\%D3. M$ K,K&-@]'O&&ZK67 <0(X% M:X6]4\O/V.3.2[=I=Q;3;N<<#;]HBQ"',,!7.#" I,Y M?+45:KCDDLF,RQ+.M&:R1+H):V#W@2T$FKUI:$G=<819KS3OE))7E.($;I2T ME8%/,L?\7X*0; _>DQ?O\V0KXP5FAS"*]R&)DF0+WV@XBY'G&VTY"P-=@IOR MZ]#CS6A7/:>F81G. BH/@_H9@_3]N_@H^KC%VWCP-M[&GMY3->:M0% %7"M9 M'CR@KKL[NY+&ZK:[GI_>/3S@RL) 0[D)R,W6F/811- M.A_6^U9X\[P9G@( ) % 9 >&PO=V]R:W-H965T@ME7%Y,L< M2[&;.;YS.%@66:[-@1M/:Y;A"O5C?2_)+P_L'^V MVDG+FBEI\YHP=2''#MJ5>BMU7;/4,#%\B2F57V#6^(XJ8;)4650LF MNRIX\V7[M@Y'@+'W"B!H 8'-NPEDL[QFFL53*78@C3>QF8V5:M&47,%-4U9: MTFU!.!U_$QK!#^$CS+>*[I2"%694=0U+K(74!<_@_0-;EZ@^3%U-(0W035KZ M>4,?O$+O!W GN,X5W/ 4T_\)7,JU2S@X)#P/SC)>8W(!H=^'P N",WQA5X#0 M\H5G"J"@$7A*7X..3J/-R$Q4S1*<.303"N4S.O&[-_[0^W0FMZC++3K''B_Q M&?D682-%!3=[C9*S$A;VKT"I8/T"7U!DDM5YD< 5#:6"7U8*/.!>P[P4R=/O M4ZK.QCVMZB&'NE MF:GV6PBB_L"[-)NP/QA'M/$O^]%XV+OE5J696)(Z"GWP^V$PH'4\BGH/0M/I MH2R$'O2#R&OX+AL^_-6 MW3&9%5Q!B1N">A>C@0.RF?_&T**V,[<6FGIEMSD]F2B- ]UO!/UVK6$"=(]P M_!=02P,$% @ $%![5D_;QAJ4 @ B@8 !D !X;"]W;W)K&ULC57;3N,P$/V541:M0&+)I:$LW392+ZR6!Q"BA7TVR:2Q M<.QB.VWY^[6=$+JEK?J2>.PY9^9,DI/^2LA752!J6)>,JX%7:+WH^;Y*"RR) MNA +Y.8D%[(DVH1R[JN%1)(Y4,G\* BZ?DDH]Y*^VWN025]4FE&.#Q)4599$ MOH^0B=7 "[V/C4*:[4QAJLDAB,*Q8']IIHN!]].##'-2,?TH5G^PT7-I^5+!E+O"JLZ],A732FE1 M-F 3EY37=[)NYK !"+M[ %$#B+8!\1Y IP%TC@7$#<"-VJ^EN#E,B"9)7XH5 M2)MMV.S"#=.AC7S*[6.?:FE.J<'IY%YHA!!^P#W1E400.8PJ99*4@M,):D*9 M@AFN=478F4E[FD[@].0,3H!RF!6B4H1GJN]KTXME]-.F[JBN&^VI&T9P)[@N M%-SP#+/_"7PCHE42?2@910<9)YA>0"<\ARB(PAT-C8^'!SO@D^/AT0$UG?:Y M=!Q?O(?OEJ>B1)B1-8R08TXUC(>/-U,8IGK7M&NV2\=F/_5E$G4#HV.Y.8$= M2=LYDX-M61/JJ05)<> 9EU$HE^@EW[^%W>#7 =%Q*SH^*'I,5 'F?0*WN'FK MZ)(PY%J= S'ZB93OE,_AF; *SV$F-&&[9A%_D1E>7T=;LSC8R?$ZZZ%]K1A? M77Y.MAZ&O_&5EBCGSNT4I*+BNG[-V]W64(?.1[;V1V%O7/OB)TWMTG=$SBE7 MP# WE,'%E6E)ULY7!UHLG!>\"&V2Z,'S2!+=#^?I)_4$L# M!!0 ( !!0>U; 2*Z_JP8 *@H 9 >&PO=V]R:W-H965T>WA%G4MSO*/L*]]@+,!+X(?\NK418GO5 MZ7!O@P/$+^D6A_+.BK( "=EDZP[?,HR6<:? [T#+ZG<"1,+69!Q?F[/)F$;" M)R&>,\"C($#L=8I]NKMNV:VW"P]DO1'J0F*/VJ&I^6URU+>81][ D%@>37,YYA MWU=(TH]O*6@K&U-UW/_]AOXQ#EX&\X0XGE'_#[(4F^O6L 66>(4B7SS0W:\X M#:BG\#SJ\_@3[%);JP6\B L:I)VE!P$)DV_TDA*QUP&.#G2 :0=X; < MVZ&;=NC&S"2AQ#RX2*#)F-$=8,I:HJD?,9EQ;QD^"=6\+P23=XGL)R;W5& MP0>P2"8>T!58D'5(5L1#H0 WGD>C4)!P#>;4)Q[!'%RX6"#B<_"(7T2$_/> M;Q"3-T@('C*EKT\0U>, U&X([&HH-![?A$B^+ M !T99Q8L? MV"K6(+O8N@6.W ;0@!%\6+KAX]^9\C7^SX]'L9C3W>#1+BU8( MWU53^SOR(]P&CU0@OVZB$NQ> MC*U6DN>)->X\[U/5:.%J_5/+VQ7?(@]?M^3ZQ3%[QJW)SS_9?>L73?3=+/JN M-GH72U"/(+74M(%L^3A9=<(EN DH$^1[>N^>AEM&EY&7- \RDHS7WXL7=JTR M*35&P[*1VZTP!P=[1H5X>UF\/6V\6' M?*C4U$^1M/!P78R]BOO=WL IQ=BKN-_OC^Q2C%IO?W#N^QD7?2T7'TE(!/[P M6;Y>EN!3*%"X)D\^!C>6_/GFJ,KXL])M-7*U),8Q< MY=MZF7]DVJ0U/)?YXV%9 *K%2YLXAN1ZRHU)--<46I'QO):P]<7$:8E3+13L M0.+(VQF*K)/T"652T,^,HKFFT(HSD1<(MKY"J$Y M6[WGU#6TKE<-": 21?E*#):SZQSRWL[UO:T7^',DU&Z4/GM,ZO&9 M4337%%IQ.S.7]U O[XN2\^!F58I2V*0I2_8C;%R]33&&7%[#_R6OOW"\BGSP MF:PPN%!R^GUMA/HQH 5>9=?Z35ZC ML46I',7&!#O<#^C-?(EZLZ5YN[6R+S M@7PO;YVGC,%J\6%7=C!A5>Y6K5R]4S\:=*Z>H5X]UP?=+A1DM10X-55!A8&J M466CU]4[^*,$Y'(6ZN7L(0+NL:B-NRI%^]6XM4.>_%A4ASRXR0US_0L;]&\> M+%C0E=C)^J^XUZU]L>C13WVQ&$5S3:$5FK55M\AM."BG M7=5H-"HOZ^<0QS 7QU OCH]5=Z/J/XC#BKRK&G5AN=2L0QHY]:NTDXM41R]2 MM<^$+"/OI ,HD#[F.B'./4Q,8KFFD(KTIOK9T>O;1N6ZN/T<\,8SF'YK.]Y M,I?GD,].+I\=O7QN3%7TTIRJAL1P2J])--<46I'>O3,H>J%N)E7U8_0TJ6IT M"]L46L)E9^\(5X#9.CX*QT&\_Y8<<,JN9L?M;N)#9J7K4_O*30[-Y3#)&;X[ MQ-8DY,#'*PEI70[D.L^28W%)0]!M?%#LB0I!@_CG!J,E9LI WE]1*MX::H#L M<.+D/U!+ P04 " 04'M6(J<^1@4# !?# &0 'AL+W=OU0D/;C9R=M6C1P:1%\2?QV]SSW./9=.@LA;]0<4<-=RKCJ>G.M MLQ/?5_$<4Z(.18;IUB;"1['9%K M1CF.)*@\38F\'R 3BZX7>JN!*SJ;:SO@]SH9F>$8]74VDJ;G5UZF-$6NJ. @ M,>EZ_?!D$#:L0;'B.\6%VFB##64BQ(WM7$R[7F 9(<-86Q?$O&[Q%!FSG@R/ M/TNG7H5I#3?;*^^?B^!-,!.B\%2P'W2JYUWOR(,I)B1G^DHLON RH*;U%PNF MBBZ60FP8A*TG#**E053P+H$*EF=$DUY'B@5( MN]IXLXTBU,+:D*/<[LI82S-+C9WN?14:(8*/,"ZW!40"8SKC-*$QX1KZ<2QR MKBF?P4@P&E-4#Q=?*TQR!I=&6V7[?:50*S@X0TTH4Q\ZOC8T+9@?+RD-2DK1 M$Y3""(:"Z[F"EB#*(@BA[]Z)5J]\-=X MPM^0GF?EH=37W6/Q.[_8V.H'&2;%=GFKD)?DHF01 OS]3U/;"?"GF*W*OZMUQ?;#='<*G:[ M(MO>5>Q3D6:Y1@ECD>@%D5B#"ZX)G]$)P_*H.[5W NZI_5$5SM'K:^^&V/ZA M'U=DC]W:D[L7W2A.[WL*'0;K'!*\OM1;,-I;M0XW?XWGN, M<_L;QO^*&$"BQS2A8F#%4F97MBVB&%(L+ED&5+U9,)YBJ:9\:8N, YX;4IK8 MGN,$=HH)M89]LS;APSY;R810F' D5FF*^=,($K896*ZU7;@CRUCJ!7O8S_ 2 MIB ?L@E7,[M4F9,4J"",(@Z+@77M7H4]C3> 'P0V8F>,="8SQO[JR=?YP')T M0)! )+4"5H\UW$"2:"$5QK]"TRJWU,3=\5;]B\E=Y3+# FY8\I/,93RPNA:: MPP*O$GG'-K=0Y-/6>A%+A/E%FP+K6"A:" M$L63PV], O+01S3-?4=L@:9D20@2DT1<*,S#-$3G9Q?H#!&*[F.V$IC.1=^6*FJ]MQT5 M$8[R"+TC$;H>&C,J8X$^TSG,]P5LE6Z9L[?->>0U*H807:*6^P%YCN?5!'3S M^7P?N-P=^#,&?KUQC2&?#?=4DT*NAK\4ID.(*!I>X] 7P- MUO#].S=P/M59>TJQ\$1B>Y5KEY5KO]GVG!GL614XW8KM=:ANSZ_8?HAR>T[0 MK;<]*(,/&H.?QB3+E.^VNJZW7X#S6TSX1>-):!1][4DXI5AX(K&]8G;*8G;> M?!(Z!^ZU_$Y0.0B'(*_K=RKGH ;D=OSZ8] M(^\V1OY=QL#+CTF3\XTZKW7^ ME&+AB<3VZM-K\$$E5LBK,&XU7^_O=-_I,"7IH\3R'0. M^6>Y7"U;Q6O3(5761ZJ%S#N^9YF\_QQCOB14H 062M*Y[*B(>-[3Y1/),M/E MS)A4/9,9QJH-!JX!ZOV"J4ZGF.@-RL9Z^!]02P,$% @ $%![5L&ULK5==;]HP%/TK M5E9-G;0U'X1 .T!J2;?UH5-5UNUAVH-)+L1J8C/;0/OO9SMI"DG(J)07L)US M3WSN/7*N1UO&'T4"(-%3EE(QMA(I5Q>V+:($,BS.V JH>K)@/,-23?G2%BL. M.#9!66I[CA/8&2;4FHS,VAV?C-A:IH3"'4=BG668/U]!RK9CR[5>%N[),I%Z MP9Z,5G@),Y /JSNN9G;)$I,,J"",(@Z+L77I7H2N"3"(GP2V8F>,M)0Y8X]Z MB9EC 5.6_B*Q M3,;6T$(Q+/ ZE?=L^PT*07W-%[%4F%^T+;".A:*UD"PK@M4.,D+S?_Q4)&(G MP T.!'A%@%<-\ \$](J WK$!?A'@F\SD4DP>0BSQ9,39%G&-5FQZ8))IHI5\ M0G7=9Y*KIT3%R_GK ME_GK=VB$G"O8*6!0J?'T_Y"P#ND[S2X(2A5!JXJO0('C%*G# EW&ZFPD0G*L M/R/E"=1FC5;RMUJC2[*P([*]I [*I XZM,:@7GV.6\P?P7S#CC%&*^];C=$E6=@1V5X^S\M\GG=HC/-:05VW M>F@T8?R*,>J8@=_L"]=Y[7B<5B7W*C>81XFQ1@@;U?NN3&]RC#G:N=_JCD[9 MPJ[8]O.ZTTFZ'3JD(-OK'9R*0QHPM>]* Z9_7K&(O=,?9\"7YIXAD.E$\V:P M7"WO,I>F@Z^L7^D[CNF[7VGR"Y(Z8I:$"I3"0E$Z9P.U(9[?.?*)9"O3A<^9 M5#V]&2;JG@9< ]3S!5.=>#'1+RAO?I-_4$L#!!0 ( !!0>U8)0;";M0( M )L' 9 >&PO=V]R:W-H965TH2P)#GB@L]]4ICUC>^K],2*JJOY1H$[N125=3@5!6^7BN@F2-5W ^# M8.Q7E DOGKBUI8HGLC:<"5@JHNNJHNKO'+C<3KV!MUNX8T5I[((?3]:T@!68 MW^NEPIG?13;W )@0< M4F,C4'QM8 &91HJK0T(-C2=*;HFR:(QF!ZZ8CHWRF;"VKXS"788\$_^0 M!DA(/I!5XSN1.5FQ0K"&\C( MO2LP#F8;4/B]D(6L*O1U55*%E)^UT0;Q-LY% H8RKB\QD&ZVVQ<3Y%RSHSEN[(ZS[643C\;A>.)O]DO4 QI%GP]!21\HC#K0@=RHDQN=E.N^ M3.PI.YGP5+,-Y8 ?=:OX'7G1FZ2"5]K>122G$ >J1IVJT7\SD6ILYO:/RUPI M$/6.XM$YAO: WAK:!WICJ+_7MBI0A6O_FKB&T_RDW6IWP\Q<8WVU/L>;I[DH M7L(TU]8M5043FG#(,61P_1$34\U5T$R,7+OF^" -MEHW+/'V!&4!N)]+;)#M MQ![0W;Y4" #!!@ &0 'AL+W=O/ MOJ_2 DNB;L4:N7F2"UD2;:9RY:NU1)(Y4DQ4N4+^LY]+,_-8EHR5R104'B?G( M&P>/TZ&-=P%_*&[5WAAL)DLAWNSD9S;R>A8(&:;:.A!SV^ 4&;-&!N-OX^FU M6UKA_GCG_MWE;G)9$H53P5YIIHN1=^]!ACFIF'X6VQ_8Y#.P?JE@REUAV\3V M/$@KI479B U!27E])^_-.>P)@N$)0=@(PD-!_X0@:@212[0F4<\I7]KC7**G(NHZK=ALX M-_N1;I+[A]C?["=P'!+=M2&?(/LM9/\LY%R*#76?KJU\MJL\:2K?Q5D;#O<@ M#C&/(P:#;LQ!BSDXB_DJJ<8;D>>=1(.C_6Z"X("I(R;J9AJV3,.OU1=Y=KZR MP^/*WAW@=80\'.#Y>]V@1+ER35*!*U3]D;2K;1\>N_9SL#XQ_;ENIQ\V=7-_ M(M*\J@H8YL:R=WMG@&3=,.N)%FO79Y+DS?:29V@_:O ME?P'4$L#!!0 ( !!0>U;(IW^\JP( ,( 9 >&PO=V]R:W-H965T MM%*6_E,H%6"U":;MHMM5=-NUPX< M@E6#F>U\]-_O&"A*@72Y 7^\[_%SCL&>[85\43F )H>"EVINY5I7M[:MDAP* MJJY%!27.9$(65&-7;FQ52:!I;2JX[3G.U"XH*ZUX5H\]R'@FMIJS$AXD4=NB MH/+U'KC8SRW7>AMX9)ME.I];D452R.B6ZT>Q_P9M/A,3+Q%*W!.]?@MP:_3K0AJ]-:4DWCF11[(HT:HYE& M79O:C=FPTNSB2DN<9>C3\4^A@03D,[E+$KF%E'PYX >B0.'0JME9(K+A[.42 M-&5<7:'N>;4DEQ=7Y(*PDCSE8JMHF:J9K9'/K&(G+O &0-)61, MCZ;:Q)[4L+T+$0.&\J) JTYX)&JQQ"G@^5==^+T&/\C>@<9 M=I#AAY"_= X2S^<&M2WBZ$:'@]4CK_\!#C5!> (PZ@"C#P&?A,;J]8^T,TB"- .U:@;^N59 , *D* M 9 >&PO=V]R:W-H965T(!K9Y)O3(2XTIKGQ?QRGF3)_) @5]64J5,T-=M?)UH9 E MSBC/_"@(^G[.N/#&0S?VH,9#69J,"WQ0H,L\9^II@IGQZ8\55J[( _ M'A9LA7,TGXH'13V_44EXCD)S*4#A3L&L-W(S?.6[T7AOL4A92?K&= MNV3D!98(,XR-E6#TM\8I9IE5(HZ_:U&O\6D-]]O/ZN_=XFDQ"Z9Q*K///#'I MR!MXD."2E9F9R,X%X*DVJX%0DF+P5\@F[(HV?R2=2J>(/Q&73##D1!%,&G^0VTV M$>DZW?-CNA0&;7AL0P'7I4FEXN8)_KC'?('J3_B'0F50"9;!#-P&1P(W:!@&;V;HP+Q<_$7W+!@)M]N"VYE2'$(;O$:+CJ%= M-FB7WX!&-]S7XUV^QCM&%P:[*S;X]CU']\J499RX!6?P7C$1IUR["QDFDI;2 MNCO;"=ZX/<.]1R3\WB>[5MR_7L+SH[&.=B11*\GM%7'W3*VX MT)#ADDR#LPM*KZKJHJIC9.%JD84T5-FX9DJU)"H[@;XO)=4C=<&ULG5;1;ILP%/T5"_6AE98"!D)2)9&:L&I]Z!0U[?;LPDU !3NS MG:;[^]F&LA2<*.I+@NUS[CW'7.P[V3/^*G( B=ZKDHJIDTNYO7%=D>90$7'- MMD#5RIKQBD@UY!M7;#F0S)"JTL6>-W0K4E!G-C%S2SZ;L)TL"PI+CL2NJ@C_ M.X>2[:>.[WQ,/!:;7.H)=S;9D@VL0#YOEUR-W#9*5E1 1<$HXK">.K?^33+6 M> /X5'#PC[>2%L5<]N,^FCJ<%00FIU!&(^GN#!92E#J1D_&EB.FU*33Q\ M_HA^9[PK+R]$P(*5OXM,YE-GY* ,UF17RD>V_P&-GTC'2UDIS"_:-UC/0>E. M2%8U9*6@*FC]3]Z;?3@@^,,C!-P0<)<0'B$$#2$XEQ VA-#L3&W%[$-"))E- M.-LCKM$JFGXPFVG8RGY!]6M?2:Y6"\63LY], HK0 -W3E%6 GL@["#5RO,&[],0)*B%%<*^[Q*T.7%%;I !45/.=L)0C,Q<:72I[.X::-E M7FO!1[3X&#TP*G.!OM,,LL\!7&6L=8<_W,WQR8@)I-MX.BDX"0'=MUQJSO^6IG$O5PA'G5$]S%!T*FEI(\9!/A(;8]:T:,S2B6!-:AB MR6SJ1_VL4?>[6UA 0=S].&V@8&S7/V[UCT_JMQWN-A?CWL$0=DIBT8<,_&C8 M\6 !X2",.R;<@PNM KXQC8% *=M169_^[6S;>]R:*[P>U98"<4(E0, )0, 9 >&PO=V]R:W-H965T M)(; (6>RX+)F;=1:OO1]V6Z M@9+(/M\"TV]R+DJB]%"L?;D50#(+*@L_Q'CHEX0R;SZUJ/,A#^?;LD:'D']VCX(/?(;EHR6P"3E# G(9][G MX&,26("U^$WA($^>D9&RXOS)#.ZSF8>-1U! J@P%T7][6$!1&";MQ]^:U&O6 M-,#3YR/[5RM>BUD1"0M>_*&9VLR\L8\"<(T7?.U$:B+RR#[)S U^(:A>%1X5W8R9A VD>#X#T* M<1@Z'%K<#@\<\.1V..Y0,VCR-;!\T06^8\1E$W&A(^Z*<\438$MDCO]^COM& MPOY4_$U6R36K,RE1(R7JE&(V#2!:[3ME]MU[Q'2ETWLMKU6N@$%.E4M>Y'(I M"%OR:JO@W I'+7U.,QQ%;H%Q(S#N%/@ NC Q8 IE5!\> 2P%Z=+23=/#_0B_ M<9VE1>SR.QH-6_)B1ZSCRM%EO8'SLFD=\.1H=I[FP6C?M&LEB+5M>Z6N MHSNFJKZFF6U:Z\^VH6S-WYF6V[:!KS15O_Z=B#5E$A60:TK<'^DK0%0M<#50 M?&N;PA57NL6TCQO]V0#"&.CW.=>-83TP"S0?(O-_4$L#!!0 ( !!0>U8\ MDE2,& 0 $4/ 9 >&PO=V]R:W-H965TUJM^V]=LAD8RU@SG8>VD]_8T() )@9_\;VS!]/#T*^J"V )L0,G4C&4)J[O>2,W93QSYM/BV8.<3\5.)SR#!TG4+DV9_/8>$G&8.=3Y M\>"1/V^U>>#.ISE[AB?07_('B7=N%67-4\@4%QF1L)DY=_1V02/C4%A\Y7!0 MM6MB4ED)\6)N/JQGCF>(((%8FQ ,__:P@"0QD9#CGS*H4XUI'.O7/Z+_7B2/ MR:R8@H5(_N9KO9TYD4/6L&&[1#^*PY]0)C0T\6*1J.*7'$I;SR'Q3FF1ELY( MD/+L],^.Y434'&C8X>"7#OZU#D'I$!2)GLB*M)9,L_E4B@.1QAJCF8MB;@IO MS(9G9AF?M,2W'/WT_%YH($,R(!^R6*1 /K,C*+Q=B#07&61:$;$A][B?EK ! M*6%M3,A'SE8\X9JC\9LE:,83]1;=OCPMR9M7;\DKPC/R>2MVBF5K-74UHIH! MW;C$>G_"\CNPEA#?D(#^2GS/]RWNB^O=Z:6[BQ-4S9)?S9)?Q LZX]5ROU,* MM#6G4Y#0'L04Y*W*60PS!RM.@=R#,W_]"QUY[VP9_J1@%_D&5;Y!7_3Y78+E MS;(8"#8*LA:[E=[L$JRY6.PR>^ZG@,,BH.D=^[F9^7T]HUZ3"\ZPX@S[.>-8 M[G!9X(AM38$5[!1A5!LUI&&#K&U#_8D=;5BA#7O1GK2(7P:FPZP)5I;A8Z9Q MV1"'K>&#J#EY%AM_:$<<58BC7L3'URS-WRV)QDT=X^[F]I4=M2?'BT8-/*M1 M8.<;5WSC7KY/.4B\V9:]M,PM!.%E5D42_9@N5R4DXIRTDMY_^DCB9F4W["(#TRN;6"3]@3Z M#:ZVB4\[BH-Z9]GQ>MG^D$(I'H36!I+VD7UFR M*RJ75%W1RDA;HP^BR;#):+&JMZ-+QK,\T5XUL.D3N=MHD.1:>M^RR%%SA]JL M<"$ZZ,]B0X/KU;7V96$%[16N_ZNQ/RO:9>)G]:+]\O7;,095?&"9%BSVN%[F M@Q<_0W&XF)_6#3^@"$N%U/Q[IX#0MH -QK7V6V9KL:)^V%7+9Z6C_5+W("%G MO%^%:5N_D+ ):#$:=17P6>5HO\Q=(2.T+5^#4=!LA#:K*.C:_F>5H_TR9VF% M_U4$;4D;T'#26F^+F4_#+N"S^-%^]6N=!GHZ=]3ZYAM-F@)M,<(2:U"ZM3.. M.6#^Q>0SSQ2NZ0:]O)LQNLO3F>UTHT5>''M60N,AJKC&ULU9UK;^.X&87_"N$.BAD@:TOR-=,D0":Z"YD- MDIE9%$4_,#83"Z.+5Z)S*?KC2UUL68I,R]B3;9L/B2WS??C*X@E%ZH@Z>XZ3 MG^F2,4Y>PB!*SWM+SE>?!X-TOF0A3?OQBD7BDXL7%L3/YSVUM]EPZS\N>;9A M<'&VHH_LCO'OJYM$O!ML*0L_9%'JQQ%)V,-Y[U+][ V5+" O\<-GS^G.:Y+M MRGT<_\S>.(OSGI)EQ (VYQF"BC]/[(H%0482>?Q>0GO;.K/ W=<;NIGOO-B9 M>YJRJSCXS5_PY7EOUB,+]D#7 ;^-GVU6[M XX\WC(,U_D^>RK-(C\W7*X[ , M%AF$?E3\I2_E%[$3H([V!&AE@-8,&.X)&)8!PZXUC,J 43-@NB=@7 :,&P': M>$_ I R8=$UI6@9,NP;,RH!9UX#3,N"TZ]>J*ILCIW2M0]T>[*+1%:TD;V(Z MY?3B+(F?29*5%[SL1=Y.\WC1LOPHD]0=3\2GOHCC%U]CSLB4_$+N>#S_^4O6 M.A?D\IDFBY1\U!FG?I"2;^R%KVGP213[?J>3CQ\^D0]D0-(E35A*_(A\CWR> MGNQL^+:,URF-%F+CA]K[LP$766=U#^9EAF:1H;8G0U4CUW'$ERDQH@5;U $# ML;O;?=8V^_Q%DQ(OUX]]HFHG1%,TK26A*WGX-7T5D7NC]0.5KY(^449[PPUY M^-?X2>2NYN%*VY[A:DNXW3V\+7FG<[@R:0EW#Q\W2>Z> M/-JET:9R]532"(=;X0USWF@/[R[3"KE)_#DC'X5"%G$0T"0E*Y84.OK4DN,7 M*3/K?C^G*SIGYSW1OZ8L>6*]B[_^19TH?VMKYDB8CH09!6R6P[*3@J<+M:\. MSP9/NRW];:%1_[1>QGI;9MI7M'HA&YFZ@X2Y2)@'@M5:^VC;VD>'6WO9NUS% MH3@A3&E^2G69)#1Z9.(DC9/[5[);[H:^YIOSWNB$_+K* D2'8HD(GO$^+:.=3AK2:BDS'=7+.,C$723, \%J MBIEL%3.1*N8JCD0GE,\XQ _%J.J$7(;Q6BC"2=-U8B3 MS>;\W.[CWQE-6L=%TLR.%2$2IB-A!A)FRH^F)@Y*-AX=DK"8Y%1G9$%?V^9) M+61:-A+F(&$N$N:!8#6EGFZ5>BI7:G;RE\^-%THD_[AFX3U+_MDF+2GJ6&DA M83H29B!A)A)F(6$V$N8@82X2YH%@-76I2G7I2GGOR0GC][7/7XD3I3Q99Q^D MY%>^9 GA2QKMGW+,IQ*+JUVM_629^.[81&T,PZ_:RFB-<;C>4DB4&O5GC!D%2FK6R2W8\>Q2APG9UJ'NRHI,D=+2$D38?2#"C-+&F[?>1PW!00LD8; M2G.@-!=*\U"TNB K7X;:P9@AFU_9E5LVM=*J*ZA1 TK3H30#2C-+6NW"T[ Y M8PFMTH;2'"C-A=(\%*TNK,H"HG;Q@$B$59P[2F=)Y%4)*K>7 #2\(\;+-%V'&TD;+RLVS\>0<2"803;+ MBE879V6' M4;OX8=Y%G+=^^I.8"6/$B3@3R?/]VH1:9: T'4HS2IJJUK2I*+/3^D]3J\@D M+"C-AM(<*,V%TCP4K:[5RD6C=K'1O&]'JOM/_H)%B_U2A1IJH#0=2C-*6J,; M549-:2(KM: T&TISH#072O-0M+HT*]N,*O?-7/N1'ZY#^400U"\#I>E0F@&E MF5":!:794)H#I;E0FH>BU6]_KHPS6A?CS!_J^PI#6WFU<>N*V6L=^AXC>6A++^ M$^K3@=)T*,TX<"S&Y?T2I^7]$JVB129D06DVE.9 :2Z4YJ%H==%6-AY-;N.Y MIB\'!Y%RQ-&J@KITH#0#2C.A- M*LZ$T!TISH30/1:L+K++S:%WL/'_J(!)J M_H'2="C-@-+, P=R)!E$0HT^4)H#I;E0FH>BU:59&7TTN=&GV?>A!I%00PZ4 MID-I!I1F0FD6E&9#:0Z4YD)I'HI6UV1EW-'^^\:=0X-(J&D'2M.A-./ L9@T M;KIO%2W4T .EV5": Z6Y4)J'HM5%6QEZ-+FAQXGF0G_^$R,W 8WR=4?E/234 M>@.EZ5": :694)H%I=E0F@.EN5":AZ+5Q58YU65O0-G%YJ(AZ+5A5GY<;0#Z]C\<6&6=R-G*R(6 M:\1?/E$_H/?*FX5.7"OLCS+HP4+M?Q :0:49I:T^F(DS;O]H57:4)H# MI;EM7\>DN:2*UU9J=^V\^IKOE?-F*#=L"/F((<=F6= KNO(Y#3::N"V2+Q9D M,]=\G;!\R5 :E6O$2\0AK_=8<4!I.I1F0&GFL&6Q&V6H-9>1AYIIH#0'2G.A M- ]%*]0VV'G,2G5)CB M$4+7-'GTHY0$[$$@E?YTW"-)\52>X@V/5_G#5.YCSN,P?[ED=,&2K(#X_"&. M^>9-5L'VV4@7_P%02P,$% @ $%![5BU(4.#+!@ (2@ !D !X;"]W M;W)K&ULO9I=;]LV%(;_"N$F10NDLDC*7VEB(''6 MK0/2!4V[712]8"3:%B*)+DG;#; ?/Y*212?ZL&M/NHDM2N1YSTL>/8[$BS7C MCV).J00_XR@1EYVYE(OS;E?X,QD>J0S[IBP2D)3*2'J# MC\%EQ]6*:$1]J8<@ZF-%)S2*]$A*QX]LT$X>4W?<_KX9_8-)7B7S0 2=L.B? M,)#SR\ZP P(Z)E( Z3])/\ MS(S8ZH!110>4=4 O.D!"-V83BY@4W _)YP*\#LG MB527?$T"RH&<4Z 7#/B8^#31$P+N(I* -S=4DC 2;X%(NX4)^#)G2T&20%QT MI1*NPW?]3.1U*A)5B(0(W+)$S@7X384-G@_051GG::--VM>H=L0;ZCL PS.E M'B%P KH;H>E'302<&XM-!*_2V!6-'Y1',(WB@F^WIN%[6?ZU8^E2/A<+XM/+ MCJI50?F*=L:O7\&^^[Y&J95">K5"/I"0@Q6)EA0LE'$FM)$3L"@B7-A6KL-TK?2]0M(I3IK21?^DK- MU7*F[FH HJSVZJJB-LJ!53'*UZ9Z/N93*R6E![)J.]3*X7M,-DRR%8#Z*Z8KPE M3ZH*]ZC$^A@'EB*TA(*-( H6&051OV*E6$K!]C %BYSJ.SWX M8"-\@T7 5;ML$0?;8QPL0J[,Y7I!.URV;(1'P''!PPAX^Q1D$VR$%HZP$3K" M(AY1^4)!EHZH/3JB(AT'CNN]6"@[!-4O%&3IB!JA(RK2L@'2O%PA$U D=4 L=*ERT<47MP1*5P++A\#!R1A2,Z'(ZWA/MS /O[5&03 M=$26CJ@1.J*]Z8@M'7%[=,1[T7&'H/J5@BT=<2-TQ'O3$5LZXO;HB/>BXPY! M.SS>>H1Y.!W_),E2/QI&O3WJL3[.@?6(+2%Q(X3$14)6K17+1]P>'W&1CSVG M5U@KQ_ 16S[B1OB(BWRL\MC2$;='1URD8YG'Q] 16SKBP^EX0_WL?4-_G_<- M30 26T#B1@")BX#LE2\6SP+2:P^07A&0GC-X^9QAAZ#ZQ>)90'J- -(K K+* M8PM(KSU >D5 EGE\#" ]"TCO<$#^V@O ^D"'O@'<>@78S#O DO\A1Q4OMSS+ M2*\]1GI%1GJ..ZB0:&GG-4([K^2_P4J_+.^\]GCG%7E7XY/R( IZ:2$IF&V+K*)Y&_C(B>V*4)J\]?1\1_ M?'?OSUFD)CYF 8T<\%62$Y\N201B,*5NDH)A2YXHFH.4BF;V)MU MH\3JITSF(1,5)P EVG[Z8#FIP!20) ?U+N MAX*FA@G31H18QCJ;OH-ZIJ7G#'I&':!"AK%)6%(>BS/@P5.P8LJ#, KEDY+G M>*<@5)J591+P31P"L#,Z!4&X"@.JCI]"&@7F=&6^A=MB5=;Z-71EUGI-_O]) M]YXG[>K>=[#D6L0T%&IM9='U3A;[JRW;BP(=\&%K MC5;W%Q4#*#NUQG0Y::O69B.3NE*9S,F,;KMF'<_TGF#'&Z0CZ*_NF(TX_ECK3&S4$U_1*=*GJM6; ?P=#]:>B#9PFSI>F!2LMA\G5,24*XO4.>GC,G-@0Z0 M[PH<_P=02P,$% @ $%![5@ MC%$2!0 XQ0 !D !X;"]W;W)K&ULQ5C;;N,V$/T5PALLLH!CB?(]ZQA(XBW:A^T&FZ1% M4?2!EL86&TE422J._[Y#2I9OLNRZ*?IBBY&0PXY6@CYHD( 3=[B*%$W MC5#K]-IQE!]"S%1+I)#@R$S(F&ELRKFC4@DLL$)QY'BNVW-BQI/&>&3['N1X M)#(=\00>)%%9'#.YO(-(+&X:M+'J^,[GH38=SGB4LCD\@GY.'R2VG!(EX#$D MBHN$2)C=-&[I]<1SC8"=\0N'A=KX)H;*5(@7T_@IN&FXQB*(P-<&@N'?*]Q# M%!DDM..O K11ZC2"F]\K]!\L>20S90KN1?0K#W1XTQ@T2 SED7ZNUC\" 6A MKL'S1:3L+UD4<]T&\3.E15P(HP4Q3_)_]E8X8D/ ZQT0\ H!;T> M@\(M N! M]JZ&0P*=0J!C/9-3L7Z8,,W&(RD61)K9B&8^K#.M--+GB8G[HY8XRE%.CW\6 M&DB?7)%'+?R7*^/"@-PNF S4JI-\2VV(;DV(N%Z2RPEHQB/U"6<\/T[(Y<4G MD.>$:]7+TQISVF5(VA:O MY%S]5>2H'ZED@D^&OXVZ_,W)>-XVO56:VE6N5,A]N M&KAO*)"OT!A__$![[N<:*IV22N=4*DVRL#F(RXN]@L0]A< ;2)\K(*GD/EBN M@8@B)A5)0>:\*VGG2@<;M&FGY;5WB->:=B;Q;DF\^R^(2S [LHFOCRM9XMZ7 ML8A$?(9.^ V8K"1=K[!+EF <1TELDH/T2,"65=DUJZ9'>Z1YA M\[F$.<.MAR-_CJ>(3UY9E$$5\1RWNQ%MK[L=ZOMZU;_3/ZHT5WEF^MIC.7[Z#D,3B-QWMF[6 O:SLMM[_#NM:N M,UD/2];#6M982,R Z^/1&QZ/7JVF,WE0=WVHNZ<_X%3J/!+#>LG.9;Y0S MM);Y/4M\+"J/AK" V8IA;_?HK-=U+A=OS<4[G#0=ZMP:$6)XPYVZ=370=M6KFL7^K\4+[2R>J'#74['BIQM5NO"A-8?\,76 MSJ81'/5]=\^MG=Y>OM>J.WE*U M<8#[647F$8V=577HYN6A(E[G8*%9CW6N=]8E##VIALF]\X\*S@)XJS+<.QK^ MBT*%FDIE^PJ[/O*]^B,?B]RG$ X3)7B#UR%71-O47S!%?!;Y6<3,HLGO_78* M8L0B2W23\!EAR;))IDNR"+D?VD$_$LHLJIC)%]!%8HF9';L7<8H2'S\,/-K_ MK(BRSP>(BE=DB*>8<6VZFLO2-.*^M<6L*4Q5'P#O\W9P)V^%-60EF>&U7T9+ M8X2P+Q.J2>(LTAP!#96EG95D5B'*%*\0*IO^";XF6A!@2$9E^),#M,C3!K/< MZEPS>@D1-LS/;_FXH)+ ?+G6D1?]ENO9K@L\;(=-S#V5@GW1BI:MJH [&R\V M,D*K^KWK^ZKYMW2( L.J$<]=/> Y M:Y/RY[^O3,YQ+9$(9FB>V^IC;LC\12UO:)':-Z:IT%K$]C,$AG$R$W!\)H1> M-8R"\EUS_#=02P,$% @ $%![5M>J/*@*!0 D!H !D !X;"]W;W)K M&ULK5E1<]HX$/XK&M]-IYU),#;@D!2828A]UXL%8VN_3:C^O;*U&*\I>>0P@T,\L M)7QLQ4+D-[;-PQ@RS#LT!R)[9I1E6,A;-K=YS@!'&I2EMMOM>G:&$V)-1KKM MB4U&="'2A, 30WR199BM[R"EJ['E6)N&3\D\%JK!GHQR/(=G$%_R)R;O[(HE M2C(@/*$$,9B-K5OG)G \!= 6_R6PXCO_D9K*"Z6OZN9#-+:ZRB-((12* LO+ M$J:0IHI)^O&C)+6J,15P]_^&/="3EY-YP1RF-/V:1"(>6T,+13##BU1\HJM_ MH9S00/&%-.7Z%ZU*VZZ%P@47-"O!TH,L(<45_RP#L0-P>@T MP2XOP+Z#8!> M">B=.D*_!/1/'6%0 @:_ KP&@%<"M)AV$2P=Z7LL\&3$Z HQ92W9U!\MET;+ M "=$/5G/@LG>1.+$Y",5@*[0)7H6-'R]5")%Z':%6<1EXT=*EL#%I@G=JN<@ M$6OT]AX$3E+^;H-$7T@B2JMO#Y"] /LN^_Y&-N(Q9L WEX2@SS%=<$PB/K*% MG()RQ Y+=X/"7;?!7<=%#Y2(F".?1!#M$]AR[E4 W$T IFXKX^UBWD&.>X'< MKNO6.'3?#G_ :XEL1/M'!L]9!W7[C?"@'7X/80?UG#KX7BQZU!""I.0.7J#L_R]5+74'POT O.$$-5'9R@'EM (O95R%L*^JW%_VCJ<6C1O M>(Y#&%MR5>3 EF!-WOSE>-WW=4*8)/--D@4%F:?)U%*^G+AN?V0O:Z3H5U+T MS4IQ@59Z%54&2V#RK8!REH2@N@N)M%@135/,^+:U3K>[=M^^.=_KQ&X%G2NV M23+?)%E0D UWQ!YT^L-ZM0>5VH/6B#XK)2[O].([I9G\;.!8OWAO&<-D#O)5 M+D5?HUV[)[S6S7K-O4#^CX5:F#\0+MA"=7#T*&*ILH@Q08^YHN,7Z!_))_0J M_'12!@\.'FUG.]="JAH3U]NW\0]MY*=/=]\HJ"'J>_6!]:K >JV!U=,%L\G1 M/F)#>W5;:,>T\ M9T?:))MOE"THV?:RIM?PNG'<;:#=TP)M-FO:!VW*FE;4V5J:9/.-L@4EVR]9 MT_#)[6RK",Z?E!& 1*<7$-I'.EL+HR4$HVR!4U-$Z#5L*YUM%<'YDS+"GA1F M,^^W*@CMJ+/5-EI#,,H6.(=5!*_C-*BMJ@C[+=OMKW-T-_KUF*H)1R*&K?IS MM6.#C#"4-+G"X.?=N8%)X7'H@D@\*,+%3=6;E2+"F=NIJH MO5,LSX#-];$&E[NCS94Q3HMT,49S4/ MF,T3PE$*,SEU9?/Y]_20( 'L% 9 >&PO=V]R:W-H965T MQD;5AE>U9L M.A:JBR?)3?OWHV3'2[NFZTLL43R'/&3(Z4:;!ULC.GB20ME95#O77,2Q+6J4 MS)[H!A6]5-I(YNAJUK%M#+(R@*2(T]'H-):,JRB;!MO29%/=.L$5+@W85DIF MGN?,->SV?/5VAAPR]L.M^S201%:YV6 M/9@RD%QU7_;4UV$'D)SN :0]('T-V!=AW /&'P5,>L D5*:3$NJ0,\>RJ=$; M,-Z;V/PA%#.@23Y7ONVWSM K)YS+?FB'< Z?X$HV0C\CPAP55MS!4C %ASDZ MQH6%.WQR+1-'Y'E_F\/AP1$< %=P5^O6,E7::>PH'4\:%WWH>1%: M*U=;N%(EEB\)8M(QB$FW8N;INXPY%B/WE$S M'EHS#GR3O7P564I84)$,7[5A3GQ7CK?-,I!S6QCT+S2S+STOI6Z5>ZLM7=C/ M(:Q?"X\9I?NX6Z?_>N3_>B1?S@>?3F^\\[>4:-9AO"T4/J^NJ8-UV""787!> MV>>T6;I%\)>F6TO7S*RYLB"P(LK1R1EE9+I1[RY.-^'/O]*.1BD<:]J.:+P# MO5>:!J"_^ ##OLW^ %!+ P04 " 04'M6V4+WEAT# "Z"@ &0 'AL M+W=OSNTG:OV?6=DU2N2:5\I)XUW/.SIP9S\YHI\UONT9T M<".%LN-@[5Q^'H8V7:-DMJ-S5/1FJ8UDCI9F%=K<(,L*D!1A'$7#4#*N@LFH MV%N8R4AOG. *%P;L1DIF;B]0Z-TXZ 9W&U_X:NW\1C@9Y6R%5^B^Y0M#J[!F MR;A$9;E68' Y#J;=\V3H[0N#[QQW=N\9?"376O_VBP_9.(B\0R@P=9Z!T=\6 M9RB$)R(W_E2<07VD!^X_W[&_*V*G6*Z9Q9D6/WCFUN/@=0 9+ME&N"]Z]QZK M> :>+]7"%K^PJVRC -*-=5I68/) ODRAEZRPGG M)I^T0W@#+V&FI>2.*L!98"JCM7).@/>Z!3QN@,^/AS>=GAP/CUK$Z-4)[A5\_0?X M/N=HF,\D?$3ZH,X@N:$>8['!LXM6)M^QSFW.4AP'U)(LFBT&DV=/NL/H;9/( M)=F@(//=:CLA-;;[.I86W7C?I'//*/F/T8$F_5J3?JLFB9(,KMB*6;>1"-L. M+.RM[\"8\=12Z9M<>]&HD?V\1'F-YE>37*V'/%:N4Y+-3TF6G(CL(%.#.E.# MUDQ]Y(ZORDS0E>4$^@9U!E.I-\K!=,<,M0QP&CZ[-1I8,.-NFU(U:*JB^+#4 M9JVN/#8%IR1+3D1VD()AG8)A>PJTM7NWP2U,T]30%7#F^[7O*Q=,,)4V-I16 MYL=^(:6LH=[E[1$LRJF(PNIK^3R;JMWZP%L6LP=]_9G-)B5 M<]0_FG*JNV1FQ94%@4NBC#JOJ&Y,.2F5"Z?S8A2XUHX&B^)Q3<,E&F] [Y>: MQH%JX0^HQ]7)7U!+ P04 " 04'M6T.*W;+@" #M!P &0 'AL+W=O MQ,;RGD@YHA:EB5C*M^ M,-.ZN@A#E<^P)*HE*N3F9B)D2;39RFFH*HFD<*"2A4D4G84EH3Q(>^YL)-.> MF&M&.8XDJ'E9$KD>(!/+?A 'CP=C.IUI>Q"FO8I,\0;U;3629A<".C6@ MXY3QJ3@=,J))VI-B"=):&S:[<&(ZM$F?3O5";2*Q?&%> M>QUXK\D>KW$"UX+KF8(K7F#QE" T*31Y)(]Y#)*#C!GF+6C'IY!$2;(CH.'S MX?$.>/9\>'0@FW;S*FW'U]G#M_46IW#GZA<+N%R8FRE"1E4NYES#F&AS/T*9 M(]>[7L)[BGT!V"ZP2*-6U#[OA8M-?0X&9)O/A:I(COW =!>%Z)QM]&X^S*-KU9F#BG<)9]GZFZ47[Q5>MXB3C9-6EM& MV3^,?!KA1B,L44[=0%'@OA3?2YK39F9=NE:]=3XPL\R/GK\T?A!>$SFE7 '# MB:&,6N]-8-(/%[_1HG+M]EYHT[S=F,=-!,^_0-02P,$ M% @ $%![5AO,[?8' P ]0H !D !X;"]W;W)K&ULG99K;YLP&(7_BL6JJ976\S$4Q-1W+"LP8D\2(QGG;C$=CEDE*$IAQ)+(XQOSY$BC; M30S;>&FX)>N-U UF-$[Q&NY /J0SKFIFY;(D,22"L 1Q6$V,;_9H:N>"O,WM$3BEP'FOP"T%;AZT(,MC76&)HS%G.\1U;^6F"_GC7TP"LBUTCGZGP+$DR1I=@YH7H9INL,PXD415V*IH1M<$ MSPDM&D^O0&)"Q9GJ^W!WA4Y/SM )(@FZW[!,X&0IQJ94D'HH(0N7G*KU5MI%M MN][8W-91>ZWU!AV)%"]@8J@=*(!OP8@^?[(#ZVL/N%N!NX? O2[P0A74P:W M;H#W6A\)[E7@WB%POPO<:X'[OMO@[G4^DMNON/U#W$$7M]_B]@*KP=WK?"1W M4'$'O=SW3&**:+ZY4_RLCFC9N6V#5@[7L<)&D-ZAC@PRJ((,>H-<@Q C=?I( M4-ZR*\*@%>'<<9MKJ'>0(R.$582P-\),6R82;3'-0)^YQ=]"7\_XMO7Z M4;3ZEQ)+UN=J'<4?12Y]WS /W>8N*7O5H9TPM/90US[E]N&=W$EEM\=KKY!^ M]X\N$;-V)]$7PAO,UR01:AI7RMZZ&"@:7MRQBHID:7Y-F3.I+CUY<:/NIJ[>Z].-T+!YP$%7#6=II6N@]_-E "A/J"-'=O$AX\OQGL/\-@ M?+FC[(6O"1'H+8X2?M59"[&YZ':YOR8QYF=T0Q)Y9DE9C(7<9:LNWS""@]0H MCKJ680R[,0Z3SN0R/?; )I=T*Z(P(0\,\6T<8_9^32*ZN^J8G8\#C^%J+=2! M[N1R@U?DB8COFPU3$+S,F, M1G^$@5A?=<8=%) EWD;BD>X\DE_00/%\&O'T%^WRMD8'^5LN:)P;RPCB,,G^ M\5O>$24#L_>)@94;6'6#_B<&O=R@=ZQ!/S?HUPV&GQ@,Q MQ=&IM/S^9*.3+Z?H"PH3]+RF6RXQ_+(K9'S*2]?/8W&R6*Q/8C$M=$<3L>;( M20(2- \/6 XU@"ZLF>*[K$^NN?:TA+O\#LRS*_(,BRC(9Z9WMHF_ADR+&5N MGC>8VWKS>U^*O!?'Z\N=E@[AYOWM1UWC%=UV_JNLI M]@J=]U)>_Q/>32(((UP@YTVF?4Z^HFD7A!V%]- M:M#RVZH!$F9#PAQ(V!P2YD+"/"!818N#0HL#O189]0D).%HR&J,;SK?R 4L0 M7:);FJR^R?P4IP]A36H:'-QMEFD8U?MMIHVBK<@@84X&&Y;"K\4^_]<6;E,7 MC,U:R@&*NC+,PV*8A]IAOI:CJ@9U&A,6^AC=$LQ5&:5*JQG>A')HBX2#_D;. MSVVX4;655 %.RL56N=6M=**@,T:"4)^PM-&U35B0,!L2YD#"YI P%Q+F <$J M2AX52AY!U4Q:4%O1C0YN<=FRGN9L2)?.Z"#O'!1#D/Y<2)@'!*MH9%QH9*S5 M2/K6>)-PP;8J9TF)J,?82?H:=MJD%"VNK5+TL0T-%*>O@TW)"#(.!Q(VAX2Y MD# /"%81VGDAM/-V0BNRTR,6,C4]"?D7H ?"?'D:KTB3^+0NVHHO@YEFN5@Y M,WJCVBN2#>G4@83-(6$N),P#@E649AK[.3'COZ[4]1[:2@V49H/2'%#:')3F M@M*\G%8I3"RK5)A4Y5::@C6U3:^VDIB6VEIBD#0;E.;DM')Y-JK7 M@_.\T4#7R 6-RX.B575C[75C:763*N7Y&*5H.:V5 DFS06E.3BN+8'BH%$B7 M+BC-@Z)5);6?)3?UT^1U2?V1?ON3==7TE3!95-6K+BH/H^^!_><)4_]]XF BY5K> QP] MI4N?D)3K#\Q"O(C(YRD7]!,#*,W.:?4D:=:_2CN@;N>@-!>4YD'1,KUU2VN- M9!9=I>O../+I-A'9NIKB:+&V;9JNZ*H==\P+-UNAML=D"^;N,%N%"4<164JD M<3:2-PS+UJ!E.X)NTA5-"RH$C=/-M10O8:J!/+^D5'SL* ?%2L#)/U!+ P04 M " 04'M6(U*(GNH" !E"@ &0 'AL+W=OVJ8M:R,!'=HDV! =VXMI+]STTE@D=K#= M%K[]SDG( @U95R'>)'9\=_[_SA?K1FLA;U4,H,E]FG UMF*MLV/;5F$,*55' M(@..*Y&0*=4XE0M;91+H/'=*$]MS'-].*>-6,,J_780T66BK\7Z,Y0\/1,O%(G*GV1=VCH6"9=* MB[1T1@4IX\6;WI=YJ#FXW1<6YR;Z1AW)SB5$M<9>BG@Z]" W%=G%=I-L9#FRP2(B J?:\CH0[&Z/P%-6:(^H-W-=$+V]SZ0/<(X^1Z+I<+@ M:F1K5&WVML-2X6FAT'M!X03"(])Q#XCG>%Z#^]GV[NY3=QMS527,JQ+FY?&Z M+\2[ *7P8*1$8)()F1Q%!OZ-9D= MI_<,I;.!TAL.FTFZ%4FWE>13I?I"4%XO6?+K$M(9R-]-:EN#F@OT6&4TA+&% M-Z0"N0(K>/_.]9V/377X2L&>\/?C6%^%PXY+;K.!64?^+;->: -. 75*Y8%R1!"(,[QSU48LLFIIB MHD66]P4SH;'+R(A:32R MTI-J$291=!+6C,L@&_NU:YV-54N"2[S68-JZ9OK/%(5:3H(X>%JXX?.*W$*8 MC1LVQUND^^9:VUDXJ)2\1FFXDJ!Q-@G.X[,\=7@/^,EQ:=;&X)P\*/7H)I?E M)(A<0BBP(*? [&>!%RB$$[)I_.XU@R&D(ZZ/G]2_>N_6RP,S>*'$+UY2-0D^ M!E#BC+6";M3R&_9^CIU>H83QO[#LL*X(\Z[*SX<\@9L6RLU1*T0ULU-_"'Z=G6/I?NVF]) MVUUN>91]5X00)_ !?E"%&BYEH6J$_2\K^[ ,'L!^CL2X,'"'*VJ9.+#0^]L< M]O<.8 ^XA+M*M8;)THQ#L@DYV;#H@T^[X,F6X#;NE9)4&?@B2RR?"X36R6 G M>;(S3=Y4S+$X@E%\"$F4)!L2NMB='F^@Y[O3HS?I234: CZ MVSB$.T5,;#KH3NC8"[E27V0CZW^Q;OTU)/WT')*_AIP>#Y!G%M+!0KJ;A>YA M'7;/;).#]%7LZ(6!_R+R-W-Q'?3,-*S 26!;I$&]P"![_RX^B3YONJQPK:IJ MU'/?G0P4JI74OU967< -]0$ $$ 9 >&PO=V]R:W-H965T0(*Z26E!JS32=@N"AX6JY?+L)I/$6L<.]J0I?[^VDX8BT7U) M/.,Y9\Y#<2&7744W4WC%F\QH;;F>Z1>5N2FT:3LXT%;.M05X$ M4"-9,I^O6,.%BK(T^'8F2W5'4BC<&;!=TW#S9X-2]^LHCBZ.O:AJ\@Z6I2VO M\(#TH]T99[&)I1 -*BNT H/E.KJ/[S8+'Q\"?@KL[=49?"5'K9^\\:581W,O M""7FY!FX^YWP :7T1$[&[Y$SFE)ZX/7YPOXIU.YJ.7*+#UK^$@75Z^A#! 66 MO).TU_UG'.M9>KY<2QN^T ^QRV4$>6=)-R/8*6B$&O[\//;A"A"O;@"2$9 $ MW4.BH'++B6>IT3T8'^W8_"&4&M!.G%!^* 6VU(J I>;9&XD!:^XYDZ+E^GC%QNS\#R,<]FR)/ " !&"0 &0 'AL+W=O^0)@$!/>4;X4$N$**YT MG4<)Y)A?T *(W%E0EF,AIVRI\X(!CBM0GNF687AZCE.B^8-J[8'Y UJ*+"7P MP! O\QRSYQ%D=#W43.UE89(N$Z$6=']0X"6$(&;% Y,SO66)TQP(3RE!#!9# M[=J\"GHJO@KXD<*:;XR1RF1.Z:.:W,5#S5""((-(* 8L7RNX@2Q31%+&WX93 M:X]4P,WQ"_NW*G>9RQQSN*'9SS06R5#K:RB&!2XS,:'K[]#DXRJ^B&:\>J)U M$VMH*"JYH'D#E@KRE-1O_-3480-@>GL 5@.P=@'.'H#= .SW IP&X%25J5.I MZA!@@?T!HVO$5+1D4X.JF!5:II\297LHF-Q-)4[X]U0 ,FUTCD8EEWN!)E!0)E*RE)L36 $I #S<.9&.WEMD5G[.'K_&BL[(UTJV0ZHM? M^99K.?+4U6:Z'5'.I7&Y'15T1)FV]\JU)=YIQ3L'Q<_N[Z:W 0JGU]/;L"N# M@W#U$[SB!8Y@J,F_' >V LW__,GTC*]=OAZ3+#@2V5;9W+9L[H<]KY'>EION MKILW'5&VVW=V/'\;95XZ?:_;OXTQ;LAHF\Z !3 7)_064O:R;J@/;JY/\#4$L#!!0 ( !!0>U:? MPVQZP0( %X) 9 >&PO=V]R:W-H965T^B$RBX/TQY,C^_8Z=-(,N("HA M+0^)CWV^[]P<'P\W4CWH#,"0IYP+/?(R8XIKW]=)!CG5'5F P)6E5#DU**J5 MKPL%-'6@G/M1$ S\G#+AQ4,W-U/Q4):&,P$S1729YU3]O@4N-R,O])XG[MDJ M,W;"CX<%7<$&A,;R4+* M!RM\3D=>8!T"#HFQ#!0_:Q@#YY8(W7BL.;W&I 5NCY_9/[K8,98%U3"6_ =+ M33;RKCR2PI*6W-S+S2>HXW$.)I)K]R:;2G> RDFICS(O%QH>2Q"&3-?V?38!0QG7Y"L\F9+R M'C8 I\>#P\.)*/;5++K^'I[ M^,8RS_'/FQN9/%R0"5NS%$2J+\@,%)G;FN$L)!P'*3EC@J22HZ!)@>NNIN-&I/L6M=T 1&'AY3&M0:O/C=FW 0?&BK1T5VY@?K7EY2#5:_-R2K+)*_J4?_?^SH?MO^N@QVGA=[&&5Z 0%D%7%]*;%FU8 TT5ZKX#U!+ P04 " 04'M6L0+MNCT# M #L$P #0 'AL+W-T>6QEUY-B9X[)VOWZ^=II^X(LZ'K:R5#3V/3[G'MLWQ#"HS4JP MNSEC)EJ60M9#,C>F^A#']73.2EI?J(I)BQ1*E]38KI[%=:49S6L@E2+N=3II M7%(NR6@@%^5-:>IHJA;2#$G:AB)_^YP/23=]3R(O-U8Y&Y*'L[<_%LI3=R4GGX?QZ/W[F@',2!T4O#Q"]Z'1P80 Q\?0P\>>T,>FK76DW_-0*>>(I M1NL':#;+A@D=C)P=-)UG9N.$XV:W1X-"R\"Z!P:Y M$*W!'O&!T:"BQC M;VS'#7;!)U#4M.]7E74XTW35[5V2#<'=;)*)TCG3;9HN M68=& \$*L*/Y; YWHZH80&-4:1LYIS,EJ?.P9C0-*SME0MS!4_J]V-%>%EM[ MVH$=E6W3&FJ:7L9W0'];S6MORR8OTHTJ_JC,IX6=CG1]J!5VJUG!EZZ_+%H# MF'H75Z=5)58?!9_)DOG)'YQP-*!K7C17FO^RV:!4IC; -(D>F39\NAWYJ6EU MSY9F74[+ O?<>X6>_^XZSYADFHIMT[;VCWF57^RX>:W]"\_NU\J^XZ#)Y.KX M/3:O\F,WF1Z_R20[?H_- >C83?9?@\GCW.ZX.61LG61VSC%M-(+SXI!\@Y.I MV"2-)@LN#)=-;\[SG,DGQQDK;^C$_BFSHV_'YZR@"V'N6W!(-NVO+.>+,FM' MW<)"-*,V[2\PO6[:'E9M+BYSMF3YN.GJV<0U(]NP69L+"/O(C;O"",;Q6!@! M#,N#.< XGH7E^9_FTT?GXS',6S^(]%%.'^5X5@@9NP^6)\S)[!6>:98E29IB M*SH>!QV,L75+4_@)JV'>@('E@4Q_MM;X;N,5\GP=8'OZ7(5@,\4K$9LIOM: MA-<-&%D6WFTL#S"P7<.>8!S),@R!6@S7:)HBJY/" M)[P_V%.2)%D61@ +.T@2#(&G$4U:7BKL

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

U;I MUEY0E00 -LE / " 20- 0!X;"]W;W)K8F]O:RYX;6Q0 M2P$"% ,4 " 04'M6##^0_.4! !_(0 &@ @ 'F$0$ M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 04'M6C^&W M:=,! V(0 $P @ $#% $ 6T-O;G1E;G1?5'EP97-=+GAM 7;%!+!08 0 ! '<1 '%@$ ! end XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 145 318 1 true 49 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.psychemedics.com/20221231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity Consolidated Statements of Shareholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals) Sheet http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals Consolidated Statements of Shareholders' Equity (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows Sheet http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Nature of Business Sheet http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business Note 1 - Nature of Business Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Accounts Receivable Sheet http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable Note 3 - Accounts Receivable Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Accrued Expenses Sheet http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses Note 4 - Accrued Expenses Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Income Taxes Sheet http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes Note 5 - Income Taxes Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Preferred Stock Sheet http://www.psychemedics.com/20221231/role/statement-note-6-preferred-stock Note 6 - Preferred Stock Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Stock-based Awards Sheet http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards Note 7 - Stock-based Awards Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Employee Benefit Plan Sheet http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan Note 8 - Employee Benefit Plan Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Commitments and Contingencies Sheet http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies Note 9 - Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Operating Leases Sheet http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases- Note 10 - Operating Leases Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Debt and Other Financing Arrangements Sheet http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements Note 11 - Debt and Other Financing Arrangements Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Other Income (Expense) Sheet http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense Note 12 - Other Income (Expense) Notes 19 false false R20.htm 019 - Disclosure - Note 13 - Business Segment Reporting Sheet http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting Note 13 - Business Segment Reporting Notes 20 false false R21.htm 020 - Disclosure - Note 14 - Subsequent Event Sheet http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event- Note 14 - Subsequent Event Notes 21 false false R22.htm 021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies 22 false false R23.htm 022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies 23 false false R24.htm 023 - Disclosure - Note 3 - Accounts Receivable (Tables) Sheet http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-tables Note 3 - Accounts Receivable (Tables) Tables http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable 24 false false R25.htm 024 - Disclosure - Note 4 - Accrued Expenses (Tables) Sheet http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-tables Note 4 - Accrued Expenses (Tables) Tables http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses 25 false false R26.htm 025 - Disclosure - Note 5 - Income Taxes (Tables) Sheet http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables Note 5 - Income Taxes (Tables) Tables http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes 26 false false R27.htm 026 - Disclosure - Note 7 - Stock-based Awards (Tables) Sheet http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables Note 7 - Stock-based Awards (Tables) Tables http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards 27 false false R28.htm 027 - Disclosure - Note 10 - Operating Leases (Tables) Sheet http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-tables Note 10 - Operating Leases (Tables) Tables http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases- 28 false false R29.htm 028 - Disclosure - Note 11 - Debt and Other Financing Arrangements (Tables) Sheet http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-tables Note 11 - Debt and Other Financing Arrangements (Tables) Tables http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements 29 false false R30.htm 029 - Disclosure - Note 13 - Business Segment Reporting (Tables) Sheet http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-tables Note 13 - Business Segment Reporting (Tables) Tables http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting 30 false false R31.htm 030 - Disclosure - Note 1 - Nature of Business (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business-details-textual Note 1 - Nature of Business (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business 31 false false R32.htm 031 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables 32 false false R33.htm 032 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details) Details 33 false false R34.htm 033 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details) Details 34 false false R35.htm 034 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details) Details 35 false false R36.htm 035 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details) Details 36 false false R37.htm 036 - Disclosure - Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details) Details 37 false false R38.htm 037 - Disclosure - Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details) Details 38 false false R39.htm 038 - Disclosure - Note 5 - Income Taxes (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual Note 5 - Income Taxes (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables 39 false false R40.htm 039 - Disclosure - Note 5 - Income Taxes - Summary of Income Tax Provision (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details Note 5 - Income Taxes - Summary of Income Tax Provision (Details) Details 40 false false R41.htm 040 - Disclosure - Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details) Details 41 false false R42.htm 041 - Disclosure - Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details) Details 42 false false R43.htm 042 - Disclosure - Note 7 - Stock-based Awards (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual Note 7 - Stock-based Awards (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables 43 false false R44.htm 043 - Disclosure - Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details) Details 44 false false R45.htm 044 - Disclosure - Note 7 - Stock-based Awards - Stock Option Activity (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details Note 7 - Stock-based Awards - Stock Option Activity (Details) Details 45 false false R46.htm 045 - Disclosure - Note 7 - Stock-based Awards - Nonvested Award Activity (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details Note 7 - Stock-based Awards - Nonvested Award Activity (Details) Details 46 false false R47.htm 046 - Disclosure - Note 8 - Employee Benefit Plan (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan-details-textual Note 8 - Employee Benefit Plan (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan 47 false false R48.htm 047 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual Note 9 - Commitments and Contingencies (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies 48 false false R49.htm 048 - Disclosure - Note 10 - Operating Leases (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-details-textual Note 10 - Operating Leases (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-tables 49 false false R50.htm 049 - Disclosure - Note 10 - Operating Leases - Maturities of Lease Liabilities (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details Note 10 - Operating Leases - Maturities of Lease Liabilities (Details) Details 50 false false R51.htm 050 - Disclosure - Note 11 - Debt and Other Financing Arrangements (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual Note 11 - Debt and Other Financing Arrangements (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-tables 51 false false R52.htm 051 - Disclosure - Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) Details 52 false false R53.htm 052 - Disclosure - Note 12 - Other Income (Expense) (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense-details-textual Note 12 - Other Income (Expense) (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense 53 false false R54.htm 053 - Disclosure - Note 13 - Business Segment Reporting (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-details-textual Note 13 - Business Segment Reporting (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-tables 54 false false R55.htm 054 - Disclosure - Note 13 - Business Segment Reporting - Revenue by Major Source (Details) Sheet http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details Note 13 - Business Segment Reporting - Revenue by Major Source (Details) Details 55 false false R56.htm 055 - Disclosure - Note 14 - Subsequent Event (Details Textual) Sheet http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-details-textual Note 14 - Subsequent Event (Details Textual) Details http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event- 56 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept TreasuryStockShares in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. pmd20221231_10k.htm 35, 36 [dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 26 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. pmd20221231_10k.htm 76, 88, 98, 109, 3828, 3830, 3832, 3833, 3834, 3835, 3836, 3837, 3838, 3839, 3840, 3841, 3842, 3843, 3844, 3845, 3846, 3847, 3848, 3849 [dq-0542-Deprecated-Concept] Concept LondonInterbankOfferedRateLIBORMember in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. pmd20221231_10k.htm 4737 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 238 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, pmd:DeferredTaxLiabilitiesExcessOfTaxOverBookDepreciationAndAmortization, pmd:DeferredTaxLiabilitiesOperatingLease, pmd:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseBenefitSharebasedCompensationCostPercent, pmd:EffectiveIncomeTaxRateReconciliationPermanentDifferences, pmd:IncomeTaxReconciliationForeignIncomeTaxWitholdings, pmd:IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes, pmd:IncreaseDecreaseInOperatingLeaseLiabilities, pmd:NumberOfMajorCustomers, pmd:OtherNonoperatingExpenseSettlement, pmd:PaymentsForProceedsFromOtherAssets, pmd:PaymentsOfEquipmentFinancing, pmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeriod, pmd:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod, us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax, us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation, us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent, us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs, us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect, us-gaap:CashEquivalentsAtCarryingValue, us-gaap:CommonStockDividendsPerShareDeclared, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:ComprehensiveIncomeNetOfTax, us-gaap:CurrentFederalTaxExpenseBenefit, us-gaap:CurrentForeignTaxExpenseBenefit, us-gaap:CurrentStateAndLocalTaxExpenseBenefit, us-gaap:DeferredFederalIncomeTaxExpenseBenefit, us-gaap:DeferredIncomeTaxExpenseBenefit, us-gaap:DeferredIncomeTaxLiabilities, us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit, us-gaap:DeferredTaxAssetsValuationAllowance, us-gaap:DeferredTaxLiabilitiesPrepaidExpenses, us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount, us-gaap:DividendsCommonStockCash, us-gaap:EarningsPerShareBasic, us-gaap:EarningsPerShareDiluted, us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree, us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo, us-gaap:GainsLossesOnExtinguishmentOfDebt, us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, us-gaap:IncomeTaxExpenseBenefit, us-gaap:IncreaseDecreaseInAccountsPayable, us-gaap:IncreaseDecreaseInAccountsReceivable, us-gaap:IncreaseDecreaseInDeferredIncomeTaxes, us-gaap:IncreaseDecreaseInIncomeTaxesReceivable, us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets, us-gaap:InterestIncomeOther, us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount, us-gaap:LongTermDebtCurrent, us-gaap:NetCashProvidedByUsedInFinancingActivities, us-gaap:NetCashProvidedByUsedInInvestingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetIncomeLoss, us-gaap:NonoperatingIncomeExpense, us-gaap:NumberOfOperatingSegments, us-gaap:OperatingIncomeLoss, us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent, us-gaap:OtherNonoperatingIncomeExpense, us-gaap:PaymentsOfDividendsCommonStock, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ProceedsFromIssuanceOfCommonStock, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:RetainedEarningsAccumulatedDeficit, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2, us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised, us-gaap:StockholdersEquity, us-gaap:TreasuryStockShares, us-gaap:TreasuryStockValue - pmd20221231_10k.htm 8, 10, 13, 14, 15, 16, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250 pmd20221231_10k.htm ex_490004.htm ex_490005.htm ex_490006.htm ex_490007.htm ex_490008.htm ex_490009.htm ex_490010.htm ex_492590.htm ex_492591.htm ex_492598.htm pmd-20221231.xsd pmd-20221231_cal.xml pmd-20221231_def.xml pmd-20221231_lab.xml pmd-20221231_pre.xml perf_graph.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "pmd20221231_10k.htm": { "axisCustom": 0, "axisStandard": 22, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 679, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 145, "dts": { "calculationLink": { "local": [ "pmd-20221231_cal.xml" ] }, "definitionLink": { "local": [ "pmd-20221231_def.xml" ] }, "inline": { "local": [ "pmd20221231_10k.htm" ] }, "labelLink": { "local": [ "pmd-20221231_lab.xml" ] }, "presentationLink": { "local": [ "pmd-20221231_pre.xml" ] }, "schema": { "local": [ "pmd-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 467, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 203, "http://www.psychemedics.com/20221231": 35, "http://xbrl.sec.gov/dei/2022": 6, "total": 244 }, "keyCustom": 37, "keyStandard": 281, "memberCustom": 20, "memberStandard": 28, "nsprefix": "pmd", "nsuri": "http://www.psychemedics.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 3 - Accounts Receivable", "menuCat": "Notes", "order": "10", "role": "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable", "shortName": "Note 3 - Accounts Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 4 - Accrued Expenses", "menuCat": "Notes", "order": "11", "role": "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses", "shortName": "Note 4 - Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 5 - Income Taxes", "menuCat": "Notes", "order": "12", "role": "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "shortName": "Note 5 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 6 - Preferred Stock", "menuCat": "Notes", "order": "13", "role": "http://www.psychemedics.com/20221231/role/statement-note-6-preferred-stock", "shortName": "Note 6 - Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 7 - Stock-based Awards", "menuCat": "Notes", "order": "14", "role": "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "shortName": "Note 7 - Stock-based Awards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 8 - Employee Benefit Plan", "menuCat": "Notes", "order": "15", "role": "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan", "shortName": "Note 8 - Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 9 - Commitments and Contingencies", "menuCat": "Notes", "order": "16", "role": "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies", "shortName": "Note 9 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 10 - Operating Leases", "menuCat": "Notes", "order": "17", "role": "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-", "shortName": "Note 10 - Operating Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 11 - Debt and Other Financing Arrangements", "menuCat": "Notes", "order": "18", "role": "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "shortName": "Note 11 - Debt and Other Financing Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 12 - Other Income (Expense)", "menuCat": "Notes", "order": "19", "role": "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense", "shortName": "Note 12 - Other Income (Expense)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 13 - Business Segment Reporting", "menuCat": "Notes", "order": "20", "role": "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting", "shortName": "Note 13 - Business Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 14 - Subsequent Event", "menuCat": "Notes", "order": "21", "role": "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-", "shortName": "Note 14 - Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "pmd:RisksAndUncertaintiesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "22", "role": "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "pmd:RisksAndUncertaintiesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 3 - Accounts Receivable (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-tables", "shortName": "Note 3 - Accounts Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 4 - Accrued Expenses (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-tables", "shortName": "Note 4 - Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 5 - Income Taxes (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables", "shortName": "Note 5 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 7 - Stock-based Awards (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables", "shortName": "Note 7 - Stock-based Awards (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 10 - Operating Leases (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-tables", "shortName": "Note 10 - Operating Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 11 - Debt and Other Financing Arrangements (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-tables", "shortName": "Note 11 - Debt and Other Financing Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 13 - Business Segment Reporting (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-tables", "shortName": "Note 13 - Business Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "pmd:IncomeTaxBenefitCARESAct", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 1 - Nature of Business (Details Textual)", "menuCat": "Details", "order": "31", "role": "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business-details-textual", "shortName": "Note 1 - Nature of Business (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "pmd:IncomeTaxBenefitCARESAct", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "menuCat": "Details", "order": "32", "role": "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details)", "menuCat": "Details", "order": "33", "role": "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details)", "menuCat": "Details", "order": "34", "role": "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ProductOrServiceAxis-TestingMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pmd:ScheduleOfStockBasedCompensationExpenseTableTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details)", "menuCat": "Details", "order": "35", "role": "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pmd:ScheduleOfStockBasedCompensationExpenseTableTextBlock", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details)", "menuCat": "Details", "order": "36", "role": "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details)", "menuCat": "Details", "order": "37", "role": "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details", "shortName": "Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details)", "menuCat": "Details", "order": "38", "role": "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details", "shortName": "Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 5 - Income Taxes (Details Textual)", "menuCat": "Details", "order": "39", "role": "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual", "shortName": "Note 5 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 5 - Income Taxes - Summary of Income Tax Provision (Details)", "menuCat": "Details", "order": "40", "role": "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details", "shortName": "Note 5 - Income Taxes - Summary of Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details)", "menuCat": "Details", "order": "41", "role": "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details", "shortName": "Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details)", "menuCat": "Details", "order": "42", "role": "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details", "shortName": "Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2020-11-11", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 7 - Stock-based Awards (Details Textual)", "menuCat": "Details", "order": "43", "role": "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual", "shortName": "Note 7 - Stock-based Awards (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2020-11-11", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_AwardDateAxis-November112020Member", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details)", "menuCat": "Details", "order": "44", "role": "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details", "shortName": "Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 7 - Stock-based Awards - Stock Option Activity (Details)", "menuCat": "Details", "order": "45", "role": "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details", "shortName": "Note 7 - Stock-based Awards - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-StockUnitAwardMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 7 - Stock-based Awards - Nonvested Award Activity (Details)", "menuCat": "Details", "order": "46", "role": "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details", "shortName": "Note 7 - Stock-based Awards - Nonvested Award Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-StockUnitAwardMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 8 - Employee Benefit Plan (Details Textual)", "menuCat": "Details", "order": "47", "role": "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan-details-textual", "shortName": "Note 8 - Employee Benefit Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)", "menuCat": "Details", "order": "48", "role": "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual", "shortName": "Note 9 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2021-12-06_2021-12-06_LitigationCaseAxis-EnmaSagastumeVPsychemedicsCorporationMember", "decimals": "-5", "lang": null, "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 10 - Operating Leases (Details Textual)", "menuCat": "Details", "order": "49", "role": "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-details-textual", "shortName": "Note 10 - Operating Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Shareholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity", "shortName": "Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 10 - Operating Leases - Maturities of Lease Liabilities (Details)", "menuCat": "Details", "order": "50", "role": "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details", "shortName": "Note 10 - Operating Leases - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 11 - Debt and Other Financing Arrangements (Details Textual)", "menuCat": "Details", "order": "51", "role": "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual", "shortName": "Note 11 - Debt and Other Financing Arrangements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2020-05-01_2020-05-01_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details)", "menuCat": "Details", "order": "52", "role": "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details", "shortName": "Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "i_2022-12-31_LongtermDebtTypeAxis-EquipmentLoanArrangementMember", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 12 - Other Income (Expense) (Details Textual)", "menuCat": "Details", "order": "53", "role": "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense-details-textual", "shortName": "Note 12 - Other Income (Expense) (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:InterestIncomeOther", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 13 - Business Segment Reporting (Details Textual)", "menuCat": "Details", "order": "54", "role": "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-details-textual", "shortName": "Note 13 - Business Segment Reporting (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 13 - Business Segment Reporting - Revenue by Major Source (Details)", "menuCat": "Details", "order": "55", "role": "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details", "shortName": "Note 13 - Business Segment Reporting - Revenue by Major Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_StatementGeographicalAxis-US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2023-03-21_2023-03-21_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 14 - Subsequent Event (Details Textual)", "menuCat": "Details", "order": "56", "role": "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-details-textual", "shortName": "Note 14 - Subsequent Event (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2023-03-21_2023-03-21_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)", "menuCat": "Statements", "order": "6", "role": "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "shortName": "Consolidated Statements of Shareholders' Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "pmd:DepreciationAndAmortizationExcludingRouAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "pmd:DepreciationAndAmortizationExcludingRouAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 1 - Nature of Business", "menuCat": "Notes", "order": "8", "role": "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business", "shortName": "Note 1 - Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pmd20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 49, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information", "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business", "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-tables", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-tables", "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense", "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-tables", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-tables", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-tables", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables", "http://www.psychemedics.com/20221231/role/statement-note-6-preferred-stock", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables", "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan", "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r481", "r482", "r483" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information", "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business", "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-tables", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-tables", "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense", "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-tables", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-tables", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-tables", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables", "http://www.psychemedics.com/20221231/role/statement-note-6-preferred-stock", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables", "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan", "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "pmd_AccruedShippingCurrent": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued shipping obligations.", "label": "Accrued shipping expense" } } }, "localname": "AccruedShippingCurrent", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "pmd_April42022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to April 4, 2022.", "label": "April 4, 2022 [Member]" } } }, "localname": "April42022Member", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "pmd_August122022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to August 12, 2022.", "label": "August 12, 2022 [Member]" } } }, "localname": "August122022Member", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "pmd_BancOfAmericaLeasingAndCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Informaiton related to an equipment financing agreement with Banc of America Leasing and Capital LLC.", "label": "Banc of America Leasing and Capital [Member]" } } }, "localname": "BancOfAmericaLeasingAndCapitalMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "pmd_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). In addition, discloses the accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Basis of Presentation and Consolidation, Policy [Policy Text Block]" } } }, "localname": "BasisOfPresentationAndConsolidationPolicyPolicyTextBlock", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "pmd_CapitalizedSoftwareAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to capitalized software and equipment.", "label": "Capitalized Software and Equipment [Member]" } } }, "localname": "CapitalizedSoftwareAndEquipmentMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "pmd_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to customer one.", "label": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "pmd_December162020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to December 16, 2020.", "label": "December 16, 2020 [Member]" } } }, "localname": "December162020Member", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "pmd_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.", "label": "Capitalized research expenses" } } }, "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "pmd_DeferredTaxAssetsOperatingLease": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease.", "label": "pmd_DeferredTaxAssetsOperatingLease", "verboseLabel": "Operating lease" } } }, "localname": "DeferredTaxAssetsOperatingLease", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "pmd_DeferredTaxLiabilitiesExcessOfTaxOverBookDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from excess of tax over book depreciation and amortization.", "label": "pmd_DeferredTaxLiabilitiesExcessOfTaxOverBookDepreciationAndAmortization", "negatedLabel": "Excess of tax over book depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesExcessOfTaxOverBookDepreciationAndAmortization", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "pmd_DeferredTaxLiabilitiesOperatingLease": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from operating lease.", "label": "pmd_DeferredTaxLiabilitiesOperatingLease", "negatedTerseLabel": "Operating lease" } } }, "localname": "DeferredTaxLiabilitiesOperatingLease", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "pmd_DepreciationAndAmortizationExcludingRouAssetAmortization": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of depreciation and amortization expense, excluding amortization expense for right-of-use asset from operating lease.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortizationExcludingRouAssetAmortization", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "pmd_EffectiveIncomeTaxRateReconciliationChangeInTaxRateForCarrybackClaim": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in tax rate for carryback claim.", "label": "Difference in tax rate for carryback claim" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInTaxRateForCarrybackClaim", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details" ], "xbrltype": "percentItemType" }, "pmd_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseBenefitSharebasedCompensationCostPercent": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.", "label": "Stock based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseBenefitSharebasedCompensationCostPercent", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details" ], "xbrltype": "percentItemType" }, "pmd_EffectiveIncomeTaxRateReconciliationPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent differences.", "label": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details" ], "xbrltype": "percentItemType" }, "pmd_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credit (expense).", "label": "pmd_EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent", "negatedLabel": "Federal R&D Credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditExpenseResearchPercent", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details" ], "xbrltype": "percentItemType" }, "pmd_EnmaSagastumeVPsychemedicsCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Enma Sagastume v. Psychemedics Corporation.", "label": "Enma Sagastume v. Psychemedics Corporation [Member]" } } }, "localname": "EnmaSagastumeVPsychemedicsCorporationMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pmd_EquipmentLoanArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the Equipment Loan Arrangement.", "label": "Equipment Loan Arrangement [Member]" } } }, "localname": "EquipmentLoanArrangementMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details" ], "xbrltype": "domainItemType" }, "pmd_IncentivePlan2006Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the 2006 incentive plan.", "label": "Incentive Plan 2006 [Member]" } } }, "localname": "IncentivePlan2006Member", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "domainItemType" }, "pmd_IncomeTaxBenefitCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax benefit related to the CARES Act.", "label": "pmd_IncomeTaxBenefitCARESAct", "terseLabel": "Income Tax Benefit CARES Act" } } }, "localname": "IncomeTaxBenefitCARESAct", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business-details-textual" ], "xbrltype": "monetaryItemType" }, "pmd_IncomeTaxReconciliationForeignIncomeTaxWitholdings": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Foreign taxes, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxWitholdings", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details" ], "xbrltype": "percentItemType" }, "pmd_IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses and income taxes incurred but not yet paid.", "label": "pmd_IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedExpensesAndAccruedIncomeTaxes", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "pmd_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating lease liabilities during the period.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "pmd_January252021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to date.", "label": "January 25, 2021 [Member]" } } }, "localname": "January252021Member", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "pmd_LaboratoryEquipment": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of laboratory equipment held for productive use", "label": "Laboratory equipment" } } }, "localname": "LaboratoryEquipment", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "pmd_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to laboratory equipment.", "label": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details" ], "xbrltype": "domainItemType" }, "pmd_LegalCostCapitalized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of legal costs capitalized.", "label": "pmd_LegalCostCapitalized", "terseLabel": "Legal Cost Capitalized" } } }, "localname": "LegalCostCapitalized", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pmd_LegalCostCapitalizedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents amortization related to legal cost capitalized.", "label": "pmd_LegalCostCapitalizedAmortization", "terseLabel": "Legal Cost Capitalized, Amortization" } } }, "localname": "LegalCostCapitalizedAmortization", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pmd_LegalCostCapitalizedNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the legal cost capitalized, net.", "label": "pmd_LegalCostCapitalizedNet", "terseLabel": "Legal Cost Capitalized, Net" } } }, "localname": "LegalCostCapitalizedNet", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pmd_March162021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to date.", "label": "March 16, 2021 [Member]" } } }, "localname": "March162021Member", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "pmd_May132021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to date.", "label": "May 13, 2021 [Member]" } } }, "localname": "May132021Member", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "pmd_May202022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to May 20, 2022", "label": "May 20, 2022 [Member]" } } }, "localname": "May202022Member", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "pmd_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_November112020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to November 11, 2020.", "label": "November 11, 2020 [Member]" } } }, "localname": "November112020Member", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "pmd_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "pmd_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "pmd_OperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of operating loss carryforwards not subject to expiration.", "label": "pmd_OperatingLossCarryforwardsNotSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Not Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "pmd_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of operating loss carryforwards subject to expiration.", "label": "pmd_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "pmd_OtherAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for other assets.", "label": "Other Assets [Policy Text Block]" } } }, "localname": "OtherAssetsPolicyTextBlock", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "pmd_OtherNonoperatingExpenseSettlement": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as settlement.", "label": "pmd_OtherNonoperatingExpenseSettlement", "negatedLabel": "Settlements" } } }, "localname": "OtherNonoperatingExpenseSettlement", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "pmd_OtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents other revenue sources not otherwise disclosed.", "label": "Other Revenue [Member]" } } }, "localname": "OtherRevenueMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details" ], "xbrltype": "domainItemType" }, "pmd_PaycheckProtectionProgramCaresActMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents loan designed to provide funds for small businesses to keep their employees on the payroll.", "label": "Paycheck Protection Program CARES Act [Member]" } } }, "localname": "PaycheckProtectionProgramCaresActMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "pmd_PaymentsForProceedsFromOtherAssets": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow from other assets.", "label": "pmd_PaymentsForProceedsFromOtherAssets", "negatedLabel": "Other assets" } } }, "localname": "PaymentsForProceedsFromOtherAssets", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "pmd_PaymentsOfEquipmentFinancing": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow in relating to equity financing during the year.", "label": "pmd_PaymentsOfEquipmentFinancing", "negatedLabel": "Payments of equipment financing" } } }, "localname": "PaymentsOfEquipmentFinancing", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "pmd_ProvisionForRecoveriesOfDoubtfulAccounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the provision for (recoveries of) doubtful accounts.", "label": "Provision for doubtful accounts" } } }, "localname": "ProvisionForRecoveriesOfDoubtfulAccounts", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "pmd_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for risks and uncertainties.", "label": "Risks and Uncertainties [Policy Text Block]" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "pmd_ScheduleOfStockBasedCompensationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Stock Based Compensation Expense [Table Text Block]" } } }, "localname": "ScheduleOfStockBasedCompensationExpenseTableTextBlock", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "pmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were converted to common stock during the reporting period.", "label": "pmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeriod", "negatedTerseLabel": "Converted to common stock (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeriod", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details" ], "xbrltype": "sharesItemType" }, "pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.", "label": "pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod", "negatedTerseLabel": "Cancelled (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details" ], "xbrltype": "sharesItemType" }, "pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which the instruments, excluding stock (or unit) options, that were converted to common stock during the reporting period", "label": "Converted to common stock, weighted average price per share (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockWeightedAverageExercisePrice", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details" ], "xbrltype": "perShareItemType" }, "pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of equity instrument other than option.", "label": "pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice", "terseLabel": "Granted, weighted average price per share (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details" ], "xbrltype": "perShareItemType" }, "pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAndNonvestedWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the equity instrument other than option.", "label": "pmd_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAndNonvestedWeightedAverageExercisePrice", "periodEndLabel": "Outstanding & Unvested at end of period, weighted average price per share (in dollars per share)", "periodStartLabel": "Outstanding & Unvested at beginning of period, weighted average price per share (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAndNonvestedWeightedAverageExercisePrice", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details" ], "xbrltype": "perShareItemType" }, "pmd_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to equity instrument other than stock options that were forfeited.", "label": "Forfeited, weighted average price per share (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details" ], "xbrltype": "perShareItemType" }, "pmd_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to equity instrument other than stock options that were cancelled.", "label": "Cancelled, weighted average price per share (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageExercisePrice", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details" ], "xbrltype": "perShareItemType" }, "pmd_ShippingCollectionHairMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to shipping and hair collection services.", "label": "Shipping/Collection (Hair) [Member]" } } }, "localname": "ShippingCollectionHairMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details" ], "xbrltype": "domainItemType" }, "pmd_SoftwareDevelopmentCostCapitalized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The software development cost capitalized as of the balance sheet date.", "label": "pmd_SoftwareDevelopmentCostCapitalized", "terseLabel": "Software Development Cost Capitalized" } } }, "localname": "SoftwareDevelopmentCostCapitalized", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pmd_StockUnitAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to stock unit awards.", "label": "Stock Unit Award [Member]" } } }, "localname": "StockUnitAwardMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "pmd_TestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents testing services.", "label": "Testing [Member]" } } }, "localname": "TestingMember", "nsuri": "http://www.psychemedics.com/20221231", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details" ], "xbrltype": "domainItemType" }, "pmd_statement-statement-note-10-operating-leases-maturities-of-lease-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Operating Leases - Maturities of Lease Liabilities (Details)" } } }, "localname": "statement-statement-note-10-operating-leases-maturities-of-lease-liabilities-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-10-operating-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Operating Leases" } } }, "localname": "statement-statement-note-10-operating-leases-tables", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details)" } } }, "localname": "statement-statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-11-debt-and-other-financing-arrangements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Debt and Other Financing Arrangements" } } }, "localname": "statement-statement-note-11-debt-and-other-financing-arrangements-tables", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-13-business-segment-reporting-revenue-by-major-source-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Business Segment Reporting - Revenue by Major Source (Details)" } } }, "localname": "statement-statement-note-13-business-segment-reporting-revenue-by-major-source-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-13-business-segment-reporting-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Business Segment Reporting" } } }, "localname": "statement-statement-note-13-business-segment-reporting-tables", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details)" } } }, "localname": "statement-statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-3-accounts-receivable-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Accounts Receivable" } } }, "localname": "statement-statement-note-3-accounts-receivable-tables", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-4-accrued-expenses-summary-of-accrued-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details)" } } }, "localname": "statement-statement-note-4-accrued-expenses-summary-of-accrued-expenses-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-4-accrued-expenses-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Accrued Expenses" } } }, "localname": "statement-statement-note-4-accrued-expenses-tables", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details)" } } }, "localname": "statement-statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details)" } } }, "localname": "statement-statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-5-income-taxes-summary-of-income-tax-provision-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Income Taxes - Summary of Income Tax Provision (Details)" } } }, "localname": "statement-statement-note-5-income-taxes-summary-of-income-tax-provision-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-5-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Income Taxes" } } }, "localname": "statement-statement-note-5-income-taxes-tables", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-7-stockbased-awards-nonvested-award-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Stock-based Awards - Nonvested Award Activity (Details)" } } }, "localname": "statement-statement-note-7-stockbased-awards-nonvested-award-activity-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-7-stockbased-awards-stock-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Stock-based Awards - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-7-stockbased-awards-stock-option-activity-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details)" } } }, "localname": "statement-statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-note-7-stockbased-awards-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Stock-based Awards" } } }, "localname": "statement-statement-note-7-stockbased-awards-tables", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "pmd_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.psychemedics.com/20221231", "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r254", "r468", "r519", "r567" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r272", "r273", "r274", "r275", "r317", "r418", "r430", "r452", "r453", "r465", "r469", "r477", "r518", "r559", "r560", "r561", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r272", "r273", "r274", "r275", "r317", "r418", "r430", "r452", "r453", "r465", "r469", "r477", "r518", "r559", "r560", "r561", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r254", "r468", "r519", "r567" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r250", "r419", "r466", "r475", "r513", "r514", "r519", "r566" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r250", "r419", "r466", "r475", "r513", "r514", "r519", "r566" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r272", "r273", "r274", "r275", "r316", "r317", "r344", "r345", "r346", "r417", "r418", "r430", "r452", "r453", "r465", "r469", "r477", "r512", "r518", "r560", "r561", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r272", "r273", "r274", "r275", "r316", "r317", "r344", "r345", "r346", "r417", "r418", "r430", "r452", "r453", "r465", "r469", "r477", "r512", "r518", "r560", "r561", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r251", "r252", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r467", "r476", "r519" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r251", "r252", "r438", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r467", "r476", "r519" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r13", "r474" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r256", "r257" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowance for doubtful accounts of $87 and $89 at December 31, 2022 and 2021, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation and employee benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses", "totalLabel": "Total Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r18", "r99" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued vacation expense" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r81", "r168" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r28", "r29", "r172", "r426", "r435", "r436" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r26", "r29", "r124", "r413", "r431", "r432", "r491", "r492", "r493", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r8" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r353", "r354", "r355", "r499", "r500", "r501", "r553" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r49", "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "us-gaap_AdjustmentForAmortization", "terseLabel": "Amortization, Total" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Tax withholding related to vested shares from employee stock plans" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "terseLabel": "Stock compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r89", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Exercise of stock options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Stock compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r173", "r258", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs", "negatedLabel": "Write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r138", "r152", "r170", "r192", "r231", "r241", "r246", "r259", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r386", "r388", "r393", "r474", "r516", "r517", "r557" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r164", "r174", "r192", "r259", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r386", "r388", "r393", "r474", "r516", "r517", "r557" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r319", "r320", "r321", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r343", "r344", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "stringItemType" }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of the state of California.", "label": "California Franchise Tax Board [Member]" } } }, "localname": "CaliforniaFranchiseTaxBoardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r569" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Computer software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r51", "r166", "r454" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r45", "r51", "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash, end of year", "periodStartLabel": "Cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r45", "r130" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "us-gaap_CashEquivalentsAtCarryingValue", "terseLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r144", "r157" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r83", "r269", "r270", "r440", "r515" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Dividends declared, per share (in dollars per share)", "terseLabel": "Common Stock, Dividends, Per Share, Declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r499", "r500", "r553" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r89" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r7", "r474" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.005 par value; 50,000 shares authorized 6,349 shares and 6,257 shares issued at December 31, 2022 and 2021, respectively, 5,681 shares outstanding and 5,589 shares outstanding at December 31, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r100", "r101", "r102", "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r30", "r176", "r178", "r184", "r422", "r427" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Total Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r472", "r508", "r509" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r63", "r64", "r128", "r129", "r254", "r439" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r63", "r64", "r128", "r129", "r254", "r437", "r439" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r63", "r64", "r128", "r129", "r254", "r439", "r568" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r149", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r63", "r64", "r128", "r129", "r254" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r63", "r64", "r128", "r129", "r254", "r439" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentLiabilityReserveEstimatePolicy": { "auth_ref": [ "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.", "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]" } } }, "localname": "ContingentLiabilityReserveEstimatePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r54", "r55", "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_ConversionOfStockAmountIssued1", "terseLabel": "Conversion of Stock, Amount Issued" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r35", "r419" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of revenues" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r497", "r549", "r551" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r497", "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Total Current" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r497", "r549", "r551" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r62", "r254" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r88", "r191", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r301", "r308", "r309", "r310" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r139", "r141", "r151", "r195", "r285", "r286", "r287", "r288", "r289", "r291", "r297", "r298", "r299", "r300", "r302", "r303", "r304", "r305", "r306", "r307", "r403", "r460", "r461", "r462", "r463", "r464", "r495" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r20", "r286" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r21", "r195", "r285", "r286", "r287", "r288", "r289", "r291", "r297", "r298", "r299", "r300", "r302", "r303", "r304", "r305", "r306", "r307", "r403", "r460", "r461", "r462", "r463", "r464", "r495" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Month)" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "us-gaap_DebtWeightedAverageInterestRate", "terseLabel": "Debt, Weighted Average Interest Rate" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r497", "r550", "r551" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r360", "r361" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r49", "r119", "r372", "r378", "r379", "r497" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "totalLabel": "Total Deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r4", "r5", "r140", "r150", "r367" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Gross Deferred Tax Liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r497", "r550", "r551" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r368" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Gross Deferred Tax Assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r117", "r548" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "R&D tax credits" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r547" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net Deferred Tax Assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r547" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Deferred Tax Assets After Valuation Allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r117", "r548" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "NOL carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r117", "r548" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r117", "r548" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r117", "r548" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r369" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses", "negatedTerseLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r49", "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "us-gaap_DepreciationAndAmortization", "terseLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r318", "r349", "r350", "r352", "r357", "r470" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-6-preferred-stock", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "us-gaap_DividendsCommonStockCash", "negatedLabel": "Cash dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r185", "r201", "r202", "r203", "r204", "r205", "r209", "r211", "r213", "r214", "r215", "r217", "r391", "r392", "r423", "r428", "r457" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic net loss per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r185", "r201", "r202", "r203", "r204", "r205", "r211", "r213", "r214", "r215", "r217", "r391", "r392", "r423", "r428", "r457" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted net loss per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r59", "r60" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r394" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r363" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r193", "r363", "r380" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r546", "r552" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Increase/(decrease) in valuation reserve" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r546", "r552" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State income taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r546", "r552" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r546", "r552" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r89", "r162", "r180", "r181", "r182", "r196", "r197", "r198", "r200", "r206", "r208", "r218", "r260", "r313", "r353", "r354", "r355", "r374", "r375", "r390", "r395", "r396", "r397", "r398", "r399", "r400", "r413", "r431", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r263", "r264", "r265", "r266", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r80" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Office furniture and equipment" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r494", "r510", "r511" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "us-gaap_GainLossOnDispositionOfAssets", "negatedLabel": "Loss on sale of fixed assets" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r49", "r86", "r87" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on forgiveness of PPP Loan", "negatedLabel": "Forgiveness of PPP loan" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r36" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General & administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r34", "r192", "r231", "r240", "r245", "r248", "r259", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r393", "r459", "r516" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r31", "r135", "r145", "r160", "r231", "r240", "r245", "r248", "r424", "r459" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Net loss before provision for (benefit from) income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r193", "r364", "r365", "r371", "r376", "r381", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r194", "r207", "r208", "r230", "r362", "r377", "r382", "r429" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for (benefit from) income taxes", "totalLabel": "Income Tax Provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r179", "r358", "r359", "r365", "r366", "r370", "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r46", "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r143", "r158", "r489" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r48" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r48" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r48" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes", "negatedLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "auth_ref": [ "r48" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.", "label": "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable", "negatedTerseLabel": "Income tax receivable" } } }, "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r48" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r133", "r147", "r183", "r229", "r402" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "terseLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "us-gaap_InterestIncomeOther", "terseLabel": "Interest Income, Other" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r186", "r188", "r189" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r80" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r411" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r411" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r411" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r411" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r411" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r17", "r192", "r259", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r387", "r388", "r389", "r393", "r458", "r516", "r557", "r558" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r12", "r142", "r155", "r474", "r496", "r506", "r554" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total Liabilities and Shareholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r19", "r165", "r192", "r259", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r387", "r388", "r389", "r393", "r474", "r516", "r557", "r558" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r15", "r495" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r15", "r495" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "us-gaap_LitigationSettlementAmountAwardedToOtherParty", "terseLabel": "Litigation Settlement, Amount Awarded to Other Party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r3", "r141", "r153", "r298", "r311", "r461", "r462" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "us-gaap_LongTermDebt", "terseLabel": "Long-Term Debt, Total", "totalLabel": "Long-term debt from equipment financing" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Current portion of long-term debt", "negatedTerseLabel": "Less current portion of long-term debt from equipment financing" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r84", "r195", "r303" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r84", "r195", "r303" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r171" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "us-gaap_LongTermDebtNoncurrent", "terseLabel": "Long-term debt from equipment financing, net of current portion", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.", "label": "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime", "terseLabel": "Long-Term Debt, Weighted Average Interest Rate, over Time" } } }, "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r21", "r85" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r271", "r487" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "us-gaap_LossContingencyAccrualAtCarryingValue", "terseLabel": "Loss Contingency Accrual, Ending Balance" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_MajorCustomersPolicyPolicyTextBlock": { "auth_ref": [ "r61", "r63", "r64", "r69" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.", "label": "Major Customers, Policy [Policy Text Block]" } } }, "localname": "MajorCustomersPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r187" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r187" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r45", "r47", "r50" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r32", "r50", "r146", "r159", "r163", "r175", "r177", "r182", "r192", "r199", "r201", "r202", "r203", "r204", "r207", "r208", "r212", "r231", "r240", "r245", "r248", "r259", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r392", "r393", "r459", "r516" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r54", "r55", "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Purchases of equipment through accounts payable and accrued liabilities" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r37" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r231", "r240", "r245", "r248", "r459" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating (loss) income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r555" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r405" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of lease liabilities", "totalLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r405" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of operating lease liabilities", "terseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r405" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Long-term operating lease liabilities", "verboseLabel": "Long-term portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r406", "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r404" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r494" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "ROU asset amortization" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r410", "r473" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r409", "r473" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r116" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r125" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r169" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r121", "r122", "r123" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Foreign currency translation, net of taxes", "terseLabel": "Foreign currency translation, net of taxes" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r98", "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r38" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r43" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "us-gaap_PaymentsOfDividendsCommonStock", "negatedLabel": "Cash dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r40" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment and capitalized software development costs" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r6", "r312" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r6", "r312" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "Preferred Stock [Text Block]" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-6-preferred-stock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r6", "r474" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r490" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r41" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from stock options and tax withholding related to vested shares from employee stock plans" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r42" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from long term det", "terseLabel": "Proceeds from Issuance of Long-term Debt, Total" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r39" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from sale of fixed assets" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r80", "r167" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentGross", "totalLabel": "Property, Plant and Equipment, Gross, Ending Balance" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r82", "r156", "r425", "r474" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentNet", "terseLabel": "Property, Plant and Equipment, Net, Ending Balance", "totalLabel": "Property, Plant and Equipment, Net, Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and equipment:" } } }, "localname": "PropertyPlantAndEquipmentNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r82", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, plant and equipment, useful life (Year)", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_RepaymentsOfLongTermDebt", "terseLabel": "Repayments of Long-term Debt, Total" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r112", "r161", "r565" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research & development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r77", "r78", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r9", "r94", "r154", "r434", "r436", "r474" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r162", "r196", "r197", "r198", "r200", "r206", "r208", "r260", "r353", "r354", "r355", "r374", "r375", "r390", "r431", "r433" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r227", "r228", "r239", "r243", "r244", "r250", "r251", "r254", "r314", "r315", "r419" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenues", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r408", "r473" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets acquired through operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r254", "r503" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock": { "auth_ref": [ "r70", "r507" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss of financing receivable, classified as current.", "label": "Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]" } } }, "localname": "ScheduleOfCreditLossesForFinancingReceivablesCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r21", "r90", "r91", "r92", "r93", "r131", "r132", "r134", "r148", "r461", "r463", "r498" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r103", "r105", "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r224", "r225", "r226", "r231", "r232", "r242", "r246", "r247", "r248", "r249", "r250", "r253", "r254", "r255" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r233", "r234", "r235", "r236", "r237", "r238", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Marketing & selling" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details" ], "xbrltype": "domainItemType" }, "us-gaap_SettlementLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.", "label": "Accrued legal settlement" } } }, "localname": "SettlementLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r48" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "terseLabel": "Share-Based Payment Arrangement, Accelerated Cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Outstanding & Unvested at end of period (in shares)", "periodStartLabel": "Outstanding & Unvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Shares issued \u2013 vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "negatedLabel": "Shares issued \u2013 vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Shares granted (in shares)", "terseLabel": "Shares granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding (in shares)", "periodStartLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r319", "r320", "r321", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r343", "r344", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Canceled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Fair value per share (in dollars per share)", "terseLabel": "Fair value per share (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r322", "r341", "r342", "r343", "r344", "r347", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r58", "r190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r25", "r89", "r162", "r180", "r181", "r182", "r196", "r197", "r198", "r200", "r206", "r208", "r218", "r260", "r313", "r353", "r354", "r355", "r374", "r375", "r390", "r395", "r396", "r397", "r398", "r399", "r400", "r413", "r431", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business", "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-tables", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-tables", "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense", "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-tables", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-tables", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-tables", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables", "http://www.psychemedics.com/20221231/role/statement-note-6-preferred-stock", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables", "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan", "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r196", "r197", "r198", "r218", "r419" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals", "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business", "http://www.psychemedics.com/20221231/role/statement-note-1-nature-of-business-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-maturities-of-lease-liabilities-details", "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-tables", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-schedule-of-debt-repayments-details", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-tables", "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense", "http://www.psychemedics.com/20221231/role/statement-note-12-other-income-expense-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-revenue-by-major-source-details", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-tables", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-revenue-by-major-source-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-stock-compensation-expense-by-income-statement-account-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-useful-lives-of-assets-details", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-summary-of-the-allowance-for-doubtful-accounts-details", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-tables", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-tables", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-components-of-net-deferred-tax-liabilities-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-reconciliation-of-effective-rate-with-federal-statutory-rate-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-summary-of-income-tax-provision-details", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables", "http://www.psychemedics.com/20221231/role/statement-note-6-preferred-stock", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-nonvested-award-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-summary-of-shares-granted-under-the-2006-incentive-plan-details", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables", "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan", "http://www.psychemedics.com/20221231/role/statement-note-8-employee-benefit-plan-details-textual", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.psychemedics.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r6", "r7", "r89", "r94", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercise of stock options (in shares)", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r7", "r10", "r11", "r72", "r474", "r496", "r506", "r554" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Shareholders' Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r401", "r415" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r401", "r415" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r401", "r415" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-", "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r414", "r416" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-14-subsequent-event-" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-10-operating-leases-tables", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-tables", "http://www.psychemedics.com/20221231/role/statement-note-13-business-segment-reporting-tables", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.psychemedics.com/20221231/role/statement-note-3-accounts-receivable-tables", "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-tables", "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-tables", "http://www.psychemedics.com/20221231/role/statement-note-7-stockbased-awards-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r116" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued taxes" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-4-accrued-expenses-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r24", "r95" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r24", "r95" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r24", "r95", "r96" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Less - Treasury stock, at cost, 668 shares" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r65", "r66", "r67", "r219", "r220", "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements", "http://www.psychemedics.com/20221231/role/statement-note-11-debt-and-other-financing-arrangements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r502" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details": { "order": 0.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Dilutive common equivalent shares (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r210", "r215" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)", "totalLabel": "Weighted average common shares outstanding, assuming dilution (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r209", "r215" ], "calculation": { "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)", "terseLabel": "Weighted average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://www.psychemedics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-basic-and-diluted-weighted-average-common-shares-outstanding-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.psychemedics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "https://asc.fasb.org/topic&trid=2127225", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "https://asc.fasb.org/topic&trid=2122503", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(13)(b))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(19))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r479": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r481": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r482": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r483": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r484": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r485": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r486": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/subtopic&trid=2196772", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org/topic&trid=49130413", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 84 0001171843-23-001908-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-001908-xbrl.zip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�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